
<html lang="en"     class="pb-page"  data-request-id="b4acfcb1-b6ec-4e30-8499-19398d4a586a"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;issue:issue:10.1021/jmcmar.2019.62.issue-1;wgroup:string:ACHS website Group;article:article:10.1021/acs.jmedchem.8b00280;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Discovery of Allosteric, Potent, Subtype Selective, and Peripherally Restricted TrkA Kinase Inhibitors" /></meta><meta name="dc.Creator" content="Sharan K.  Bagal" /></meta><meta name="dc.Creator" content="Kiyoyuki  Omoto" /></meta><meta name="dc.Creator" content="David C.  Blakemore" /></meta><meta name="dc.Creator" content="Peter J.  Bungay" /></meta><meta name="dc.Creator" content="James G.  Bilsland" /></meta><meta name="dc.Creator" content="Philip J.  Clarke" /></meta><meta name="dc.Creator" content="Matthew S.  Corbett" /></meta><meta name="dc.Creator" content="Ciaran N.  Cronin" /></meta><meta name="dc.Creator" content="J. Jean  Cui" /></meta><meta name="dc.Creator" content="Rebecca  Dias" /></meta><meta name="dc.Creator" content="Neil J.  Flanagan" /></meta><meta name="dc.Creator" content="Samantha E.  Greasley" /></meta><meta name="dc.Creator" content="Rachel  Grimley" /></meta><meta name="dc.Creator" content="Eric  Johnson" /></meta><meta name="dc.Creator" content="David  Fengas" /></meta><meta name="dc.Creator" content="Linda  Kitching" /></meta><meta name="dc.Creator" content="Michelle L.  Kraus" /></meta><meta name="dc.Creator" content="Indrawan  McAlpine" /></meta><meta name="dc.Creator" content="Asako  Nagata" /></meta><meta name="dc.Creator" content="Gareth J.  Waldron" /></meta><meta name="dc.Creator" content="Joseph S.  Warmus" /></meta><meta name="dc.Description" content="Tropomyosin receptor kinases (TrkA, TrkB, TrkC) are activated by hormones of the neurotrophin family: nerve growth factor (NGF), brain derived neurotrophic factor (BDNF), neurotrophin 3 (NT3), and ..." /></meta><meta name="Description" content="Tropomyosin receptor kinases (TrkA, TrkB, TrkC) are activated by hormones of the neurotrophin family: nerve growth factor (NGF), brain derived neurotrophic factor (BDNF), neurotrophin 3 (NT3), and ..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="April 19, 2018" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.8b00280" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright © 2018 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.8b00280" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.8b00280" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.8b00280" /></link>
        
    
    

<title>Discovery of Allosteric, Potent, Subtype Selective, and Peripherally Restricted TrkA Kinase Inhibitors | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.8b00280" /></meta><meta property="og:title" content="Discovery of Allosteric, Potent, Subtype Selective, and Peripherally Restricted TrkA Kinase Inhibitors" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-1/acs.jmedchem.8b00280/20190107/images/large/jm-2018-00280z_0019.jpeg" /></meta><meta property="og:description" content="Tropomyosin receptor kinases (TrkA, TrkB, TrkC) are activated by hormones of the neurotrophin family: nerve growth factor (NGF), brain derived neurotrophic factor (BDNF), neurotrophin 3 (NT3), and neurotrophin 4 (NT4). Moreover, the NGF antibody tanezumab has provided clinical proof of concept for inhibition of the TrkA kinase pathway in pain leading to significant interest in the development of small molecule inhibitors of TrkA. However, achieving TrkA subtype selectivity over TrkB and TrkC via a Type I and Type II inhibitor binding mode has proven challenging and Type III or Type IV allosteric inhibitors may present a more promising selectivity design approach. Furthermore, TrkA inhibitors with minimal brain availability are required to deliver an appropriate safety profile. Herein, we describe the discovery of a highly potent, subtype selective, peripherally restricted, efficacious, and well-tolerated series of allosteric TrkA inhibitors that culminated in the delivery of candidate quality compound 23." /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta><meta name="twitter:description" content="Tropomyosin receptor kinases (TrkA, TrkB, TrkC) are activated by hormones of the neurotrophin family: nerve growth factor (NGF), brain derived neurotrophic factor (BDNF), neurotrophin 3 (NT3), and neurotrophin 4 (NT4). Moreover, the NGF antibody tanezumab has provided clinical proof of concept for inhibition of the TrkA kinase pathway in pain leading to significant interest in the development of small molecule inhibitors of TrkA. However, achieving TrkA subtype selectivity over TrkB and TrkC via a Type I and Type II inhibitor binding mode has proven challenging and Type III or Type IV allosteric inhibitors may present a more promising selectivity design approach. Furthermore, TrkA inhibitors with minimal brain availability are required to deliver an appropriate safety profile. Herein, we describe the discovery of a highly potent, subtype selective, peripherally restricted, efficacious, and well-tolerated series of allosteric TrkA inhibitors that culminated in the delivery of candidate quality compound 23." /></meta><meta name="twitter:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-1/acs.jmedchem.8b00280/20190107/images/large/jm-2018-00280z_0019.jpeg" /></meta><meta name="twitter:title" content="Discovery of Allosteric, Potent, Subtype Selective, and Peripherally Restricted TrkA Kinase Inhibitors" /></meta>
        
            <meta property="og:type" content="Article" /></meta>
        

        
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.8b00280"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/ke1q~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-6ee29527b3d8ff00a106.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.8b00280">
            
        





































    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-12/achre4.2021.54.issue-12/20210615/achre4.2021.54.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-6/amrcda.2021.2.issue-6/20210625/amrcda.2021.2.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-6/aabmcb.2021.4.issue-6/20210621/aabmcb.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-6/aaembp.2021.3.issue-6/20210622/aaembp.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-6/aaemcq.2021.4.issue-6/20210628/aaemcq.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-25/aamick.2021.13.issue-25/20210630/aamick.2021.13.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-6/aanmf6.2021.4.issue-6/20210625/aanmf6.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-6/aapmcd.2021.3.issue-6/20210611/aapmcd.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-6/abseba.2021.7.issue-6/20210614/abseba.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-12/accacs.2021.11.issue-12/20210618/accacs.2021.11.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-6/acscii.2021.7.issue-6/20210623/acscii.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-6/acbcct.2021.16.issue-6/20210618/acbcct.2021.16.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-3/achsc5.2021.28.issue-3/20210524/achsc5.2021.28.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-12/acncdm.2021.12.issue-12/20210616/acncdm.2021.12.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-6/aesccq.2021.5.issue-6/20210617/aesccq.2021.5.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-6/aelccp.2021.6.issue-6/20210611/aelccp.2021.6.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-6/aeecco.2021.1.issue-6/20210611/aeecco.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-6/aewcaa.2021.1.issue-6/20210611/aewcaa.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-5/afsthl.2021.1.issue-5/20210618/afsthl.2021.1.issue-5.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-6/aidcbc.2021.7.issue-6/20210611/aidcbc.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-6/amlccd.2021.10.issue-6/20210615/amlccd.2021.10.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-6/amlcef.2021.3.issue-6/20210607/amlcef.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-6/amclct.2021.12.issue-6/20210610/amclct.2021.12.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-6/ancac3.2021.15.issue-6/20210622/ancac3.2021.15.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-25/acsodf.2021.6.issue-25/20210629/acsodf.2021.6.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-6/apchd5.2021.8.issue-6/20210616/apchd5.2021.8.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-6/ascefj.2021.6.issue-6/20210625/ascefj.2021.6.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-25/ascecg.2021.9.issue-25/20210628/ascecg.2021.9.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-6/asbcd6.2021.10.issue-6/20210618/asbcd6.2021.10.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-25/ancham.2021.93.issue-25/20210629/ancham.2021.93.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-25/bichaw.2021.60.issue-25/20210629/bichaw.2021.60.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-6/bcches.2021.32.issue-6/20210616/bcches.2021.32.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-6/bomaf6.2021.22.issue-6/20210614/bomaf6.2021.22.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-24/cgeabj.2021.99.issue-24/20210628-01/cgeabj.2021.99.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-6/crtoec.2021.34.issue-6/20210621/crtoec.2021.34.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-12/chreay.2021.121.issue-12/20210623/chreay.2021.121.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-12/cmatex.2021.33.issue-12/20210622/cmatex.2021.33.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-6/cgdefu.2021.21.issue-6/20210602/cgdefu.2021.21.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-12/enfuem.2021.35.issue-12/20210617/enfuem.2021.35.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-12/esthag.2021.55.issue-12/20210615/esthag.2021.55.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-6/estlcu.2021.8.issue-6/20210608/estlcu.2021.8.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-25/iecred.2021.60.issue-25/20210630/iecred.2021.60.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-12/inocaj.2021.60.issue-12/20210621/inocaj.2021.60.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-6/jaaucr.2021.1.issue-6/20210628/jaaucr.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-25/jafcau.2021.69.issue-25/20210630/jafcau.2021.69.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-6/jceaax.2021.66.issue-6/20210610/jceaax.2021.66.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-6/jceda8.2021.98.issue-6/20210608/jceda8.2021.98.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-6/jcisd8.2021.61.issue-6/20210628/jcisd8.2021.61.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-6/jctcce.2021.17.issue-6/20210608/jctcce.2021.17.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/jmcmar.2021.64.issue-12/20210624/jmcmar.2021.64.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-6/jnprdf.2021.84.issue-6/20210625/jnprdf.2021.84.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-12/joceah.2021.86.issue-12/20210618/joceah.2021.86.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-24/jpcafh.2021.125.issue-24/20210624/jpcafh.2021.125.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-24/jpcbfk.2021.125.issue-24/20210624/jpcbfk.2021.125.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-24/jpccck.2021.125.issue-24/20210624/jpccck.2021.125.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-24/jpclcd.2021.12.issue-24/20210624/jpclcd.2021.12.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-6/jprobs.2021.20.issue-6/20210604/jprobs.2021.20.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-25/jacsat.2021.143.issue-25/20210630/jacsat.2021.143.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-6/jamsef.2021.32.issue-6/20210602/jamsef.2021.32.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-25/langd5.2021.37.issue-25/20210629/langd5.2021.37.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-12/mamobx.2021.54.issue-12/20210622/mamobx.2021.54.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-6/mpohbp.2021.18.issue-6/20210607/mpohbp.2021.18.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-12/nalefd.2021.21.issue-12/20210623/nalefd.2021.21.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-12/orlef7.2021.23.issue-12/20210618/orlef7.2021.23.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-6/oprdfk.2021.25.issue-6/20210618/oprdfk.2021.25.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-12/orgnd7.2021.40.issue-12/20210628/orgnd7.2021.40.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.8b00280&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.8b00280&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.8b00280&amp;href=/doi/10.1021/acs.jmedchem.8b00280" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2019</span><span class="cit-fg-volume">, 62</span><span class="cit-fg-issue">, 1</span><span class="cit-fg-pageRange">, 247-265</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/62/1" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.8b00161" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.8b00315" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery of Allosteric, Potent, Subtype Selective, and Peripherally Restricted TrkA Kinase Inhibitors</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Sharan K. Bagal</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Sharan K. Bagal</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Worldwide Medicinal Chemistry, Pfizer Global R&D U.K., The Portway Building, Granta Park, Cambridge CB21 6GS, U.K.</div></div><span class="conrtib-corresp"><strong>*</strong>E-mail: <a href="/cdn-cgi/l/email-protection#4e3d262f3c2f20602c2f292f220e213b3a22212125602d2123"><span class="__cf_email__" data-cfemail="04776c6576656a2a6665636568446b7170686b6b6f2a676b69">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Sharan+K.++Bagal">Sharan K. Bagal</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-0955-271X" title="Orcid link">http://orcid.org/0000-0003-0955-271X</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Kiyoyuki Omoto</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Kiyoyuki Omoto</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Worldwide Medicinal Chemistry, Pfizer Global R&D U.K., The Portway Building, Granta Park, Cambridge CB21 6GS, U.K.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Kiyoyuki++Omoto">Kiyoyuki Omoto</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">David C. Blakemore</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">David C. Blakemore</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Worldwide Medicinal Chemistry, Pfizer Global R&D U.K., The Portway Building, Granta Park, Cambridge CB21 6GS, U.K.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=David+C.++Blakemore">David C. Blakemore</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Peter J. Bungay</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Peter J. Bungay</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pharmacokinetics, Dynamics & Metabolism, Pfizer Global R&D U.K., The Portway Building, Granta Park, Cambridge CB21 6GS, U.K.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Peter+J.++Bungay">Peter J. Bungay</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">James G. Bilsland</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">James G. Bilsland</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pfizer Global R&D U.K., The Portway Building, Granta Park, Cambridge CB21 6GS, U.K.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=James+G.++Bilsland">James G. Bilsland</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Philip J. Clarke</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Philip J. Clarke</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Peakdale Molecular, Discovery Park House, Ramsgate Road, Sandwich, Kent CT13 9ND, U.K.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Philip+J.++Clarke">Philip J. Clarke</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Matthew S. Corbett</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Matthew S. Corbett</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pfizer Global R&D, Groton Laboratories, Eastern Point Road, Groton, Connecticut 06340, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Matthew+S.++Corbett">Matthew S. Corbett</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Ciaran N. Cronin</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ciaran N. Cronin</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pfizer Global R&D, La Jolla Laboratories, 10770 Science Center Drive, San Diego, California 92121, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ciaran+N.++Cronin">Ciaran N. Cronin</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">J. Jean Cui</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">J. Jean Cui</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pfizer Global R&D, La Jolla Laboratories, 10770 Science Center Drive, San Diego, California 92121, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=J.+Jean++Cui">J. Jean Cui</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Rebecca Dias</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Rebecca Dias</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pfizer Global R&D U.K., The Portway Building, Granta Park, Cambridge CB21 6GS, U.K.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Rebecca++Dias">Rebecca Dias</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Neil J. Flanagan</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Neil J. Flanagan</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pfizer Global R&D U.K., The Portway Building, Granta Park, Cambridge CB21 6GS, U.K.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Neil+J.++Flanagan">Neil J. Flanagan</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Samantha E. Greasley</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Samantha E. Greasley</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pfizer Global R&D, La Jolla Laboratories, 10770 Science Center Drive, San Diego, California 92121, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Samantha+E.++Greasley">Samantha E. Greasley</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Rachel Grimley</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Rachel Grimley</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pfizer Global R&D U.K., The Portway Building, Granta Park, Cambridge CB21 6GS, U.K.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Rachel++Grimley">Rachel Grimley</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Eric Johnson</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Eric Johnson</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pfizer Global R&D, La Jolla Laboratories, 10770 Science Center Drive, San Diego, California 92121, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Eric++Johnson">Eric Johnson</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">David Fengas</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">David Fengas</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Peakdale Molecular, Discovery Park House, Ramsgate Road, Sandwich, Kent CT13 9ND, U.K.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=David++Fengas">David Fengas</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Linda Kitching</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Linda Kitching</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pfizer Global R&D U.K., The Portway Building, Granta Park, Cambridge CB21 6GS, U.K.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Linda++Kitching">Linda Kitching</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Michelle L. Kraus</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Michelle L. Kraus</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pfizer Global R&D, La Jolla Laboratories, 10770 Science Center Drive, San Diego, California 92121, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Michelle+L.++Kraus">Michelle L. Kraus</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Indrawan McAlpine</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Indrawan McAlpine</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pfizer Global R&D, La Jolla Laboratories, 10770 Science Center Drive, San Diego, California 92121, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Indrawan++McAlpine">Indrawan McAlpine</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Asako Nagata</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Asako Nagata</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pfizer Global R&D, La Jolla Laboratories, 10770 Science Center Drive, San Diego, California 92121, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Asako++Nagata">Asako Nagata</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Gareth J. Waldron</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Gareth J. Waldron</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pfizer Global R&D U.K., The Portway Building, Granta Park, Cambridge CB21 6GS, U.K.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Gareth+J.++Waldron">Gareth J. Waldron</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Joseph S. Warmus</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Joseph S. Warmus</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pfizer Global R&D, Groton Laboratories, Eastern Point Road, Groton, Connecticut 06340, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Joseph+S.++Warmus">Joseph S. Warmus</a></span></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.8b00280&amp;href=/doi/10.1021%2Facs.jmedchem.8b00280" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2019</span></span><span class="cit-volume">, 62</span><span class="cit-issue">, 1</span><span class="cit-pageRange">, 247–265</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">April 19, 2018</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>19 February 2018</li><li><span class="item_label"><b>Published</b> online</span>19 April 2018</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 10 January 2019</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.8b00280" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b00280</a></div><div class="article_header-article-copyright"><strong>Copyright © 2018 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D247%26pageCount%3D19%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DSharan%2BK.%2BBagal%252C%2BKiyoyuki%2BOmoto%252C%2BDavid%2BC.%2BBlakemore%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D62%26issueNum%3D1%26contentID%3Dacs.jmedchem.8b00280%26title%3DDiscovery%2Bof%2BAllosteric%252C%2BPotent%252C%2BSubtype%2BSelective%252C%2Band%2BPeripherally%2BRestricted%2BTrkA%2BKinase%2BInhibitors%26numPages%3D19%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D265%26publicationDate%3DJanuary%2B2019">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.8b00280"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">5000</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">14</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.8b00280" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery of Allosteric, Potent, Subtype Selective, and Peripherally Restricted TrkA Kinase Inhibitors&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Sharan&quot;,&quot;last_name&quot;:&quot;K. Bagal&quot;},{&quot;first_name&quot;:&quot;Kiyoyuki&quot;,&quot;last_name&quot;:&quot;Omoto&quot;},{&quot;first_name&quot;:&quot;David&quot;,&quot;last_name&quot;:&quot;C. Blakemore&quot;},{&quot;first_name&quot;:&quot;Peter&quot;,&quot;last_name&quot;:&quot;J. Bungay&quot;},{&quot;first_name&quot;:&quot;James&quot;,&quot;last_name&quot;:&quot;G. Bilsland&quot;},{&quot;first_name&quot;:&quot;Philip&quot;,&quot;last_name&quot;:&quot;J. Clarke&quot;},{&quot;first_name&quot;:&quot;Matthew&quot;,&quot;last_name&quot;:&quot;S. Corbett&quot;},{&quot;first_name&quot;:&quot;Ciaran&quot;,&quot;last_name&quot;:&quot;N. Cronin&quot;},{&quot;first_name&quot;:&quot;J.&quot;,&quot;last_name&quot;:&quot;Jean Cui&quot;},{&quot;first_name&quot;:&quot;Rebecca&quot;,&quot;last_name&quot;:&quot;Dias&quot;},{&quot;first_name&quot;:&quot;Neil&quot;,&quot;last_name&quot;:&quot;J. Flanagan&quot;},{&quot;first_name&quot;:&quot;Samantha&quot;,&quot;last_name&quot;:&quot;E. Greasley&quot;},{&quot;first_name&quot;:&quot;Rachel&quot;,&quot;last_name&quot;:&quot;Grimley&quot;},{&quot;first_name&quot;:&quot;Eric&quot;,&quot;last_name&quot;:&quot;Johnson&quot;},{&quot;first_name&quot;:&quot;David&quot;,&quot;last_name&quot;:&quot;Fengas&quot;},{&quot;first_name&quot;:&quot;Linda&quot;,&quot;last_name&quot;:&quot;Kitching&quot;},{&quot;first_name&quot;:&quot;Michelle&quot;,&quot;last_name&quot;:&quot;L. Kraus&quot;},{&quot;first_name&quot;:&quot;Indrawan&quot;,&quot;last_name&quot;:&quot;McAlpine&quot;},{&quot;first_name&quot;:&quot;Asako&quot;,&quot;last_name&quot;:&quot;Nagata&quot;},{&quot;first_name&quot;:&quot;Gareth&quot;,&quot;last_name&quot;:&quot;J. Waldron&quot;},{&quot;first_name&quot;:&quot;Joseph&quot;,&quot;last_name&quot;:&quot;S. Warmus&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2018&quot;,&quot;month&quot;:&quot;04&quot;,&quot;day&quot;:&quot;19&quot;,&quot;issue&quot;:&quot;1&quot;,&quot;volume&quot;:&quot;62&quot;,&quot;pages&quot;:&quot;247-265&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.8b00280&quot;},&quot;abstract&quot;:&quot;Tropomyosin receptor kinases (TrkA, TrkB, TrkC) are activated by hormones of the neurotrophin family: nerve growth factor (NGF), brain derived neurotrophic factor (BDNF), neurotrophin 3 (NT3), and neurotrophin 4 (NT4). Moreover, the NGF antibody tanezumab has provided clinical proof of concept for inhibition of the TrkA kinase pathway in pain leading to significant interest in the development of small molecule inhibitors of TrkA. However, achieving TrkA subtype selectivity over TrkB and TrkC via a Type I and Type II inhibitor binding mode has proven challenging and Type III or Type IV allosteric inhibitors may present a more promising selectivity design approach. Furthermore, TrkA inhibitors with minimal brain availability are required to deliver an appropriate safety profile. Herein, we describe the discovery of a highly potent, subtype selective, peripherally restricted, efficacious, and well-tolerated series of allosteric TrkA inhibitors that culminated in the delivery of candidate quality compound 23.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.8b00280&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b00280" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.8b00280&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b00280" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.8b00280&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b00280" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.8b00280&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b00280&amp;href=/doi/10.1021/acs.jmedchem.8b00280" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.8b00280" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.8b00280" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (8 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b00280&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.8b00280%26sid%3Dliteratum%253Aachs%26pmid%3D29672039%26genre%3Darticle%26aulast%3DBagal%26date%3D2019%26atitle%3DDiscovery%2Bof%2BAllosteric%252C%2BPotent%252C%2BSubtype%2BSelective%252C%2Band%2BPeripherally%2BRestricted%2BTrkA%2BKinase%2BInhibitors%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D62%26issue%3D1%26spage%3D247%26epage%3D265%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=292366" title="Ligands">Ligands</a>,</li><li><a href="/action/doSearch?ConceptID=291754" title="Molecules">Molecules</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291711" title="Selectivity">Selectivity</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/62/1" title="Go to Volume 62, Issue 1"><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-1/jmcmar.2019.62.issue-1/20190110/jmcmar.2019.62.issue-1.largecover.jpg" alt="Go to Volume 62, Issue 1"/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-1/acs.jmedchem.8b00280/20190107/images/medium/jm-2018-00280z_0019.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-1/acs.jmedchem.8b00280/20190107/images/large/jm-2018-00280z_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00280&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Tropomyosin receptor kinases (TrkA, TrkB, TrkC) are activated by hormones of the neurotrophin family: nerve growth factor (NGF), brain derived neurotrophic factor (BDNF), neurotrophin 3 (NT3), and neurotrophin 4 (NT4). Moreover, the NGF antibody tanezumab has provided clinical proof of concept for inhibition of the TrkA kinase pathway in pain leading to significant interest in the development of small molecule inhibitors of TrkA. However, achieving TrkA subtype selectivity over TrkB and TrkC via a Type I and Type II inhibitor binding mode has proven challenging and Type III or Type IV allosteric inhibitors may present a more promising selectivity design approach. Furthermore, TrkA inhibitors with minimal brain availability are required to deliver an appropriate safety profile. Herein, we describe the discovery of a highly potent, subtype selective, peripherally restricted, efficacious, and well-tolerated series of allosteric TrkA inhibitors that culminated in the delivery of candidate quality compound <b>23</b>.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="specialIssueNotice" class="extra-info-sec articleNote"><h4>SPECIAL ISSUE</h4><p class="last">This article is part of the <a href="/toc/jmcmar/62/1"><issue-title>Allosteric Modulators</issue-title></a> special issue.</p></div><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_73501" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_73501" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Tropomyosin receptor kinases are a family of three tyrosine kinases (TrkA, TrkB, TrkC) activated by peptidic hormones of the neurotrophin family: nerve growth factor (NGF), brain derived neurotrophic factor (BDNF), neurotrophin 3 (NT3), and neurotrophin 4 (NT4) (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>).<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Preclinical and clinical studies have identified a crucial role for NGF in the pathogenesis of inflammatory pain,<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> with neutralizing antibodies such as tanezumab demonstrating efficacy in preclinical pain models and in clinical trials for osteoarthritis, chronic low back pain, and interstitial cystitis.<a onclick="showRef(event, 'ref3 ref4 ref5 ref6'); return false;" href="javascript:void(0);" class="ref ref3 ref4 ref5 ref6">(3−6)</a> Since NGF binds to the TrkA kinase receptor, this has provided clinical proof of concept for inhibition of the TrkA pathway in pain and has also led to significant interest in the development of small molecule modulators of TrkA.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-1/acs.jmedchem.8b00280/20190107/images/medium/jm-2018-00280z_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-1/acs.jmedchem.8b00280/20190107/images/large/jm-2018-00280z_0001.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Neurotrophins and their receptors. The neurotrophins exhibit specific interactions with the three Trk receptors: NGF binds TrkA, BDNF and NT-4 binds TrkB, and NT-3 binds TrkC.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-1/acs.jmedchem.8b00280/20190107/images/large/jm-2018-00280z_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00280&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">A key concern in the development of TrkA kinase inhibitors for the treatment of chronic pain is achieving sufficient TrkA selectivity over TrkB and TrkC. TrkB is expressed throughout the body with the BDNF/TrkB axis involved in excitatory signaling, long-term potentiation, and feeding behavior.<a onclick="showRef(event, 'ref7 ref8 ref9 ref10'); return false;" href="javascript:void(0);" class="ref ref7 ref8 ref9 ref10">(7−10)</a> Moreover, human genetic data has linked decreased function of TrkB with obesity and developmental delay.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> BDNF has been shown to play a role in regulating the arterial baroreceptor reflex and in modulating heart contraction force.<a onclick="showRef(event, 'ref12 ref13 ref14'); return false;" href="javascript:void(0);" class="ref ref12 ref13 ref14">(12−14)</a> TrkC is widely expressed in neural and non-neural tissues and has wide physiological functions that include the development and survival of the sympathetic nervous system.<a onclick="showRef(event, 'ref15 ref16'); return false;" href="javascript:void(0);" class="ref ref15 ref16">(15,16)</a></div><div class="NLM_p">Most small molecule kinase inhibitors are ATP competitive Type I or Type II binders, by reference to the highly conserved aspartate-phenylalanine-glycine (DFG) motif in the beginning of the activation loop in the C-lobe of the kinase domain. Type I inhibitors such as the JAK inhibitor tofacitinib (recently approved for rheumatoid arthritis) binds in the ATP pocket in a DFG-in conformation,<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> while Type II inhibitors such as imatinib bind in the ATP pocket and extend into a less conserved allosteric region that is formed following a conformational change to the DFG-out structure.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> While Type I and II inhibitors can display high levels of selectivity, TrkA, TrkB, and TrkC kinases have no residue difference in the ATP binding site, suggesting that achieving TrkA selectivity over TrkB/C in this site may be extremely challenging. Moreover, our previous work on the pan-Trk inhibitor program where isoform nonselective TrkA/B/C inhibitors were progressed into clinical development, suggested that Type I and Type II binders tend to exhibit pan-Trk activity rather than subtype selectivity.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> One known method for achieving isoform selectivity within closely related kinases is the identification of Type III and Type IV allosteric ligands.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> Type III ligands bind in an adjacent site to the ATP binding site without making any interactions with the hinge region of the ATP binding site. Trametinib is a Type III inhibitor of MEK1/2 kinases and is the first allosteric kinase inhibitor approved by the FDA, being accepted as a single-agent for the treatment of patients with either B-Raf V600E or V600K mutated metastatic melanoma (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>).<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> Other allosteric kinase inhibitors that bind in a pocket adjacent to the ATP binding site include allosteric Akt inhibitors such as MK-2206. MK-2206 targets a unique allosteric pocket at the catalytic kinase domain and the regulatory pleckstrin homology (PH) domain of the inactive conformation of Akt and is currently under clinical investigation in numerous Phase I and II oncology trials.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> Type IV inhibitors bind to a site that is distant from the ATP binding site, exemplified by GNF-2 that binds the myristoyl pocket of the C-lobe of the kinase domain of Abl (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>).<a onclick="showRef(event, 'ref23 ref24'); return false;" href="javascript:void(0);" class="ref ref23 ref24">(23,24)</a> An advantage of Type III and Type IV inhibitors is that the comparatively low sequence homology of allosteric sites provides unique opportunities for more specific inhibition and minimal off-target pharmacology, for example, Type I and Type II Akt inhibitors tend to exhibit relatively poor kinome selectivity, whereas allosteric Akt inhibitor MK-2206 is reported to be more than 100-fold selective over 256 kinases screened.<a onclick="showRef(event, 'ref22 ref25'); return false;" href="javascript:void(0);" class="ref ref22 ref25">(22,25)</a></div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-1/acs.jmedchem.8b00280/20190107/images/medium/jm-2018-00280z_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-1/acs.jmedchem.8b00280/20190107/images/large/jm-2018-00280z_0002.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Allosteric inhibitors Trametinib, MK-2206, and GNF-2.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-1/acs.jmedchem.8b00280/20190107/images/large/jm-2018-00280z_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00280&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Inspection of an apo TrkA protein crystal structure generated at Pfizer indicated TrkA protein prefers to adopt a DFG-out autoinhibitory conformation. The DFG-out conformation is stabilized by edge to face interactions between three phenylalanines: DFG motif Phe669, gatekeeper Phe589, and back pocket Phe575 (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>). Moreover, the presence of these residues serve to illustrate the uniqueness of TrkA since according to our understanding only five kinases exhibit the FFF motif, three of which are the Trks. This motif combined with Leu564 from the α-C helix creates a hydrophobic binding pocket behind the gatekeeper Phe589 that could, in theory, accommodate a Type III allosteric ligand. Moreover this is a similar allosteric pocket to that formed by the kinases IGFR-1R and c-Src.<a onclick="showRef(event, 'ref26 ref27'); return false;" href="javascript:void(0);" class="ref ref26 ref27">(26,27)</a> In these cases, the kinase adopts a DFG-out conformation revealing a hydrophobic pocket adjacent to the ATP binding site, and Type III ligands have been shown to bind to these allosteric sites by X-ray crystallography.<a onclick="showRef(event, 'ref26 ref27'); return false;" href="javascript:void(0);" class="ref ref26 ref27">(26,27)</a> Hence, the apo TrkA protein crystal structure suggested that an allosteric approach utilizing a Type III binder to achieve TrkA selectivity over TrkB/C was a reasonable proposition.</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-1/acs.jmedchem.8b00280/20190107/images/medium/jm-2018-00280z_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-1/acs.jmedchem.8b00280/20190107/images/large/jm-2018-00280z_0003.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Apo crystal structure of TrkA protein highlighting a hydrophobic pocket potentially suitable for an allosteric Type III binder.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-1/acs.jmedchem.8b00280/20190107/images/large/jm-2018-00280z_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00280&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The high level of expression of TrkA in cholinergic neurons of the central nervous system (CNS) and the effect of ablation of the TrkA gene that leads to dysfunction in cholinergic circuitry in preclinical species raised the risk of CNS adverse events in the development of TrkA inhibitors for the treatment of chronic pain.<a onclick="showRef(event, 'ref28 ref29 ref30'); return false;" href="javascript:void(0);" class="ref ref28 ref29 ref30">(28−30)</a> Furthermore, clinical studies on CE-245677, a pan-Trk/Tie2 kinase inhibitor identified by Pfizer as a potential treatment of certain cancers, identified CNS side-effects leading to the suspension of Phase I multiple dose trials. Adverse events included cognitive deficits, personality changes, and sleep disturbances that fully resolved upon cessation of dosing.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> Preclinical studies with CE-245677 demonstrated both efficacy in pain models and CNS side-effects (changes in electroencephalography (EEG), cognitive function, body weight, and hypothalamic mRNA).<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> The efficacy of TrkA kinase inhibitors is expected to be driven by target engagement in peripheral neurons. Therefore, as safety and toleration risks are associated with CNS Trk receptor occupancy, safety risks can be addressed by restricting TrkA inhibitors to the peripheral compartment. Experience within Pfizer and the wider pharmaceutical community suggests that small molecules can be developed that possess acceptable oral bioavailability but are also peripherally restricted.<a onclick="showRef(event, 'ref33 ref34 ref35 ref36 ref37'); return false;" href="javascript:void(0);" class="ref ref33 ref34 ref35 ref36 ref37">(33−37)</a> This profile can be delivered by designing compounds within physicochemical space appropriate for absorption across the gastrointestinal epithelium (e.g., molecular weight (MW) < 500, polar surface area (PSA) < 140, <10 rotatable bonds),<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> while combining activity as substrates for the blood–brain barrier (BBB) efflux transporters P-glycoprotein (P-gp) and Breast Cancer Resistance Protein (BCRP).<a onclick="showRef(event, 'ref33 ref34 ref35 ref39'); return false;" href="javascript:void(0);" class="ref ref33 ref34 ref35 ref39">(33−35,39)</a></div><div class="NLM_p">A risk inherent in this strategy derives from the presence of P-gp and BCRP in the apical membrane of intestinal epithelial cells, the same efflux transporter proteins found at the BBB (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>). Hence, drugs acting as efflux substrates could also be restricted in transport across the intestinal epithelium, resulting in poor absorption from the gut lumen with low and variable oral bioavailability. However, at commonly prescribed oral drug doses of adequately soluble compounds (10–500 mg), the gut intraluminal drug concentration is likely to be in the range of hundreds of micromolar. This would produce a high concentration gradient and hence a high driving force for flux of compound across the epithelium. In addition, saturation of efflux transporters is expected to occur at such gut luminal concentrations, given that substrates of P-gp typically possess <i>K</i><sub>m</sub> values in the range 1–100 μM. These considerations suggest that in most cases, and particularly for drugs with high intrinsic permeability, the risk of poor absorption and nonlinear pharmacokinetics of orally delivered efflux substrates may be low.<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a></div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-1/acs.jmedchem.8b00280/20190107/images/medium/jm-2018-00280z_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-1/acs.jmedchem.8b00280/20190107/images/large/jm-2018-00280z_0004.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Schematic illustration of absorption of an orally administered drug across the intestinal epithelium and its distribution across the brain vascular endothelium that forms the BBB. The presence of tight junctions between cells in both structures limits the paracellular movement of drug molecules. <i>C</i><sub>p</sub> = total plasma concentration, <i>C</i><sub>p,u</sub> = unbound plasma concentration, <i>C</i><sub>b,u</sub> = unbound brain concentration, and <i>C</i><sub>i,u</sub> = unbound intracellular concentration. According to the free drug hypothesis, unbound concentrations determine the drug pharmacological effect, and at the BBB, <i>C</i><sub>b,u</sub> may be less than <i>C</i><sub>p,u</sub> if the drug is a substrate for efflux transporters.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-1/acs.jmedchem.8b00280/20190107/images/large/jm-2018-00280z_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00280&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_54106" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_54106" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> Hit Identification</h3><div class="NLM_p">We recently reported the discovery of a potent pan-Trk inhibitor <b>1</b> as a development clinical candidate.<a onclick="showRef(event, 'ref19 ref41'); return false;" href="javascript:void(0);" class="ref ref19 ref41">(19,41)</a> Ligand <b>1</b> is an equipotent inhibitor of all three Trk kinases and was identified by following up a high throughput screen (HTS) of the full Pfizer file using TrkA and TrkB cell based assays.<a onclick="showRef(event, 'ref19 ref32 ref41'); return false;" href="javascript:void(0);" class="ref ref19 ref32 ref41">(19,32,41)</a> It is a Type II inhibitor that binds to the inactive form of TrkA in a DFG-out conformation (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>A). In order to find TrkA subtype selective hits, the HTS data set was reanalyzed to focus on compounds selective for TrkA over TrkB. The selection criteria were as follows: demonstration of some possibility for TrkA selectivity over TrkB in the existing data set (≥2-fold or not determined), chemotypes that were not known pan-Trk inhibitors from the Pfizer pan-Trk program,<a onclick="showRef(event, 'ref32 ref41'); return false;" href="javascript:void(0);" class="ref ref32 ref41">(32,41)</a> and lack of a common kinase hinge binder.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> Based on this analysis, a set of ∼250 compounds was prioritized for test at TrkA and TrkB in cell based assays at high concentration of 50 μM.<a onclick="showRef(event, 'ref41 ref43'); return false;" href="javascript:void(0);" class="ref ref41 ref43">(41,43)</a> The data generated suggested that the vast majority of these compounds were not active at TrkA (TrkA cell IC<sub>50</sub> > 50 μM) or were nonselective over TrkB (<2-fold). However, a promising hit (<b>2</b>) emerged that was active at TrkA (TrkA cell IC<sub>50</sub> 3.3 μM) and >10-fold selective over TrkB (TrkB cell IC<sub>50</sub> > 50 μM) (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>). The allosteric nature of this hit was confirmed via X-ray crystallography with a 1.93 Å cocrystal structure of <b>2</b> with TrkA protein. Compound <b>2</b> was indeed a Type III binder at TrkA with the activation loop and juxtamembrane (JM) domain contributing to the binding site (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>C). This binding site is similar to that reported by Furuya and Su.<a onclick="showRef(event, 'ref44 ref45'); return false;" href="javascript:void(0);" class="ref ref44 ref45">(44,45)</a> In this structure TrkA adopts a DFG-out conformation similar to the apo TrkA structure and is reminiscent of the allosteric binders to the receptor tyrosine kinase IGFR-1R. <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a> highlights the difference in binding mode between pan-Trk inhibitor <b>1</b> and TrkA selective inhibitor <b>2</b>. Whereas both compounds bind to the DFG-out conformation, the pan-Trk ligand <b>1</b> interacts with the kinase hinge and extends into the DFG pocket, while the TrkA selective ligand <b>2</b> does not interact with the hinge and binds exclusively in a hydrophobic allosteric pocket supported by the JM domain. The ligand bound overlay of <b>1</b> and <b>2</b> in <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>B indicates an area of common ligand occupancy in the DFG pocket. <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>A highlights key protein–ligand interactions between <b>2</b> and TrkA protein. There are hydrogen bonds between the side chain of Asp668 on the activation loop and NH of <b>2</b>, and between main chain NHs of Leu486 and Gly485 on the JM domain with the carbonyl oxygen of <b>2</b>. Lys544 forms a pi–cation interaction with the unsubstituted aryl ring. Moreover, this aryl unit participates in hydrophobic van der Waals interactions with Phe589, Leu486, Leu564, and other nearby lipophilic regions (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figures <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a> and <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>). A halogen bond may also be identified between the aromatic <i>ortho</i>-Cl group in <b>2</b> and main chain carbonyl of His648. The observed TrkA selectivity over TrkB/C can be explained by the allosteric binding mode because the ligand interacts with the JM domain. The JM domain of TrkA is shorter than TrkB/C, and TrkA has a number of residue differences in the protein–ligand interacting region when compared with TrkB/C (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>). Thus, the JM conformation presented to ligand <b>2</b> by TrkA is likely to be different from that presented by TrkB/C leading to preferential ligand binding at TrkA. Moreover, Kania et al. have recently discussed the impact of JM domain conformation on protein–ligand interaction with the class of VEGFR inhibitors and concluded that the greatest potency and drug efficiency was garnered from interactions that worked with a natural autoinhibitory state of the enzyme.<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> In this case, the allosteric series exemplified by ligand <b>2</b> stabilizes the autoinhibitory apo state of TrkA. Su and Furuya reported similar binding modes of TrkA inhibitors.<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a></div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-1/acs.jmedchem.8b00280/20190107/images/medium/jm-2018-00280z_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-1/acs.jmedchem.8b00280/20190107/images/large/jm-2018-00280z_0005.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. (A) Cocrystal structure of pan-Trk inhibitor <b>1</b> bound to TrkA protein in a DFG-out conformation; ligand <b>1</b> shown in CPK space filling model; some parts of the G-loop, activation loop, and JM domain are not solved. (B) Overlay of the bound conformation in TrkA protein of DFG-out binder <b>1</b> (gray) and allosteric ligand <b>2</b> (magenta) indicating a region of common TrkA binding site occupancy. (C) Cocrystal structure of <b>2</b> bound to TrkA protein in a DFG-out conformation that is similar to the apo DFG-out conformation. Ligand <b>2</b> binds in an allosteric pocket created by the activation loop and JM domain; ligand <b>2</b> shown in CPK space filling model.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-1/acs.jmedchem.8b00280/20190107/images/large/jm-2018-00280z_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00280&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-1/acs.jmedchem.8b00280/20190107/images/medium/jm-2018-00280z_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-1/acs.jmedchem.8b00280/20190107/images/large/jm-2018-00280z_0006.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. (A) Cocrystal structure of TrkA selective ligand <b>2</b> bound to TrkA protein highlighting key protein–ligand interactions with white dashed lines with distances given in Å. (B) Cocrystal structure of TrkA selective ligand <b>2</b> bound to TrkA protein highlighting locations and thermodynamic properties of selected water molecules estimated by WaterMap. Oxygen atoms of selected waters are highlighted as CPK spheres with thermodynamic profiles. Water coloring scheme represents the stability of the water: unstable waters (high δG) are colored red and stable waters (low δG) are colored blue.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-1/acs.jmedchem.8b00280/20190107/images/large/jm-2018-00280z_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00280&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-1/acs.jmedchem.8b00280/20190107/images/medium/jm-2018-00280z_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-1/acs.jmedchem.8b00280/20190107/images/large/jm-2018-00280z_0007.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Sequence alignment of the TrkA, TrkB, and TrkC JM domains. The motif interacting with TrkA selective allosteric ligand <b>2</b> is highlighted in red and indicates the putative origin of TrkA selectivity over TrkB/C.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-1/acs.jmedchem.8b00280/20190107/images/large/jm-2018-00280z_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00280&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i5" class="anchor-spacer"></div><h3 class="article-section__title" id="_i5"> Hit to Lead Optimization</h3><div class="NLM_p">Allosteric hit <b>2</b> exhibited the following profile: TrkA cell IC<sub>50</sub> 3.3 μM, ligand efficiency (LE) 0.33, and lipophilic efficiency (LipE) 2.2 (LipE = −Log(TrkA cell IC<sub>50</sub>) – LogD). While this LE provided a reasonable starting point, the potency and LipE required significant improvement. Moreover, the potential for drug action at this allosteric site represented a key question: will sufficient potency and LipE be achievable in this lipophilic binding site such that a clinical candidate is a viable proposition? Analysis of the cocrystal structure shown in <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>A determined the optimization strategy for hit <b>2</b>. A number of ligands that bind to kinases in the DFG-out conformation interact with the backbone NH of the DFG motif, for example, pan-Trk ligand <b>1</b>,<a onclick="showRef(event, 'ref19 ref41'); return false;" href="javascript:void(0);" class="ref ref19 ref41">(19,41)</a> imatinib,<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> and BIRB 796.<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> The corresponding interaction with the main chain Asp668 NH could be targeted by building on the meta position of the dichlorophenyl unit of <b>2</b> (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>A). The pyrazole methyl group has a vector toward the kinase exit, which is solvent exposed. This vector could be used to append polarity and decrease the lipophilicity of ligand <b>2</b> (LogD 3.3). Bound water molecules identified by crystallography were also analyzed using WaterMap (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>B), which maps the locations and thermodynamic properties of water molecules that solvate protein binding sites.<a onclick="showRef(event, 'ref49 ref50'); return false;" href="javascript:void(0);" class="ref ref49 ref50">(49,50)</a> A number of relatively unstable water molecules calculated to have an unfavorable free energy and enthalpy relative to solvent water (colored red, <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>B) were identified in the direction of the kinase hinge. Such water molecules have been reported to be successfully replaced by lipophilic groups.<a onclick="showRef(event, 'ref49 ref50'); return false;" href="javascript:void(0);" class="ref ref49 ref50">(49,50)</a> A cluster of water molecules that appeared to be more stable (colored blue, <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>B) could be identified at the pyrazole methyl, consistent with the methyl pointing toward solvent. Based upon the considerations outlined above, ligand <b>2</b> was optimized to lead molecule <b>3</b> (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>). A series of virtual molecules was designed based on a Suzuki coupling reaction with commercially or internally available acids (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>). Eleven thousand molecules were created and docked against the X-ray structure of <b>2</b> (see <a class="ref internalNav" href="#sec5" aria-label="Experimental Section">Experimental Section</a>). The molecules were then prioritized based on docking score as well as presence/absence of hydrogen bond with backbone NH of Asp668 in a docking pose. One hundred molecules were selected for synthesis and tested in the TrkA and TrkB cellular assays. As a result, <b>3</b> showed a significant improvement in potency (TrkA cell IC<sub>50</sub> 50 nM) and LipE (5) and maintained >80-fold TrkA selectivity over TrkB/C in cell based assays (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>).<a onclick="showRef(event, 'ref41 ref43'); return false;" href="javascript:void(0);" class="ref ref41 ref43">(41,43)</a> There was no strong correlation between docking score and potency, but it was clear that the hit rate of the virtual library was enhanced. Note that ligand <b>3</b>, wherein an aminopyridine group was appended at the meta position of the dichlorophenyl unit of <b>2</b>, was ranked 15th in the 100 molecule set for docking score. Docking of <b>3</b> suggested that this fragment not only formed a hydrogen bond with NH in Asp668 using the pyridyl N atom but also formed a hydrogen bond with the main chain C═O Asp668 via the amino hydrogen bond donor (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>A,B). Furthermore, the aminopyridine fragment displaced some of the unstable waters identified in <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>B (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>A,B). The methyl pyrazole was substituted with a primary carboxamide in order to decrease LogD and interact with the side chain of Arg673 via a hydrogen bond with the carboxamide C═O (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>B). The amide moiety also replaced some of the moderately stable waters identified in <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>B and interacted with the water network in this region. Lead molecule <b>3</b> exhibited a significant improvement in potency (TrkA cell IC<sub>50</sub> 50 nM) and LipE (5) and maintained >80-fold TrkA selectivity over TrkB/C in cell based assays (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>).<a onclick="showRef(event, 'ref41 ref43'); return false;" href="javascript:void(0);" class="ref ref41 ref43">(41,43)</a> The improvement in potency and LipE achieved in <b>3</b> while retaining TrkA subtype selectivity suggested that design of candidate quality molecules binding to the allosteric site of TrkA was an achievable prospect. Ligand <b>3</b> was screened for protein kinase selectivity at ca. 400 biochemical kinase assays (including TrkA) from Invitrogen at a concentration of 1 μM (see <a href="/doi/suppl/10.1021/acs.jmedchem.8b00280/suppl_file/jm8b00280_si_001.pdf" class="ext-link">Supporting Information</a>). Pleasingly, <b>3</b> exhibited excellent TrkA selectivity with >80% inhibition of TrkA and <25% inhibition of all other kinases observed, a selectivity profile that can be attributed to the unique nature of the allosteric pocket.<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a> Furthermore, wide ligand binding profiling in 83 target assays (Cerep) at a concentration of 10 μM to assess off-target liabilities indicated a relatively clean profile (four hits with % inhibition >50% at 10 μM, all of which corresponded with IC<sub>50</sub> or EC<sub>50</sub> > 6 μM). Lead molecule <b>3</b> was evaluated by surface plasmon resonance (SPR) binding methods with immobilized TrkA protein (residues 441–796) using Biacore instrumentation. With nonactivated unphosphorylated TrkA protein, ligand <b>3</b> demonstrated fast association and dissociation kinetics (<i>K</i><sub>a</sub> = 2 × 10<sup>7</sup> M<sup>–1</sup> s<sup>–1</sup>; <i>K</i><sub>d</sub> = 1 s<sup>–1</sup>) and <i>K</i><sub>D</sub> (80 nM) consistent with TrkA cell potency. When activated phosphorylated TrkA protein was used in the SPR assay, there was a substantial reduction in signal from ligand <b>3</b> binding, indicating that allosteric ligands prefer to bind to the nonactivated unphosphorylated state of TrkA. This finding was further corroborated by screening in nonactivated TrkA and activated phosphorylated TrkA biochemical enzyme assays where <b>3</b> was approximately 6-fold more potent against the nonactivated TrkA construct (TrkA nonactivated enzyme IC<sub>50</sub> 25 nM, TrkA activated enzyme IC<sub>50</sub> 150 nM) (see <a href="/doi/suppl/10.1021/acs.jmedchem.8b00280/suppl_file/jm8b00280_si_001.pdf" class="ext-link">Supporting Information</a>).<a onclick="showRef(event, 'ref41 ref43'); return false;" href="javascript:void(0);" class="ref ref41 ref43">(41,43)</a> The preference of allosteric ligands for the inactive state of TrkA protein can be rationalized by consideration of protein conformation. In the autoinhibitory DFG-out conformation, the allosteric binding site can be formed, whereas in the phosphorylated state, the JM domain will move to allow the activation loop to access an active DFG-in conformation. In the latter case, the allosteric binding site is blocked by the activation loop making the allosteric binding site less readily accessible.<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a></div><figure id="sch1" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-1/acs.jmedchem.8b00280/20190107/images/medium/jm-2018-00280z_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-1/acs.jmedchem.8b00280/20190107/images/large/jm-2018-00280z_0012.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Optimization of Allosteric Hit <b>2</b> to Lead Molecule <b>3</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-1/acs.jmedchem.8b00280/20190107/images/large/jm-2018-00280z_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00280&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig8" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-1/acs.jmedchem.8b00280/20190107/images/medium/jm-2018-00280z_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-1/acs.jmedchem.8b00280/20190107/images/large/jm-2018-00280z_0008.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. (A) Cocrystal structure of lead molecule <b>3</b> bound to TrkA protein highlighting key protein–ligand interactions with white dashed lines with distances given in Å. (B) Cocrystal structure of lead molecule <b>3</b> bound to TrkA protein highlighting interactions with Arg673 and Asp668 with white dashed lines. Parts of TrkA protein omitted for clarity. (C) Cocrystal structure of lead molecule <b>3</b> bound to TrkA protein highlighting allosteric binding site surface with brown representing hydrophobic regions, green representing neutral polarity regions, and blue representing polar regions.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-1/acs.jmedchem.8b00280/20190107/images/large/jm-2018-00280z_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00280&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="sch2" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-1/acs.jmedchem.8b00280/20190107/images/medium/jm-2018-00280z_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-1/acs.jmedchem.8b00280/20190107/images/large/jm-2018-00280z_0013.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Lead Molecule <b>3</b> via Introduction of an Aminopyridine Moiety Using a Two-step–One-pot Borylation–Suzuki Coupling Methodology<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-1/acs.jmedchem.8b00280/20190107/images/large/jm-2018-00280z_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00280&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) NaNO<sub>2</sub>, BF<sub>3</sub>·OEt<sub>2</sub>, DCM, −15 °C, 97%; (ii) pyridine, MeOH; (iii) K<sub>2</sub>CO<sub>3</sub>, DCM, rt, 30% over three steps; (iv) T<sub>3</sub>P, pyridine, Me-THF, 85 °C, 73%; (v) bis(pinacolato)diboron, KOAc, Pd(dppf)Cl<sub>2,</sub> dioxane, 100 °C, 3 h; (vi) Na<sub>2</sub>CO<sub>3</sub>, Pd(dppf)Cl, dioxane, H<sub>2</sub>O, 110 °C, 16 h, 60% over two steps; (vii) H<sub>2</sub>O<sub>2</sub>, K<sub>2</sub>CO<sub>3,</sub> DMSO, rt, 3 h, 58%.</p></p></figure><div class="NLM_p">Further in vitro studies were carried out to understand metabolic liabilities of ligands <b>2</b> and <b>3</b>. Hit molecule <b>2</b> exhibited moderate metabolic turnover in human liver microsomes (HLM) and human hepatocytes (hHep) (intrinsic clearance (CL<sub>int</sub>) in HLM 35 μL/min/mg protein, hHep 48 μL/min/million cells, see <a class="ref internalNav" href="#sec5" aria-label="Experimental Section">Experimental Section</a>). Lead molecule <b>3</b> is a unit lower in LogD when compared with <b>2</b>, resulting in greater metabolic stability in human in vitro systems (HLM < 8 μL/min/mg protein, hHep 18 μL/min/million cells). However, the presence of an amino group resulted in turnover in the human in vitro glucuronidation turnover assay (HLMUGT) with CL<sub>int</sub> of 29 μL/min/mg protein (see <a class="ref internalNav" href="#sec5" aria-label="Experimental Section">Experimental Section</a>). Such metabolism via conjugation of the NH<sub>2</sub> unit was the major pathway, as determined by metabolite identification (data not shown). Aneugeneticity can be a property presented by kinase inhibitors so ligand <b>3</b> was also assessed for genetic toxicity via an in vitro micronucleus (IVMN) assay.<a onclick="showRef(event, 'ref52 ref53'); return false;" href="javascript:void(0);" class="ref ref52 ref53">(52,53)</a> Ligand <b>3</b> induced micronuclei in Chinese hamster ovary (CHO) cultures, with the presence of kinetochore staining indicating that the genotoxic activity was aneugenic and not clastogenic in nature (see <a class="ref internalNav" href="#sec5" aria-label="Experimental Section">Experimental Section</a>). TrkA inhibitors that would be restricted to the peripheral drug compartment following oral administration were required so that safety concerns associated with TrkA receptors expressed in the CNS could be avoided. In order to achieve the desired peripheral restriction (free brain/free plasma ratio (<i>C</i><sub>b,u</sub>/<i>C</i><sub>p,u</sub>) ≤ 5%) TrkA inhibitors that were also substrates of P-gp and BCRP efflux transporters expressed at the BBB were preferred.<a onclick="showRef(event, 'ref33 ref34 ref39'); return false;" href="javascript:void(0);" class="ref ref33 ref34 ref39">(33,34,39)</a> In the assay format used presently to assess P-gp and BCRP efflux, P-gp and BCRP substrates are characterized as having an efflux ratio (ER) > 2.5. While hit <b>2</b> was not a P-gp substrate, ligand <b>3</b> was a substrate of both P-gp and BCRP, which is consistent with the higher MW and PSA of <b>3</b> relative to <b>2</b> (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>).<a onclick="showRef(event, 'ref33 ref34 ref39'); return false;" href="javascript:void(0);" class="ref ref33 ref34 ref39">(33,34,39)</a> The CNS penetration of <b>3</b> was assessed in vivo in rat and was confirmed to be peripherally restricted with <i>C</i><sub>b,u</sub>/<i>C</i><sub>p,u</sub> of 0.04. Further oral and i.v. rat PK studies revealed that, while <b>3</b> exhibited relatively low clearance (CL) in vivo, it also had low oral bioavailability (6%) (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). The measured passive permeability of <b>3</b> assessed in the RRCK transcellular flux assay was consistent with good absorption (RRCK P<sub>app</sub> 17 × 10<sup>–6</sup> cm s<sup>–1</sup>),<a onclick="showRef(event, 'ref54 ref55'); return false;" href="javascript:void(0);" class="ref ref54 ref55">(54,55)</a> suggesting that low oral bioavailability could have resulted from presystemic metabolism. Incubation of <b>3</b> with rat intestinal microsomes in the presence of UDPGA and NADPH revealed high turnover (CL<sub>int</sub> 175 μL/min/mg), presumably via glucuronidation on the amino group (as identified via metabolite identification). Turnover of <b>3</b> was also detectable in human intestinal microsomes (HIM) (CL<sub>int</sub> 4.5 μL/min/mg) and in HLM supplemented with UDPGA (HLMUGT, CL<sub>int</sub> 29 μL/min/mg). The most effective method of reducing intestinal metabolism (and hence improving oral bioavailability) while maintaining TrkA potency was the removal of the amino unit as exemplified by ligands <b>4</b>–<b>10</b> (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Tables <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a> and <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>). <i>N</i>-Acyl derivative <b>4</b> (TrkA cell IC<sub>50</sub> 0.034 μM, LogD 2.7, LipE 4.8) is likely to have a reduced glucuronidation liability. However, the acetyl group was chemically unstable, and ligand <b>4</b> underwent <i>N</i>-deacetylation in buffer systems at pH 7.5. <i>N</i>-Acetyl amide stability can be improved by reversing the amide,<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a> and in this case, reversing the amide to yield <b>5</b> improved chemical and metabolic stability (HLMUGT CL<sub>int</sub> < 1.9 μL/min/mg, hHep 3.1 μL/min/million cells). However, reverse amide <b>5</b> was >1000-fold weaker at TrkA, possibly due to a repulsive interaction between the C═O of <b>5</b> and main chain C═O of Asp668. Introduction of a polarized CH in <b>6</b> using a CHF<sub>2</sub> moiety resulted in a 20-fold decrease in potency at TrkA (TrkA cell IC<sub>50</sub> 1.1 μM) when compared with <b>3</b>. Introduction of a lipophilic group on the 3-position of the aminopyridine as in <b>9</b> (R<sub>2</sub> = Cl, <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>) improved TrkA potency by 3-fold (TrkA cell IC<sub>50</sub> 16 nM) but also increased the glucuronidation rate significantly (HLMUGT CL<sub>int</sub> 209 μL/min/mg). Removal of the amino group in <b>9</b> to give <b>8</b> reduced glucuronidation to a minimum (HLMUGT CL<sub>int</sub> < 1.9 μL/min/mg), and only caused a moderate 7-fold loss in potency and 0.4 unit reduction in LipE (TrkA cell IC<sub>50</sub> 110 nM, LipE 4.2). Moreover, <b>8</b> gave no measurable turnover in HIM or RIM. Based on the promising in vitro metabolism profile, <b>8</b> was progressed to PK studies in rat using oral and i.v. administration, which indicated low systemic CL (plasma CL 13.4 mL/min/kg) and high oral bioavailability (85%) (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). The corresponding fluorinated derivative <b>7</b> had a similar excellent in vivo rat oral/i.v. PK profile (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). The ability of <b>7</b> and <b>8</b> to act as substrates for P-gp and BCRP was also assessed. Ligand <b>7</b> was not a P-gp substrate but was a moderate BCRP substrate (P-gp ER 2.1, BCRP ER 4.8), while ligand <b>8</b> was a moderate P-gp substrate and not a BCRP substrate (P-gp ER 3, BCRP ER 2). In order to understand the level of restriction from the CNS achievable with these compounds, both <b>7</b> and <b>8</b> were progressed to CNS penetration studies in rat. Gratifyingly, both compounds were peripherally restricted with <i>C</i><sub>b,u</sub>/<i>C</i><sub>p,u</sub> ≈ 0.1 and provided evidence that good oral absorption combined with restriction from the CNS was achievable in this chemical series. By removal of the amino group in <b>3</b>, oral absorption was improved, e.g., in compounds <b>7</b>–<b>8</b>. However, a hydrogen bond between the amino group and main chain C═O of Asp668 (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>) was sacrificed resulting in a potency and LipE loss, shown, for example, by comparing <b>8</b> and <b>9</b> in <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>. In order to improve the potency and LipE of <b>7</b> and <b>8</b>, the cocrystal structure of <b>3</b> was further analyzed. <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>C shows the binding site surface of ligand <b>3</b> when bound to TrkA protein, revealing a buried lipophilic pocket, which can be accessed by substitution on the 2-Cl-aryl ring and pyridyl ring. Moreover, hit molecule <b>2</b> has a <i>p</i>-Cl group that appears to fill this buried pocket (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>). The above analysis suggested that increasing van der Waals interactions between ligand and protein utilizing the buried lipophilic pocket can be used to increase potency and LipE at TrkA. To this end, a Cl group was introduced on the 4-position (R<sub>3</sub>) of the 2-Cl-aryl unit of <b>3</b> to give <b>10</b> (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). Ligand <b>10</b> had a substantial 25-fold improvement in potency and 0.8 unit increase in LipE relative to <b>3</b> (TrkA cell IC<sub>50</sub> 2 nM, LipE 5.8). The corresponding desamino derivative <b>11</b> (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>) was also potent with a reasonable LipE (TrkA cell IC<sub>50</sub> 14 nM, LipE 4.9). In order to find the ideal 4-aryl (R<sub>3</sub>) substituents, the cocrystal structure of <b>3</b> was used to estimate the optimal dihedral angle between the aryl-pyridyl rings to occupy the lipophilic pocket while maintaining interactions with Asp668 and was identified as approximately 45°. A hypothetical list of 3-pyridyl (R<sub>2</sub>) and 4-aryl (R<sub>3</sub>) substituents was then created for triage, e.g., cyclopropyl, F, methyl, phenyl, cyclohexyl, methoxy, etc. (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>). For each potential synthesis target, torsion scans were performed to estimate strain energy of dihedral angle of 45° (dE). Finally, the compounds were docked into TrkA protein to assess how well the substituent occupied the pocket by visual inspection. 3-Pyridyl (R<sub>2</sub>) and 4-aryl (R<sub>3</sub>) substituents prioritized for synthesis demonstrated the following properties: dE < 1 kcal mol<sup>–1</sup> and good occupancy in the lipophilic pocket without causing a clash with TrkA protein. By application of these properties as desirable criteria, the compounds <b>12</b>–<b>25</b> shown in <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a> were prepared. All compounds synthesized successfully retained TrkA potency (TrkA cell IC<sub>50</sub> < 0.35 μM) and where measured, demonstrated >30-fold TrkA selectivity over TrkB/C in cell based assays (data not shown).<a onclick="showRef(event, 'ref43 ref57'); return false;" href="javascript:void(0);" class="ref ref43 ref57">(43,57)</a></div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Compounds <b>3</b>, <b>7</b>, <b>8</b>, <b>23</b>, and <b>24</b>: Pharmacokinetic Properties in Rat<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="5" align="center" char=".">i.v. administration</th><th class="rowsep1 colsep0" colspan="3" align="center" char=".">p.o. administration</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">ID</th><th class="colsep0 rowsep0" align="center" char=".">dose (mg/kg)</th><th class="colsep0 rowsep0" align="center" char="."><i>T</i><sub>1/2</sub> (h)</th><th class="colsep0 rowsep0" align="center" char=".">plasma CL (mL/min/kg)</th><th class="colsep0 rowsep0" align="center" char="."><i>V</i><sub>d</sub> (L/kg)</th><th class="colsep0 rowsep0" align="center" char="."><i>C</i><sub>b,u</sub>/<i>C</i><sub>p,u</sub></th><th class="colsep0 rowsep0" align="center" char=".">dose (mg/kg)</th><th class="colsep0 rowsep0" align="center" char="."><i>T</i><sub>max</sub> (h)</th><th class="colsep0 rowsep0" align="center" char=".">oral <i>F</i> (%)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>3</b></td><td class="colsep0 rowsep0" align="char" char=".">1</td><td class="colsep0 rowsep0" align="char" char=".">1.6</td><td class="colsep0 rowsep0" align="char" char=".">31.5</td><td class="colsep0 rowsep0" align="char" char=".">1.3</td><td class="colsep0 rowsep0" align="char" char=".">0.041</td><td class="colsep0 rowsep0" align="char" char=".">3</td><td class="colsep0 rowsep0" align="char" char=".">0.5</td><td class="colsep0 rowsep0" align="char" char=".">6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7</b></td><td class="colsep0 rowsep0" align="char" char=".">1</td><td class="colsep0 rowsep0" align="char" char=".">3.2</td><td class="colsep0 rowsep0" align="char" char=".">2.8</td><td class="colsep0 rowsep0" align="char" char=".">0.46</td><td class="colsep0 rowsep0" align="char" char=".">0.10</td><td class="colsep0 rowsep0" align="char" char=".">3</td><td class="colsep0 rowsep0" align="char" char=".">4</td><td class="colsep0 rowsep0" align="char" char=".">∼100</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8</b></td><td class="colsep0 rowsep0" align="char" char=".">1</td><td class="colsep0 rowsep0" align="char" char=".">3.2</td><td class="colsep0 rowsep0" align="char" char=".">13.4</td><td class="colsep0 rowsep0" align="char" char=".">1.1</td><td class="colsep0 rowsep0" align="char" char=".">0.076</td><td class="colsep0 rowsep0" align="char" char=".">3</td><td class="colsep0 rowsep0" align="char" char=".">0.9</td><td class="colsep0 rowsep0" align="char" char=".">85</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>23</b></td><td class="colsep0 rowsep0" align="char" char=".">0.5</td><td class="colsep0 rowsep0" align="char" char=".">2.7</td><td class="colsep0 rowsep0" align="char" char=".">11.9</td><td class="colsep0 rowsep0" align="char" char=".">2.8</td><td class="colsep0 rowsep0" align="char" char=".">0.014</td><td class="colsep0 rowsep0" align="char" char=".">2</td><td class="colsep0 rowsep0" align="char" char=".">4</td><td class="colsep0 rowsep0" align="char" char=".">72</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>24</b></td><td class="colsep0 rowsep0" align="char" char=".">0.5</td><td class="colsep0 rowsep0" align="char" char=".">4.1</td><td class="colsep0 rowsep0" align="char" char=".">11.6</td><td class="colsep0 rowsep0" align="char" char=".">1.6</td><td class="colsep0 rowsep0" align="char" char=".">0.015</td><td class="colsep0 rowsep0" align="char" char=".">2</td><td class="colsep0 rowsep0" align="char" char=".">3</td><td class="colsep0 rowsep0" align="char" char=".">46</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">Compounds were administered via intravenous (i.v.) and oral (p.o.) routes to separate groups of two male rats. <i>C</i><sub>b,u</sub>/<i>C</i><sub>p,u</sub> was determined separately following i.v. infusion in four male rats. There were no adverse effects of the compounds at the doses used. The vehicle used was 0.5% methyocellulose 0.5% HPMCAS, and 20 mM Tris(hydroxymethyl)aminomethane (pH = 7.4). Further details of PK and CNS penetration experiments are given in the <a class="ref internalNav" href="#sec5" aria-label="Experimental Section">Experimental Section</a>.</p></div></div></div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Pyridyl Ring SAR and Associated in Vitro Data</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-1/acs.jmedchem.8b00280/20190107/images/medium/jm-2018-00280z_0016.gif" alt="" id="fx1" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">ID</th><th class="colsep0 rowsep0" align="center">R1</th><th class="colsep0 rowsep0" align="center">R2</th><th class="colsep0 rowsep0" align="center">R3</th><th class="colsep0 rowsep0" align="center" char=".">TrkA cell IC<sub>50</sub> (μM)<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center" char=".">LogD<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center" char=".">LipE<a class="ref internalNav" href="#t2fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center" char=".">HLM<a class="ref internalNav" href="#t2fn4" aria-label="d">d</a></th><th class="colsep0 rowsep0" align="center" char=".">HLM UGT<a class="ref internalNav" href="#t2fn5" aria-label="e">e</a></th><th class="colsep0 rowsep0" align="center" char=".">hHep<a class="ref internalNav" href="#t2fn6" aria-label="f">f</a></th><th class="colsep0 rowsep0" align="center" char=".">RRCK P<sub>app</sub><a class="ref internalNav" href="#t2fn7" aria-label="g">g</a></th><th class="colsep0 rowsep0" align="center" char=".">P-gp ER</th><th class="colsep0 rowsep0" align="center" char=".">BCRP ER</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4</b></td><td class="colsep0 rowsep0" align="left">NAc</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="char" char=".">0.034</td><td class="colsep0 rowsep0" align="char" char=".">2.7</td><td class="colsep0 rowsep0" align="char" char=".">4.8</td><td class="colsep0 rowsep0" align="char" char=".">ND</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char=".">10.0</td><td class="colsep0 rowsep0" align="char" char=".">20</td><td class="colsep0 rowsep0" align="char" char=".">11</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5</b></td><td class="colsep0 rowsep0" align="left">CONH<sub>2</sub></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="char" char=".">>50</td><td class="colsep0 rowsep0" align="char" char=".">2.3</td><td class="colsep0 rowsep0" align="char" char=".">NA</td><td class="colsep0 rowsep0" align="char" char="."><8</td><td class="colsep0 rowsep0" align="char" char="."><1.9</td><td class="colsep0 rowsep0" align="char" char=".">3.1</td><td class="colsep0 rowsep0" align="char" char=".">6.1</td><td class="colsep0 rowsep0" align="char" char=".">20</td><td class="colsep0 rowsep0" align="char" char=".">ND</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6</b></td><td class="colsep0 rowsep0" align="left">CHF<sub>2</sub></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="char" char=".">1.1</td><td class="colsep0 rowsep0" align="char" char=".">3.5</td><td class="colsep0 rowsep0" align="char" char=".">2.5</td><td class="colsep0 rowsep0" align="char" char=".">11.5</td><td class="colsep0 rowsep0" align="char" char=".">ND</td><td class="colsep0 rowsep0" align="char" char=".">12.0</td><td class="colsep0 rowsep0" align="char" char=".">8.5</td><td class="colsep0 rowsep0" align="char" char=".">2.1</td><td class="colsep0 rowsep0" align="char" char=".">ND</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">F</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="char" char=".">0.074</td><td class="colsep0 rowsep0" align="char" char=".">2.6</td><td class="colsep0 rowsep0" align="char" char=".">4.5</td><td class="colsep0 rowsep0" align="char" char="."><8</td><td class="colsep0 rowsep0" align="char" char="."><1.9</td><td class="colsep0 rowsep0" align="char" char=".">8</td><td class="colsep0 rowsep0" align="char" char=".">19</td><td class="colsep0 rowsep0" align="char" char=".">2.1</td><td class="colsep0 rowsep0" align="char" char=".">4.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="char" char=".">0.11</td><td class="colsep0 rowsep0" align="char" char=".">2.8</td><td class="colsep0 rowsep0" align="char" char=".">4.2</td><td class="colsep0 rowsep0" align="char" char="."><8</td><td class="colsep0 rowsep0" align="char" char="."><1.9</td><td class="colsep0 rowsep0" align="char" char=".">13</td><td class="colsep0 rowsep0" align="char" char=".">14</td><td class="colsep0 rowsep0" align="char" char=".">3.0</td><td class="colsep0 rowsep0" align="char" char=".">2.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>9</b></td><td class="colsep0 rowsep0" align="left">NH<sub>2</sub></td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="char" char=".">0.016</td><td class="colsep0 rowsep0" align="char" char=".">3.2</td><td class="colsep0 rowsep0" align="char" char=".">4.6</td><td class="colsep0 rowsep0" align="char" char=".">10.3</td><td class="colsep0 rowsep0" align="char" char=".">209</td><td class="colsep0 rowsep0" align="char" char=".">78</td><td class="colsep0 rowsep0" align="char" char=".">11</td><td class="colsep0 rowsep0" align="char" char=".">14</td><td class="colsep0 rowsep0" align="char" char=".">ND</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10</b></td><td class="colsep0 rowsep0" align="left">NH<sub>2</sub></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="char" char=".">0.002</td><td class="colsep0 rowsep0" align="char" char=".">2.9</td><td class="colsep0 rowsep0" align="char" char=".">5.8</td><td class="colsep0 rowsep0" align="char" char=".">19</td><td class="colsep0 rowsep0" align="char" char=".">7</td><td class="colsep0 rowsep0" align="char" char=".">23</td><td class="colsep0 rowsep0" align="char" char=".">11</td><td class="colsep0 rowsep0" align="char" char=".">11</td><td class="colsep0 rowsep0" align="char" char=".">ND</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="char" char=".">0.014</td><td class="colsep0 rowsep0" align="char" char=".">3.0</td><td class="colsep0 rowsep0" align="char" char=".">4.9</td><td class="colsep0 rowsep0" align="char" char="."><8</td><td class="colsep0 rowsep0" align="char" char="."><1.9</td><td class="colsep0 rowsep0" align="char" char=".">17</td><td class="colsep0 rowsep0" align="char" char=".">17</td><td class="colsep0 rowsep0" align="char" char=".">4.2</td><td class="colsep0 rowsep0" align="char" char=".">ND</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">TrkA data were generated in PathHunter cells from DiscoveRx with at least three tests on three different assay runs.<a onclick="showRef(event, 'ref43 ref57'); return false;" href="javascript:void(0);" class="ref ref43 ref57">(43,57)</a></p></div><div class="footnote" id="t2fn2"><sup><sup>b</sup></sup><p class="last">LogD measured at pH 7.4.</p></div><div class="footnote" id="t2fn3"><sup><sup>c</sup></sup><p class="last">LipE = −Log(TrkA cell IC<sub>50</sub>) – LogD.</p></div><div class="footnote" id="t2fn4"><sup><sup>d</sup></sup><p class="last">Human liver microsome metabolic CL<sub>int</sub> in μL/min/mg protein.</p></div><div class="footnote" id="t2fn5"><sup><sup>e</sup></sup><p class="last">Human liver microsome glucuronidation CL<sub>int</sub> in μL/min/mg.</p></div><div class="footnote" id="t2fn6"><sup><sup>f</sup></sup><p class="last">Human hepatocyte CL<sub>int</sub> in μL/min/million cells.</p></div><div class="footnote" id="t2fn7"><sup><sup>g</sup></sup><p class="last">Apparent permeability (×10<sup>–6</sup> cm s<sup>–1</sup>) measured with low efflux MDCKII cell line (RRCK). Data for LogD, HLM, HLMUGT, hHep, RRCK, P-gp, and BCRP were results from at least two replicate determinations.<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a> ND denotes not determined.</p></div></div></div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Summary of Lead Optimization and Associated in Vitro Data</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-1/acs.jmedchem.8b00280/20190107/images/medium/jm-2018-00280z_0017.gif" alt="" id="fx2" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-1/acs.jmedchem.8b00280/20190107/images/medium/jm-2018-00280z_0018.gif" alt="" id="fx3" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last">TrkA data were generated in PathHunter cells from DiscoveRx with at least three tests on three different assay runs.<a onclick="showRef(event, 'ref43 ref57'); return false;" href="javascript:void(0);" class="ref ref43 ref57">(43,57)</a></p></div><div class="footnote" id="t3fn2"><sup><sup>b</sup></sup><p class="last">LogD measured at pH 7.4.</p></div><div class="footnote" id="t3fn3"><sup><sup>c</sup></sup><p class="last">LipE = −Log(TrkA cell IC<sub>50</sub>) – LogD.</p></div><div class="footnote" id="t3fn4"><sup><sup>d</sup></sup><p class="last">Human liver microsome metabolic CL<sub>int</sub> in μL/min/mg protein.</p></div><div class="footnote" id="t3fn5"><sup><sup>e</sup></sup><p class="last">Human hepatocyte CL<sub>int</sub> in μL/min/million cells.</p></div><div class="footnote" id="t3fn6"><sup><sup>f</sup></sup><p class="last">Apparent permeability (×10<sup>–6</sup> cm s<sup>–1</sup>) measured with low efflux MDCKII cell line (RRCK). Data for LogD, HLM, hHep, RRCK, P-gp, and BCRP were results from at least two replicate determinations.<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a> ND denotes not determined.</p></div></div><div></div></div><div class="NLM_p">When F or methyl groups were introduced at R<sub>3</sub>, e.g., <b>12</b> and <b>13</b>, TrkA potency was 2–3-fold weaker than chloro derivative <b>11</b> with a marginally lower LipE (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Tables <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a> and <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>). Moreover, the methyl group in <b>13</b> carried a greater metabolic liability (HLM CL<sub>int</sub> 46 μL/min/mg protein, hHep 36 μL/min/million cells). Methoxy, difluoromethoxy, and cyclopropyl substituted compounds <b>14</b>–<b>16</b> were less potent than <b>11</b> at TrkA (up to 24-fold weaker), with up to a unit lower LipE, perhaps due to a combination of substituent size, dipole, and conformational effects. The CF<sub>3</sub> analogue <b>20</b> was potent at TrkA (TrkA cell IC<sub>50</sub> 0.03 μM) but was less LipE efficient (LipE 4.5) than the corresponding chloro derivative <b>18</b> (LipE 5.1). Introduction of R<sub>2</sub> = F in ligands <b>12</b> and <b>18</b> to give fluorinated compounds <b>17</b> and <b>19</b>, respectively, increased TrkA potency by ca. 3–4-fold and LipE by ca. 0.4–0.5 units. The F group may occupy part of the binding site highlighted in <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>C and also contribute to increasing the population of desired bioactive conformer in water. TrkA active compounds can also result from R<sub>2</sub> = Cl as exemplified by <b>8</b> and <b>9</b> (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). However, a comparison of ligands <b>7</b> and <b>8</b> (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>) reveals that the smaller F derivative <b>7</b> (TrkA cell IC<sub>50</sub> 0.074 μM, LipE 4.5) is more potent and LipE efficient than <b>8</b> (TrkA cell IC<sub>50</sub> 0.11 μM, LipE 4.2), which is consistent with the size of the binding site pocket occupied by R<sub>2</sub> in TrkA (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>C). The R<sub>1</sub> substituent had a vector toward the kinase exit and appeared to tolerate a range of substituents such as alcohols, amines, and heterocycles, e.g., <b>18</b>–<b>25</b> (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>). Secondary amides were generally more potent and LipE efficient than tertiary amides; e.g., 5-[[2-chloro-5-(2-pyridyl)benzoyl]amino]-<i>N</i>,<i>N</i>-dimethyl-1-phenyl-pyrazole-3-carboxamide, the dimethyl amide derivative of ligand <b>3</b> (−C(O)N(CH<sub>3</sub>)<sub>2</sub>, TrkA cell IC<sub>50</sub> 0.095 μM, LipE 4.6), was ca. 2-fold less potent and had a lower LipE than <b>3</b> (TrkA cell IC<sub>50</sub> 0.05 μM, LipE 5.0), possibly because the additional HBD in <b>3</b> interacts with the water network (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figures <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>B and <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a>B). Despite the R<sub>1</sub> substituent SAR being relatively tolerant, the key challenge was balancing the properties required for a clinical candidate consistent with a once or twice daily dosing regimen. In particular, potency (TrkA cell IC<sub>50</sub> < 15 nM), apparent permeability (RRCK P<sub>app</sub> > 5 × 10<sup>–6</sup> cm s<sup>–1</sup>),<a onclick="showRef(event, 'ref54 ref55'); return false;" href="javascript:void(0);" class="ref ref54 ref55">(54,55)</a> P-gp and BCRP efflux (ER > 2.5), and metabolic stability (hHep CL<sub>int</sub> ≤ 5 μL/min/million cells) were important parameters that needed to be balanced within certain ranges to predict with reasonable probability the desired dose and PK profile in humans, using physiologically based pharmacokinetic modeling.<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> For example, although amines such as <b>21</b> were potent TrkA inhibitors (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>), they often exhibited poor apparent permeability (RRCK P<sub>app</sub> 0.72 × 10<sup>–6</sup> cm s<sup>–1</sup>), which could limit oral absorption.<a onclick="showRef(event, 'ref54 ref55'); return false;" href="javascript:void(0);" class="ref ref54 ref55">(54,55)</a> Oxetane derivative <b>22</b> was a potent TrkA inhibitor (TrkA cell IC<sub>50</sub> 9.9 nM) but appeared to be chemically unstable at low pH ≤ 2, which made clinical development more complicated (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>). The oxetane instability was postulated to involve ring opening of the protonated oxetane. The primary alcohols <b>18</b>–<b>19</b> appeared promising as they met the desired potency, apparent permeability, and P-gp and BCRP efflux substrate profile, although the metabolic stability in hHep was still moderate (hHep CL<sub>int</sub> ≈ 10 μL/min/million cells). Several known metabolic pathways for primary alcohols such as <b>18</b>–<b>19</b> involve oxidation or conjugation of the alcohol moiety. In order to reduce metabolism involving the primary alcohol, tertiary alcohols <b>23</b>–<b>25</b> were prepared. Alcohols <b>23</b>–<b>24</b> exhibited higher metabolic stability in hHep (hHep CL<sub>int</sub> = 3–5 μL/min/million cells) than <b>18</b>–<b>19</b> (hHep CL<sub>int</sub> ≈ 10 μL/min/million cells) despite being more lipophilic than <b>18</b>–<b>19</b> (δLogD + 0.5). This suggested that a major metabolism pathway for <b>18</b>–<b>19</b> involved the primary alcohol group, and this pathway can be successfully attenuated by introduction of the gem-dimethyl group.<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a> Ligands <b>23</b> and <b>24</b> met the desired criteria for potency (TrkA cell IC<sub>50</sub> = 10 and 4.7 nM), permeability (RRCK P<sub>app</sub> = 16 and 12 × 10<sup>–6</sup> cm s<sup>–1</sup>), P-gp (ER = 28 and 23) and BCRP (ER = 103 and 69) efflux, and metabolic stability (hHep CL<sub>int</sub> = 4.7 and 3.7 μL/min/10<sup>6</sup> cells), respectively. Assuming CL is predicted accurately from metabolism in hHep, systemic CL of <b>23</b> and <b>24</b> in human is predicted to be 0.59 and 0.74 mL/min/kg, respectively, resulting in predicted human PK half-lives of approximately 30 h in both cases. Moreover, oral/i.v. PK studies in rats indicated that both compounds possess sufficient permeability in the intestine to achieve adequate absorption via the oral route, in spite of the presence of active efflux, as oral bioavailability was 72 and 46% for <b>23</b> and <b>24</b>, respectively (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). Moreover, both compounds displayed marked peripheral restriction that was likely to be the result of efflux via P-gp and/or BCRP at the BBB because of the much lower unbound systemic exposure of the compounds than prevails in the gut lumen following oral administration (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). Compound <b>23</b> was progressed in preference to <b>24</b> due to its slightly higher oral bioavailability in rat and a more favorable CYP induction profile in vitro (data not shown).<a onclick="showRef(event, 'ref60'); return false;" href="javascript:void(0);" class="ref ref60">(60)</a></div><div class="NLM_p"><a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a> shows a 1.94 Å cocrystal structure of <b>23</b> with TrkA protein. The pyridyl N forms a hydrogen bond with NH Asp668 as seen with lead molecule <b>3</b> (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>). The 2,4-dichloro aryl unit occupies the lipophilic pocket identified in <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a> using the 4-Cl group, with the dihedral angle between the pyridyl-aryl groups being 45.8°. The terminal amide C═O interacts with the side chain of Arg673 along with some of the structural waters (two waters shown in <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>) and forms part of the water network. The tertiary alcohol also interacts with water as it approaches regions that are more solvent exposed.</div><figure id="fig9" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-1/acs.jmedchem.8b00280/20190107/images/medium/jm-2018-00280z_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-1/acs.jmedchem.8b00280/20190107/images/large/jm-2018-00280z_0009.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. (A) Cocrystal structure of candidate molecule <b>23</b> bound to TrkA protein highlighting key protein–ligand interactions with white dashed lines with distances given in Å. (B) Cocrystal structure of candidate molecule <b>23</b> bound to TrkA protein highlighting interactions with Arg673 and waters with white dashed lines. Parts of TrkA protein omitted for clarity.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-1/acs.jmedchem.8b00280/20190107/images/large/jm-2018-00280z_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00280&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Compound <b>23</b> was 180-fold selective over TrkB and 70-fold selective over TrkC in cell based assays (TrkB cell IC<sub>50</sub> 1.8 μM, TrkC cell IC<sub>50</sub> 0.70 μM).<a onclick="showRef(event, 'ref41 ref43 ref57'); return false;" href="javascript:void(0);" class="ref ref41 ref43 ref57">(41,43,57)</a> Ligand <b>23</b> was screened for kinase selectivity in 392 biochemical kinase assays (including TrkA) from Invitrogen at a concentration of 10 μM (see <a href="/doi/suppl/10.1021/acs.jmedchem.8b00280/suppl_file/jm8b00280_si_001.pdf" class="ext-link">Supporting Information</a>). Pleasingly, <b>23</b> exhibited exquisite TrkA selectivity with >95% inhibition of TrkA and <15% inhibition of all other kinases observed.<a onclick="showRef(event, 'ref51 ref61'); return false;" href="javascript:void(0);" class="ref ref51 ref61">(51,61)</a> Furthermore, wide ligand profiling in 84 target assays at Cerep at 10 μM concentration to assess off-target based liabilities indicated a clean profile (no hits with inhibition >40% at 10 μM and only two hits having 30–40% inhibition at 10 μM). Ligand <b>23</b> was studied via SPR using nonactivated unphosphorylated TrkA protein and exhibited fast association and dissociation kinetics (<i>K</i><sub>a</sub> = 8.2 × 10<sup>6</sup> M<sup>–1</sup> s<sup>–1</sup>; <i>K</i><sub>d</sub> = 0.03 s<sup>–1</sup>) with <i>K</i><sub>D</sub> = 4.2 nM giving a residence time of 0.48 min. Compound <b>23</b> was also screened in nonactivated TrkA and activated phosphorylated TrkA biochemical enzyme assays where it exhibited 18-fold selectivity for the nonactivated TrkA construct (TrkA nonactivated enzyme IC<sub>50</sub> 4 nM, TrkA activated enzyme IC<sub>50</sub> 74 nM).<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> These data were consistent with those generated for lead molecule <b>3</b>. In fact, retrospective analysis of TrkA cell IC<sub>50</sub> data compared with nonactivated and activated phosphorylated TrkA biochemical enzyme assays indicated that for allosteric ligands the potency in the TrkA cell aligned well with that in the nonactivated TrkA enzyme assay but displayed a rightward shift of up to 15-fold in the activated phosphorylated TrkA enzyme assay (see <a href="/doi/suppl/10.1021/acs.jmedchem.8b00280/suppl_file/jm8b00280_si_001.pdf" class="ext-link">Supporting Information</a>).<a onclick="showRef(event, 'ref41 ref43 ref57'); return false;" href="javascript:void(0);" class="ref ref41 ref43 ref57">(41,43,57)</a> Genetoxicity assays such as IVMN indicated <b>23</b> had a clean profile suitable for advancement.</div><div class="NLM_p">Compound <b>23</b> was shown to inhibit NGF induced phosphorylated ERK formation in native adult rat DRGs with an IC<sub>50</sub> ≈ 57 nM and abolished sensitization to capsaicin administration to NGF-sensitized skin as demonstrated by laser Doppler imaging in vivo in anesthetized rat. For comparison the rat nonactivated enzyme IC<sub>50</sub> was 6 nM (see <a href="/doi/suppl/10.1021/acs.jmedchem.8b00280/suppl_file/jm8b00280_si_001.pdf" class="ext-link">Supporting Information</a>).</div><div class="NLM_p">Moreover, <b>23</b> was studied in the UVIH model of inflammatory pain in rats whereby its effect on thermal hyperalgesia resulting from UV burn was assessed by measuring paw withdrawal latency (<a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">10</a></a>). Single oral doses of <b>23</b> (1.2, 12, and 40 mg/kg) were administered 48 h after UV treatment and paw withdrawal latency determined at 1, 3, and 6 h post-dose. Hyperalgesia was found to be significantly reversed at doses of <b>23</b> of 12 and 40 mg/kg at each of the time-points studied (<i>p</i> < 0.01, two-way ANOVA vs vehicle). The positive control ibuprofen (100 mg/kg, p.o.) also reversed thermal hyperalgesia at the 1 and 3 h time-points. No effect was seen with any dose on thermal withdrawal response on the contralateral hindpaw (data not shown). Determination of unbound plasma concentrations of <b>23</b> in animals at 6 h post-dose showed that statistically significant efficacy was observed at unbound plasma concentrations equivalent to 0.4× (12 mg/kg) and 2.7× (40 mg/kg) TrkA cell IC<sub>50</sub> (10 nM).</div><figure id="fig11" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-1/acs.jmedchem.8b00280/20190107/images/medium/jm-2018-00280z_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-1/acs.jmedchem.8b00280/20190107/images/large/jm-2018-00280z_0011.jpeg" id="gr15" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Effect of <b>23</b> compared with vehicle and ibuprofen on UV induced hyperalgesia in rat, with ipsilateral paw data shown, <i>n</i> = 8 rats per dose group. ***<i>p</i> < 0.001, **<i>p</i> < 0.01, two-way ANOVA vs vehicle.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-1/acs.jmedchem.8b00280/20190107/images/large/jm-2018-00280z_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00280&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Ligand <b>23</b> was progressed to 4-week toxicity studies in rat where a maximum free concentration of 230× TrkA cell IC<sub>50</sub> and average free concentration of 90× TrkA cell IC<sub>50</sub> was achieved. It was found to be excluded from the CNS such that unbound exposure in the brain was <5% of plasma exposure, and no evidence of expression of CNS pharmacology was observed in EEG measurements (CE-245677 used as control). Moreover, no adverse behavioral effects were observed. Based on the favorable potency, TrkB/C selectivity and overall off-target selectivity profile, peripheral restriction, absorption, human PK predictions, and toxicity profile, Type III allosteric ligand <b>23</b> was nominated as a candidate for progression for the treatment of pain.</div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i11">Chemistry</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_57446" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_57446" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">A typical synthetic route toward amino containing derivatives such as <b>3</b> and <b>9</b>–<b>10</b> is described in <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a> and exemplified by the preparation of lead molecule <b>3</b>. Cyanopyrazole intermediate <b>26</b> was synthesized from the phenyldiazonium tetrafluoroborate by reaction with a dicyanoester followed by cyclization under basic conditions. Following amide coupling and Suzuki coupling with the bromoaminopyridine to form <b>28</b>, the cyanide was hydrolyzed to give the primary carboxamide <b>3</b>. It proved optimal to convert the nitrile through to the primary carboxamide at the end of the sequence as the presence of the carboxamide conferred a lack of solubility on intermediates in the sequence.</div><div class="NLM_p">The desamino derivatives <b>12</b>–<b>25</b> were all prepared using a key iridium-mediated borylation step (<a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>). In the case of candidate molecule <b>23</b>, this synthetic route could be used to access >500 g of intermediate <b>36</b>, which gave >300 g of final compound <b>23</b>. The iridium mediated borylation of the methyl 2,4-dichlorobenzoate <b>30</b> occurred with complete regioselectivity setting up the Suzuki coupling with 2-bromopyridine to form <b>32</b>. After hydrolysis of the ester, T3P coupling gave the pyrazole ester <b>35</b>. This was then hydrolyzed and coupled with the amino alcohol to give <b>23</b> using TPTU (<i>O</i>-(2-oxo-1(2<i>H</i>)pyridyl)-<i>N</i>,<i>N</i>,<i>N</i>′,<i>N</i>′-tetramethyluronium tetrafluoroborate). This last step initially proved challenging, but screening of amide coupling conditions identified TPTU, which proved to be very effective for a range of challenging couplings on the program. The pyrazole piece <b>34</b> was prepared as shown in <a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>.</div><figure id="sch3" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-1/acs.jmedchem.8b00280/20190107/images/medium/jm-2018-00280z_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-1/acs.jmedchem.8b00280/20190107/images/large/jm-2018-00280z_0014.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Scalable Synthesis Route Used To Prepare Candidate Molecule <b>23</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-1/acs.jmedchem.8b00280/20190107/images/large/jm-2018-00280z_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00280&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) MeOH, H<sub>2</sub>SO<sub>4,</sub> reflux, 98%; (ii) (Bpin)<sub>2,</sub> [Ir(cod)OMe]<sub>2,</sub>THF, reflux, 1–7 h; (iii) Pd(PPh<sub>3</sub>)<sub>4</sub>, K<sub>2</sub>CO<sub>3,</sub> H<sub>2</sub>O, THF, reflux, 2 h; (iv) NaOH, IMS or THF, 25 °C, 1 h (84% over three steps); (v) T<sub>3</sub>P, DIPEA, 2-Me-THF, 77%; (vi) NaOH, IMS, 25 °C, 1 h, 70%; (vii) DIPEA, DMF, rt, 2 h, 75%.</p></p></figure><figure id="sch4" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-1/acs.jmedchem.8b00280/20190107/images/medium/jm-2018-00280z_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-1/acs.jmedchem.8b00280/20190107/images/large/jm-2018-00280z_0015.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of Key Pyrazole Intermediate <b>34</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-1/acs.jmedchem.8b00280/20190107/images/large/jm-2018-00280z_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00280&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) EtOK, Et<sub>2</sub>O, EtOH, CH<sub>3</sub>CN, 0 °C to rt, 84%; (ii) PhNHNH<sub>2</sub>, EtOH, reflux, 34%.</p></p></figure></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i14">Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_58172" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_58172" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">There is significant interest in the development of small molecule modulators of TrkA for the treatment of pain based on the role for NGF in the pathogenesis of inflammatory pain and the clinical efficacy realized by NGF neutralizing antibodies. However, achieving TrkA subtype selectivity over TrkB and TrkC to support an improved safety profile is extremely challenging due to the high similarity of these kinases in the ATP binding site. Compound <b>23</b> has been discovered as a TrkA selective agent over TrkB and TrkC, through exploitation of an allosteric pocket located behind the ATP binding site. The origin of TrkA selectivity is thought to be the interactions with the JM domain, which makes up part of this pocket since the JM domain is less conserved across the Trks. The allosteric hit molecule <b>2</b> was optimized to lead molecule <b>3</b> using SBDD especially crystallographic water analysis. However, <b>3</b> underwent intestinal metabolism such that poor human PK was predicted. PK properties were improved dramatically by removal of the amino group in <b>3</b>, although potency and LipE suffered due to loss of a hydrogen bond with Asp668. In order to buy back potency and LipE, SBDD and particularly docking analysis and conformational considerations were applied. Furthermore, a peripherally restricted agent was required due to safety concerns around Trk target engagement in the CNS. The required balance of peripheral restriction and acceptable oral absorption was achieved by introducing P-gp and BCRP efflux transporter activity against a background of good apparent passive permeability. The considerations above led to the optimization of lead molecule <b>3</b> to candidate molecule <b>23</b>. Candidate <b>23</b> is an allosteric Type III binder, which is potent, selective over TrkB/C, has exquisite selectivity over the kinome and in wide ligand screening panels, and is efficacious in preclinical pain models. Moreover, <b>23</b> retained good oral absorption combined with extensive peripheral restriction, and a clean in vivo toxicity profile consistent with the exceptional in vitro selectivity of <b>23</b>. To this end, further data on the progression of allosteric TrkA selective ligand <b>23</b> will be reported in due course.</div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i15">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_44842" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_44842" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> General</h3><div class="NLM_p">Starting materials and other reagents were purchased from commercial suppliers and were used without further purification unless otherwise indicated. All reactions were performed under a positive pressure of nitrogen or argon or with a drying tube at ambient temperature (unless otherwise stated) in anhydrous solvents, unless otherwise indicated. Analytical thin-layer chromatography (TLC) was performed on glass-backed silica gel 60_F 254 plates (Analtech (0.25 mm)) and eluted with the appropriate solvent ratios (v/v). The reactions were assayed by high performance liquid chromatography (HPLC) or TLC and terminated as judged by the consumption of starting material. The TLC plates were visualized by phosphomolybdic acid stain or iodine stain. Microwave assisted reactions were run in a Biotage initiator. <sup>1</sup>H NMR spectra were recorded on a Bruker instrument operating at 400 MHz, unless otherwise indicated. <sup>1</sup>H NMR spectra are obtained as DMSO-<i>d</i><sub>6</sub> or CDCl<sub>3</sub> solutions as indicated (reported in ppm), using chloroform as the reference standard (7.25 ppm) or DMSO-<i>d</i><sub>6</sub> (2.50 ppm). Other NMR solvents were used as needed. When peak multiplicities are reported, the following abbreviations are used: s = singlet, d = doublet, t = triplet, m = multiplet, br = broadened, dd = doublet of doublets, dt = doublet of triplets. Coupling constants, when given, are reported in hertz. Mass spectral data were obtained using Waters ZQ ESCI or Applied Biosystem’s API-2000 using either electrospray ionization or atmospheric pressure chemical ionization (APCI). High-resolution mass measurements were carried out on an Agilent TOF 6200 series with ESI. Where reverse phase column chromatography has been used, either acidic or basic conditions were employed using a Biotage SNAP KP-C18 silica cartridge. Acidic conditions: between 0 and 100% of acetonitrile (with 0.1% formic acid) in water (with 0.1% formic acid). Basic conditions: between 0 and 100% of acetonitrile (with 0.1% ammonia) in water (with 0.1% ammonia, 33% aqueous ammonia used). Where preparative HPLC has been used, one of the following methods was employed. Preparative HPLC using acid: Column, Gemini 5u C18 110A 100 × 21.2 mm 5 μm; Mobile phase A, water; mobile phase B, acetonitrile; modifier, 0.1% formic acid, rt; 10 min run time; initial, 95% A, 5% B to 5% A and 95% B at 7 min, hold time 2 min, then back to 95% A, 5% B at 9.1 min. Flow rate 18 mL/min. Preparative HPLC using base: Column, Gemini 5u C18 110A 100 × 21.2 mm 5 μm; mobile phase A: water; mobile phase B: acetonitrile; modifier, 0.1% diethylamine, rt; 10 min run time; initial, 95% A, 5% B to 5% A and 95% B at 7 min, hold time 2 min, then back to 95% A, 5% B at 9.1 min. Flow rate 18 mL/min. Detectors ELSD, Polymer laboratories PL-ELS 2100; UV, Waters 2487 detector at 225 and 255 nm; Mass spectrometer, Waters ZQ using electrospray ionization. Where LCMS was employed, LCMS Agilent 1100 with column XBridge analytical C18 5um 4.6 × 50 mm was used with one of the four following conditions at 25 °C. System 1: Mobile phase A1, 0.05% formic acid in water; Mobile phase B1, 0.05% formic acid in acetonitrile. System 2: mobile phase A2, 10 mmol ammonia formate in water; Mobile phase B2, acetonitrile. System 3: Mobile phase A, water; mobile phase B, acetonitrile; Mobile phase C, 10 mmol ammonia formate in water; mobile phase D, 0.05% formic acid in acetonitrile. System 4: mobile phase A, water; mobile phase B, acetonitrile; mobile phase C, 10 mmol ammonium formate in water; mobile phase D, 0.05% formic acid in acetonitrile. The chemical yields reported below are unoptimized specific examples of one preparation. Purity criteria: Final compounds isolated as singletons >95% based on LCMS, HPLC, and/or <sup>1</sup>H NMR. The experimental procedures for all of the steps in the synthesis of all target compounds can be found in Pfizer patent applications WO2015159175 and WO2015170218.</div><div class="NLM_p last">The final synthetic step and characterization details toward the majority of compounds is provided in this Article with the remaining chemistry procedures and characterizations being detailed in the <a href="/doi/suppl/10.1021/acs.jmedchem.8b00280/suppl_file/jm8b00280_si_001.pdf" class="ext-link">Supporting Information</a>.</div></div><div id="sec5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> 5-(5-(6-Aminopyridin-2-yl)-2-chlorobenzamido)-1-phenyl-1<i>H</i>-pyrazole-3-carboxamide (<b>3</b>)</h3><div class="NLM_p last">To a solution of 5-(6-aminopyridin-2-yl)-2-chloro-<i>N</i>-(3-cyano-1-phenyl-1<i>H</i>-pyrazol-5-yl)benzamide (<b>28</b>, 90 mg, 0.22 mmol) in dimethyl sulfoxide (2.5 mL) was added potassium carbonate (60 mg, 0.44 mmol) followed by a 30% aqueous hydrogen peroxide solution (500 μL, 4.34 mmol), and the reaction was stirred at room temperature for 1 h. The reaction was diluted with ethyl acetate (65 mL) and washed with brine. The organic layer was dried over magnesium sulfate and concentrated <i>in vacuo</i>. The residue was purified using reverse phase column chromatography eluting with 0–60% acetonitrile in water to afford the title compound (28 mg, 30%). LCMS <i>m</i>/<i>z</i> 433 [M + H]<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, acetone-<i>d</i><sub>6</sub>): δ ppm 5.58 (br s, 1H), 6.58 (m, 2H), 7.13 (m, 1H), 7.23 (br s, 1H), 7.40–7.60 (m, 5H), 7.67 (m, 2H), 8.07 (d, 1H), 8.22 (s, 1H), 9.75 (br s, 1H).</div></div><div id="sec5_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> 5-(5-(6-Acetamidopyridin-2-yl)-2-chlorobenzamido)-1-phenyl-1<i>H</i>-pyrazole-3-carboxamide (<b>4</b>)</h3><div class="NLM_p last">To a solution of 5-(6-acetamidopyridin-2-yl)-2-chloro-<i>N</i>-(3-cyano-1-phenyl-1<i>H</i>-pyrazol-5-yl)benzamide (<b>41</b>, 100 mg, 0.22 mmol) in dimethyl sulfoxide (3 mL) was added potassium carbonate (60 mg, 0.44 mmol) followed by hydrogen peroxide (30% w/w solution in water, 441 μL, 4.4 mmol), and the reaction was stirred at room temperature for 2.5 h. Additional hydrogen peroxide was added (882 μL, 8.8 mmol), and the reaction was stirred for 1 h. The reaction was diluted with water (5 mL) then neutralized with 2 M aqueous hydrochloric acid and extracted into ethyl acetate (3 × 10 mL). The combined organic extracts were dried over magnesium sulfate and concentrated <i>in vacuo</i>. The residue was purified by silica gel column chromatography eluting with 80% ethyl acetate in heptanes to furnish the title compound as a colorless solid (65 mg, 62%). <sup>1</sup>H NMR (400 MHz, acetone-<i>d</i><sub>6</sub>) δ 2.19 (s, 3H), 6.55 (s, 1H), 7.27–7.68 (m, 7H), 7.83 (t, <i>J</i> = 8.0 Hz, 1H), 8.08 (d, <i>J</i> = 9.1 Hz, 1H), 8.16 (d, <i>J</i> = 8.3 Hz, 1H), 8.22 (s, 1H), 9.65 (s, 1H), 9.76 (s, 1H). LCMS <i>R</i><sub>t</sub> = 2.64 min MS <i>m</i>/<i>z</i> 475 [M + H]<sup>+</sup>.</div></div><div id="sec5_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> 6-(3-((3-Carbamoyl-1-phenyl-1<i>H</i>-pyrazol-5-yl)carbamoyl)-4-chlorophenyl)picolinamide (<b>5</b>)</h3><div class="NLM_p last">6-(4-Chloro-3-((3-cyano-1-phenyl-1<i>H</i>-pyrazol-5-yl)carbamoyl)phenyl)picolinamide (<b>42</b>, 110 mg, 0.248 mmol) was dissolved in dimethyl sulfoxide (3 mL). Potassium carbonate (69 mg, 0.497 mmol) was added, and while stirring, 35% aqueous hydrogen peroxide (0.97 mL, 9.93 mmol) was added dropwise over a few minutes. After 30 min, LCMS indicated complete conversion to desired product. The reaction was quenched by adding an aqueous solution of sodium hydrogen sulfate (20 mL), and the precipitate was filtered off. This was processed by autopurification, which returned the crude product as an off white solid. The compound was slurried in DCM (1 mL) for 0.5 h and then filtered, washed with DCM (1 mL), and pulled dry on the filter to yield 6-(3-((3-carbamoyl-1-phenyl-1<i>H</i>-pyrazol-5-yl)carbamoyl)-4-chlorophenyl)picolinamide as a cream powder (8.8 mg, 8%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ ppm 6.97 (s, 1H), 7.38 (br s, 1H), 7.46 (m, 1H), 7.54 (dd, <i>J</i> = 8.6, 6.8 Hz, 2H), 7.61–7.75 (m, 4H), 7.81 (br s, 1H), 8.03 (d, <i>J</i> = 7.5 Hz, 1H), 8.11 (t, <i>J</i> = 7.8 Hz, 1H), 8.24 (d, <i>J</i> = 7.9 Hz, 1H), 8.37–8.48 (m, 2H), 8.53 (d, <i>J</i> = 2.2 Hz, 1H), 10.80 (s, 1H). LCMS <i>R</i><sub>t</sub> = 2.47 min MS <i>m</i>/<i>z</i> 461 [M + H]<sup>+</sup>.</div></div><div id="sec5_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> 5-(2-Chloro-5-(3-fluoropyridin-2-yl)benzamido)-1-phenyl-1<i>H</i>-pyrazole-3-carboxamide (<b>7</b>)</h3><div class="NLM_p last">To a solution of 2-chloro-<i>N</i>-(3-cyano-1-phenyl-1<i>H</i>-pyrazol-5-yl)-5-(3-fluoropyridin-2-yl)benzamide (<b>43</b>, 100 mg, 0.24 mmol) in DMSO (3 mL) were added K<sub>2</sub>CO<sub>3</sub> (66 mg, 0.48 mmol) and H<sub>2</sub>O<sub>2</sub> (30% aqueous solution, 1.5 mL), and the reaction was stirred at room temperature for 18 h. The reaction was diluted with water (1 mL), and 2 M aqueous HCl (3 mL) was added, resulting in precipitation of a white solid. The solid was filtered, washed with water, and dried to afford the title compound as a colorless solid (52.8 mg, 51%). <sup>1</sup>H NMR (400 MHz, MeOH-<i>d</i><sub>4</sub>): δ ppm 7.04 (s, 1H), 7.45–7.66 (m, 7H), 7.70–7.76 (m, 1H), 8.02–8.06 (m, 2H), 8.50–8.54 (m, 1H). LCMS <i>R</i><sub>t</sub> = 4.5 min MS <i>m</i>/<i>z</i> 436 [M + H]<sup>+</sup>.</div></div><div id="sec5_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> 5-(2-Chloro-5-(3-chloropyridin-2-yl)benzamido)-1-phenyl-1<i>H</i>-pyrazole-3-carboxamide (<b>8</b>)</h3><div class="NLM_p last">Prepared according to the method described for <b>4</b> using 2-chloro-5-(3-chloropyridin-2-yl)-<i>N</i>-(3-cyano-1-phenyl-1<i>H</i>-pyrazol-5-yl)benzamide (<b>44</b>). Purification via silica gel column chromatography eluting with 50–100% EtOAc in heptanes followed by trituration with 16% DCM in pentane. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ ppm 5.44 (bs, 1H), 6.80 (bs, 1H), 7.29 (dd, <i>J</i> = 8.1, 4.7 Hz, 1H), 7.37 (s, 1H), 7.46–7.58 (m, 5H), 7.82 (m, 2H), 8.24 (d, <i>J</i> = 2.3 Hz, 1H), 8.46 (s, 1H), 8.58 (dd, <i>J</i> = 4.6, 1.5 Hz, 1H). LCMS <i>R</i><sub>t</sub> = 2.90 min MS <i>m</i>/<i>z</i> 452 [M + H]<sup>+</sup>.</div></div><div id="sec5_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> 5-(5-(6-Amino-3-chloropyridin-2-yl)-2-chlorobenzamido)-1-phenyl-1<i>H</i>-pyrazole-3-carboxamide (<b>9</b>)</h3><div class="NLM_p last">To a solution of 5-(2-chloro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamido)-1-phenyl-1<i>H</i>-pyrazole-3-carboxamide (<b>45</b>, 222 mg, 0.48 mmol) in dioxane (5 mL) were added potassium carbonate (131 mg, 0.95 mmol), 6-bromo-5-chloropyridin-2-amine (129 mg, 0.62 mmol), and water (3 mL). The reaction was degassed followed by the addition of Pd(dppf)Cl<sub>2</sub> (19 mg, 0.02 mmol) and heated to reflux for 18 h. The reaction mixture was cooled and concentrated <i>in vacuo</i>. The residue was partitioned between ethyl acetate (20 mL) and brine (20 mL). The aqueous layer was extracted with ethyl acetate, and the organic layers were combined, dried over sodium sulfate, and concentrated <i>in vacuo</i>. The residue was purified using silica gel column chromatography eluting with 50–100% EtOAc in heptanes 1:1 followed by 5% MeOH in EtOAc. Final purification using preparative HPLC gave the title compound as a white solid (6 mg, 3%). <sup>1</sup>H NMR (400 MHz, MeOH-<i>d</i><sub>4</sub>): δ ppm 6.59 (d, 1H), 7.02 (s, 1H), 7.50–7.60 (m, 5H), 7.61–7.69 (m, 2H), 7.77–7.82 (m, 2H). LCMS <i>R</i><sub>t</sub> = 2.70 min MS <i>m</i>/<i>z</i> 467 [M + H]<sup>+</sup>.</div></div><div id="sec5_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> 5-(5-(6-Aminopyridin-2-yl)-2,4-dichlorobenzamido)-1-phenyl-1<i>H</i>-pyrazole-3-carboxamide (<b>10</b>)</h3><div class="NLM_p last">Ethyl 5-(5-(6-aminopyridin-2-yl)-2,4-dichlorobenzamido)-1-phenyl-1<i>H</i>-pyrazole-3-carboxylate (<b>47</b>, 43 mg, 0.086 mmol) was dissolved in MeOH (1 mL) and NH<sub>4</sub>OH solution (3 mL), and the reaction was heated at 50 °C for 9 h. The reaction was cooled to room temperature and concentrated <i>in vacuo</i>. The residue was purified by reverse phase column chromatography eluting with 5–50% MeCN in water (0.1% NH<sub>3</sub>) to afford the title compound (15 mg, 37%). <sup>1</sup>H NMR (400 MHz, MeOH-<i>d</i><sub>4</sub>): δ ppm 6.62 (d, <i>J</i> = 8.01 Hz 1H), 6.80 (d, <i>J</i> = 7.3 Hz, 1H), 7.02 (s, 1H), 7.47–7.66 (m, 8H). LCMS <i>R</i><sub>t</sub> = 2.35 min MS <i>m</i>/<i>z</i> 467 [M + H]<sup>+</sup>.</div></div><div id="sec5_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> 5-(2,4-Dichloro-5-(pyridin-2-yl)benzamido)-1-phenyl-1<i>H</i>-pyrazole-3-carboxamide (<b>11</b>)</h3><div class="NLM_p last">To a solution of ethyl 5-(2,4-dichloro-5-(pyridin-2-yl)benzamido)-1-phenyl-1<i>H</i>-pyrazole-3-carboxylate (<b>35</b>, 120 mg, 0.249 mmol) in MeOH (2 mL) was added 880 NH<sub>3</sub> (4 mL) in a Reactivial, and the reaction was heated at 50 °C for 16 h. The reaction was concentrated <i>in vacuo</i>, and the resulting solid was washed with water and dried to afford the title compound (68 mg, 60%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ ppm 6.90 (s, 1H), 7.37 (m, 1H), 7.44–7.74 (m, 9H), 7.88 (s, 1H), 7.96 (t, <i>J</i> = 7.8 Hz, 1H), 8.73 (d, <i>J</i> = 3.7 Hz, 1H), 10.70 (br s, 1H). LCMS <i>R</i><sub>t</sub> = 2.66 min MS <i>m</i>/<i>z</i> 452 [M + H]<sup>+</sup>.</div></div><div id="sec5_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> 5-(2-Chloro-4-fluoro-5-(pyridin-2-yl)benzamido)-1-phenyl-1<i>H</i>-pyrazole-3-carboxamide (<b>12</b>)</h3><div class="NLM_p last">To a solution of 2-chloro-<i>N</i>-(3-cyano-1-phenyl-1<i>H</i>-pyrazol-5-yl)-4-fluoro-5-(pyridin-2-yl)benzamide (<b>51</b>, 23.0 mg, 55 μmol) and potassium carbonate (15.0 mg, 110 μmol) in dimethyl sulfoxide (1 μL) was added hydrogen peroxide solution (125 μL, 1.10 mmol, 30 wt % in water), and the mixture was stirred at ambient temperature for 63 h. The mixture was diluted with ethyl acetate (10 mL), and the layers were separated. The aqueous layer was washed with ethyl acetate (10 mL). The combined organic layers were washed with water (10 mL) and brine (10 mL), dried over magnesium sulfate, and filtered, and the solvent was concentrated under reduced pressure. The crude material was purified by flash column chromatography (silica), eluting with ethyl acetate to afford the title compound as a colorless solid (10 mg, 44%). <sup>1</sup>H NMR (400 MHz, MeOH-<i>d</i><sub>4</sub>): δ ppm 7.02 (s, 1H), 7.61–7.45 (m, 8H), 7.81 (d, 1H), 7.94 (m, 1H), 8.05 (d, <i>J</i> = 8.1 Hz, 1H), 8.69 (d, <i>J</i> = 4.2 Hz, 1H). MS <i>m</i>/<i>z</i> 436 [M + H]<sup>+</sup> LCMS: <i>R</i><sub>t</sub> = 0.77 min, MS <i>m</i>/<i>z</i> 436 [MH]<sup>+</sup>.</div></div><div id="sec5_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> 5-(2-Chloro-4-methyl-5-(pyridin-2-yl)benzamido)-1-phenyl-1<i>H</i>-pyrazole-3-carboxamide (<b>13</b>)</h3><div class="NLM_p last">To a mixture of 2-chloro-<i>N</i>-(3-cyano-1-phenyl-1<i>H</i>-pyrazol-5-yl)-4-methyl-5-(pyridin-2-yl)benzamide (<b>55</b>, 109 mg, 0.26 mmol) and potassium carbonate (73.0 mg, 0.53 mmol) in dimethyl sulfoxide (10 mL) was added hydrogen peroxide solution (1.1 mL, 10.5 mmol, 30 w/w % in water). The reaction was stirred at ambient temperature for 20 h. Further portions of potassium carbonate (73.0 mg, 0.53 mmol) and hydrogen peroxide solution (0.20 mL, 1.91 mmol, 30 w/w % in water) were added to the reaction and stirred at ambient temperature for a further 2 h. The reaction was quenched with water (30 mL) and extracted with ethyl acetate (2 × 30 mL). The combined organic layers were dried over magnesium sulfate and filtered, and the solvent was removed under reduced pressure. The residue was redissolved in dichloromethane (10 mL) and washed with water (10 mL). The dichloromethane layer was loaded onto an SCX cartridge and eluted with MeOH followed by 7 N NH<sub>3</sub> in MeOH. This afforded the title compound as a colorless solid (64.5 mg, 57%). <sup>1</sup>H NMR (300 MHz, MeOH-<i>d</i><sub>4</sub>): δ ppm 2.30 (s, 3H), 6.99 (s, 1H), 7.43–7.50 (m, 7H), 7.59 (d, 2H), 7.95 (td, <i>J</i> = 7.8, 1.8 Hz, 1H), 8.63 (ddd, <i>J</i> = 5.1, 1.8, 1.0 Hz, 1H). LCMS <i>R</i><sub>t</sub> = 1.82 min MS <i>m</i>/<i>z</i> 432 [M + H]<sup>+</sup>.</div></div><div id="sec5_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> 5-(2-Chloro-4-methoxy-5-(pyridin-2-yl)benzamido)-1-phenyl-1<i>H</i>-pyrazole-3-carboxamide (<b>14</b>)</h3><div class="NLM_p last">To a solution of 2-chloro-<i>N</i>-(3-cyano-1-phenyl-1<i>H</i>-pyrazol-5-yl)-4-methoxy-5-(pyridin-2-yl)benzamide (<b>56</b>, 76 mg, 0.18 mmol) in DMSO (5 mL) was added potassium carbonate (49 mg, 0.35 mmol), and the mixture was vigorously stirred. Hydrogen peroxide (30% aqueous solution, 0.8 mL, 7.08 mmol) was added dropwise, and the reaction mixture was stirred vigorously at room temperature for 2 h. Further hydrogen peroxide (30% aqueous solution, 0.8 mL, 7.08 mmol) was added, and the reaction mixture was stirred vigorously at room temperature for a further 2 h. The reaction was quenched with water (20 mL), and the mixture was extracted with ethyl acetate (2 × 20 mL). The combined organic layers were washed with water (2 × 40 mL), brine (40 mL), dried (magnesium sulfate), filtered, and concentrated under reduced pressure. The crude was purified by trituation in <i>tert</i>-butyl methyl ether, and the solid was collected by filtration and dried under reduced pressure to give the title compound as a colorless solid (48 mg, 61%). <sup>1</sup>H NMR (400 MHz, MeOH-<i>d</i><sub>4</sub>): δ ppm 3.91 (s, 3H), 7.01 (s, 1H), 7.24 (s, 1H), 7.37–7.40 (m, 1H), 7.46–7.48 (m, 1H), 7.51–7.54 (m, 2H), 7.63 (d, <i>J</i> = 7.7. Hz, 2H), 7.80–7.88 (m, 3H), 8.62 (d, <i>J</i> = 4.9 Hz, 1H). LCMS <i>R</i><sub>t</sub> = 2.23 min MS <i>m</i>/<i>z</i> 448 [M + H]<sup>+</sup>.</div></div><div id="sec5_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> 5-{[2-Chloro-4-(difluoromethoxy)-5-(pyridin-2-yl)benzoyl]amino-1-phenyl-1<i>H</i>-pyrazole-3-carboxamide (<b>15</b>)</h3><div class="NLM_p last">To a solution of 2-chloro-<i>N</i>-(3-cyano-1-phenyl-1<i>H</i>-pyrazol-5-yl)-4-(difluoromethoxy)-5-(pyridin-2-yl)benzamide (<b>60</b>, 88 mg, 0.19 mmol) in DMSO (2 mL) were added K<sub>2</sub>CO<sub>3</sub> (52 mg, 0.38 mmol) and hydrogen peroxide (50% aq. solution, 0.48 mL, 3.79 mmol), and the reaction was left to stir at room temperature for 4 h. To the vessel was added saturated KHSO<sub>4</sub> (2 mL) followed by water (11 mL) resulting in the precipitation of the product. The reaction was filtered and washed with water (3 mL), then pulled dry on the filter for 18 h to yield the title compound as a cream solid (55.3 mg, 60%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 6.89 (s, 1H), 7.19–7.67 (m, 9H), 7.62 (br s, 1H), 7.76 (d, <i>J</i> = 7.9 Hz, 1H), 7.91 (dd, <i>J</i> = 7.7, 1.9 Hz, 1H), 7.94 (d, <i>J</i> = 1.8 Hz, 1H), 8.67–8.78 (m, 1H), 10.76 (s, 1H). <sup>19</sup>F NMR (376 MHz, DMSO): δ −83.10. LCMS: <i>R</i><sub>t</sub> = 2.63 min, MS <i>m</i>/<i>z</i> 484 [M + H]<sup>+</sup>.</div></div><div id="sec5_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> 5-{[2-Chloro-4-cyclopropyl-5-(pyridin-2-yl)benzoyl]amino}-1-phenyl-1<i>H</i>-pyrazole-3-carboxamide (<b>16</b>)</h3><div class="NLM_p last">2-Chloro-<i>N</i>-(3-cyano-1-phenyl-1<i>H</i>-pyrazol-5-yl)-4-cyclopropyl-5-(pyridin-2-yl)benzamide (<b>66</b>, 135 mg, 0.31 mmol) was dissolved in DMSO (3 mL). Potassium carbonate (85 mg, 0.61 mmol) was added, followed by 30% H<sub>2</sub>O<sub>2</sub> (0.7 mL, 6.14 mmol). The reaction mixture was stirred at room temperature for 18 h. The reaction was diluted with EtOAc (50 mL) and washed with brine (3 × 25 mL), dried over sodium sulfate, and filtered, and the solvent was removed <i>in vacuo</i>. The crude material was purified by reverse phase chromatography (basic, 0.1% NH<sub>4</sub>OH), and then triturated in TBME to afford the pure title compound as a white solid (62 mg, 44%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 0.73 (dd, <i>J</i> = 5.2, 2.0 Hz, 2H), 0.88 (dd, <i>J</i> = 8.5, 2.2 Hz, 2H), 1.93–2.19 (m, 1H), 6.85 (s, 1H), 7.08 (s, 1H), 7.34 (s, 1H), 7.39–7.67 (m, 9H), 7.92 (d, <i>J</i> = 7.5 Hz, 1H), 8.70 (ddd, <i>J</i> = 4.8, 1.8, 0.9 Hz, 1H), 10.62 (s, 1H). LCMS <i>R</i><sub>t</sub> = 2.72 min, MS <i>m</i>/<i>z</i> 458.17 [M + H]<sup>+</sup>.</div></div><div id="sec5_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> 5-(2-Chloro-4-fluoro-5-(3-fluoropyridin-2-yl)benzamido)-1-phenyl-1<i>H</i>-pyrazole-3-carboxamide (<b>17</b>)</h3><div class="NLM_p last">To a solution of 2-chloro-<i>N</i>-(3-cyano-1-phenyl-1<i>H</i>-pyrazol-5-yl)-4-fluoro-5-(3-fluoropyridin-2-yl)benzamide (<b>68</b>, 89 mg, 0.20 mmol) in DMSO (5 mL) was added K<sub>2</sub>CO<sub>3</sub> (56 mg, 0.41 mmol), followed by H<sub>2</sub>O<sub>2</sub> (30% aqueous solution, 926 mg, 8.17 mmol). The reaction was stirred at room temperature for 3 h. The reaction was quenched by the addition of water (20 mL) and extracted into EtOAc (2 × 20 mL). The combined organic layers were washed with water (2 × 40 mL) and brine (40 mL), dried over magnesium sulfate, and concentrated <i>in vacuo</i>. The residue was purified using reverse phase column chromatography eluting from 5 to 45% MeCN (with 0.1% HCO<sub>2</sub>H) in water (with 0.1% HCO<sub>2</sub>H) to afford the title compound as a white solid (70 mg, 75%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ ppm 6.88 (s, 1H), 7.34 (s, 1H), 7.44 (dd, <i>J</i> = 8.4, 6.1 Hz, 1H), 7.51 (t, <i>J</i> = 7.7 Hz, 2H), 7.57–7.66 (m, 2H), 7.76 (dd, <i>J</i> = 10.9, 8.7 Hz, 2H), 7.91 (ddd, <i>J</i> = 9.9, 8.5, 1.3 Hz, 1H), 8.61 (d, <i>J</i> = 4.8 Hz, 1H), 10.78 (br s, 1H). LCMS <i>R</i><sub>t</sub> = 2.54 min, MS <i>m</i>/<i>z</i> 454 [M + H]<sup>+</sup>.</div></div><div id="sec5_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> 5-(2,4-Dichloro-5-(pyridin-2-yl)benzamido)-<i>N</i>-(2-hydroxyethyl)-1-phenyl-1<i>H</i>-pyrazole-3-carboxamide (<b>18</b>)</h3><div class="NLM_p last">Ethyl 5-(2,4-dichloro-5-(pyridin-2-yl)benzamido)-1-phenyl-1<i>H</i>-pyrazole-3-carboxylate (<b>35</b>, 300 mg, 0.62 mmol), 2-aminoethanol (144 mg, 2.36 mmol), and diisopropylethylamine (381 mg, 2.95 mmol) in methanol (2 mL) in a sealed reaction vial was heated at 50 °C for 17 h. On cooling, the reaction mixture was concentrated and purified by reverse phase column chromatography (30 g cartridge, 0.1% NH<sub>4</sub>OH additive, 3:97 to 50:50). <sup>1</sup>H NMR (400 MHz DMSO-<i>d</i><sub>6</sub>): δ ppm 3.29–3.36 (m, 2H), 3.47–3.52 (m, 2H), 4.74 (d, <i>J</i> = 5.6 Hz, 1H), 6.91 (s, 1H), 7.44–7.55 (m, 5H), 7.59–7.61 (m, 2H), 7.71 (d, <i>J</i> = 8.0 Hz, 1H), 7.74 (s, 1H), 7.88 (s, 1H), 7.96 (dt, <i>J</i> = 1.6, 7.6 Hz, 1H), 8.14 (t, <i>J</i> = 5.2 Hz, 1H), 8.74 (d, <i>J</i> = 4.4 Hz, 1H), 10.82 (s, 1H). LCMS: <i>R</i><sub>t</sub> = 2.64 min, 496 [M + H]<sup>+</sup>.</div></div><div id="sec5_17" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> 5-(2,4-Dichloro-5-(3-fluoropyridin-2-yl)benzamido)-<i>N</i>-(2-hydroxyethyl)-1-phenyl-1<i>H</i>-pyrazole-3-carboxamide (<b>19</b>)</h3><div class="NLM_p last">TPTU (2 g, 6.6 mmol) and 5-(2,4-dichloro-5-(3-fluoropyridin-2-yl)benzamido)-<i>N</i>-(2-hydroxyethyl)-1-phenyl-1<i>H</i>-pyrazole-3-carboxylic acid (<b>71</b>, 2 g, 4.4 mmol) were dissolved in DMF (10 mL) at 0 °C. DIPEA (2.36 mL, 13.2 mmol) was then added. The reaction mixture was stirred at 0 °C for 15 min. 2-Aminoethanol (366 mL, 6.6 mmol) was added, and the reaction mixture was stirred at room temperature for 18 h. The solvent was removed <i>in vacuo</i> to give a pale brown solid, which was triturated with MeOH/H<sub>2</sub>O (1:1, 100 mL) to give the title product as a white solid (1.34 g, 61%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 3.31 (q, <i>J</i> = 5.0 Hz, 2H), 3.48 (q, <i>J</i> = 6.1 Hz, 2H), 4.73 (t, <i>J</i> = 5.5 Hz, 1H), 6.90 (s, 1H), 7.40–7.67 (m, 6H), 7.76 (dd, <i>J</i> = 12.8, 8.7 Hz, 2H), 7.91 (ddd, <i>J</i> = 10.1, 8.5, 1.3 Hz, 1H), 8.13 (t, <i>J</i> = 5.8 Hz, 1H), 8.57–8.64 (m, 1H), 10.80 (s, 1H). LCMS <i>R</i><sub>t</sub> = 2.64 min, MS <i>m</i>/<i>z</i> 514 [M + H]<sup>+</sup>.</div></div><div id="sec5_18" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33"> 5-{[2-Chloro-5-(pyridin-2-yl)-4-(trifluoromethyl)benzoyl]amino}-<i>N</i>-(2-hydroxyethyl)-1-phenyl-1<i>H</i>-pyrazole-3-carboxamide (<b>20</b>)</h3><div class="NLM_p last">Ethyl 5-(2-chloro-5-(pyridin-2-yl)-4-(trifluoromethyl)benzamido)-1-phenyl-1<i>H</i>-pyrazole-3-carboxylate (<b>75</b> crude, 303 mg, 0.59 mmol), 2-aminoethanol (144 mg, 2.36 mmol), and diisopropylethylamine (381 mg, 2.95 mmol) in methanol (2 mL) in a sealed reaction vial was heated at 50 °C for 17 h. On cooling, the reaction mixture was concentrated and purified by reverse phase column chromatography (30 g cartridge, 0.1% NH<sub>4</sub>OH additive, 3:97 to 50:50). The material from this was further purified by trituration in acetonitrile to afford the title compound as a colorless solid (30 mg, 10%). <sup>1</sup>H NMR (CD<sub>3</sub>OD, 400 MHz): δ ppm 3.51 (t, <i>J</i> = 5.8 Hz, 2H), 3.70 (t, <i>J</i> = 5.8 Hz, 2H), 7.03 (s, 1H), 7.41–7.54 (m, 5H), 7.55–7.64 (m, 3H), 7.88–8.02 (m, 2H), 8.64 (dt, <i>J</i> = 4.5, 1.6 Hz, 1H). LCMS <i>R</i><sub>t</sub> = 2.55 min MS <i>m</i>/<i>z</i> 530 [M + H]<sup>+</sup>.</div></div><div id="sec5_19" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34"> <i>N</i>-(2-Aminoethyl)-5-(2,4-dichloro-5-(pyridin-2-yl)benzamido)-1-phenyl-1<i>H</i>-pyrazole-3-carboxamide (<b>21</b>)</h3><div class="NLM_p last">To a solution of 5-(2,4-dichloro-5-(pyridin-2-yl)benzamido)-1-phenyl-1<i>H</i>-pyrazole-3-carboxylic acid (<b>36</b>) (80 mg, 0.176 mmol) in THF (3 mL) was added Et<sub>3</sub>N (0.123 mL, 0.882 mmol), followed by <i>tert</i>-butyl(2-aminoethyl)carbamate (34 mg, 0.212 mmol) and HATU (100 mg, 0.265 mmol), and the reaction was allowed to stir at room temperature for 16 h. The reaction mixture was then diluted with 25 mL of EtOAc and washed with saturated sodium bicarbonate solution, water, and brine. The organic layer was dried over sodium sulfate and concentrated under reduced pressure. The crude reaction product was purified by preparative TLC (5% methanol in CH<sub>2</sub>Cl<sub>2</sub>) to afford 80 mg (76%) of <i>tert</i>-butyl-(2-(5-(2,4-dichloro-5-(pyridin-2-yl)benzamido)-1-phenyl-1<i>H</i>-pyrazole-3-carboxamido) ethyl) carbamate as off white solid. <sup>1</sup>H NMR (400 MHz DMSO-<i>d</i><sub>6</sub>): δ ppm 1.366 (s, 9H), 3.07 (m, 2H), 3.28 (m, partially obscured by HOD peak), 7.48 (t, 6.6 Hz, 2H), 7.53 (t, 7.6 Hz, 2H), 7.60 (d, 7.6 Hz, 2H), 7.71 (d, 8.0 Hz, 2H), 7.74 (s, 1H), 7.88 (s, 1H), 7.96 (t, 7.0 Hz, 1H), 8.29 (br t, 6.0 Hz, 1 H), 8.73 (br d, 4 Hz, 1H). MS <i>m</i>/<i>z</i> 595 [M + H]<sup>+</sup>. A solution of <i>tert</i>-butyl (2-(5-(2,4-dichloro-5-(pyridin-2-yl)benzamido)-1-phenyl-1<i>H</i>-pyrazole-3 carboxamido)ethyl)carbamate (80 mg, 0.134 mmol) in 4 M HCl in dioxane (2.5 mL) was stirred at room temperature for 3 h. The reaction was concentrated under reduced pressure, and the residue was triturated with ethyl ether, and the solid was dried under high vacuum for 48 h to afford 50 mg (66%) of compound <i>N</i>-(2-aminoethyl)-5-(2,4-dichloro-5-(pyridin-2-yl)benzamido)-1-phenyl-1<i>H</i>-pyrazole-3-carboxamide as an off-white solid. <sup>1</sup>H NMR (400 MHz DMSO-<i>d</i><sub>6</sub>): δ ppm 2.98 (m, 2H), 3.50 (m, 2H), 6.94 (s, 1H), 7.48–7.60 (m, 6H), 7.71 (m, 2H), 7.89 (br m, 1H), 7.99 (m, 1H), 8.50 (m, 1H), 8.74 (s, 1H), 10.87 (s, 1H). MS <i>m</i>/<i>z</i> 495 [M + H]<sup>+</sup>.</div></div><div id="sec5_20" class="NLM_sec NLM_sec_level_2"><div id="ac_i35" class="anchor-spacer"></div><h3 class="article-section__title" id="_i35"> 5-{[2,4-Dichloro-5-(pyridin-2-yl)benzoyl]amino}-<i>N</i>-(oxetan-3-yl)-1-phenyl-1<i>H</i>-pyrazole-3-carboxamide (<b>22</b>)</h3><div class="NLM_p last">To a suspension of 5-(2,4-dichloro-5-(pyridin-2-yl)benzamido)-1-phenyl-1<i>H</i>-pyrazole-3-carboxylic acid (<b>36</b>, 113 mg 0.25 mmol) in dimethylformamide (2 mL) were added diisopropylethylamine (33 mg 0.25 mmol), 3-aminooxetane (18.5 mg 0.25 mmol), and HATU (95 mg 0.25 mmol), and the solution was stirred at room temperature overnight under nitrogen. The reaction was partitioned between water and ethyl acetate (50 mL each), and the organic layer was washed with water (2 × 20 mL) and brine (10 mL). The organic layer was dried (magnesium sulfate) and evaporated, and the residue was purified by chromatography on silica using ethyl acetate eluent. The relevant fractions were combined and evaporated, and the residue freeze-dried from methanol/water to afford the title compound (20 mg, 16%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 4.62 (t, <i>J</i> = 6.5 Hz, 2H), 4.70 (t, <i>J</i> = 6.1 Hz, 2H), 5.00 (h, <i>J</i> = 7.0 Hz, 1H), 6.93 (s, 1H), 7.43–7.49 (m, 2H), 7.52 (t, <i>J</i> = 7.7 Hz, 2H), 7.57–7.63 (m, 2H), 7.69 (d, <i>J</i> = 7.9 Hz, 1H), 7.72 (s, 1H), 7.86 (s, 1H), 7.94 (td, <i>J</i> = 7.8, 1.8 Hz, 1H), 8.72 (dt, <i>J</i> = 5.0, 1.3 Hz, 1H), 9.01 (d, <i>J</i> = 6.8 Hz, 1H), 10.81 (s, 1H). LCMS <i>R</i><sub>t</sub> = 2.60 min, MS <i>m</i>/<i>z</i> 508.23 [M]<sup>+</sup>.</div></div><div id="sec5_21" class="NLM_sec NLM_sec_level_2"><div id="ac_i36" class="anchor-spacer"></div><h3 class="article-section__title" id="_i36"> 5-(2,4-Dichloro-5-(pyridin-2-yl)benzamido)-<i>N</i>-(2-hydroxy-2-methylpropyl)-1-phenyl-1<i>H</i>-pyrazole-3-carboxamide (<b>23</b>)</h3><div class="NLM_p last">To a solution of 5-(2,4-dichloro-5-(pyridin-2-yl)benzamido)-1-phenyl-1<i>H</i>-pyrazole-3-carboxylic acid (<b>36</b>, 150 mg, 0.33 mmol) and 1-amino-2-methylpropan-2-ol (50 mg, 0.66 mmol) in DMF (2 mL) were added DIPEA (0.11 mL, 0.66 mmol, 2 equiv) and HATU (188 mg, 0.50 mmol). The reaction was stirred at room temperature for 18 h. The reaction was partitioned between saturated aqueous sodium carbonate solution (50 mL) and EtOAc (50 mL). The organic layer was collected, washed with brine, dried over magnesium sulfate, and concentrated <i>in vacuo</i>. The residue was triturated with acetonitrile to afford the title compound (63 mg, 36%). <sup>1</sup>H NMR (400 MHz DMSO-<i>d</i><sub>6</sub>): δ ppm 1.08 (s, 6H), 3.23 (d, <i>J</i> = 6.1 Hz, 2H), 4.63 (s, 1H), 6.92 (s, 1H), 7.41–7.49 (m, 2H), 7.52 (dd, <i>J</i> = 8.6, 6.6 Hz, 2H), 7.60 (dd, <i>J</i> = 7.7, 1.9 Hz, 2H), 7.70 (d, <i>J</i> = 7.9 Hz, 1H), 7.73 (s, 1H), 7.84 (t, <i>J</i> = 6.2 Hz, 1H), 7.87 (s, 1H), 7.94 (td, <i>J</i> = 7.7, 1.9 Hz, 1H), 8.65–8.80 (m, 1H), 10.83 (s, 1H). LCMS <i>R</i><sub>t</sub> = 2.73 min MS <i>m</i>/<i>z</i> 524 [M + H]<sup>+</sup>.</div></div><div id="sec5_22" class="NLM_sec NLM_sec_level_2"><div id="ac_i37" class="anchor-spacer"></div><h3 class="article-section__title" id="_i37"> 5-{[2,4-Dichloro-5-(3-fluoropyridin-2-yl)benzoyl]amino}-<i>N</i>-(2-hydroxy-2-methylpropyl)-1-phenyl-1<i>H</i>-pyrazole-3-carboxamide (<b>24</b>)</h3><div class="NLM_p last">5-(2,4-Dichloro-5-(3-fluoropyridin-2-yl)benzamido)-1-phenyl-1<i>H</i>-pyrazole-3-carboxylic acid (<b>71</b>, 78 g, 166 mmol) was sonicated in DMF (300 mL) with <i>N</i>,<i>N</i>-diisopropylethylamine (58 mL, 332 mmol) to give a clear solution, which was cooled to 10 °C. TPTU (74 g, 249 mmol) was added portionwise, and the mixture was stirred at 10 °C for 20 min. A solution of 1-amino-2-methylpropan-2-ol (22.1 g, 249 mmol) in DMF (50 mL) was added dropwise at 10 °C, and the mixture was then allowed to warm to room temperature and stirred for 16 h. The reaction mixture was partitioned between EtOAc (600 mL) and water (600 mL). The aqueous layer was separated and extracted with additional EtOAc (3 × 200 mL). The combined organic layers were washed with saturated aqueous ammonium chloride solution (300 mL) and water (5 × 200 mL), dried (magnesium sulfate), and concentrated <i>in vacuo</i> to give an orange oil. The oil was treated with acetonitrile (300 mL), and the resulting solid was collected by filtration, washed with acetonitrile, and dried under vacuum to afford the title compound as a colorless solid (60 g, 66%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ ppm 1.08 (s, 6H), 3.22 (d, <i>J</i> = 6.1 Hz, 2H), 4.63 (s, 1H), 6.91 (s, 1H), 7.42–7.47 (m, 1H), 7.51 (t, <i>J</i> = 7.7 Hz, 2H), 7.56–7.66 (m, 3H), 7.68 (s, 1H), 7.83 (t, <i>J</i> = 6.2 Hz, 1H), 7.87–7.98 (m, 2H), 8.57 (d, <i>J</i> = 4.7 Hz, 1H), 10.87 (s, 1H). MS <i>m</i>/<i>z</i> 540.45 [M – H]<sup>−</sup>.</div></div><div id="sec5_23" class="NLM_sec NLM_sec_level_2"><div id="ac_i38" class="anchor-spacer"></div><h3 class="article-section__title" id="_i38"> 5-(2-Chloro-4-fluoro-5-(3-fluoropyridin-2-yl)benzamido)-<i>N</i>-(2-hydroxy-2-methylpropyl)-1-phenyl-1<i>H</i>-pyrazole-3-carboxamide (<b>25</b>)</h3><div class="NLM_p">To a solution of HATU (109 mg 0.29 mmol) and 5-(2-chloro-4-fluoro-5-(3-fluoropyridin-2-yl)benzamido)-1-phenyl-1<i>H</i>-pyrazole-3-carboxylic acid (<b>76</b>, 100 mg, 0.22 mmol) in DMF (0.9 mL) was added DIPEA (0.191 mL, 1.10 mmol). The reaction mixture was stirred at room temperature for 15 min. 1-Amino-2-methylpropan-2-ol (1.1 mL 0.23 mmol) was added, and the reaction mixture stirred at room temperature for 2 h. The reaction was diluted with EtOAc (20 mL). The solution was washed with NaHCO<sub>3</sub> (20 mL), 10% citric acid aq. solution (20 mL), and brine (20 mL). The organic phase was dried over sodium sulfate and filtered, and the solvent was removed <i>in vacuo</i>. The residue was purified by reverse phase chromatography (12 g C18 column, 0.1% NH4OH additive, 0–100% MeCN) to afford the title compound as a white solid (67 mg, 56%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 1.08 (s, 6H), 3.23 (d, <i>J</i> = 6.2 Hz, 2H), 4.63 (s, 1H), 6.92 (s, 1H), 7.45 (t, <i>J</i> = 7.4 Hz, 1H), 7.52 (t, <i>J</i> = 7.6 Hz, 2H), 7.56–7.68 (m, 4H), 7.76 (dd, <i>J</i> = 14.8, 8.7 Hz, 2H), 7.82 (t, <i>J</i> = 6.1 Hz, 1H), 7.87–7.99 (m, 1H), 8.47–8.70 (m, 1H). LCMS <i>R</i><sub>t</sub> = 2.68 min MS <i>m</i>/<i>z</i> 524 [M – H]<sup>−</sup>.</div><div id="sec5_24" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> Additional Note</h4><div class="NLM_p last">Synthesis of ligand <b>1</b> has been previously reported, and ligand <b>2</b> is commercially available.<a onclick="showRef(event, 'ref19 ref41'); return false;" href="javascript:void(0);" class="ref ref19 ref41">(19,41)</a></div></div></div><div id="sec5_25" class="NLM_sec NLM_sec_level_2"><div id="ac_i40" class="anchor-spacer"></div><h3 class="article-section__title" id="_i40"> Torsional Energy Profile and Boltzmann Population Calculations</h3><div class="NLM_p last">To examine the torsional energy profiles for two-aromatic-ring systems, a relaxed coordinate scan implemented in the Jaguar program was performed using B3LYP and the 6-31G** basis set. The bond between the two aromatic rings was rotated every 10 degrees, and each rotamer was optimized, while the bond dihedral angle was constrained to obtain a geometry-optimized conformation and a corresponding energy at each torsion angle in the scan. The lowest energy minima were further optimized without constraints using the same method and basis set, which was used to calculate the relative ab initio energy for each geometry-optimized conformation. The Boltzmann populations and abundance ratios were calculated at <i>T</i> = 298 K for each conformation using the relative ab initio energies compared to the unconstrained minimum-energy conformer.</div></div><div id="sec5_26" class="NLM_sec NLM_sec_level_2"><div id="ac_i41" class="anchor-spacer"></div><h3 class="article-section__title" id="_i41"> Computational Modeling Methods</h3><div class="NLM_p last">All molecules were prepared for docking simulation using LigPrep 2.5 (Schrödinger) to consider proper protonation states and tautomers. The docking simulation was performed with Glide 5.8 (Schrödinger) using protein models based on in-house crystal structures. In some cases, a constraint on a hydrogen bond interaction with backbone NH of Asp668 was applied during docking simulation to orientate molecules in the binding site. Docking poses were minimized using the OPLS2005 force field.</div></div><div id="sec5_27" class="NLM_sec NLM_sec_level_2"><div id="ac_i42" class="anchor-spacer"></div><h3 class="article-section__title" id="_i42"> Metabolism of Compounds in Human Liver Microsomes (HLM) in Vitro</h3><div class="NLM_p last">Stability of compounds in human liver microsomes (HLM) in vitro was determined at a compound concentration of 1 μM. Incubations (32.5 μL) contained HLM (Pfizer Global supply) at a protein concentration of 0.71 mg/mL and were supplemented with a reducing equivalent regenerating system (isocitrate/isocitrate dehydrogenase). The assay cocktail was incubated at 37 °C for up to 60 min in the presence and absence of NADP<sup>+</sup> (2 mM), and samples were withdrawn at time intervals and reactions terminated by addition to 75 μL of acetonitrile and 65 μL of water. Samples were centrifuged to remove precipitated protein, and the supernatants dried under a stream of nitrogen. Dried extracts were reconstituted in 100 μL of 50/50 acetonitrile/water + 0.1% formic acid and further diluted with 100 μL of 5/95 acetonitrile/water containing 0.1% formic acid. Following further centrifugation, samples (5 μL) were analyzed by LC–MS/MS using a QTOF Premier (s/n: HAA053) mass spectrometer (Waters) operated in positive ion mode, and data were acquired in the multiple reaction monitoring (MRM) mode using argon as the collision gas. The natural log of ratios of peak areas of test compound to a reference internal standard were plotted against incubation time and apparent intrinsic clearance (CL<sub>int</sub>) calculated form the slope of the line.</div></div><div id="sec5_28" class="NLM_sec NLM_sec_level_2"><div id="ac_i43" class="anchor-spacer"></div><h3 class="article-section__title" id="_i43"> Metabolism of Compounds in Human Liver Microsome Glucuronidation Assay (HLMUGT) in Vitro</h3><div class="NLM_p last">Rates of glucuronidation of compounds in human liver microsomes (HLMUGT) in vitro were determined at a compound concentration of 1 μM. The method was analogous to that described above for HLM except that NADP and reducing equivalent regenerating system were omitted and replaced with UDPGA (5 mM), and incubations were supplemented with 2% bovine serum albumin and 38 μg/mL alamethacin. CL<sub>int</sub> was calculated as described for HLM above.</div></div><div id="sec5_29" class="NLM_sec NLM_sec_level_2"><div id="ac_i44" class="anchor-spacer"></div><h3 class="article-section__title" id="_i44"> Metabolism of Compounds in Human and Rat Intestinal Microsomes (HIM, RIM) in Vitro</h3><div class="NLM_p last">Rates of metabolism of compounds in human and rat intestinal microsomes in vitro were determined at a compound concentration of 1 μM. The method was analogous to that described above for HLM, except that NADP, reducing equivalent regenerating system, and UDPGA (1 mM) were included in incubations in order to allow metabolism via CYP- and UGT-catalyzed reactions. CL<sub>int</sub> was calculated as described for HLM above.</div></div><div id="sec5_30" class="NLM_sec NLM_sec_level_2"><div id="ac_i45" class="anchor-spacer"></div><h3 class="article-section__title" id="_i45"> Metabolism of Compounds in Human Hepatocytes (hHep) in Vitro</h3><div class="NLM_p last">Stability of compounds in human hepatocytes (hHep) (Bioreclamation Inc., NY, USA) in vitro was determined at a compound concentration of 1 μM. Incubations (22.5 μL) in Williams E medium containing 0.5 × 10<sup>6</sup> cells/mL were carried out at 37 °C in an atmosphere of 95/5 air/CO<sub>2</sub> at 95% humidity for up to 240 min. Incubations were terminated with 50 μL of cold acetonitrile, and samples were centrifuged to remove precipitated protein. Samples of 35 μL of supernatant were diluted with 120 μL of water prior to analysis of compound by LC–MS/MS according to the method described for microsomal incubations. CL<sub>int</sub> was calculated as described for HLM above.</div></div><div id="sec5_31" class="NLM_sec NLM_sec_level_2"><div id="ac_i46" class="anchor-spacer"></div><h3 class="article-section__title" id="_i46"> Determination of Permeability in RRCK Cell Monolayers</h3><div class="NLM_p last">Apparent permeability (P<sub>app</sub>) was determined in the apical to basolateral (A/B) direction in monolayers of low transporter expressing MDCK cells (RRCK) according to published methods.<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a></div></div><div id="sec5_32" class="NLM_sec NLM_sec_level_2"><div id="ac_i47" class="anchor-spacer"></div><h3 class="article-section__title" id="_i47"> Determination of Efflux by P-gp and BCRP</h3><div class="NLM_p last">Apparent permeability (P<sub>app</sub>) was determined in apical to basolateral (A/B) and basolateral to apical (B/A) directions in monolayers of MDCK cells transfected with either human MDR1 or human BCRP according to published methods.<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> Efflux ratio (ER) was used as an index of efflux, whereby ER = P<sub>app</sub>(B/A)/P<sub>app</sub>(A/B).</div></div><div id="sec5_33" class="NLM_sec NLM_sec_level_2"><div id="ac_i48" class="anchor-spacer"></div><h3 class="article-section__title" id="_i48"> Determination of Chromosomal Events in Micronuclei of CHO Cells in Vitro</h3><div class="NLM_p last">The objective of this assay was to discern clastogenic (chromosome breakage) versus aneugenic (whole chromosome loss) chromosomal events in micronuclei of CHO cells. Cytochalasin B was used to prevent cytokinesis. Following treatment with compound for 24 h and cell fixation, slides were coated with anticentromere (kinetochore) serum, allowing for the binding of an antihuman IgG antibody to the kinetochores. The antibody, which was conjugated with a fluorescent marker to stain kinetochores, was applied to the slides. Propidium iodide stain was applied to stain the nuclear DNA of the cells. Slides were evaluated microscopically for nuclear division (>100 cells scored) and micronucleus frequency in binucleated cells (500–2000 binucleated cells scored). A minimum of 500 binucleated cells or >70 micronuclei at a single concentration were evaluated microscopically for the presence of micronuclei containing kinetochores. Criteria for a positive response included at least 2% micronucleated binucleate cells accompanied by >2-fold increase in micronucleated binucleate cells compared to the vehicle control (DMSO). The criterion for aneugenicity was a greater percent incidence of kinetochore positive micronuclei (K+; indicating the presence of whole chromosomes) over kinetochore negative micronuclei (K–; indicating the presence of chromosomal fragments) in micronucleated binucleate cells.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-2"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i49"><a href="/doi/suppl/10.1021/acs.jmedchem.8b00280" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_12325" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_12325" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the ACS publications Web site. . The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.8b00280" class="ext-link">10.1021/acs.jmedchem.8b00280</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Surface plasmon resonance data for ligands <b>3</b> and <b>23</b>, comparison of TrkA cell IC<sub>50</sub> data with nonactivated TrkA enzyme activity and activated phosphorylated TrkA enzyme activity, TrkA enzyme and cell assay protocols, inhibition of NGF induced phosphorylated ERK formation in native adult rat DRGs by ligand <b>23</b> data, protocol for ultraviolet irradiation-induced thermal hyperalgesia in rats, measurement of CNS penetration in rats, Kinase selectivity profile of lead molecule <b>3</b> and candidate molecule <b>23</b>, experimental procedures and spectral data for compounds, <sup>1</sup>H NMR spectra for compounds <b>3</b> and <b>23</b>; remaining chemistry details (<a href="/doi/suppl/10.1021/acs.jmedchem.8b00280/suppl_file/jm8b00280_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a href="/doi/suppl/10.1021/acs.jmedchem.8b00280/suppl_file/jm8b00280_si_002.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b00280/suppl_file/jm8b00280_si_001.pdf">jm8b00280_si_001.pdf (1.55 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b00280/suppl_file/jm8b00280_si_002.csv">jm8b00280_si_002.csv (1.85 kb)</a></li></ul></div></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">PDB codes are <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6D22">6D22</a> for Apo TrkA, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6D1Y">6D1Y</a> for compound <b>2</b>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6D1Z">6D1Z</a> for compound <b>3</b>, and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6D20">6D20</a> for compound <b>23</b>.</p><div class="testing" data-doi="10.1021/acs.jmedchem.8b00280" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_65206" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_65206" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sharan K. Bagal</span> - <span class="hlFld-Affiliation affiliation">Worldwide
Medicinal Chemistry, Pfizer Global R&D
U.K., The Portway Building, Granta Park, Cambridge CB21 6GS, U.K.</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-0955-271X" title="Orcid link">http://orcid.org/0000-0003-0955-271X</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#12617a7360737c3c707375737e527d67667e7d7d793c717d7f"><span class="__cf_email__" data-cfemail="56253e3724373878343731373a163923223a39393d7835393b">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kiyoyuki Omoto</span> - <span class="hlFld-Affiliation affiliation">Worldwide
Medicinal Chemistry, Pfizer Global R&D
U.K., The Portway Building, Granta Park, Cambridge CB21 6GS, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">David C. Blakemore</span> - <span class="hlFld-Affiliation affiliation">Worldwide
Medicinal Chemistry, Pfizer Global R&D
U.K., The Portway Building, Granta Park, Cambridge CB21 6GS, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Peter J. Bungay</span> - <span class="hlFld-Affiliation affiliation">Pharmacokinetics,
Dynamics & Metabolism, Pfizer Global
R&D U.K., The Portway
Building, Granta Park, Cambridge CB21 6GS, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">James G. Bilsland</span> - <span class="hlFld-Affiliation affiliation">Pfizer
Global R&D U.K., The Portway Building, Granta Park, Cambridge CB21 6GS, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Philip J. Clarke</span> - <span class="hlFld-Affiliation affiliation">Peakdale
Molecular, Discovery
Park House, Ramsgate Road, Sandwich, Kent CT13 9ND, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Matthew S. Corbett</span> - <span class="hlFld-Affiliation affiliation">Pfizer
Global R&D, Groton Laboratories, Eastern Point Road, Groton, Connecticut 06340, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ciaran N. Cronin</span> - <span class="hlFld-Affiliation affiliation">Pfizer
Global R&D, La Jolla Laboratories, 10770 Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">J. Jean Cui</span> - <span class="hlFld-Affiliation affiliation">Pfizer
Global R&D, La Jolla Laboratories, 10770 Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Rebecca Dias</span> - <span class="hlFld-Affiliation affiliation">Pfizer
Global R&D U.K., The Portway Building, Granta Park, Cambridge CB21 6GS, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Neil J. Flanagan</span> - <span class="hlFld-Affiliation affiliation">Pfizer
Global R&D U.K., The Portway Building, Granta Park, Cambridge CB21 6GS, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Samantha E. Greasley</span> - <span class="hlFld-Affiliation affiliation">Pfizer
Global R&D, La Jolla Laboratories, 10770 Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Rachel Grimley</span> - <span class="hlFld-Affiliation affiliation">Pfizer
Global R&D U.K., The Portway Building, Granta Park, Cambridge CB21 6GS, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Eric Johnson</span> - <span class="hlFld-Affiliation affiliation">Pfizer
Global R&D, La Jolla Laboratories, 10770 Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">David Fengas</span> - <span class="hlFld-Affiliation affiliation">Peakdale
Molecular, Discovery
Park House, Ramsgate Road, Sandwich, Kent CT13 9ND, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Linda Kitching</span> - <span class="hlFld-Affiliation affiliation">Pfizer
Global R&D U.K., The Portway Building, Granta Park, Cambridge CB21 6GS, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Michelle L. Kraus</span> - <span class="hlFld-Affiliation affiliation">Pfizer
Global R&D, La Jolla Laboratories, 10770 Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Indrawan McAlpine</span> - <span class="hlFld-Affiliation affiliation">Pfizer
Global R&D, La Jolla Laboratories, 10770 Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Asako Nagata</span> - <span class="hlFld-Affiliation affiliation">Pfizer
Global R&D, La Jolla Laboratories, 10770 Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Gareth J. Waldron</span> - <span class="hlFld-Affiliation affiliation">Pfizer
Global R&D U.K., The Portway Building, Granta Park, Cambridge CB21 6GS, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Joseph S. Warmus</span> - <span class="hlFld-Affiliation affiliation">Pfizer
Global R&D, Groton Laboratories, Eastern Point Road, Groton, Connecticut 06340, United States</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><p>The authors declare no competing financial interest.<br /></br></p></li></ul></div><div class="ack" id="ACK-d95e4563-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i51">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_16886" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_16886" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The authors would like to thank Dr. Katrina Gore for statistical analysis of UVIH data, Jennifer B. Munzner and Michelle Kenyon for genotoxicity assessments, and Dr. Hannah Pearce, Dr. Charlotte Lane, Dr. Veerabahu Shanmugasundaram, Dr. Hongyao Zhu, Dr. Ye Che, Dr. Cesar Augusto de Oliveira, Dr. Jane Withka, Dr. Reto Horst, Dr. Beth Lunney, Dr. Alan Brown, Dr. Robert Kania, Dr. Martin Edwards, Stephanie Scales, Fen Wang, Michelle Tran-Dube, and Dr. Klimentina Pencheva for useful discussions and Peakdale Molecular for synthesis and TCG Lifesciences for screening.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">ABBREVIATIONS USED</td></tr><tr><td class="NLM_term">AB</td><td class="NLM_def"><p class="first last">apical to basolateral</p></td></tr><tr><td class="NLM_term">ADME</td><td class="NLM_def"><p class="first last">absorption, distribution, metabolism, and excretion</p></td></tr><tr><td class="NLM_term">ADP</td><td class="NLM_def"><p class="first last">adenosine diphosphate</p></td></tr><tr><td class="NLM_term">ATP</td><td class="NLM_def"><p class="first last">adenosine triphosphate</p></td></tr><tr><td class="NLM_term">BA</td><td class="NLM_def"><p class="first last">basolateral to apical</p></td></tr><tr><td class="NLM_term">BCRP</td><td class="NLM_def"><p class="first last">breast cancer resistance protein</p></td></tr><tr><td class="NLM_term">BDNF</td><td class="NLM_def"><p class="first last">brain derived neurotrophic factor</p></td></tr><tr><td class="NLM_term">BBB</td><td class="NLM_def"><p class="first last">blood–brain barrier</p></td></tr><tr><td class="NLM_term"><i>C</i><sub>b,u</sub>/<i>C</i><sub>p,u</sub></td><td class="NLM_def"><p class="first last">unbound brain/plasma concentration ratio</p></td></tr><tr><td class="NLM_term">CHO</td><td class="NLM_def"><p class="first last">Chinese hamster ovary</p></td></tr><tr><td class="NLM_term">CPK</td><td class="NLM_def"><p class="first last">Corey–Pauling–Koltun model</p></td></tr><tr><td class="NLM_term">ERK</td><td class="NLM_def"><p class="first last">extracellular-signal-regulated kinases</p></td></tr><tr><td class="NLM_term">ID</td><td class="NLM_def"><p class="first last">compound identification number</p></td></tr><tr><td class="NLM_term">Cl<sub>int</sub></td><td class="NLM_def"><p class="first last">apparent intrinsic clearance</p></td></tr><tr><td class="NLM_term">CNS</td><td class="NLM_def"><p class="first last">central nervous system</p></td></tr><tr><td class="NLM_term">CYP</td><td class="NLM_def"><p class="first last">cytochrome P450</p></td></tr><tr><td class="NLM_term">DDI</td><td class="NLM_def"><p class="first last">drug–drug interaction</p></td></tr><tr><td class="NLM_term">DIBAL-H</td><td class="NLM_def"><p class="first last">diisobutylaluminum hydride</p></td></tr><tr><td class="NLM_term">DRG</td><td class="NLM_def"><p class="first last">dorsal root ganglia</p></td></tr><tr><td class="NLM_term">ER</td><td class="NLM_def"><p class="first last">efflux ratio</p></td></tr><tr><td class="NLM_term"><i>F</i></td><td class="NLM_def"><p class="first last">oral bioavailability</p></td></tr><tr><td class="NLM_term"><i>f</i><sub>u</sub></td><td class="NLM_def"><p class="first last">fraction unbound</p></td></tr><tr><td class="NLM_term">hHep</td><td class="NLM_def"><p class="first last">human hepatocytes</p></td></tr><tr><td class="NLM_term">HIM</td><td class="NLM_def"><p class="first last">human intestinal microsomes</p></td></tr><tr><td class="NLM_term">HLM</td><td class="NLM_def"><p class="first last">human liver microsomes</p></td></tr><tr><td class="NLM_term">IC<sub>50</sub></td><td class="NLM_def"><p class="first last">half-maximum inhibitory concentration</p></td></tr><tr><td class="NLM_term">JM</td><td class="NLM_def"><p class="first last">juxtamembrane domain</p></td></tr><tr><td class="NLM_term">IVMN</td><td class="NLM_def"><p class="first last">in vitro micronucleus</p></td></tr><tr><td class="NLM_term"><i>K</i><sub>a</sub></td><td class="NLM_def"><p class="first last">association rate</p></td></tr><tr><td class="NLM_term"><i>K</i><sub>d</sub></td><td class="NLM_def"><p class="first last">dissociation rate</p></td></tr><tr><td class="NLM_term"><i>K</i><sub>D</sub></td><td class="NLM_def"><p class="first last">dissociation constant</p></td></tr><tr><td class="NLM_term"><i>K</i><sub>m</sub></td><td class="NLM_def"><p class="first last">Michaelis–Menten constant</p></td></tr><tr><td class="NLM_term">LE</td><td class="NLM_def"><p class="first last">ligand efficiency</p></td></tr><tr><td class="NLM_term">LipE</td><td class="NLM_def"><p class="first last">lipophilic efficiency</p></td></tr><tr><td class="NLM_term">LogD</td><td class="NLM_def"><p class="first last">distribution coefficient at pH 7.4</p></td></tr><tr><td class="NLM_term">mAb</td><td class="NLM_def"><p class="first last">monoclonal antibody</p></td></tr><tr><td class="NLM_term">MDCK</td><td class="NLM_def"><p class="first last">Madine Darby canine kidney</p></td></tr><tr><td class="NLM_term">MDR1</td><td class="NLM_def"><p class="first last">multidrug resistance protein (P-glycoprotein)</p></td></tr><tr><td class="NLM_term">MW</td><td class="NLM_def"><p class="first last">molecular weight</p></td></tr><tr><td class="NLM_term">NADP</td><td class="NLM_def"><p class="first last">nicotinamide adenine dinucleotide phosphate</p></td></tr><tr><td class="NLM_term">ND</td><td class="NLM_def"><p class="first last">not determined</p></td></tr><tr><td class="NLM_term">NT3</td><td class="NLM_def"><p class="first last">neurotrophin 3</p></td></tr><tr><td class="NLM_term">NT4</td><td class="NLM_def"><p class="first last">neurotrophin 4</p></td></tr><tr><td class="NLM_term">NIS</td><td class="NLM_def"><p class="first last"><i>N</i>-iodosuccinimide</p></td></tr><tr><td class="NLM_term">NGF</td><td class="NLM_def"><p class="first last">nerve growth factor</p></td></tr><tr><td class="NLM_term">P<sub>app</sub></td><td class="NLM_def"><p class="first last">apparent permeability</p></td></tr><tr><td class="NLM_term">PDB</td><td class="NLM_def"><p class="first last">Protein Data Bank</p></td></tr><tr><td class="NLM_term">P-gp</td><td class="NLM_def"><p class="first last">P-glycoprotein</p></td></tr><tr><td class="NLM_term">PK</td><td class="NLM_def"><p class="first last">pharmacokinetics</p></td></tr><tr><td class="NLM_term">PSA</td><td class="NLM_def"><p class="first last">polar surface area</p></td></tr><tr><td class="NLM_term">RIM</td><td class="NLM_def"><p class="first last">rat intestinal microsomes</p></td></tr><tr><td class="NLM_term">RRCK</td><td class="NLM_def"><p class="first last">Ralph Russ canine kidney cell line, permeability measured with low-efflux MDCK cell line</p></td></tr><tr><td class="NLM_term">SBDD</td><td class="NLM_def"><p class="first last">structure based drug design</p></td></tr><tr><td class="NLM_term"><i>T</i><sub>1/2</sub></td><td class="NLM_def"><p class="first last">half-life</p></td></tr><tr><td class="NLM_term">Trk</td><td class="NLM_def"><p class="first last">tropomyosin related kinase</p></td></tr><tr><td class="NLM_term">UDPGA</td><td class="NLM_def"><p class="first last">uridine 5′-diphospho-glucuronic acid</p></td></tr><tr><td class="NLM_term">UGT</td><td class="NLM_def"><p class="first last">uridine 5′-diphospho-glucuronosyl transferase</p></td></tr><tr><td class="NLM_term">UVIH</td><td class="NLM_def"><p class="first last">ultraviolet burn induced hyperalgesia</p></td></tr><tr><td class="NLM_term"><i>V</i><sub>ss</sub></td><td class="NLM_def"><p class="first last">volume of distribution at steady state</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i53">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_13181" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_13181" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 62 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Skaper, S. D.</span></span> <span> </span><span class="NLM_article-title">The Neurotrophin Family of Neurotrophic Factors: An Overview</span>. <i>Methods Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>846</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">12</span>, <span class="refDoi"> DOI: 10.1007/978-1-61779-536-7_1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=10.1007%2F978-1-61779-536-7_1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=22367796" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1ensrvJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=846&publication_year=2012&pages=1-12&author=S.+D.+Skaper&title=The+Neurotrophin+Family+of+Neurotrophic+Factors%3A+An+Overview&doi=10.1007%2F978-1-61779-536-7_1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">The neurotrophin family of neurotrophic factors: an overview</span></div><div class="casAuthors">Skaper, Stephen D.</div><div class="citationInfo"><span class="NLM_cas:title">Methods in Molecular Biology (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">846</span>
        (<span class="NLM_cas:issue">Neurotrophic Factors</span>),
    <span class="NLM_cas:pages">1-12</span>CODEN:
                <span class="NLM_cas:coden">MMBIED</span>;
        ISSN:<span class="NLM_cas:issn">1064-3745</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  The neurotrophins are a family of closely related proteins that were first identified as survival factors for sympathetic and sensory neurons and have since been shown to control a no. of aspects of survival, development, and function of neurons in both the central and peripheral nervous systems.  Limiting quantities of neurotrophins during development control the nos. of surviving neurons to ensure a match between neurons and the requirement for a suitable d. of target innervation.  Biol. effects of each of the four mammalian neurotrophins are mediated through activation of one or more of the three members of the tropomyosin-related kinase (Trk) family of receptor tyrosine kinases (TrkA, TrkB, and TrkC).  In addn., all neurotrophins activate the p75 neurotrophin receptor, a member of the tumor necrosis factor receptor superfamily.  Neurotrophin engagement of Trk receptors leads to activation of Ras, phosphatidylinositol 3-kinase, phospholipase C-γl, and signaling pathways controlled through these proteins, including the mitogen-activated protein kinases.  Neurotrophin availability is required into adulthood, where they control synaptic function and plasticity and sustain neuronal cell survival, morphol., and differentiation.  This chapter will provide an overview of neurotrophin biol., their receptors, and signaling pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrx93j5UxkhubVg90H21EOLACvtfcHk0lhYcLkzk8W9bA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1ensrvJ&md5=5f575aa213b4e790fc7d1d3b44ead678</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1007%2F978-1-61779-536-7_1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F978-1-61779-536-7_1%26sid%3Dliteratum%253Aachs%26aulast%3DSkaper%26aufirst%3DS.%2BD.%26atitle%3DThe%2520Neurotrophin%2520Family%2520of%2520Neurotrophic%2520Factors%253A%2520An%2520Overview%26jtitle%3DMethods%2520Mol.%2520Biol.%26date%3D2012%26volume%3D846%26spage%3D1%26epage%3D12%26doi%3D10.1007%2F978-1-61779-536-7_1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hefti, F. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenthal, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walicke, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wyatt, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vergara, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shelton, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, A. M.</span></span> <span> </span><span class="NLM_article-title">Novel Class of Pain Drugs Based on Antagonism of NGF</span>. <i>Trends Pharmacol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>27</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">85</span>– <span class="NLM_lpage">91</span>, <span class="refDoi"> DOI: 10.1016/j.tips.2005.12.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=10.1016%2Fj.tips.2005.12.001" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2006&pages=85-91&issue=2&author=F.+F.+Heftiauthor=A.+Rosenthalauthor=P.+A.+Walickeauthor=S.+Wyattauthor=G.+Vergaraauthor=D.+L.+Sheltonauthor=A.+M.+Davies&title=Novel+Class+of+Pain+Drugs+Based+on+Antagonism+of+NGF&doi=10.1016%2Fj.tips.2005.12.001"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2005.12.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2005.12.001%26sid%3Dliteratum%253Aachs%26aulast%3DHefti%26aufirst%3DF.%2BF.%26aulast%3DRosenthal%26aufirst%3DA.%26aulast%3DWalicke%26aufirst%3DP.%2BA.%26aulast%3DWyatt%26aufirst%3DS.%26aulast%3DVergara%26aufirst%3DG.%26aulast%3DShelton%26aufirst%3DD.%2BL.%26aulast%3DDavies%26aufirst%3DA.%2BM.%26atitle%3DNovel%2520Class%2520of%2520Pain%2520Drugs%2520Based%2520on%2520Antagonism%2520of%2520NGF%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2006%26volume%3D27%26issue%3D2%26spage%3D85%26epage%3D91%26doi%3D10.1016%2Fj.tips.2005.12.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lane, N. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schnitzer, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Birbara, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mokhtarani, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shelton, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, M. T.</span></span> <span> </span><span class="NLM_article-title">Tanezumab for the Treatment of Pain from Osteoarthritis of the Knee</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>363</i></span> (<span class="NLM_issue">16</span>),  <span class="NLM_fpage">1521</span>– <span class="NLM_lpage">1531</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa0901510</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=10.1056%2FNEJMoa0901510" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=20942668" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht12ltrbI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=363&publication_year=2010&pages=1521-1531&issue=16&author=N.+E.+Laneauthor=T.+J.+Schnitzerauthor=C.+A.+Birbaraauthor=M.+Mokhtaraniauthor=D.+L.+Sheltonauthor=M.+D.+Smithauthor=M.+T.+Brown&title=Tanezumab+for+the+Treatment+of+Pain+from+Osteoarthritis+of+the+Knee&doi=10.1056%2FNEJMoa0901510"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Tanezumab for the treatment of pain from osteoarthritis of the knee</span></div><div class="casAuthors">Lane, Nancy E.; Schnitzer, Thomas J.; Birbara, Charles A.; Mokhtarani, Masoud; Shelton, David L.; Smith, Mike D.; Brown, Mark T.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">363</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">1521</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: Increased expression of nerve growth factor in injured or inflamed tissue is assocd. with increased pain.  This proof-of-concept study was designed to investigate the safety and analgesic efficacy of tanezumab, a humanized monoclonal antibody that binds and inhibits nerve growth factor.  Methods: We randomly assigned 450 patients with osteoarthritis of the knee to receive tanezumab (administered at a dose of 10, 25, 50, 100, or 200 Ag per kg of body wt.) or placebo on days 1 and 56.  The primary efficacy measures were knee pain while walking and the patient's global assessment of response to therapy.  We also assessed pain, stiffness, and phys. function using the Western Ontario and Mc-Master Universities Osteoarthritis Index (WOMAC); the rate of response using the criteria of the Outcome Measures for Rheumatol.  Committee and Osteoarthritis Research Society International Standing Committee for Clin. Trials Response Criteria Initiative (OMERACT-OARSI); and safety.  Results: When averaged over weeks 1 through 16, the mean redns. from baseline in knee pain while walking ranged from 45 to 62% with various doses of tanezumab, as compared with 22% with placebo (P < 0.001).  Tanezumab, as compared with placebo, was also assocd. with significantly greater improvements in the response to therapy as assessed with the use of the patients' global assessment measure (mean increases in score of 29 to 47% with various doses of tanezumab, as compared with 19% with placebo; P ≤ 0.001).  The rate of response according to the OMERACT-OARSI criteria ranged from 74 to 93% with tanezumab treatment, as compared with 44% with placebo (P < 0.001).  The rates of adverse events were 68% and 55% in the tanezumab and placebo groups, resp.  The most common adverse events among tanezumab-treated patients were headache (9% of the patients), upper respiratory tract infection (7%), and paresthesia (7%).  Conclusions: In this proof-of-concept study, treatment with tanezumab was assocd. with a redn. in joint pain and improvement in function, with mild and moderate adverse events, among patients with moderate-to-severe osteoarthritis of the knee.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCmt4PNNZ44LVg90H21EOLACvtfcHk0li_rtnYUce4_Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht12ltrbI&md5=fe69490dfa3d47fe8a0c286d6b020d57</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa0901510&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa0901510%26sid%3Dliteratum%253Aachs%26aulast%3DLane%26aufirst%3DN.%2BE.%26aulast%3DSchnitzer%26aufirst%3DT.%2BJ.%26aulast%3DBirbara%26aufirst%3DC.%2BA.%26aulast%3DMokhtarani%26aufirst%3DM.%26aulast%3DShelton%26aufirst%3DD.%2BL.%26aulast%3DSmith%26aufirst%3DM.%2BD.%26aulast%3DBrown%26aufirst%3DM.%2BT.%26atitle%3DTanezumab%2520for%2520the%2520Treatment%2520of%2520Pain%2520from%2520Osteoarthritis%2520of%2520the%2520Knee%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2010%26volume%3D363%26issue%3D16%26spage%3D1521%26epage%3D1531%26doi%3D10.1056%2FNEJMoa0901510" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schnitzer, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lane, N. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Birbara, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simpson, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, M. T.</span></span> <span> </span><span class="NLM_article-title">Long-Term Open-Label Study of Tanezumab for Moderate to Severe Osteoarthritic Knee Pain</span>. <i>Osteoarthritis Cartilage</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>19</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">639</span>– <span class="NLM_lpage">646</span>, <span class="refDoi"> DOI: 10.1016/j.joca.2011.01.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=10.1016%2Fj.joca.2011.01.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=21251985" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=1%3ACAS%3A280%3ADC%252BC3MrisVektg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2011&pages=639-646&issue=6&author=T.+J.+Schnitzerauthor=N.+E.+Laneauthor=C.+Birbaraauthor=M.+D.+Smithauthor=S.+L.+Simpsonauthor=M.+T.+Brown&title=Long-Term+Open-Label+Study+of+Tanezumab+for+Moderate+to+Severe+Osteoarthritic+Knee+Pain&doi=10.1016%2Fj.joca.2011.01.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Long-term open-label study of tanezumab for moderate to severe osteoarthritic knee pain</span></div><div class="casAuthors">Schnitzer T J; Lane N E; Birbara C; Smith M D; Simpson S L; Brown M T</div><div class="citationInfo"><span class="NLM_cas:title">Osteoarthritis and cartilage</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">639-46</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">OBJECTIVE:  This study was designed to evaluate the long-term safety and effectiveness of repeated doses of the humanized anti-nerve growth factor antibody, tanezumab, during open-label treatment of patients with OA knee pain.  DESIGN:  The current study (clinicaltrials.gov identifier: NCT00399490) was a multicenter, phase II, open-label, multiple-dose extension of an earlier randomized clinical trial.  All patients (N=281) received infusions of tanezumab 50μg/kg on Days 1 and 56 with subsequent doses administered at 8-week intervals (up to a total of eight infusions).  The primary endpoint of this study was safety.  Effectiveness evaluations included overall knee pain, Western Ontario and McMaster Universities Osteoarthritis (WOMAC) index subscales, and subject global assessment (SGA) of response to therapy on 0-100 point visual analog scales.  RESULTS:  Repeated administration of tanezumab resulted in a low incidence of treatment-related adverse events (AEs; 7.5%).  The rate of serious AEs was also low (2.8%) with none considered treatment-related.  Few AEs of abnormal peripheral sensation were reported; hypoesthesia was reported by nine patients (3.2%), paresthesia by seven patients (2.5%), and hyperesthesia, peripheral neuropathy, and sensory disturbance were each reported by one patient (0.4% for each).  Most AEs of abnormal peripheral sensation were rated as mild (95%) and the majority (65%) resolved before study completion.  At Week 8, overall knee pain and SGA improved from baseline by a mean (± standard error) of -12.8 (±1.78) and 8.0 (±1.66), respectively.  Similar improvements occurred for WOMAC subscales.  CONCLUSIONS:  Repeated injections of tanezumab in patients with moderate to severe knee OA provide continued pain relief and improved function with a low incidence of side effects.  Additional studies to define the efficacy and duration of pain reduction and to provide a more complete assessment of long-term safety are warranted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSP3rNjPk9h4A20zIbnCCI3fW6udTcc2eY1Cxa69yaTFbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3MrisVektg%253D%253D&md5=e489a54f543455004fe879ce02744c64</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2Fj.joca.2011.01.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.joca.2011.01.009%26sid%3Dliteratum%253Aachs%26aulast%3DSchnitzer%26aufirst%3DT.%2BJ.%26aulast%3DLane%26aufirst%3DN.%2BE.%26aulast%3DBirbara%26aufirst%3DC.%26aulast%3DSmith%26aufirst%3DM.%2BD.%26aulast%3DSimpson%26aufirst%3DS.%2BL.%26aulast%3DBrown%26aufirst%3DM.%2BT.%26atitle%3DLong-Term%2520Open-Label%2520Study%2520of%2520Tanezumab%2520for%2520Moderate%2520to%2520Severe%2520Osteoarthritic%2520Knee%2520Pain%26jtitle%3DOsteoarthritis%2520Cartilage%26date%3D2011%26volume%3D19%26issue%3D6%26spage%3D639%26epage%3D646%26doi%3D10.1016%2Fj.joca.2011.01.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Evans, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moldwin, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cossons, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darekar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mills, I. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scholfield, D.</span></span> <span> </span><span class="NLM_article-title">Proof of Concept Trial of Tanezumab for the Treatment of Symptoms Associated with Interstitial Cystitis</span>. <i>J. Urol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>185</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">1716</span>– <span class="NLM_lpage">1721</span>, <span class="refDoi"> DOI: 10.1016/j.juro.2010.12.088</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=10.1016%2Fj.juro.2010.12.088" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=21420111" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=1%3ACAS%3A528%3ADC%252BC3MXksFSqsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=185&publication_year=2011&pages=1716-1721&issue=5&author=R.+J.+Evansauthor=R.+M.+Moldwinauthor=N.+Cossonsauthor=A.+Darekarauthor=I.+W.+Millsauthor=D.+Scholfield&title=Proof+of+Concept+Trial+of+Tanezumab+for+the+Treatment+of+Symptoms+Associated+with+Interstitial+Cystitis&doi=10.1016%2Fj.juro.2010.12.088"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Proof of Concept Trial of Tanezumab for the Treatment of Symptoms Associated With Interstitial Cystitis</span></div><div class="casAuthors">Evans, R. J.; Moldwin, R. M.; Cossons, N.; Darekar, A.; Mills, I. W.; Scholfield, D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Urology (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">185</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1716-1721</span>CODEN:
                <span class="NLM_cas:coden">JOURAA</span>;
        ISSN:<span class="NLM_cas:issn">0022-5347</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Purpose: In this randomized, double-blind, placebo controlled phase 2 study we investigated tanezumab, a humanized monoclonal antibody that specifically inhibits nerve growth factor as a treatment for interstitial cystitis pain.  Materials and Methods: Patients with interstitial cystitis received a single i.v. dose of 200 μg/kg tanezumab or placebo.  Patients recorded daily pain scores (on an 11-point numerical rating scale) 7 days before attending study visits and completed a urinary symptom diary for 3 of those days.  Patients also completed the Interstitial Cystitis Symptom Index questionnaire and a global response assessment.  The primary end point was change in av. daily numerical rating scale pain score from baseline to week 6.  Secondary end points included global response assessment, Interstitial Cystitis Symptom Index score, micturition and urgency episode frequency per 24 h, and mean voided vol. per micturition.  The incidence of adverse events was also assessed.  Results: A total of 34 patients received tanezumab and 30 received placebo.  At week 6 tanezumab produced a significant redn. from baseline in av. daily pain score vs placebo (treatment difference [LS mean, 90% CI] was -1.4 [-2.2, -0.5]).  A significantly higher proportion of patients on tanezumab responded as improved in the global response assessment and tanezumab also significantly reduced urgency episode frequency vs placebo.  Tanezumab had no significant effect on Interstitial Cystitis Symptom Index score, micturition frequency or mean voided vol. per micturition.  The most common adverse events were headache (tanezumab 20.6%, placebo 16.7%) and paresthesia (tanezumab 17.6%, placebo 3.3%).  Conclusions: Tanezumab has shown preliminary efficacy in the treatment of pain assocd. with interstitial cystitis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrs8VBnrLDcAbVg90H21EOLACvtfcHk0lguVjC7hQsAHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXksFSqsL8%253D&md5=5ac5f081d2cc6eb9b8190148923bcd4f</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2Fj.juro.2010.12.088&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.juro.2010.12.088%26sid%3Dliteratum%253Aachs%26aulast%3DEvans%26aufirst%3DR.%2BJ.%26aulast%3DMoldwin%26aufirst%3DR.%2BM.%26aulast%3DCossons%26aufirst%3DN.%26aulast%3DDarekar%26aufirst%3DA.%26aulast%3DMills%26aufirst%3DI.%2BW.%26aulast%3DScholfield%26aufirst%3DD.%26atitle%3DProof%2520of%2520Concept%2520Trial%2520of%2520Tanezumab%2520for%2520the%2520Treatment%2520of%2520Symptoms%2520Associated%2520with%2520Interstitial%2520Cystitis%26jtitle%3DJ.%2520Urol.%26date%3D2011%26volume%3D185%26issue%3D5%26spage%3D1716%26epage%3D1721%26doi%3D10.1016%2Fj.juro.2010.12.088" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Katz, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borenstein, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Birbara, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bramson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nemeth, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, M. T.</span></span> <span> </span><span class="NLM_article-title">Efficacy and Safety of Tanezumab in the Treatment of Chronic Low Back Pain</span>. <i>Pain</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>152</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">2248</span>– <span class="NLM_lpage">2258</span>, <span class="refDoi"> DOI: 10.1016/j.pain.2011.05.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=10.1016%2Fj.pain.2011.05.003" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=152&publication_year=2011&pages=2248-2258&issue=10&author=N.+Katzauthor=D.+G.+Borensteinauthor=C.+Birbaraauthor=C.+Bramsonauthor=M.+A.+Nemethauthor=M.+D.+Smithauthor=M.+T.+Brown&title=Efficacy+and+Safety+of+Tanezumab+in+the+Treatment+of+Chronic+Low+Back+Pain&doi=10.1016%2Fj.pain.2011.05.003"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2Fj.pain.2011.05.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pain.2011.05.003%26sid%3Dliteratum%253Aachs%26aulast%3DKatz%26aufirst%3DN.%26aulast%3DBorenstein%26aufirst%3DD.%2BG.%26aulast%3DBirbara%26aufirst%3DC.%26aulast%3DBramson%26aufirst%3DC.%26aulast%3DNemeth%26aufirst%3DM.%2BA.%26aulast%3DSmith%26aufirst%3DM.%2BD.%26aulast%3DBrown%26aufirst%3DM.%2BT.%26atitle%3DEfficacy%2520and%2520Safety%2520of%2520Tanezumab%2520in%2520the%2520Treatment%2520of%2520Chronic%2520Low%2520Back%2520Pain%26jtitle%3DPain%26date%3D2011%26volume%3D152%26issue%3D10%26spage%3D2248%26epage%3D2258%26doi%3D10.1016%2Fj.pain.2011.05.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mattson, M. P.</span></span> <span> </span><span class="NLM_article-title">Glutamate and Neurotrophic Factors in Neuronal Plasticity and Disease</span>. <i>Ann. N. Y. Acad. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>1144</i></span>,  <span class="NLM_fpage">97</span>– <span class="NLM_lpage">112</span>, <span class="refDoi"> DOI: 10.1196/annals.1418.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=10.1196%2Fannals.1418.005" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1144&publication_year=2008&pages=97-112&author=M.+P.+Mattson&title=Glutamate+and+Neurotrophic+Factors+in+Neuronal+Plasticity+and+Disease&doi=10.1196%2Fannals.1418.005"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1196%2Fannals.1418.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1196%252Fannals.1418.005%26sid%3Dliteratum%253Aachs%26aulast%3DMattson%26aufirst%3DM.%2BP.%26atitle%3DGlutamate%2520and%2520Neurotrophic%2520Factors%2520in%2520Neuronal%2520Plasticity%2520and%2520Disease%26jtitle%3DAnn.%2520N.%2520Y.%2520Acad.%2520Sci.%26date%3D2008%26volume%3D1144%26spage%3D97%26epage%3D112%26doi%3D10.1196%2Fannals.1418.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Minichiello, L.</span></span> <span> </span><span class="NLM_article-title">TrkB Signalling Pathways in LTP and Learning</span>. <i>Nat. Rev. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">850</span>– <span class="NLM_lpage">860</span>, <span class="refDoi"> DOI: 10.1038/nrn2738</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=10.1038%2Fnrn2738" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=19927149" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsVeqsbvF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2009&pages=850-860&issue=12&author=L.+Minichiello&title=TrkB+Signalling+Pathways+in+LTP+and+Learning&doi=10.1038%2Fnrn2738"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">TrkB signaling pathways in LTP and learning</span></div><div class="casAuthors">Minichiello, Liliana</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Neuroscience</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">850-860</span>CODEN:
                <span class="NLM_cas:coden">NRNAAN</span>;
        ISSN:<span class="NLM_cas:issn">1471-003X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Understanding the mechanisms that underlie learning is one of the most fascinating and central aims of neurobiol. research.  Hippocampal long-term potentiation (LTP) is widely regarded as a prime candidate for the cellular mechanism of learning.  Receptor tyrosine kinase TrkB (also known as NTRK2), known primarily for its function during PNS and CNS development, has emerged in recent years as a potent regulator of hippocampal LTP.  Here, the author describes efforts to understand the signaling pathways and mol. mechanisms that underlie the involvement of TrkB in LTP and learning.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQ0ZpLjq1-0LVg90H21EOLACvtfcHk0lguVjC7hQsAHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsVeqsbvF&md5=61bde8b20f142253bcf101c3d418edba</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1038%2Fnrn2738&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrn2738%26sid%3Dliteratum%253Aachs%26aulast%3DMinichiello%26aufirst%3DL.%26atitle%3DTrkB%2520Signalling%2520Pathways%2520in%2520LTP%2520and%2520Learning%26jtitle%3DNat.%2520Rev.%2520Neurosci.%26date%3D2009%26volume%3D10%26issue%3D12%26spage%3D850%26epage%3D860%26doi%3D10.1038%2Fnrn2738" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mason, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lobo, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parada, L. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lutter, M.</span></span> <span> </span><span class="NLM_article-title">Trk B Signaling in Dopamine 1 Receptor Neurons Regulates Food Intake and Body Weight</span>. <i>Obesity</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>21</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">2372</span>– <span class="NLM_lpage">2376</span>, <span class="refDoi"> DOI: 10.1002/oby.20382</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=10.1002%2Foby.20382" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=23512795" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhslarsbrM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2013&pages=2372-2376&issue=11&author=B.+L.+Masonauthor=M.+K.+Loboauthor=L.+F.+Paradaauthor=M.+Lutter&title=Trk+B+Signaling+in+Dopamine+1+Receptor+Neurons+Regulates+Food+Intake+and+Body+Weight&doi=10.1002%2Foby.20382"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Trk B signaling in dopamine 1 receptor neurons regulates food intake and body weight</span></div><div class="casAuthors">Mason, Brittany L.; Lobo, Mary Kay; Parada, Luis F.; Lutter, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Obesity</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2372-2376</span>CODEN:
                <span class="NLM_cas:coden">OBESAX</span>;
        ISSN:<span class="NLM_cas:issn">1930-7381</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Objective : Loss of BDNF-TrkB signaling results in obesity in both humans and mice; however, the neural circuit that mediates this effect is unknown.  The role of TrkB signaling in dopamine-1 receptor expressing neurons in body wt. regulation was tested.  Methods : Mice with a floxed allele of the TrkB gene were paired with mice expressing Cre-recombinase under control of the D1 promoter to conditionally knock out expression of TrkB receptors from D1-neurons.  Results : Deletion of TrkB receptors from D1 neurons results in obesity in chow fed mice due to increased feed efficiency.  In contrast, loss of Trk B signaling in D1 neurons induced hyperphagia and hyperglycemia in mice maintained on high fat diet.  Conclusions : These findings indicate TrkB signaling in D1 neurons regulates body wt. by distinct mechanisms for chow and high fat diet and may be important for defending the body against the development of obesity and obesity-related disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpV2qD8g4-gkLVg90H21EOLACvtfcHk0lguVjC7hQsAHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhslarsbrM&md5=6876ea2b71a0f18c54c3d66638306471</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1002%2Foby.20382&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Foby.20382%26sid%3Dliteratum%253Aachs%26aulast%3DMason%26aufirst%3DB.%2BL.%26aulast%3DLobo%26aufirst%3DM.%2BK.%26aulast%3DParada%26aufirst%3DL.%2BF.%26aulast%3DLutter%26aufirst%3DM.%26atitle%3DTrk%2520B%2520Signaling%2520in%2520Dopamine%25201%2520Receptor%2520Neurons%2520Regulates%2520Food%2520Intake%2520and%2520Body%2520Weight%26jtitle%3DObesity%26date%3D2013%26volume%3D21%26issue%3D11%26spage%3D2372%26epage%3D2376%26doi%3D10.1002%2Foby.20382" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Noble, E. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Billington, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kotz, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span> <span> </span><span class="NLM_article-title">The Lighter Side of BDNF</span>. <i>Am. J. Physiol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>300</i></span>,  <span class="NLM_fpage">R1053</span>– <span class="NLM_lpage">R1069</span>, <span class="refDoi"> DOI: 10.1152/ajpregu.00776.2010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=10.1152%2Fajpregu.00776.2010" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=300&publication_year=2011&pages=R1053-R1069&author=E.+E.+Nobleauthor=C.+J.+Billingtonauthor=C.+M.+Kotzauthor=C.+Wang&title=The+Lighter+Side+of+BDNF&doi=10.1152%2Fajpregu.00776.2010"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1152%2Fajpregu.00776.2010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1152%252Fajpregu.00776.2010%26sid%3Dliteratum%253Aachs%26aulast%3DNoble%26aufirst%3DE.%2BE.%26aulast%3DBillington%26aufirst%3DC.%2BJ.%26aulast%3DKotz%26aufirst%3DC.%2BM.%26aulast%3DWang%26aufirst%3DC.%26atitle%3DThe%2520Lighter%2520Side%2520of%2520BDNF%26jtitle%3DAm.%2520J.%2520Physiol.%26date%3D2011%26volume%3D300%26spage%3DR1053%26epage%3DR1069%26doi%3D10.1152%2Fajpregu.00776.2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yeo, G. S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Connie Hung, C.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rochford, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keogh, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sivaramakrishnan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Rahilly, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farooqi, I. S.</span></span> <span> </span><span class="NLM_article-title">A De Novo Mutation Affecting Human TrkB Associated with Severe Obesity and Developmental Delay</span>. <i>Nat. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1187</span>– <span class="NLM_lpage">1189</span>, <span class="refDoi"> DOI: 10.1038/nn1336</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=10.1038%2Fnn1336" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=15494731" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=1%3ACAS%3A528%3ADC%252BD2cXovFamu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2004&pages=1187-1189&issue=11&author=G.+S.+H.+Yeoauthor=C.-C.+Connie+Hungauthor=J.+Rochfordauthor=J.+Keoghauthor=J.+Grayauthor=S.+Sivaramakrishnanauthor=S.+O%E2%80%99Rahillyauthor=I.+S.+Farooqi&title=A+De+Novo+Mutation+Affecting+Human+TrkB+Associated+with+Severe+Obesity+and+Developmental+Delay&doi=10.1038%2Fnn1336"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">A de novo mutation affecting human TrkB associated with severe obesity and developmental delay</span></div><div class="casAuthors">Yeo, Giles S. H.; Connie Hung, Chiao-Chien; Rochford, Justin; Keogh, Julia; Gray, Juliette; Sivaramakrishnan, Shoba; O'Rahilly, Stephen; Farooqi, I. Sadaf</div><div class="citationInfo"><span class="NLM_cas:title">Nature Neuroscience</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1187-1189</span>CODEN:
                <span class="NLM_cas:coden">NANEFN</span>;
        ISSN:<span class="NLM_cas:issn">1097-6256</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">An 8-yr-old male with a complex developmental syndrome and severe obesity was heterozygous for a de novo missense mutation resulting in a Y722C substitution in the neurotrophin receptor TrkB.  This mutation markedly impaired receptor autophosphorylation and signaling to MAP kinase.  Mutation of NTRK2, which encodes TrkB, seems to result in a unique human syndrome of hyperphagic obesity.  The assocd. impairment in memory, learning and nociception seen in the proband reflects the crucial role of TrkB in the human nervous system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoOFn7CEYjaXLVg90H21EOLACvtfcHk0liLI4hfFe34Ig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXovFamu7s%253D&md5=1df8713e7b0f3b437cb552a81c2ca628</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1038%2Fnn1336&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnn1336%26sid%3Dliteratum%253Aachs%26aulast%3DYeo%26aufirst%3DG.%2BS.%2BH.%26aulast%3DConnie%2BHung%26aufirst%3DC.-C.%26aulast%3DRochford%26aufirst%3DJ.%26aulast%3DKeogh%26aufirst%3DJ.%26aulast%3DGray%26aufirst%3DJ.%26aulast%3DSivaramakrishnan%26aufirst%3DS.%26aulast%3DO%25E2%2580%2599Rahilly%26aufirst%3DS.%26aulast%3DFarooqi%26aufirst%3DI.%2BS.%26atitle%3DA%2520De%2520Novo%2520Mutation%2520Affecting%2520Human%2520TrkB%2520Associated%2520with%2520Severe%2520Obesity%2520and%2520Developmental%2520Delay%26jtitle%3DNat.%2520Neurosci.%26date%3D2004%26volume%3D7%26issue%3D11%26spage%3D1187%26epage%3D1189%26doi%3D10.1038%2Fnn1336" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Caporali, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emanueli, C.</span></span> <span> </span><span class="NLM_article-title">Cardiovascular Actions of Neurotrophins</span>. <i>Physiol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>89</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">279</span>– <span class="NLM_lpage">308</span>, <span class="refDoi"> DOI: 10.1152/physrev.00007.2008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=10.1152%2Fphysrev.00007.2008" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=89&publication_year=2009&pages=279-308&issue=1&author=A.+Caporaliauthor=C.+Emanueli&title=Cardiovascular+Actions+of+Neurotrophins&doi=10.1152%2Fphysrev.00007.2008"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1152%2Fphysrev.00007.2008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1152%252Fphysrev.00007.2008%26sid%3Dliteratum%253Aachs%26aulast%3DCaporali%26aufirst%3DA.%26aulast%3DEmanueli%26aufirst%3DC.%26atitle%3DCardiovascular%2520Actions%2520of%2520Neurotrophins%26jtitle%3DPhysiol.%2520Rev.%26date%3D2009%26volume%3D89%26issue%3D1%26spage%3D279%26epage%3D308%26doi%3D10.1152%2Fphysrev.00007.2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Martin, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jenkins, V. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsieh, H.-y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balkowiec, A.</span></span> <span> </span><span class="NLM_article-title">Brain-Derived Neurotrophic Factor in Arterial Baroreceptor Pathways: Implications for Activity-Dependent Plasticity at Baroafferent Synapses</span>. <i>J. Neurochem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>108</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">450</span>– <span class="NLM_lpage">464</span>, <span class="refDoi"> DOI: 10.1111/j.1471-4159.2008.05781.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=10.1111%2Fj.1471-4159.2008.05781.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=19054281" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=1%3ACAS%3A528%3ADC%252BD1MXptFCqsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2009&pages=450-464&issue=2&author=J.+L.+Martinauthor=V.+K.+Jenkinsauthor=H.-y.+Hsiehauthor=A.+Balkowiec&title=Brain-Derived+Neurotrophic+Factor+in+Arterial+Baroreceptor+Pathways%3A+Implications+for+Activity-Dependent+Plasticity+at+Baroafferent+Synapses&doi=10.1111%2Fj.1471-4159.2008.05781.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Brain-derived neurotrophic factor in arterial baroreceptor pathways: implications for activity-dependent plasticity at baroafferent synapses</span></div><div class="casAuthors">Martin, Jessica L.; Jenkins, Victoria K.; Hsieh, Hui-ya; Balkowiec, Agnieszka</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neurochemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">108</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">450-464</span>CODEN:
                <span class="NLM_cas:coden">JONRA9</span>;
        ISSN:<span class="NLM_cas:issn">0022-3042</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Functional characteristics of the arterial baroreceptor reflex change throughout ontogenesis, including perinatal adjustments of the reflex gain and adult resetting during hypertension.  However, the cellular mechanisms that underlie these functional changes are not completely understood.  Here, we provide evidence that brain-derived neurotrophic factor (BDNF), a neurotrophin with a well-established role in activity-dependent neuronal plasticity, is abundantly expressed in vivo by a large subset of developing and adult rat baroreceptor afferents.  Immunoreactivity to BDNF is present in the cell bodies of baroafferent neurons in the nodose ganglion, their central projections in the solitary tract, and terminal-like structures in the lower brainstem nucleus tractus solitarius.  Using ELISA in situ combined with elec. field stimulation, we show that native BDNF is released from cultured newborn nodose ganglion neurons in response to patterns that mimic the in vivo activity of baroreceptor afferents.  In particular, high-frequency bursting patterns of baroreceptor firing, which are known to evoke plastic changes at baroreceptor synapses, are significantly more effective at releasing BDNF than tonic patterns of the same av. frequency.  Together, our study indicates that BDNF expressed by first-order baroreceptor neurons is a likely mediator of both developmental and post-developmental modifications at first-order synapses in arterial baroreceptor pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrsiGm9hRdDRbVg90H21EOLACvtfcHk0liLI4hfFe34Ig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXptFCqsg%253D%253D&md5=06d33880034c6d000dd689a27f0d58a5</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1111%2Fj.1471-4159.2008.05781.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1471-4159.2008.05781.x%26sid%3Dliteratum%253Aachs%26aulast%3DMartin%26aufirst%3DJ.%2BL.%26aulast%3DJenkins%26aufirst%3DV.%2BK.%26aulast%3DHsieh%26aufirst%3DH.-y.%26aulast%3DBalkowiec%26aufirst%3DA.%26atitle%3DBrain-Derived%2520Neurotrophic%2520Factor%2520in%2520Arterial%2520Baroreceptor%2520Pathways%253A%2520Implications%2520for%2520Activity-Dependent%2520Plasticity%2520at%2520Baroafferent%2520Synapses%26jtitle%3DJ.%2520Neurochem.%26date%3D2009%26volume%3D108%26issue%3D2%26spage%3D450%26epage%3D464%26doi%3D10.1111%2Fj.1471-4159.2008.05781.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fulgenzi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomassoni-Ardori, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Babini, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Becker, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrick, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puverel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tessarollo, L.</span></span> <span> </span><span class="NLM_article-title">BDNF Modulates Heart Contraction Force and Long-Term Homeostasis through Truncated TrkB.T1 Receptor Activation</span>. <i>J. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>210</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1003</span>– <span class="NLM_lpage">1012</span>, <span class="refDoi"> DOI: 10.1083/jcb.201502100</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=10.1083%2Fjcb.201502100" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=210&publication_year=2015&pages=1003-1012&issue=6&author=G.+Fulgenziauthor=F.+Tomassoni-Ardoriauthor=L.+Babiniauthor=J.+Beckerauthor=C.+Barrickauthor=S.+Puverelauthor=L.+Tessarollo&title=BDNF+Modulates+Heart+Contraction+Force+and+Long-Term+Homeostasis+through+Truncated+TrkB.T1+Receptor+Activation&doi=10.1083%2Fjcb.201502100"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1083%2Fjcb.201502100&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1083%252Fjcb.201502100%26sid%3Dliteratum%253Aachs%26aulast%3DFulgenzi%26aufirst%3DG.%26aulast%3DTomassoni-Ardori%26aufirst%3DF.%26aulast%3DBabini%26aufirst%3DL.%26aulast%3DBecker%26aufirst%3DJ.%26aulast%3DBarrick%26aufirst%3DC.%26aulast%3DPuverel%26aufirst%3DS.%26aulast%3DTessarollo%26aufirst%3DL.%26atitle%3DBDNF%2520Modulates%2520Heart%2520Contraction%2520Force%2520and%2520Long-Term%2520Homeostasis%2520through%2520Truncated%2520TrkB.T1%2520Receptor%2520Activation%26jtitle%3DJ.%2520Cell%2520Biol.%26date%3D2015%26volume%3D210%26issue%3D6%26spage%3D1003%26epage%3D1012%26doi%3D10.1083%2Fjcb.201502100" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lindholm, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castrén, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsoulfas, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolbeck, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berzaghi, M. d. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leingärtner, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heisenberg, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tessarollo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parada, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thoenen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tesarollo, L.</span></span> <span> </span><span class="NLM_article-title">Neurotrophin-3 Induced by Tri-Iodothyronine in Cerebellar Granule Cells Promotes Purkinje Cell Differentiation</span>. <i>J. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>122</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">443</span>– <span class="NLM_lpage">450</span>, <span class="refDoi"> DOI: 10.1083/jcb.122.2.443</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=10.1083%2Fjcb.122.2.443" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=122&publication_year=1993&pages=443-450&issue=2&author=D.+Lindholmauthor=E.+Castr%C3%A9nauthor=P.+Tsoulfasauthor=R.+Kolbeckauthor=M.+d.+P.+Berzaghiauthor=A.+Leing%C3%A4rtnerauthor=C.+Heisenbergauthor=L.+Tessarolloauthor=L.+Paradaauthor=H.+Thoenenauthor=L.+Tesarollo&title=Neurotrophin-3+Induced+by+Tri-Iodothyronine+in+Cerebellar+Granule+Cells+Promotes+Purkinje+Cell+Differentiation&doi=10.1083%2Fjcb.122.2.443"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1083%2Fjcb.122.2.443&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1083%252Fjcb.122.2.443%26sid%3Dliteratum%253Aachs%26aulast%3DLindholm%26aufirst%3DD.%26aulast%3DCastr%25C3%25A9n%26aufirst%3DE.%26aulast%3DTsoulfas%26aufirst%3DP.%26aulast%3DKolbeck%26aufirst%3DR.%26aulast%3DBerzaghi%26aufirst%3DM.%2Bd.%2BP.%26aulast%3DLeing%25C3%25A4rtner%26aufirst%3DA.%26aulast%3DHeisenberg%26aufirst%3DC.%26aulast%3DTessarollo%26aufirst%3DL.%26aulast%3DParada%26aufirst%3DL.%26aulast%3DThoenen%26aufirst%3DH.%26aulast%3DTesarollo%26aufirst%3DL.%26atitle%3DNeurotrophin-3%2520Induced%2520by%2520Tri-Iodothyronine%2520in%2520Cerebellar%2520Granule%2520Cells%2520Promotes%2520Purkinje%2520Cell%2520Differentiation%26jtitle%3DJ.%2520Cell%2520Biol.%26date%3D1993%26volume%3D122%26issue%3D2%26spage%3D443%26epage%3D450%26doi%3D10.1083%2Fjcb.122.2.443" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, X.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rush, R. A.</span></span> <span> </span><span class="NLM_article-title">Functional Roles of Neurotrophin 3 in the Developing and Mature Sympathetic Nervous System</span>. <i>Mol. Neurobiol.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">185</span>– <span class="NLM_lpage">197</span>, <span class="refDoi"> DOI: 10.1007/BF02740622</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=10.1007%2FBF02740622" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=8989769" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=1%3ACAS%3A528%3ADyaK2sXms1Chuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=1996&pages=185-197&issue=3&author=X.-F.+Zhouauthor=R.+A.+Rush&title=Functional+Roles+of+Neurotrophin+3+in+the+Developing+and+Mature+Sympathetic+Nervous+System&doi=10.1007%2FBF02740622"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Functional roles of neurotrophin 3 in the developing and mature sympathetic nervous system</span></div><div class="casAuthors">Zhou, Xin-Fu; Rush, Robert A.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Neurobiology</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">185-197</span>CODEN:
                <span class="NLM_cas:coden">MONBEW</span>;
        ISSN:<span class="NLM_cas:issn">0893-7648</span>.
    
            (<span class="NLM_cas:orgname">Humana</span>)
        </div><div class="casAbstract">A review, with ∼75 refs., on the evidence published in recent years indicating that another member of the NGF family, neurotrophin 3 (NT3), plays both a complementary and overlapping role in the development and maturation of sympathetic neurons.  In migratory neural crest cells, expression of the high-affinity receptor, trkC, and promotion of mitosis by NT3 suggest an involvement in gangliogenesis, since sympathetic neuroblasts express both NT3 and trkC and require NT3 for their proliferation, differentiation, and survival, it has been proposed that the factor acts at this developmental stage as an autocrine or paracrine factor.  However, NT3 also acts in parallel with NGF to promote the survival of postmitotic neurons during late development.  Both trkC and trkA are expressed in sympathetic neurons and function as high-affinity receptors for NT3.  NT3 is synthesized in sympathetic effector tissues and the endogenous factor is retrogradely transported to accumulate within the cell soma.  Thus, in addn. to its role in the differentiation of sympathetic neurons, NT3, like NGF, is also an effector tissue-derived neurotrophic factor for these neurons in maturity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr975ZuRFusjrVg90H21EOLACvtfcHk0libRu4PN-NawA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXms1Chuw%253D%253D&md5=871d2498b71e56ae44f375bd21a3df2f</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1007%2FBF02740622&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252FBF02740622%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DX.-F.%26aulast%3DRush%26aufirst%3DR.%2BA.%26atitle%3DFunctional%2520Roles%2520of%2520Neurotrophin%25203%2520in%2520the%2520Developing%2520and%2520Mature%2520Sympathetic%2520Nervous%2520System%26jtitle%3DMol.%2520Neurobiol.%26date%3D1996%26volume%3D13%26issue%3D3%26spage%3D185%26epage%3D197%26doi%3D10.1007%2FBF02740622" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Flanagan, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blumenkopf, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brissette, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casavant, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shang-Poa, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doty, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elliott, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hines, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kent, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kudlacz, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lillie, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magnuson, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCurdy, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munchhof, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perry, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sawyer, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strelevitz, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Subramanyam, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whipple, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Changelian, P. S.</span></span> <span> </span><span class="NLM_article-title">Discovery of CP-690,550: A Potent and Selective Janus Kinase (JAK) Inhibitor for the Treatment of Autoimmune Diseases and Organ Transplant Rejection</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span> (<span class="NLM_issue">24</span>),  <span class="NLM_fpage">8468</span>– <span class="NLM_lpage">8484</span>, <span class="refDoi"> DOI: 10.1021/jm1004286</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm1004286" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVOgt7vP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=8468-8484&issue=24&author=M.+E.+Flanaganauthor=T.+A.+Blumenkopfauthor=W.+H.+Brissetteauthor=M.+F.+Brownauthor=J.+M.+Casavantauthor=C.+Shang-Poaauthor=J.+L.+Dotyauthor=E.+A.+Elliottauthor=M.+B.+Fisherauthor=M.+Hinesauthor=C.+Kentauthor=E.+M.+Kudlaczauthor=B.+M.+Lillieauthor=K.+S.+Magnusonauthor=S.+P.+McCurdyauthor=M.+J.+Munchhofauthor=B.+D.+Perryauthor=P.+S.+Sawyerauthor=T.+J.+Strelevitzauthor=C.+Subramanyamauthor=J.+Sunauthor=D.+A.+Whippleauthor=P.+S.+Changelian&title=Discovery+of+CP-690%2C550%3A+A+Potent+and+Selective+Janus+Kinase+%28JAK%29+Inhibitor+for+the+Treatment+of+Autoimmune+Diseases+and+Organ+Transplant+Rejection&doi=10.1021%2Fjm1004286"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of CP-690,550: A Potent and Selective Janus Kinase (JAK) Inhibitor for the Treatment of Autoimmune Diseases and Organ Transplant Rejection</span></div><div class="casAuthors">Flanagan, Mark E.; Blumenkopf, Todd A.; Brissette, William H.; Brown, Matthew F.; Casavant, Jeffrey M.; Chang, Shang-Poa; Doty, Jonathan L.; Elliott, Eileen A.; Fisher, Michael B.; Hines, Michael; Kent, Craig; Kudlacz, Elizabeth M.; Lillie, Brett M.; Magnuson, Kelly S.; McCurdy, Sandra P.; Munchhof, Michael J.; Perry, Bret D.; Sawyer, Perry S.; Strelevitz, Timothy J.; Subramanyam, Chakrapani; Sun, Jianmin; Whipple, David A.; Changelian, Paul S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">8468-8484</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">There is a crit. need for safer and more convenient treatments for organ transplant rejection and autoimmune disorders such as rheumatoid arthritis.  Janus tyrosine kinases (JAK1, JAK3) are expressed in lymphoid cells and are involved in the signaling of multiple cytokines important for various T cell functions.  Blockade of the JAK1/JAK3-STAT pathway with a small mol. was anticipated to provide therapeutic immunosuppression/immunomodulation.  The Pfizer compd. library was screened against the catalytic domain of JAK3 resulting in the identification of a pyrrolopyrimidine-based series of inhibitors represented by the hexahydrocarbazolyl pyrrolopyrimidine CP-352,664.  Synthetic analogs of CP-352,664 were screened against the JAK enzymes and evaluated in an IL-2 induced T cell blast proliferation assay.  Select compds. were evaluated in rodent efficacy models of allograft rejection and destructive inflammatory arthritis.  Optimization within this chem. series led to identification of the cyanoacetylpiperidinylamino pyrrolopyrimidine CP-690,550, a potential first-in-class JAK inhibitor for treatment of autoimmune diseases and organ transplant rejection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbFS_8DSHkDbVg90H21EOLACvtfcHk0libRu4PN-NawA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVOgt7vP&md5=c1d31ce42ab3f1c1f3029c6f4f48df1a</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1021%2Fjm1004286&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm1004286%26sid%3Dliteratum%253Aachs%26aulast%3DFlanagan%26aufirst%3DM.%2BE.%26aulast%3DBlumenkopf%26aufirst%3DT.%2BA.%26aulast%3DBrissette%26aufirst%3DW.%2BH.%26aulast%3DBrown%26aufirst%3DM.%2BF.%26aulast%3DCasavant%26aufirst%3DJ.%2BM.%26aulast%3DShang-Poa%26aufirst%3DC.%26aulast%3DDoty%26aufirst%3DJ.%2BL.%26aulast%3DElliott%26aufirst%3DE.%2BA.%26aulast%3DFisher%26aufirst%3DM.%2BB.%26aulast%3DHines%26aufirst%3DM.%26aulast%3DKent%26aufirst%3DC.%26aulast%3DKudlacz%26aufirst%3DE.%2BM.%26aulast%3DLillie%26aufirst%3DB.%2BM.%26aulast%3DMagnuson%26aufirst%3DK.%2BS.%26aulast%3DMcCurdy%26aufirst%3DS.%2BP.%26aulast%3DMunchhof%26aufirst%3DM.%2BJ.%26aulast%3DPerry%26aufirst%3DB.%2BD.%26aulast%3DSawyer%26aufirst%3DP.%2BS.%26aulast%3DStrelevitz%26aufirst%3DT.%2BJ.%26aulast%3DSubramanyam%26aufirst%3DC.%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DWhipple%26aufirst%3DD.%2BA.%26aulast%3DChangelian%26aufirst%3DP.%2BS.%26atitle%3DDiscovery%2520of%2520CP-690%252C550%253A%2520A%2520Potent%2520and%2520Selective%2520Janus%2520Kinase%2520%2528JAK%2529%2520Inhibitor%2520for%2520the%2520Treatment%2520of%2520Autoimmune%2520Diseases%2520and%2520Organ%2520Transplant%2520Rejection%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26issue%3D24%26spage%3D8468%26epage%3D8484%26doi%3D10.1021%2Fjm1004286" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Capdeville, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buchdunger, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmermann, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matter, A.</span></span> <span> </span><span class="NLM_article-title">Glivec (STI571, Imatinib), a Rationally Developed, Targeted Anticancer Drug</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>1</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">493</span>– <span class="NLM_lpage">502</span>, <span class="refDoi"> DOI: 10.1038/nrd839</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=10.1038%2Fnrd839" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=12120256" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=1%3ACAS%3A528%3ADC%252BD38XkvFKlurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2002&pages=493-502&issue=7&author=R.+Capdevilleauthor=E.+Buchdungerauthor=J.+Zimmermannauthor=A.+Matter&title=Glivec+%28STI571%2C+Imatinib%29%2C+a+Rationally+Developed%2C+Targeted+Anticancer+Drug&doi=10.1038%2Fnrd839"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug</span></div><div class="casAuthors">Capdeville, Renaud; Buchdunger, Elisabeth; Zimmermann, Juerg; Matter, Alex</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">493-502</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  In the early 1980s, it became apparent that the work of pioneers such as Robert Weinberg, Mariano Barbacid and many others in identifying cancer-causing genes in humans was opening the door to a new era in anticancer research.  Motivated by this, and by dissatisfaction with the limited efficacy and tolerability of available anticancer modalities, a drug discovery program was initiated with the aim of rationally developing targeted anticancer therapies.  Here, we describe how this program led to the discovery and continuing development of Glivec (Gleevec in the United States), the first selective tyrosine-kinase inhibitor to be approved for the treatment of a cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoeI0HV4de6ObVg90H21EOLACvtfcHk0lif7GWm7wgGFg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XkvFKlurY%253D&md5=c8f6b7a66f74b64f0dedb5e641097acc</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1038%2Fnrd839&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd839%26sid%3Dliteratum%253Aachs%26aulast%3DCapdeville%26aufirst%3DR.%26aulast%3DBuchdunger%26aufirst%3DE.%26aulast%3DZimmermann%26aufirst%3DJ.%26aulast%3DMatter%26aufirst%3DA.%26atitle%3DGlivec%2520%2528STI571%252C%2520Imatinib%2529%252C%2520a%2520Rationally%2520Developed%252C%2520Targeted%2520Anticancer%2520Drug%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2002%26volume%3D1%26issue%3D7%26spage%3D493%26epage%3D502%26doi%3D10.1038%2Fnrd839" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Skerratt, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bagal, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bilsland, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bungay, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cole, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibson, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morao, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nedderman, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Omoto, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryckmans, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skinner, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stupple, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waldron, G.</span></span> <span> </span><span class="NLM_article-title">The Discovery of a Potent, Selective, and Peripherally Restricted Pan-Trk Inhibitor (PF-06273340) for the Treatment of Pain</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span> (<span class="NLM_issue">22</span>),  <span class="NLM_fpage">10084</span>– <span class="NLM_lpage">10099</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00850</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00850" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslWjsbfL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=10084-10099&issue=22&author=S.+E.+Skerrattauthor=M.+Andrewsauthor=S.+K.+Bagalauthor=J.+Bilslandauthor=D.+Brownauthor=P.+J.+Bungayauthor=S.+Coleauthor=K.+R.+Gibsonauthor=R.+Jonesauthor=I.+Moraoauthor=A.+Neddermanauthor=K.+Omotoauthor=C.+Robinsonauthor=T.+Ryckmansauthor=K.+Skinnerauthor=P.+Stuppleauthor=G.+Waldron&title=The+Discovery+of+a+Potent%2C+Selective%2C+and+Peripherally+Restricted+Pan-Trk+Inhibitor+%28PF-06273340%29+for+the+Treatment+of+Pain&doi=10.1021%2Facs.jmedchem.6b00850"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">The Discovery of a Potent, Selective, and Peripherally Restricted Pan-Trk Inhibitor (PF-06273340) for the Treatment of Pain</span></div><div class="casAuthors">Skerratt, Sarah E.; Andrews, Mark; Bagal, Sharan K.; Bilsland, James; Brown, David; Bungay, Peter J.; Cole, Susan; Gibson, Karl R.; Jones, Russell; Morao, Inaki; Nedderman, Angus; Omoto, Kiyoyuki; Robinson, Colin; Ryckmans, Thomas; Skinner, Kimberly; Stupple, Paul; Waldron, Gareth</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">10084-10099</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The neurotrophin family of growth factors, comprised of nerve growth factor (NGF), brain derived neurotrophic factor (BDNF), neurotrophin 3 (NT3) and neurotrophin 4 (NT4), is implicated in the physiol. of chronic pain.  Given the clin. efficacy of anti-NGF monoclonal antibody (mAb) therapies, there is significant interest in the development of small mol. modulators of neurotrophin activity.  Neurotrophins signal through the tropomyosin related kinase (Trk) family of tyrosine kinase receptors, hence Trk kinase inhibition represents a potentially "druggable" point of intervention.  To deliver the safety profile required for chronic, non-life threatening pain indications, highly kinase-selective Trk inhibitors with minimal brain availability are sought.  Herein the authors describe how the use of SBDD, 2D QSAR models and Matched Mol. Pair data in compd. design enabled the delivery of the highly potent, kinase-selective and peripherally restricted clin. candidate PF-06273340.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo67CFmGAkmRrVg90H21EOLACvtfcHk0lif7GWm7wgGFg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslWjsbfL&md5=f8c904a92c1716062c217fefe2374ce6</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00850&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00850%26sid%3Dliteratum%253Aachs%26aulast%3DSkerratt%26aufirst%3DS.%2BE.%26aulast%3DAndrews%26aufirst%3DM.%26aulast%3DBagal%26aufirst%3DS.%2BK.%26aulast%3DBilsland%26aufirst%3DJ.%26aulast%3DBrown%26aufirst%3DD.%26aulast%3DBungay%26aufirst%3DP.%2BJ.%26aulast%3DCole%26aufirst%3DS.%26aulast%3DGibson%26aufirst%3DK.%2BR.%26aulast%3DJones%26aufirst%3DR.%26aulast%3DMorao%26aufirst%3DI.%26aulast%3DNedderman%26aufirst%3DA.%26aulast%3DOmoto%26aufirst%3DK.%26aulast%3DRobinson%26aufirst%3DC.%26aulast%3DRyckmans%26aufirst%3DT.%26aulast%3DSkinner%26aufirst%3DK.%26aulast%3DStupple%26aufirst%3DP.%26aulast%3DWaldron%26aufirst%3DG.%26atitle%3DThe%2520Discovery%2520of%2520a%2520Potent%252C%2520Selective%252C%2520and%2520Peripherally%2520Restricted%2520Pan-Trk%2520Inhibitor%2520%2528PF-06273340%2529%2520for%2520the%2520Treatment%2520of%2520Pain%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26issue%3D22%26spage%3D10084%26epage%3D10099%26doi%3D10.1021%2Facs.jmedchem.6b00850" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gavrin, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saiah, E.</span></span> <span> </span><span class="NLM_article-title">Approaches to Discover Non-ATP Site Kinase Inhibitors</span>. <i>MedChemComm</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>4</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">41</span>– <span class="NLM_lpage">51</span>, <span class="refDoi"> DOI: 10.1039/C2MD20180A</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=10.1039%2FC2MD20180A" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvVymsr7N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=41-51&issue=1&author=L.+K.+Gavrinauthor=E.+Saiah&title=Approaches+to+Discover+Non-ATP+Site+Kinase+Inhibitors&doi=10.1039%2FC2MD20180A"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Approaches to discover non-ATP site kinase inhibitors</span></div><div class="casAuthors">Gavrin, Lori Krim; Saiah, Eddine</div><div class="citationInfo"><span class="NLM_cas:title">MedChemComm</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">41-51</span>CODEN:
                <span class="NLM_cas:coden">MCCEAY</span>;
        ISSN:<span class="NLM_cas:issn">2040-2503</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A review.  The catalytic domain of kinases shows a high degree of sequence homol., esp. for kinases that belong to the same family.  They share a common ATP binding site with a conserved activation loop and similar three-dimensional structure.  Consequently, a major challenge in kinase research exists in achieving selectivity among the >500 family members, since they all process the same substrate.  In addn. to requiring selectivity against other kinases, ATP site inhibitors must also bind tightly to overcome the high physiol. concn. of ATP in the cell.  Furthermore, the development of novel ATP site inhibitors is becoming increasingly challenging, as many ATP competitive scaffolds have previously been disclosed.  In order to develop compds. with better selectivity among kinases, inhibitors that bind outside the ATP site show great promise and are currently being explored by many groups.  This review will highlight the most commonly used methods to discover small mol. Type III and IV kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo7xJcf4-RJ9rVg90H21EOLACvtfcHk0lif7GWm7wgGFg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvVymsr7N&md5=97acf2247e5516c1649c1d964c867656</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1039%2FC2MD20180A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC2MD20180A%26sid%3Dliteratum%253Aachs%26aulast%3DGavrin%26aufirst%3DL.%2BK.%26aulast%3DSaiah%26aufirst%3DE.%26atitle%3DApproaches%2520to%2520Discover%2520Non-ATP%2520Site%2520Kinase%2520Inhibitors%26jtitle%3DMedChemComm%26date%3D2013%26volume%3D4%26issue%3D1%26spage%3D41%26epage%3D51%26doi%3D10.1039%2FC2MD20180A" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Abe, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kikuchi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayakawa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iida, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagahashi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maeda, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakamoto, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsumoto, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miura, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsumura, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seki, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inaba, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawasaki, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamaguchi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kakefuda, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nanayama, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurachi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hori, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshida, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kakegawa, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilmartin, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richter, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moss, K. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laquerre, S. G.</span></span> <span> </span><span class="NLM_article-title">Discovery of a Highly Potent and Selective MEK Inhibitor: GSK1120212 (JTP-74057 DMSO Solvate)</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>2</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">320</span>– <span class="NLM_lpage">324</span>, <span class="refDoi"> DOI: 10.1021/ml200004g</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml200004g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2011&pages=320-324&issue=4&author=H.+Abeauthor=S.+Kikuchiauthor=K.+Hayakawaauthor=T.+Iidaauthor=N.+Nagahashiauthor=K.+Maedaauthor=J.+Sakamotoauthor=N.+Matsumotoauthor=T.+Miuraauthor=K.+Matsumuraauthor=N.+Sekiauthor=T.+Inabaauthor=H.+Kawasakiauthor=T.+Yamaguchiauthor=R.+Kakefudaauthor=T.+Nanayamaauthor=H.+Kurachiauthor=Y.+Horiauthor=T.+Yoshidaauthor=J.+Kakegawaauthor=Y.+Watanabeauthor=A.+G.+Gilmartinauthor=M.+C.+Richterauthor=K.+G.+Mossauthor=S.+G.+Laquerre&title=Discovery+of+a+Highly+Potent+and+Selective+MEK+Inhibitor%3A+GSK1120212+%28JTP-74057+DMSO+Solvate%29&doi=10.1021%2Fml200004g"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Fml200004g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml200004g%26sid%3Dliteratum%253Aachs%26aulast%3DAbe%26aufirst%3DH.%26aulast%3DKikuchi%26aufirst%3DS.%26aulast%3DHayakawa%26aufirst%3DK.%26aulast%3DIida%26aufirst%3DT.%26aulast%3DNagahashi%26aufirst%3DN.%26aulast%3DMaeda%26aufirst%3DK.%26aulast%3DSakamoto%26aufirst%3DJ.%26aulast%3DMatsumoto%26aufirst%3DN.%26aulast%3DMiura%26aufirst%3DT.%26aulast%3DMatsumura%26aufirst%3DK.%26aulast%3DSeki%26aufirst%3DN.%26aulast%3DInaba%26aufirst%3DT.%26aulast%3DKawasaki%26aufirst%3DH.%26aulast%3DYamaguchi%26aufirst%3DT.%26aulast%3DKakefuda%26aufirst%3DR.%26aulast%3DNanayama%26aufirst%3DT.%26aulast%3DKurachi%26aufirst%3DH.%26aulast%3DHori%26aufirst%3DY.%26aulast%3DYoshida%26aufirst%3DT.%26aulast%3DKakegawa%26aufirst%3DJ.%26aulast%3DWatanabe%26aufirst%3DY.%26aulast%3DGilmartin%26aufirst%3DA.%2BG.%26aulast%3DRichter%26aufirst%3DM.%2BC.%26aulast%3DMoss%26aufirst%3DK.%2BG.%26aulast%3DLaquerre%26aufirst%3DS.%2BG.%26atitle%3DDiscovery%2520of%2520a%2520Highly%2520Potent%2520and%2520Selective%2520MEK%2520Inhibitor%253A%2520GSK1120212%2520%2528JTP-74057%2520DMSO%2520Solvate%2529%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D2%26issue%3D4%26spage%3D320%26epage%3D324%26doi%3D10.1021%2Fml200004g" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yap, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patnaik, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fearen, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olmos, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papadopoulos, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baird, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delgado, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lupinacci, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riisnaes, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pope, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heaton, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garrett, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sullivan, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Bono, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tolcher, A. W.</span></span> <span> </span><span class="NLM_article-title">First-in-Man Clinical Trial of the Oral Pan-AKT Inhibitor MK-2206 in Patients with Advanced Solid Tumors</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>29</i></span> (<span class="NLM_issue">35</span>),  <span class="NLM_fpage">4688</span>– <span class="NLM_lpage">4695</span>, <span class="refDoi"> DOI: 10.1200/JCO.2011.35.5263</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=10.1200%2FJCO.2011.35.5263" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=22025163" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtlOnsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2011&pages=4688-4695&issue=35&author=T.+A.+Yapauthor=L.+Yanauthor=A.+Patnaikauthor=I.+Fearenauthor=D.+Olmosauthor=K.+Papadopoulosauthor=R.+D.+Bairdauthor=L.+Delgadoauthor=A.+Taylorauthor=L.+Lupinacciauthor=R.+Riisnaesauthor=L.+L.+Popeauthor=S.+P.+Heatonauthor=G.+Thomasauthor=M.+D.+Garrettauthor=D.+M.+Sullivanauthor=J.+S.+de+Bonoauthor=A.+W.+Tolcher&title=First-in-Man+Clinical+Trial+of+the+Oral+Pan-AKT+Inhibitor+MK-2206+in+Patients+with+Advanced+Solid+Tumors&doi=10.1200%2FJCO.2011.35.5263"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors</span></div><div class="casAuthors">Yap, Timothy A.; Yan, Li; Patnaik, Amita; Fearen, Ivy; Olmos, David; Papadopoulos, Kyriakos; Baird, Richard D.; Delgado, Liliana; Taylor, Adekemi; Lupinacci, Lisa; Riisnaes, Ruth; Pope, Lorna L.; Heaton, Simon P.; Thomas, George; Garrett, Michelle D.; Sullivan, Daniel M.; de Bono, Johann S.; Tolcher, Anthony W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">35</span>),
    <span class="NLM_cas:pages">4688-4695</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose AKT signaling is frequently deregulated in human cancers.  MK-2206 is a potent, oral allosteric inhibitor of all AKT isoforms with antitumor activity in preclin. models.  A phase I study of MK-2206 was conducted to investigate its safety, max.-tolerated dose (MTD), pharmacokinetics (PKs), pharmacodynamics (PDs), and preliminary antitumor efficacy.  Patients and Methods Patients with advanced solid tumors received MK-2206 on alternate days.  Paired tumor biopsies were mandated at the MTD for biomarker studies.  PD studies incorporated tumor and hair follicle analyses, and putative predictive biomarker studies included tumor somatic mutation analyses and immunohistochem. for phosphatase and tensin homolog (PTEN) loss.  Results Thirty-three patients received MK-2206 at 30, 60, 75, or 90 mg on alternate days.  Dose-limiting toxicities included skin rash and stomatitis, establishing the MTD at 60 mg.  Drug-related toxicities included skin rash (51.5%), nausea (36.4%), pruritus (24.2%), hyperglycemia (21.2%), and diarrhea (21.2%).  PKs (area under the concn.-time curve from 0 to 48 h and max. measured plasma concn.) were dose proportional.  Phosphorylated serine 473 AKT declined in all tumor biopsies assessed (P = .015), and phosphorylated threonine 246 proline-rich AKT substrate 40 was suppressed in hair follicles at 6 h (P = .008), on days 7 (P = .028) and 15 (P = .025) with MK-2206; reversible hyperglycemia and increases in insulin c-peptide were also obsd., confirming target modulation.  A patient with pancreatic adenocarcinoma (PTEN loss; KRAS G12D mutation) treated at 60 mg on alternate days experienced a decrease of approx. 60% in cancer antigen 19-9 levels and 23% shrinkage in tumor measurements.  Two patients with pancreatic neuroendocrine tumors had minor tumor responses.  Conclusion MK-2206 was well tolerated, with evidence of AKT signaling blockade.  Rational combination trials are ongoing to maximize clin. benefit with this therapeutic strategy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdHD9mhSwVT7Vg90H21EOLACvtfcHk0lgIkKknfzaSKA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtlOnsLw%253D&md5=2ee8b8985e337a161807b9c862b573d2</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1200%2FJCO.2011.35.5263&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2011.35.5263%26sid%3Dliteratum%253Aachs%26aulast%3DYap%26aufirst%3DT.%2BA.%26aulast%3DYan%26aufirst%3DL.%26aulast%3DPatnaik%26aufirst%3DA.%26aulast%3DFearen%26aufirst%3DI.%26aulast%3DOlmos%26aufirst%3DD.%26aulast%3DPapadopoulos%26aufirst%3DK.%26aulast%3DBaird%26aufirst%3DR.%2BD.%26aulast%3DDelgado%26aufirst%3DL.%26aulast%3DTaylor%26aufirst%3DA.%26aulast%3DLupinacci%26aufirst%3DL.%26aulast%3DRiisnaes%26aufirst%3DR.%26aulast%3DPope%26aufirst%3DL.%2BL.%26aulast%3DHeaton%26aufirst%3DS.%2BP.%26aulast%3DThomas%26aufirst%3DG.%26aulast%3DGarrett%26aufirst%3DM.%2BD.%26aulast%3DSullivan%26aufirst%3DD.%2BM.%26aulast%3Dde%2BBono%26aufirst%3DJ.%2BS.%26aulast%3DTolcher%26aufirst%3DA.%2BW.%26atitle%3DFirst-in-Man%2520Clinical%2520Trial%2520of%2520the%2520Oral%2520Pan-AKT%2520Inhibitor%2520MK-2206%2520in%2520Patients%2520with%2520Advanced%2520Solid%2520Tumors%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2011%26volume%3D29%26issue%3D35%26spage%3D4688%26epage%3D4695%26doi%3D10.1200%2FJCO.2011.35.5263" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adrian, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jahnke, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowan-Jacob, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iacob, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sim, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powers, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dierks, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, G.-R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okram, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wojciechowski, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fendrich, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strauss, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vajpai, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grzesiek, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuntland, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bursulaya, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Azam, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manley, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engen, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daley, G. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warmuth, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span> <span> </span><span class="NLM_article-title">Targeting Bcr-Abl by Combining Allosteric with ATP-Binding-Site Inhibitors</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>463</i></span> (<span class="NLM_issue">7280</span>),  <span class="NLM_fpage">501</span>– <span class="NLM_lpage">506</span>, <span class="refDoi"> DOI: 10.1038/nature08675</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=10.1038%2Fnature08675" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=463&publication_year=2010&pages=501-506&issue=7280&author=J.+Zhangauthor=F.+J.+Adrianauthor=W.+Jahnkeauthor=S.+W.+Cowan-Jacobauthor=A.+G.+Liauthor=R.+E.+Iacobauthor=T.+Simauthor=J.+Powersauthor=C.+Dierksauthor=F.+Sunauthor=G.-R.+Guoauthor=Q.+Dingauthor=B.+Okramauthor=Y.+Choiauthor=A.+Wojciechowskiauthor=X.+Dengauthor=G.+Liuauthor=G.+Fendrichauthor=A.+Straussauthor=N.+Vajpaiauthor=S.+Grzesiekauthor=T.+Tuntlandauthor=Y.+Liuauthor=B.+Bursulayaauthor=M.+Azamauthor=P.+W.+Manleyauthor=J.+R.+Engenauthor=G.+Q.+Daleyauthor=M.+Warmuthauthor=N.+S.+Gray&title=Targeting+Bcr-Abl+by+Combining+Allosteric+with+ATP-Binding-Site+Inhibitors&doi=10.1038%2Fnature08675"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1038%2Fnature08675&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature08675%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DAdrian%26aufirst%3DF.%2BJ.%26aulast%3DJahnke%26aufirst%3DW.%26aulast%3DCowan-Jacob%26aufirst%3DS.%2BW.%26aulast%3DLi%26aufirst%3DA.%2BG.%26aulast%3DIacob%26aufirst%3DR.%2BE.%26aulast%3DSim%26aufirst%3DT.%26aulast%3DPowers%26aufirst%3DJ.%26aulast%3DDierks%26aufirst%3DC.%26aulast%3DSun%26aufirst%3DF.%26aulast%3DGuo%26aufirst%3DG.-R.%26aulast%3DDing%26aufirst%3DQ.%26aulast%3DOkram%26aufirst%3DB.%26aulast%3DChoi%26aufirst%3DY.%26aulast%3DWojciechowski%26aufirst%3DA.%26aulast%3DDeng%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DG.%26aulast%3DFendrich%26aufirst%3DG.%26aulast%3DStrauss%26aufirst%3DA.%26aulast%3DVajpai%26aufirst%3DN.%26aulast%3DGrzesiek%26aufirst%3DS.%26aulast%3DTuntland%26aufirst%3DT.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DBursulaya%26aufirst%3DB.%26aulast%3DAzam%26aufirst%3DM.%26aulast%3DManley%26aufirst%3DP.%2BW.%26aulast%3DEngen%26aufirst%3DJ.%2BR.%26aulast%3DDaley%26aufirst%3DG.%2BQ.%26aulast%3DWarmuth%26aufirst%3DM.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DTargeting%2520Bcr-Abl%2520by%2520Combining%2520Allosteric%2520with%2520ATP-Binding-Site%2520Inhibitors%26jtitle%3DNature%26date%3D2010%26volume%3D463%26issue%3D7280%26spage%3D501%26epage%3D506%26doi%3D10.1038%2Fnature08675" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, E. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aggarwal, A. K.</span></span> <span> </span><span class="NLM_article-title">The Ins and Outs of Bcr-Abl Inhibition</span>. <i>Genes Cancer</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>3</i></span> (<span class="NLM_issue">5–6</span>),  <span class="NLM_fpage">447</span>– <span class="NLM_lpage">454</span>, <span class="refDoi"> DOI: 10.1177/1947601912462126</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=10.1177%2F1947601912462126" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=23226582" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjsVSlur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=447-454&issue=5%E2%80%936&author=E.+P.+Reddyauthor=A.+K.+Aggarwal&title=The+Ins+and+Outs+of+Bcr-Abl+Inhibition&doi=10.1177%2F1947601912462126"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">The ins and outs of Bcr-Abl inhibition</span></div><div class="casAuthors">Reddy, E. Premkumar; Aggarwal, Aneel K.</div><div class="citationInfo"><span class="NLM_cas:title">Genes & Cancer</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">5-6</span>),
    <span class="NLM_cas:pages">447-454, 8</span>CODEN:
                <span class="NLM_cas:coden">GCEAAY</span>;
        ISSN:<span class="NLM_cas:issn">1947-6019</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">The development of inhibitors against Abl has changed the landscape for the treatment of chronic myelogenous leukemia (CML) and cancer in general.  Beginning with the monumental discovery and approval of imatinib for CML, a second generation of inhibitors, nilotinib and dasatinib, has now gained approval for the treatment of CML.  Notably, these second-generation inhibitors are active against many of the mutations in the Abl kinase that confer resistance to imatinib.  However, resistance remains a major problem, and new inhibitors such as ponatinib and GNF2/GNF5 have been developed, with activity towards the common gatekeeper T315I mutation.  We review here the mechanisms of Abl inhibition with an emphasis on structural elements that are important for the selectivity and design of new mols.  In particular, we focus on how changes in the conformation of the P-loop, the activation loop, the DFG motif, and other structural elements of Abl have been instrumental in developing an understanding of inhibitor binding.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkLh2d24eNB7Vg90H21EOLACvtfcHk0lgIkKknfzaSKA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjsVSlur4%253D&md5=0e8f9f9577b585c0bc28e06beee83d49</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1177%2F1947601912462126&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1947601912462126%26sid%3Dliteratum%253Aachs%26aulast%3DReddy%26aufirst%3DE.%2BP.%26aulast%3DAggarwal%26aufirst%3DA.%2BK.%26atitle%3DThe%2520Ins%2520and%2520Outs%2520of%2520Bcr-Abl%2520Inhibition%26jtitle%3DGenes%2520Cancer%26date%3D2012%26volume%3D3%26issue%3D5%25E2%2580%25936%26spage%3D447%26epage%3D454%26doi%3D10.1177%2F1947601912462126" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Craig, W. L.</span></span> <span> </span><span class="NLM_article-title">The Akt/PKB Family of Protein Kinases: A Review of Small Molecule Inhibitors and Progress Towards Target Validation: A 2009 Update</span>. <i>Curr. Top. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">458</span>– <span class="NLM_lpage">477</span>, <span class="refDoi"> DOI: 10.2174/156802610790980602</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=10.2174%2F156802610790980602" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=20180757" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2010&pages=458-477&issue=4&author=W.+L.+Craig&title=The+Akt%2FPKB+Family+of+Protein+Kinases%3A+A+Review+of+Small+Molecule+Inhibitors+and+Progress+Towards+Target+Validation%3A+A+2009+Update&doi=10.2174%2F156802610790980602"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.2174%2F156802610790980602&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F156802610790980602%26sid%3Dliteratum%253Aachs%26aulast%3DCraig%26aufirst%3DW.%2BL.%26atitle%3DThe%2520Akt%252FPKB%2520Family%2520of%2520Protein%2520Kinases%253A%2520A%2520Review%2520of%2520Small%2520Molecule%2520Inhibitors%2520and%2520Progress%2520Towards%2520Target%2520Validation%253A%2520A%25202009%2520Update%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2010%26volume%3D10%26issue%3D4%26spage%3D458%26epage%3D477%26doi%3D10.2174%2F156802610790980602" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Simard, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kluter, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grutter, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Getlik, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rabiller, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rode, H. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rauh, D.</span></span> <span> </span><span class="NLM_article-title">A New Screening Assay for Allosteric Inhibitors of cSrc</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>5</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">394</span>– <span class="NLM_lpage">396</span>, <span class="refDoi"> DOI: 10.1038/nchembio.162</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=10.1038%2Fnchembio.162" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=19396179" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=1%3ACAS%3A528%3ADC%252BD1MXltValtLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2009&pages=394-396&issue=6&author=J.+R.+Simardauthor=S.+Kluterauthor=C.+Grutterauthor=M.+Getlikauthor=M.+Rabillerauthor=H.+B.+Rodeauthor=D.+Rauh&title=A+New+Screening+Assay+for+Allosteric+Inhibitors+of+cSrc&doi=10.1038%2Fnchembio.162"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">A new screening assay for allosteric inhibitors of cSrc</span></div><div class="casAuthors">Simard, Jeffrey R.; Klueter, Sabine; Gruetter, Christian; Getlik, Matthaeus; Rabiller, Matthias; Rode, Haridas B.; Rauh, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">394-396</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Targeting kinases outside the highly conserved ATP pocket is thought to be a promising strategy for overcoming bottlenecks in kinase inhibitor research, such as limited selectivity and drug resistance.  Here we report the development and application of a direct binding assay to detect small mols. that stabilize the inactive conformation of the tyrosine kinase cSrc.  Protein X-ray crystallog. validated the assay results and confirmed an exclusively allosteric binding mode.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpMs1P4WsnsYLVg90H21EOLACvtfcHk0ljn6sXdAIq0SQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXltValtLY%253D&md5=2ae7854a35d3eae39a764f8ef4f9fd47</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.162&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.162%26sid%3Dliteratum%253Aachs%26aulast%3DSimard%26aufirst%3DJ.%2BR.%26aulast%3DKluter%26aufirst%3DS.%26aulast%3DGrutter%26aufirst%3DC.%26aulast%3DGetlik%26aufirst%3DM.%26aulast%3DRabiller%26aufirst%3DM.%26aulast%3DRode%26aufirst%3DH.%2BB.%26aulast%3DRauh%26aufirst%3DD.%26atitle%3DA%2520New%2520Screening%2520Assay%2520for%2520Allosteric%2520Inhibitors%2520of%2520cSrc%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2009%26volume%3D5%26issue%3D6%26spage%3D394%26epage%3D396%26doi%3D10.1038%2Fnchembio.162" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Heinrich, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grädler, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Böttcher, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blaukat, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shutes, A.</span></span> <span> </span><span class="NLM_article-title">Allosteric IGF-1R Inhibitors</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>1</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">199</span>– <span class="NLM_lpage">203</span>, <span class="refDoi"> DOI: 10.1021/ml100044h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml100044h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2010&pages=199-203&issue=5&author=T.+Heinrichauthor=U.+Gr%C3%A4dlerauthor=H.+B%C3%B6ttcherauthor=A.+Blaukatauthor=A.+Shutes&title=Allosteric+IGF-1R+Inhibitors&doi=10.1021%2Fml100044h"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Fml100044h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml100044h%26sid%3Dliteratum%253Aachs%26aulast%3DHeinrich%26aufirst%3DT.%26aulast%3DGr%25C3%25A4dler%26aufirst%3DU.%26aulast%3DB%25C3%25B6ttcher%26aufirst%3DH.%26aulast%3DBlaukat%26aufirst%3DA.%26aulast%3DShutes%26aufirst%3DA.%26atitle%3DAllosteric%2520IGF-1R%2520Inhibitors%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D1%26issue%3D5%26spage%3D199%26epage%3D203%26doi%3D10.1021%2Fml100044h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mueller, M.</span></span> <span> </span><span class="NLM_article-title">In Vivo Function of NGF/TrkA Signaling in the Cholinergic Neurons of the Murine Basal Forebrain</span>. Ph.D Dissertation, Ludwig-Maximilians-University, Munich, <span class="NLM_year">2005</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2005&author=M.+Mueller&title=In+Vivo+Function+of+NGF%2FTrkA+Signaling+in+the+Cholinergic+Neurons+of+the+Murine+Basal+Forebrain"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMueller%26aufirst%3DM.%26atitle%3DIn%2520Vivo%2520Function%2520of%2520NGF%252FTrkA%2520Signaling%2520in%2520the%2520Cholinergic%2520Neurons%2520of%2520the%2520Murine%2520Basal%2520Forebrain%26date%3D2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mufson, E. J.</span>; <span class="NLM_string-name">Kordower, J. H.</span></span> <span> </span><span class="NLM_article-title">Nerve Growth Factor Systems in Alzheimer’s Disease</span>. In  <i>Cerebral Cortex</i>, <span class="NLM_contrib-group"><span class="NLM_string-name">Peters, A.</span>, <span class="NLM_string-name">Morrison, J. H.</span></span>, Eds.; <span class="NLM_publisher-name">Springer</span>: <span class="NLM_publisher-loc">Boston</span>, <span class="NLM_year">1999</span>; Vol.  <span class="NLM_volume">14</span>, pp  <span class="NLM_fpage">681</span>– <span class="NLM_lpage">731</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=10.1007%2F978-1-4615-4885-0_19" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1999&pages=681-731&author=E.+J.+Mufson&author=J.+H.+Kordowerauthor=A.+Peters&author=J.+H.+Morrison&title=Cerebral+Cortex"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1007%2F978-1-4615-4885-0_19&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1007%252F978-1-4615-4885-0_19%26sid%3Dliteratum%253Aachs%26aulast%3DMufson%26aufirst%3DE.%2BJ.%26atitle%3DNerve%2520Growth%2520Factor%2520Systems%2520in%2520Alzheimer%25E2%2580%2599s%2520Disease%26btitle%3DCerebral%2520Cortex%26aulast%3DPeters%26aufirst%3DA.%26pub%3DSpringer%26date%3D1999%26volume%3D14%26spage%3D681%26epage%3D731" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez-Ortiz, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yui, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rubenstein, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reichardt, L. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parada, L. F.</span></span> <span> </span><span class="NLM_article-title">TrkA Gene Ablation in Basal Forebrain Results in Dysfunction of the Cholinergic Circuitry</span>. <i>J. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>32</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">4065</span>– <span class="NLM_lpage">4079</span>, <span class="refDoi"> DOI: 10.1523/JNEUROSCI.6314-11.2012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=10.1523%2FJNEUROSCI.6314-11.2012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=22442072" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=1%3ACAS%3A528%3ADC%252BC38XkslCmt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2012&pages=4065-4079&issue=12&author=E.+Sanchez-Ortizauthor=D.+Yuiauthor=D.+Songauthor=Y.+Liauthor=J.+L.+Rubensteinauthor=L.+F.+Reichardtauthor=L.+F.+Parada&title=TrkA+Gene+Ablation+in+Basal+Forebrain+Results+in+Dysfunction+of+the+Cholinergic+Circuitry&doi=10.1523%2FJNEUROSCI.6314-11.2012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">TrkA gene ablation in basal forebrain results in dysfunction of the cholinergic circuitry</span></div><div class="casAuthors">Sanchez-Ortiz, Efrain; Yui, Daishi; Song, Dongli; Li, Yun; Rubenstein, John L.; Reichardt, Louis F.; Parada, Luis F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">4065-4079</span>CODEN:
                <span class="NLM_cas:coden">JNRSDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-6474</span>.
    
            (<span class="NLM_cas:orgname">Society for Neuroscience</span>)
        </div><div class="casAbstract">Dysfunction of basal forebrain cholinergic neurons (BFCNs) is an early pathol. hallmark of Alzheimer's disease (AD).  Numerous studies have indicated that nerve growth factor (NGF) supports survival and phenotypic differentiation of BFCNs.  Consistent with a potential link to AD pathogenesis, TrkA, a NGF receptor, is expressed in cholinergic forebrain neuronal populations including those in BF and striatum, and is markedly reduced in individuals with mild cognitive impairment (MCI) without dementia and early-stage AD.  To investigate the role of TrkA in the development, connectivity, and function of the BF cholinergic system and its contribution to AD pathol., we have generated a forebrain-specific conditional TrkA knock-out mouse line.  Our findings show a key role for TrkA signaling in establishing the BF cholinergic circuitry through the ERK pathway, and demonstrate that the normal developmental increase of choline acetyltransferase expression becomes critically dependent on TrkA signaling before neuronal connections are established.  Moreover, the anatomical and physiol. deficits caused by lack of TrkA signaling in BFCNs have selective impact on cognitive activity.  These data demonstrate that TrkA loss results in cholinergic BF dysfunction and cognitive decline that is reminiscent of MCI and early AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9qproimMfdrVg90H21EOLACvtfcHk0ljn6sXdAIq0SQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XkslCmt74%253D&md5=fac45c446552ea69e72cdd15200d54c2</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1523%2FJNEUROSCI.6314-11.2012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1523%252FJNEUROSCI.6314-11.2012%26sid%3Dliteratum%253Aachs%26aulast%3DSanchez-Ortiz%26aufirst%3DE.%26aulast%3DYui%26aufirst%3DD.%26aulast%3DSong%26aufirst%3DD.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DRubenstein%26aufirst%3DJ.%2BL.%26aulast%3DReichardt%26aufirst%3DL.%2BF.%26aulast%3DParada%26aufirst%3DL.%2BF.%26atitle%3DTrkA%2520Gene%2520Ablation%2520in%2520Basal%2520Forebrain%2520Results%2520in%2520Dysfunction%2520of%2520the%2520Cholinergic%2520Circuitry%26jtitle%3DJ.%2520Neurosci.%26date%3D2012%26volume%3D32%26issue%3D12%26spage%3D4065%26epage%3D4079%26doi%3D10.1523%2FJNEUROSCI.6314-11.2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamb, M. L.</span></span> <span> </span><span class="NLM_article-title">Trk Kinase Inhibitors as New Treatments for Cancer and Pain</span>. <i>Expert Opin. Ther. Pat.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>19</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">305</span>– <span class="NLM_lpage">319</span>, <span class="refDoi"> DOI: 10.1517/13543770902721261</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=10.1517%2F13543770902721261" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=19441906" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjslWlu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=305-319&issue=3&author=T.+Wangauthor=D.+Yuauthor=M.+L.+Lamb&title=Trk+Kinase+Inhibitors+as+New+Treatments+for+Cancer+and+Pain&doi=10.1517%2F13543770902721261"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Trk kinase inhibitors as new treatments for cancer and pain</span></div><div class="casAuthors">Wang, Tao; Yu, Dingwei; Lamb, Michelle L.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">305-319</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Background: Tropomyosin-related kinases (Trks) are a family of receptor tyrosine kinases activated by neurotrophins.  Trks play important roles in pain sensation as well as tumor cell growth and survival signaling.  Thus, inhibitors of Trk receptor kinases might provide targeted treatments for pain and cancer.  Objective: This paper reviews those patent applications since 2002 claiming small-mol. inhibitors of Trk receptor kinases.  Methods: Primary literature and patents were searched with SciFinder and Google Scholar.  Patents were selected based on their relevance to Trks and were evaluated and representative compds. were listed as examples.  Results/conclusion: Several series of Trk inhibitors with excellent in vitro potencies have been reported and a no. of compds. have gone into the clinic.  It should be noted that few of these inhibitors are Trk selective, demonstrating that targeting Trk kinases for treatment of pain and/or cancer offers a promising but also challenging approach.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvknvXUUz2DbVg90H21EOLACvtfcHk0lgLNkRTPRbDWg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjslWlu7o%253D&md5=ffc2d3e33102631cac7b89dce7f96a5a</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1517%2F13543770902721261&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543770902721261%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DT.%26aulast%3DYu%26aufirst%3DD.%26aulast%3DLamb%26aufirst%3DM.%2BL.%26atitle%3DTrk%2520Kinase%2520Inhibitors%2520as%2520New%2520Treatments%2520for%2520Cancer%2520and%2520Pain%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2009%26volume%3D19%26issue%3D3%26spage%3D305%26epage%3D319%26doi%3D10.1517%2F13543770902721261" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bagal, S. K.</span></span> The Discovery and Optimization of a Series of Potent, Selective and CNS Restricted Pan-Trk Ligands. In  <i>Kinase 2014: Past, Present and Beyond, 6th RSC/SCI Symposium on Kinase Inhibitor Design</i>, The Barry Cross Conference Centre, Cambridge, 19–20 May 2014.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Bagal%2C+S.+K.+The+Discovery+and+Optimization+of+a+Series+of+Potent%2C+Selective+and+CNS+Restricted+Pan-Trk+Ligands.+In+Kinase+2014%3A+Past%2C+Present+and+Beyond%2C+6th+RSC%2FSCI+Symposium+on+Kinase+Inhibitor+Design%2C+The+Barry+Cross+Conference+Centre%2C+Cambridge%2C+19%E2%80%9320+May+2014."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dconf-proc%26sid%3Dliteratum%253Aachs%26aulast%3DBagal%26aufirst%3DS.%2BK.%26jtitle%3DKinase%25202014%253A%2520Past%252C%2520Present%2520and%2520Beyond%252C%25206th%2520RSC%252FSCI%2520Symposium%2520on%2520Kinase%2520Inhibitor%2520Design" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bagal, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bungay, P.</span></span> <span> </span><span class="NLM_article-title">Restricting CNS Penetration of Drugs to Minimise Adverse Events: Role of Drug Transporters</span>. <i>Drug Discovery Today: Technol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">79</span>– <span class="NLM_lpage">85</span>, <span class="refDoi"> DOI: 10.1016/j.ddtec.2014.03.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=10.1016%2Fj.ddtec.2014.03.008" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2014&pages=79-85&author=S.+Bagalauthor=P.+Bungay&title=Restricting+CNS+Penetration+of+Drugs+to+Minimise+Adverse+Events%3A+Role+of+Drug+Transporters&doi=10.1016%2Fj.ddtec.2014.03.008"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1016%2Fj.ddtec.2014.03.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ddtec.2014.03.008%26sid%3Dliteratum%253Aachs%26aulast%3DBagal%26aufirst%3DS.%26aulast%3DBungay%26aufirst%3DP.%26atitle%3DRestricting%2520CNS%2520Penetration%2520of%2520Drugs%2520to%2520Minimise%2520Adverse%2520Events%253A%2520Role%2520of%2520Drug%2520Transporters%26jtitle%3DDrug%2520Discovery%2520Today%253A%2520Technol.%26date%3D2014%26volume%3D12%26spage%3D79%26epage%3D85%26doi%3D10.1016%2Fj.ddtec.2014.03.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cole, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bagal, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El-Kattan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fenner, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hay, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kempshall, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lunn, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varma, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stupple, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Speed, W.</span></span> <span> </span><span class="NLM_article-title">Full Efficacy with No CNS Side-Effects: Unachievable Panacea or Reality?? DMPK Considerations in Design of Drugs with Limited Brain Penetration</span>. <i>Xenobiotica</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>42</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">11</span>– <span class="NLM_lpage">27</span>, <span class="refDoi"> DOI: 10.3109/00498254.2011.617847</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=10.3109%2F00498254.2011.617847" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2012&pages=11-27&issue=1&author=S.+Coleauthor=S.+Bagalauthor=A.+El-Kattanauthor=K.+Fennerauthor=T.+Hayauthor=S.+Kempshallauthor=G.+Lunnauthor=M.+Varmaauthor=P.+Stuppleauthor=W.+Speed&title=Full+Efficacy+with+No+CNS+Side-Effects%3A+Unachievable+Panacea+or+Reality%3F%3F+DMPK+Considerations+in+Design+of+Drugs+with+Limited+Brain+Penetration&doi=10.3109%2F00498254.2011.617847"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.3109%2F00498254.2011.617847&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F00498254.2011.617847%26sid%3Dliteratum%253Aachs%26aulast%3DCole%26aufirst%3DS.%26aulast%3DBagal%26aufirst%3DS.%26aulast%3DEl-Kattan%26aufirst%3DA.%26aulast%3DFenner%26aufirst%3DK.%26aulast%3DHay%26aufirst%3DT.%26aulast%3DKempshall%26aufirst%3DS.%26aulast%3DLunn%26aufirst%3DG.%26aulast%3DVarma%26aufirst%3DM.%26aulast%3DStupple%26aufirst%3DP.%26aulast%3DSpeed%26aufirst%3DW.%26atitle%3DFull%2520Efficacy%2520with%2520No%2520CNS%2520Side-Effects%253A%2520Unachievable%2520Panacea%2520or%2520Reality%253F%253F%2520DMPK%2520Considerations%2520in%2520Design%2520of%2520Drugs%2520with%2520Limited%2520Brain%2520Penetration%26jtitle%3DXenobiotica%26date%3D2012%26volume%3D42%26issue%3D1%26spage%3D11%26epage%3D27%26doi%3D10.3109%2F00498254.2011.617847" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wager, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liras, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mente, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trapa, P.</span></span> <span> </span><span class="NLM_article-title">Strategies to Minimize CNS Toxicity: In Vitro High-Throughput Assays and Computational Modeling</span>. <i>Expert Opin. Drug Metab. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">531</span>– <span class="NLM_lpage">542</span>, <span class="refDoi"> DOI: 10.1517/17425255.2012.677028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=10.1517%2F17425255.2012.677028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=22458547" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=1%3ACAS%3A528%3ADC%252BC38XlvV2qs7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2012&pages=531-542&issue=5&author=T.+T.+Wagerauthor=J.+L.+Lirasauthor=S.+Menteauthor=P.+Trapa&title=Strategies+to+Minimize+CNS+Toxicity%3A+In+Vitro+High-Throughput+Assays+and+Computational+Modeling&doi=10.1517%2F17425255.2012.677028"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Strategies to minimize CNS toxicity: in vitro high-throughput assays and computational modeling</span></div><div class="casAuthors">Wager, Travis T.; Liras, Jennifer L.; Mente, Scot; Trapa, Patrick</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Metabolism & Toxicology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">531-542</span>CODEN:
                <span class="NLM_cas:coden">EODMAP</span>;
        ISSN:<span class="NLM_cas:issn">1742-5255</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: Healthy functioning of the brain is dependent on the ability of the blood-brain barrier (BBB) and other central nervous system (CNS) barriers to protect the neurocompartments from potential disruptive and damaging xenobiotic agents.  In vitro high-throughput (HT) screens and computational models that assess a compd.'s ability to pass through or disrupt the BBB have become important tools in the identification of new well-tolerated peripheral drugs and safer chem. products such as pesticides.  Leveraging these HT in vitro assays and computational BBB tools together with the current understanding of brain penetration may enable the drug discovery community to minimize access of drug candidates into the CNS compartment.  Areas covered: This article reviews aspects of the most recent in vitro and computational approaches designed to provide an early assessment of a compd.'s ability to access the neurocompartment.  This article also provides insight into using these tools to identify compds. that have restricted access to the neurocompartment.  Expert opinion: The development of safer peripheral-acting medicines and chem. products can be achieved through prospective design and early assessment with HT assays of the BBB in conjunction with computational models.  Exclusion or significantly reduced access of a compd. to the neurocompartment will increase the odds of identifying a compd. with reduced CNS-related adverse drug reactions.  A holistic approach to compd. design and evaluation that incorporates prospective design principles (e.g., optimization of physicochem. properties), leverages HT in vitro assays and integrates the use of BBB computational models may yield the best-in-class' peripherally acting product.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOhde-T8d1UrVg90H21EOLACvtfcHk0lgLNkRTPRbDWg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XlvV2qs7s%253D&md5=d4bb73a8839594465407435be2019601</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1517%2F17425255.2012.677028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17425255.2012.677028%26sid%3Dliteratum%253Aachs%26aulast%3DWager%26aufirst%3DT.%2BT.%26aulast%3DLiras%26aufirst%3DJ.%2BL.%26aulast%3DMente%26aufirst%3DS.%26aulast%3DTrapa%26aufirst%3DP.%26atitle%3DStrategies%2520to%2520Minimize%2520CNS%2520Toxicity%253A%2520In%2520Vitro%2520High-Throughput%2520Assays%2520and%2520Computational%2520Modeling%26jtitle%3DExpert%2520Opin.%2520Drug%2520Metab.%2520Toxicol.%26date%3D2012%26volume%3D8%26issue%3D5%26spage%3D531%26epage%3D542%26doi%3D10.1517%2F17425255.2012.677028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kalvass, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polli, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bourdet, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, Q. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zamek-Gliszczynski, M.
J.</span></span> <span> </span><span class="NLM_article-title">Why Clinical Modulation of Efflux Transport at the Human Blood-Brain Barrier Is Unlikely: The ITC Evidence-Based Position</span>. <i>Clin. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>94</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">80</span>– <span class="NLM_lpage">94</span>, <span class="refDoi"> DOI: 10.1038/clpt.2013.34</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=10.1038%2Fclpt.2013.34" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=23588303" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=1%3ACAS%3A528%3ADC%252BC3sXpvVOrtbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=94&publication_year=2013&pages=80-94&issue=1&author=J.+C.+Kalvassauthor=J.+W.+Polliauthor=D.+L.+Bourdetauthor=B.+Fengauthor=S.+M.+Huangauthor=X.+Liuauthor=Q.+R.+Smithauthor=L.+K.+Zhangauthor=M.%0AJ.+Zamek-Gliszczynski&title=Why+Clinical+Modulation+of+Efflux+Transport+at+the+Human+Blood-Brain+Barrier+Is+Unlikely%3A+The+ITC+Evidence-Based+Position&doi=10.1038%2Fclpt.2013.34"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Why Clinical Modulation of Efflux Transport at the Human Blood-Brain Barrier Is Unlikely: The ITC Evidence-Based Position</span></div><div class="casAuthors">Kalvass, J. C.; Polli, J. W.; Bourdet, D. L.; Feng, B.; Huang, S.-M.; Liu, X.; Smith, Q. R.; Zhang, L. K.; Zamek-Gliszczynski, M. J.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacology & Therapeutics (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">94</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">80-94</span>CODEN:
                <span class="NLM_cas:coden">CLPTAT</span>;
        ISSN:<span class="NLM_cas:issn">0009-9236</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Drug interactions due to efflux transport inhibition at the blood-brain barrier (BBB) have been receiving increasing scrutiny because of the theor. possibility of adverse central nervous system (CNS) effects identified in preclin. studies.  In this review, evidence from pharmacokinetic, pharmacodynamic, imaging, pharmacogenetic, and pharmacovigilance studies, along with drug safety reports, is presented supporting a low probability of modulating transporters at the human BBB by currently marketed drugs.  Clin. Pharmacol. & Therapeutics (2013); 94 1, 80-94. doi:10.1038/clpt.2013.34.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfxdzZMTG6_7Vg90H21EOLACvtfcHk0liEUcq_0K3dHg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXpvVOrtbY%253D&md5=c106f689e1c83f58eb6d0dbc527cf0fa</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1038%2Fclpt.2013.34&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fclpt.2013.34%26sid%3Dliteratum%253Aachs%26aulast%3DKalvass%26aufirst%3DJ.%2BC.%26aulast%3DPolli%26aufirst%3DJ.%2BW.%26aulast%3DBourdet%26aufirst%3DD.%2BL.%26aulast%3DFeng%26aufirst%3DB.%26aulast%3DHuang%26aufirst%3DS.%2BM.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DSmith%26aufirst%3DQ.%2BR.%26aulast%3DZhang%26aufirst%3DL.%2BK.%26aulast%3DZamek-Gliszczynski%26aufirst%3DM.%2BJ.%26atitle%3DWhy%2520Clinical%2520Modulation%2520of%2520Efflux%2520Transport%2520at%2520the%2520Human%2520Blood-Brain%2520Barrier%2520Is%2520Unlikely%253A%2520The%2520ITC%2520Evidence-Based%2520Position%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%26date%3D2013%26volume%3D94%26issue%3D1%26spage%3D80%26epage%3D94%26doi%3D10.1038%2Fclpt.2013.34" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Giacomini, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, S.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tweedie, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benet, L. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brouwer, K. L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dahlin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evers, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hillgren, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffmaster, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishikawa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keppler, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niemi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polli, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugiyama, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swaan, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ware, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wah Yee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zamek-Gliszczynski, M.
J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span> <span> </span><span class="NLM_article-title">Membrane Transporters in Drug Development</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">215</span>– <span class="NLM_lpage">236</span>, <span class="refDoi"> DOI: 10.1038/nrd3028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=10.1038%2Fnrd3028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=20190787" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=1%3ACAS%3A528%3ADC%252BC3cXisFelu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2010&pages=215-236&issue=3&author=K.+M.+Giacominiauthor=S.-M.+Huangauthor=D.+J.+Tweedieauthor=L.+Z.+Benetauthor=K.+L.+R.+Brouwerauthor=X.+Chuauthor=A.+Dahlinauthor=R.+Eversauthor=V.+Fischerauthor=K.+M.+Hillgrenauthor=K.+A.+Hoffmasterauthor=T.+Ishikawaauthor=D.+Kepplerauthor=R.+B.+Kimauthor=C.+A.+Leeauthor=M.+Niemiauthor=J.+W.+Polliauthor=Y.+Sugiyamaauthor=P.+W.+Swaanauthor=J.+A.+Wareauthor=S.+H.+Wrightauthor=S.+Wah+Yeeauthor=M.%0AJ.+Zamek-Gliszczynskiauthor=L.+Zhang&title=Membrane+Transporters+in+Drug+Development&doi=10.1038%2Fnrd3028"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Membrane transporters in drug development</span></div><div class="casAuthors">Giacomini, Kathleen M.; Huang, Shiew-Mei; Tweedie, Donald J.; Benet, Leslie Z.; Brouwer, Kim L. R.; Chu, Xiaoyan; Dahlin, Amber; Evers, Raymond; Fischer, Volker; Hillgren, Kathleen M.; Hoffmaster, Keith A.; Ishikawa, Toshihisa; Keppler, Dietrich; Kim, Richard B.; Lee, Caroline A.; Niemi, Mikko; Polli, Joseph W.; Sugiyama, Yuicchi; Swaan, Peter W.; Ware, Joseph A.; Wright, Stephen H.; Wah Yee, Sook; Zamek-Gliszczynski, Maciej J.; Zhang, Lei</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">215-236</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Membrane transporters can be major determinants of the pharmacokinetic, safety and efficacy profiles of drugs.  This presents several key questions for drug development, including which transporters are clin. important in drug absorption and disposition, and which in vitro methods are suitable for studying drug interactions with these transporters.  In addn., what criteria should trigger follow-up clin. studies, and which clin. studies should be conducted if needed.  In this article, we provide the recommendations of the International Transporter Consortium on these issues, and present decision trees that are intended to help guide clin. studies on the currently recognized most important drug transporter interactions.  The recommendations are generally intended to support clin. development and filing of a new drug application.  Overall, it is advised that the timing of transporter investigations should be driven by efficacy, safety and clin. trial enrollment questions (for example, exclusion and inclusion criteria), as well as a need for further understanding of the absorption, distribution, metab. and excretion properties of the drug mol., and information required for drug labeling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoiBIf0gk93W7Vg90H21EOLACvtfcHk0liEUcq_0K3dHg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXisFelu74%253D&md5=89d9ce746284c1814fb01cd9b9a72027</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1038%2Fnrd3028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3028%26sid%3Dliteratum%253Aachs%26aulast%3DGiacomini%26aufirst%3DK.%2BM.%26aulast%3DHuang%26aufirst%3DS.-M.%26aulast%3DTweedie%26aufirst%3DD.%2BJ.%26aulast%3DBenet%26aufirst%3DL.%2BZ.%26aulast%3DBrouwer%26aufirst%3DK.%2BL.%2BR.%26aulast%3DChu%26aufirst%3DX.%26aulast%3DDahlin%26aufirst%3DA.%26aulast%3DEvers%26aufirst%3DR.%26aulast%3DFischer%26aufirst%3DV.%26aulast%3DHillgren%26aufirst%3DK.%2BM.%26aulast%3DHoffmaster%26aufirst%3DK.%2BA.%26aulast%3DIshikawa%26aufirst%3DT.%26aulast%3DKeppler%26aufirst%3DD.%26aulast%3DKim%26aufirst%3DR.%2BB.%26aulast%3DLee%26aufirst%3DC.%2BA.%26aulast%3DNiemi%26aufirst%3DM.%26aulast%3DPolli%26aufirst%3DJ.%2BW.%26aulast%3DSugiyama%26aufirst%3DY.%26aulast%3DSwaan%26aufirst%3DP.%2BW.%26aulast%3DWare%26aufirst%3DJ.%2BA.%26aulast%3DWright%26aufirst%3DS.%2BH.%26aulast%3DWah%2BYee%26aufirst%3DS.%26aulast%3DZamek-Gliszczynski%26aufirst%3DM.%2BJ.%26aulast%3DZhang%26aufirst%3DL.%26atitle%3DMembrane%2520Transporters%2520in%2520Drug%2520Development%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2010%26volume%3D9%26issue%3D3%26spage%3D215%26epage%3D236%26doi%3D10.1038%2Fnrd3028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leeson, P.
D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Springthorpe, B.</span></span> <span> </span><span class="NLM_article-title">The Influence of Drug-Like Concepts on Decision-Making in Medicinal Chemistry</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">881</span>– <span class="NLM_lpage">890</span>, <span class="refDoi"> DOI: 10.1038/nrd2445</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=10.1038%2Fnrd2445" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=17971784" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=1%3ACAS%3A528%3ADC%252BD2sXht1els7rL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=881-890&issue=11&author=P.%0AD.+Leesonauthor=B.+Springthorpe&title=The+Influence+of+Drug-Like+Concepts+on+Decision-Making+in+Medicinal+Chemistry&doi=10.1038%2Fnrd2445"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">The influence of drug-like concepts on decision-making in medicinal chemistry</span></div><div class="casAuthors">Leeson, Paul D.; Springthorpe, Brian</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">881-890</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Despite the wide acceptance of drug-like principles such as the 'rule of five', this anal. of mols. currently being synthesized in leading pharmaceutical companies reveals that their phys. properties differ significantly from those of recently discovered oral drugs.  The marked increase in lipophilicity in particular could increase the likelihood of attrition in drug development.  The application of guidelines linked to the concept of drug-likeness, such as the 'rule of five', has gained wide acceptance as an approach to reduce attrition in drug discovery and development.  However, despite this acceptance, anal. of recent trends reveals that the phys. properties of mols. that are currently being synthesized in leading drug discovery companies differ significantly from those of recently discovered oral drugs and compds. in clin. development.  The consequences of the marked increase in lipophilicity - the most important drug-like phys. property - include a greater likelihood of lack of selectivity and attrition in drug development.  Tackling the threat of compd.-related toxicol. attrition needs to move to the mainstream of medicinal chem. decision-making.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTUeonLD6iebVg90H21EOLACvtfcHk0liEUcq_0K3dHg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXht1els7rL&md5=5665a9e2dc266a1ee096e20625757ef7</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1038%2Fnrd2445&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2445%26sid%3Dliteratum%253Aachs%26aulast%3DLeeson%26aufirst%3DP.%2BD.%26aulast%3DSpringthorpe%26aufirst%3DB.%26atitle%3DThe%2520Influence%2520of%2520Drug-Like%2520Concepts%2520on%2520Decision-Making%2520in%2520Medicinal%2520Chemistry%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2007%26volume%3D6%26issue%3D11%26spage%3D881%26epage%3D890%26doi%3D10.1038%2Fnrd2445" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bagal, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bungay, P. J.</span></span> <span> </span><span class="NLM_article-title">Minimizing Drug Exposure in the CNS While Maintaining Good Oral Absorption</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>3</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">948</span>– <span class="NLM_lpage">950</span>, <span class="refDoi"> DOI: 10.1021/ml300378n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml300378n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=948-950&issue=12&author=S.+K.+Bagalauthor=P.+J.+Bungay&title=Minimizing+Drug+Exposure+in+the+CNS+While+Maintaining+Good+Oral+Absorption&doi=10.1021%2Fml300378n"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1021%2Fml300378n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml300378n%26sid%3Dliteratum%253Aachs%26aulast%3DBagal%26aufirst%3DS.%2BK.%26aulast%3DBungay%26aufirst%3DP.%2BJ.%26atitle%3DMinimizing%2520Drug%2520Exposure%2520in%2520the%2520CNS%2520While%2520Maintaining%2520Good%2520Oral%2520Absorption%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D3%26issue%3D12%26spage%3D948%26epage%3D950%26doi%3D10.1021%2Fml300378n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tachibana, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kato, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugiyama, Y.</span></span> <span> </span><span class="NLM_article-title">Prediction of Nonlinear Intestinal Absorption of CYP3A4 and P-Glycoprotein Substrates from Their in Vitro Km Values</span>. <i>Pharm. Res.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>29</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">651</span>– <span class="NLM_lpage">668</span>, <span class="refDoi"> DOI: 10.1007/s11095-011-0579-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=10.1007%2Fs11095-011-0579-2" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2012&pages=651-668&issue=3&author=T.+Tachibanaauthor=M.+Katoauthor=Y.+Sugiyama&title=Prediction+of+Nonlinear+Intestinal+Absorption+of+CYP3A4+and+P-Glycoprotein+Substrates+from+Their+in+Vitro+Km+Values&doi=10.1007%2Fs11095-011-0579-2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1007%2Fs11095-011-0579-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11095-011-0579-2%26sid%3Dliteratum%253Aachs%26aulast%3DTachibana%26aufirst%3DT.%26aulast%3DKato%26aufirst%3DM.%26aulast%3DSugiyama%26aufirst%3DY.%26atitle%3DPrediction%2520of%2520Nonlinear%2520Intestinal%2520Absorption%2520of%2520CYP3A4%2520and%2520P-Glycoprotein%2520Substrates%2520from%2520Their%2520in%2520Vitro%2520Km%2520Values%26jtitle%3DPharm.%2520Res.%26date%3D2012%26volume%3D29%26issue%3D3%26spage%3D651%26epage%3D668%26doi%3D10.1007%2Fs11095-011-0579-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, M. D.</span>; <span class="NLM_string-name">Bagal, S. K.</span>; <span class="NLM_string-name">Gibson, K. R.</span>; <span class="NLM_string-name">Omoto, K.</span>; <span class="NLM_string-name">Ryckmans, T.</span>; <span class="NLM_string-name">Skerratt, S. E.</span>; <span class="NLM_string-name">Stupple, P. A.</span></span> <span> </span><span class="NLM_article-title">Pyrrolo[2,3-<span class="smallcaps smallerCapital">d</span>]Pyrimidine Derivatives as Inhibitors of Tropomyosin-Related Kinases and Their Preparation and Use in the Treatment of Pain</span>. <span class="NLM_patent">WO2012137089A1</span>, <span class="NLM_year">2012</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=M.+D.+Andrews&author=S.+K.+Bagal&author=K.+R.+Gibson&author=K.+Omoto&author=T.+Ryckmans&author=S.+E.+Skerratt&author=P.+A.+Stupple&title=Pyrrolo%5B2%2C3-d%5DPyrimidine+Derivatives+as+Inhibitors+of+Tropomyosin-Related+Kinases+and+Their+Preparation+and+Use+in+the+Treatment+of+Pain"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DAndrews%26aufirst%3DM.%2BD.%26atitle%3DPyrrolo%255B2%252C3-d%255DPyrimidine%2520Derivatives%2520as%2520Inhibitors%2520of%2520Tropomyosin-Related%2520Kinases%2520and%2520Their%2520Preparation%2520and%2520Use%2520in%2520the%2520Treatment%2520of%2520Pain%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xing, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rai, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lunney, E. A.</span></span> <span> </span><span class="NLM_article-title">Scaffold Mining of Kinase Hinge Binders in Crystal Structure Database</span>. <i>J. Comput.-Aided Mol. Des.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>28</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">13</span>– <span class="NLM_lpage">23</span>, <span class="refDoi"> DOI: 10.1007/s10822-013-9700-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=10.1007%2Fs10822-013-9700-4" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2014&pages=13-23&issue=1&author=L.+Xingauthor=B.+Raiauthor=E.+A.+Lunney&title=Scaffold+Mining+of+Kinase+Hinge+Binders+in+Crystal+Structure+Database&doi=10.1007%2Fs10822-013-9700-4"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1007%2Fs10822-013-9700-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10822-013-9700-4%26sid%3Dliteratum%253Aachs%26aulast%3DXing%26aufirst%3DL.%26aulast%3DRai%26aufirst%3DB.%26aulast%3DLunney%26aufirst%3DE.%2BA.%26atitle%3DScaffold%2520Mining%2520of%2520Kinase%2520Hinge%2520Binders%2520in%2520Crystal%2520Structure%2520Database%26jtitle%3DJ.%2520Comput.-Aided%2520Mol.%2520Des.%26date%3D2014%26volume%3D28%26issue%3D1%26spage%3D13%26epage%3D23%26doi%3D10.1007%2Fs10822-013-9700-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bagal, S. K.</span>; <span class="NLM_string-name">Cui, J. J.</span>; <span class="NLM_string-name">Greasley, S. E.</span>; <span class="NLM_string-name">Lunney, E. A.</span>; <span class="NLM_string-name">McAlpine, I. J.</span>; <span class="NLM_string-name">Nagata, A.</span>; <span class="NLM_string-name">Ninkovic, S.</span>; <span class="NLM_string-name">Omoto, K.</span>; <span class="NLM_string-name">Skerratt, S. E.</span>; <span class="NLM_string-name">Warmus, J. S.</span></span> <span> </span><span class="NLM_article-title">Pyrazole Derivatives as Tropomyosin-Related Kinase Antagonists and Their Preparation and Use for the Treatment of TrkA-Related Diseases</span>. <span class="NLM_patent">WO2015159175A1</span>, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=S.+K.+Bagal&author=J.+J.+Cui&author=S.+E.+Greasley&author=E.+A.+Lunney&author=I.+J.+McAlpine&author=A.+Nagata&author=S.+Ninkovic&author=K.+Omoto&author=S.+E.+Skerratt&author=J.+S.+Warmus&title=Pyrazole+Derivatives+as+Tropomyosin-Related+Kinase+Antagonists+and+Their+Preparation+and+Use+for+the+Treatment+of+TrkA-Related+Diseases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBagal%26aufirst%3DS.%2BK.%26atitle%3DPyrazole%2520Derivatives%2520as%2520Tropomyosin-Related%2520Kinase%2520Antagonists%2520and%2520Their%2520Preparation%2520and%2520Use%2520for%2520the%2520Treatment%2520of%2520TrkA-Related%2520Diseases%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Su, H.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rickert, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burlein, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narayan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bukhtiyarova, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurzy, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stump, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reid, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krasowska-Zoladek, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tummala, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shipman, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kornienko, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lemaire, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krosky, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heller, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Achab, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chamberlin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saradjian, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sauvagnat, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ziebell, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nickbarg, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanders, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bilodeau, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carroll, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lumb, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soisson, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henze, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooke, A. J.</span></span> <span> </span><span class="NLM_article-title">Structural Characterization of Nonactive Site, TrkA-Selective Kinase Inhibitors</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>114</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">E297</span>– <span class="NLM_lpage">E306</span>, <span class="refDoi"> DOI: 10.1073/pnas.1611577114</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=10.1073%2Fpnas.1611577114" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2017&pages=E297-E306&issue=3&author=H.-P.+Suauthor=K.+Rickertauthor=C.+Burleinauthor=K.+Narayanauthor=M.+Bukhtiyarovaauthor=D.+M.+Hurzyauthor=C.+A.+Stumpauthor=X.+Zhangauthor=J.+Reidauthor=A.+Krasowska-Zoladekauthor=S.+Tummalaauthor=J.+M.+Shipmanauthor=M.+Kornienkoauthor=P.+A.+Lemaireauthor=D.+Kroskyauthor=A.+Hellerauthor=A.+Achabauthor=C.+Chamberlinauthor=P.+Saradjianauthor=B.+Sauvagnatauthor=X.+Yangauthor=M.+R.+Ziebellauthor=E.+Nickbargauthor=J.+M.+Sandersauthor=M.+T.+Bilodeauauthor=S.+S.+Carrollauthor=K.+J.+Lumbauthor=S.+M.+Soissonauthor=D.+A.+Henzeauthor=A.+J.+Cooke&title=Structural+Characterization+of+Nonactive+Site%2C+TrkA-Selective+Kinase+Inhibitors&doi=10.1073%2Fpnas.1611577114"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1611577114&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1611577114%26sid%3Dliteratum%253Aachs%26aulast%3DSu%26aufirst%3DH.-P.%26aulast%3DRickert%26aufirst%3DK.%26aulast%3DBurlein%26aufirst%3DC.%26aulast%3DNarayan%26aufirst%3DK.%26aulast%3DBukhtiyarova%26aufirst%3DM.%26aulast%3DHurzy%26aufirst%3DD.%2BM.%26aulast%3DStump%26aufirst%3DC.%2BA.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DReid%26aufirst%3DJ.%26aulast%3DKrasowska-Zoladek%26aufirst%3DA.%26aulast%3DTummala%26aufirst%3DS.%26aulast%3DShipman%26aufirst%3DJ.%2BM.%26aulast%3DKornienko%26aufirst%3DM.%26aulast%3DLemaire%26aufirst%3DP.%2BA.%26aulast%3DKrosky%26aufirst%3DD.%26aulast%3DHeller%26aufirst%3DA.%26aulast%3DAchab%26aufirst%3DA.%26aulast%3DChamberlin%26aufirst%3DC.%26aulast%3DSaradjian%26aufirst%3DP.%26aulast%3DSauvagnat%26aufirst%3DB.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DZiebell%26aufirst%3DM.%2BR.%26aulast%3DNickbarg%26aufirst%3DE.%26aulast%3DSanders%26aufirst%3DJ.%2BM.%26aulast%3DBilodeau%26aufirst%3DM.%2BT.%26aulast%3DCarroll%26aufirst%3DS.%2BS.%26aulast%3DLumb%26aufirst%3DK.%2BJ.%26aulast%3DSoisson%26aufirst%3DS.%2BM.%26aulast%3DHenze%26aufirst%3DD.%2BA.%26aulast%3DCooke%26aufirst%3DA.%2BJ.%26atitle%3DStructural%2520Characterization%2520of%2520Nonactive%2520Site%252C%2520TrkA-Selective%2520Kinase%2520Inhibitors%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2017%26volume%3D114%26issue%3D3%26spage%3DE297%26epage%3DE306%26doi%3D10.1073%2Fpnas.1611577114" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Furuya, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Momose, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katsuno, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fushimi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muranaka, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Handa, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ozawa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinoshita, T.</span></span> <span> </span><span class="NLM_article-title">The Juxtamembrane Region of TrkA Kinase Is Critical for Inhibitor Selectivity</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>27</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">1233</span>– <span class="NLM_lpage">1236</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2017.01.056</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=10.1016%2Fj.bmcl.2017.01.056" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2017&pages=1233-1236&issue=5&author=N.+Furuyaauthor=T.+Momoseauthor=K.+Katsunoauthor=N.+Fushimiauthor=H.+Muranakaauthor=C.+Handaauthor=T.+Ozawaauthor=T.+Kinoshita&title=The+Juxtamembrane+Region+of+TrkA+Kinase+Is+Critical+for+Inhibitor+Selectivity&doi=10.1016%2Fj.bmcl.2017.01.056"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2017.01.056&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2017.01.056%26sid%3Dliteratum%253Aachs%26aulast%3DFuruya%26aufirst%3DN.%26aulast%3DMomose%26aufirst%3DT.%26aulast%3DKatsuno%26aufirst%3DK.%26aulast%3DFushimi%26aufirst%3DN.%26aulast%3DMuranaka%26aufirst%3DH.%26aulast%3DHanda%26aufirst%3DC.%26aulast%3DOzawa%26aufirst%3DT.%26aulast%3DKinoshita%26aufirst%3DT.%26atitle%3DThe%2520Juxtamembrane%2520Region%2520of%2520TrkA%2520Kinase%2520Is%2520Critical%2520for%2520Inhibitor%2520Selectivity%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D27%26issue%3D5%26spage%3D1233%26epage%3D1236%26doi%3D10.1016%2Fj.bmcl.2017.01.056" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McTigue, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, Y.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solowiej, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kania, R. S.</span></span> <span> </span><span class="NLM_article-title">Molecular Conformations, Interactions, and Properties Associated with Drug Efficiency and Clinical Performance among VEGFR TK Inhibitors</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>109</i></span> (<span class="NLM_issue">45</span>),  <span class="NLM_fpage">18281</span>– <span class="NLM_lpage">18289</span>, <span class="refDoi"> DOI: 10.1073/pnas.1207759109</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=10.1073%2Fpnas.1207759109" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=22988103" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhslymtb3I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2012&pages=18281-18289&issue=45&author=M.+McTigueauthor=B.+W.+Murrayauthor=J.+H.+Chenauthor=Y.-L.+Dengauthor=J.+Solowiejauthor=R.+S.+Kania&title=Molecular+Conformations%2C+Interactions%2C+and+Properties+Associated+with+Drug+Efficiency+and+Clinical+Performance+among+VEGFR+TK+Inhibitors&doi=10.1073%2Fpnas.1207759109"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular conformations, interactions, and properties associated with drug efficiency and clinical performance among VEGFR TK inhibitors</span></div><div class="casAuthors">McTigue, Michele; Murray, Brion William; Chen, Jeffrey H.; Deng, Ya-Li; Solowiej, James; Kania, Robert S.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue">45</span>),
    <span class="NLM_cas:pages">18281-18289, S18281/1-S18281/7</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Analyses of compds. in clin. development have shown that ligand efficient-mols. with privileged phys. properties and low dose are less likely to fail in the various stages of clin. testing, have fewer postapproval withdrawals, and are less likely to receive black box safety warnings.  However, detailed side-by-side examn. of mol. interactions and properties within single drug classes are lacking.  As a class, VEGF receptor tyrosine kinase inhibitors (VEGFR TKIs) have changed the landscape of how cancer is treated, particularly in clear cell renal cell carcinoma, which is molecularly linked to the VEGF signaling axis.  Despite the clear role of the mol. target, member mols. of this validated drug class exhibit distinct clin. efficacy and safety profiles in comparable renal cell carcinoma clin. studies.  The first head-to-head randomized phase III comparative study between active VEGFR TKIs has confirmed significant differences in clin. performance.  To elucidate how fundamental drug potency-efficiency is achieved and impacts differentiation within the VEGFR TKI class, we detd. potencies, time dependence, selectivities, and X-ray structures of the drug-kinase complexes using a VEGFR2 TK construct inclusive of the important juxtamembrane domain.  Collectively, the studies elucidate unique drug-kinase interactions that are dependent on distinct juxtamembrane domain conformations, resulting in significant potency and ligand efficiency differences.  The identified structural trends are consistent with in vitro measurements, which translate well to clin. performance, underscoring a principle that may be broadly applicable to prospective drug design for optimal in vivo performance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpsIUWiD4sXtbVg90H21EOLACvtfcHk0lh8u_E4tYPO7A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhslymtb3I&md5=4a5ec677298a8c924c0f9557ca688a79</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1207759109&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1207759109%26sid%3Dliteratum%253Aachs%26aulast%3DMcTigue%26aufirst%3DM.%26aulast%3DMurray%26aufirst%3DB.%2BW.%26aulast%3DChen%26aufirst%3DJ.%2BH.%26aulast%3DDeng%26aufirst%3DY.-L.%26aulast%3DSolowiej%26aufirst%3DJ.%26aulast%3DKania%26aufirst%3DR.%2BS.%26atitle%3DMolecular%2520Conformations%252C%2520Interactions%252C%2520and%2520Properties%2520Associated%2520with%2520Drug%2520Efficiency%2520and%2520Clinical%2520Performance%2520among%2520VEGFR%2520TK%2520Inhibitors%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2012%26volume%3D109%26issue%3D45%26spage%3D18281%26epage%3D18289%26doi%3D10.1073%2Fpnas.1207759109" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schindler, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bornmann, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pellicena, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, W. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clarkson, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuriyan, J.</span></span> <span> </span><span class="NLM_article-title">Structural Mechanism for STI-571 Inhibition of Abelson Tyrosine Kinase</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>289</i></span> (<span class="NLM_issue">5486</span>),  <span class="NLM_fpage">1938</span>– <span class="NLM_lpage">1942</span>, <span class="refDoi"> DOI: 10.1126/science.289.5486.1938</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=10.1126%2Fscience.289.5486.1938" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=10988075" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=1%3ACAS%3A528%3ADC%252BD3cXms1altLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=289&publication_year=2000&pages=1938-1942&issue=5486&author=T.+Schindlerauthor=W.+Bornmannauthor=P.+Pellicenaauthor=W.+T.+Millerauthor=B.+Clarksonauthor=J.+Kuriyan&title=Structural+Mechanism+for+STI-571+Inhibition+of+Abelson+Tyrosine+Kinase&doi=10.1126%2Fscience.289.5486.1938"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Structural mechanism for STI-571 inhibition of Abelson tyrosine kinase</span></div><div class="casAuthors">Schindler, Thomas; Bornmann, William; Pellicena, Patricia; Miller, W. Todd; Clarkson, Bayard; Kuriyan, John</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, D. C.)</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">289</span>
        (<span class="NLM_cas:issue">5486</span>),
    <span class="NLM_cas:pages">1938-1942</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">The inadvertent activation of the Abelson tyrosine kinase (Abl) causes chronic myelogenous leukemia (CML).  A small-mol. inhibitor of Abl (STI-571) is effective in the treatment of CML.  We report the crystal structure of the catalytic domain of Abl, complexed to a variant of STI-571.  Crit. to the binding of STI-571 is the adoption by the kinase of an inactive conformation, in which a centrally located "activation loop" is not phosphorylated.  The conformation of this loop is distinct from that in active protein kinases, as well as in the inactive form of the closely related Src kinases.  These results suggest that compds. that exploit the distinctive inactivation mechanisms of individual protein kinases can achieve both high affinity and high specificity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9eAZqIQ1aebVg90H21EOLACvtfcHk0li055OOXgEcRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXms1altLc%253D&md5=56bb233f010f099d0073020ac6b9db59</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1126%2Fscience.289.5486.1938&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.289.5486.1938%26sid%3Dliteratum%253Aachs%26aulast%3DSchindler%26aufirst%3DT.%26aulast%3DBornmann%26aufirst%3DW.%26aulast%3DPellicena%26aufirst%3DP.%26aulast%3DMiller%26aufirst%3DW.%2BT.%26aulast%3DClarkson%26aufirst%3DB.%26aulast%3DKuriyan%26aufirst%3DJ.%26atitle%3DStructural%2520Mechanism%2520for%2520STI-571%2520Inhibition%2520of%2520Abelson%2520Tyrosine%2520Kinase%26jtitle%3DScience%26date%3D2000%26volume%3D289%26issue%3D5486%26spage%3D1938%26epage%3D1942%26doi%3D10.1126%2Fscience.289.5486.1938" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pargellis, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Churchill, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cirillo, P. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilmore, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graham, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grob, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hickey, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moss, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pav, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Regan, J.</span></span> <span> </span><span class="NLM_article-title">Inhibition of P38 MAP Kinase by Utilizing a Novel Allosteric Binding Site</span>. <i>Nat. Struct. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">268</span>– <span class="NLM_lpage">272</span>, <span class="refDoi"> DOI: 10.1038/nsb770</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=10.1038%2Fnsb770" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2002&pages=268-272&issue=4&author=C.+Pargellisauthor=L.+Tongauthor=L.+Churchillauthor=P.+F.+Cirilloauthor=T.+Gilmoreauthor=A.+G.+Grahamauthor=P.+M.+Grobauthor=E.+R.+Hickeyauthor=N.+Mossauthor=S.+Pavauthor=J.+Regan&title=Inhibition+of+P38+MAP+Kinase+by+Utilizing+a+Novel+Allosteric+Binding+Site&doi=10.1038%2Fnsb770"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1038%2Fnsb770&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnsb770%26sid%3Dliteratum%253Aachs%26aulast%3DPargellis%26aufirst%3DC.%26aulast%3DTong%26aufirst%3DL.%26aulast%3DChurchill%26aufirst%3DL.%26aulast%3DCirillo%26aufirst%3DP.%2BF.%26aulast%3DGilmore%26aufirst%3DT.%26aulast%3DGraham%26aufirst%3DA.%2BG.%26aulast%3DGrob%26aufirst%3DP.%2BM.%26aulast%3DHickey%26aufirst%3DE.%2BR.%26aulast%3DMoss%26aufirst%3DN.%26aulast%3DPav%26aufirst%3DS.%26aulast%3DRegan%26aufirst%3DJ.%26atitle%3DInhibition%2520of%2520P38%2520MAP%2520Kinase%2520by%2520Utilizing%2520a%2520Novel%2520Allosteric%2520Binding%2520Site%26jtitle%3DNat.%2520Struct.%2520Biol.%26date%3D2002%26volume%3D9%26issue%3D4%26spage%3D268%26epage%3D272%26doi%3D10.1038%2Fnsb770" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sherman, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farid, R.</span></span> <span> </span><span class="NLM_article-title">Understanding Kinase Selectivity through Energetic Analysis of Binding Site Waters</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>5</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">618</span>– <span class="NLM_lpage">627</span>, <span class="refDoi"> DOI: 10.1002/cmdc.200900501</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=10.1002%2Fcmdc.200900501" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=20183853" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=1%3ACAS%3A528%3ADC%252BC3cXktFyqtLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2010&pages=618-627&issue=4&author=D.+D.+Robinsonauthor=W.+Shermanauthor=R.+Farid&title=Understanding+Kinase+Selectivity+through+Energetic+Analysis+of+Binding+Site+Waters&doi=10.1002%2Fcmdc.200900501"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Understanding Kinase Selectivity Through Energetic Analysis of Binding Site Waters</span></div><div class="casAuthors">Robinson, Daniel D.; Sherman, Woody; Farid, Ramy</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">618-627</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Kinases remain an important drug target class within the pharmaceutical industry; however, the rational design of kinase inhibitors is plagued by the complexity of gaining selectivity for a small no. of proteins within a family of more than 500 related enzymes.  Herein we show how a computational method for identifying the location and thermodn. properties of water mols. within a protein binding site can yield insight into previously inexplicable selectivity and structure-activity relationships.  Four kinase systems (Src family, Abl/c-Kit, Syk/ZAP-70, and CDK2/4) were investigated, and differences in predicted water mol. locations and energetics were able to explain the exptl. obsd. binding selectivity profiles.  The successful predictions across the range of kinases studied here suggest that this methodol. could be generally applicable for predicting selectivity profiles in related targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqlI79hNfoE67Vg90H21EOLACvtfcHk0li055OOXgEcRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXktFyqtLk%253D&md5=5b68c7a5768c46eb50bb27cb34df2c09</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.200900501&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.200900501%26sid%3Dliteratum%253Aachs%26aulast%3DRobinson%26aufirst%3DD.%2BD.%26aulast%3DSherman%26aufirst%3DW.%26aulast%3DFarid%26aufirst%3DR.%26atitle%3DUnderstanding%2520Kinase%2520Selectivity%2520through%2520Energetic%2520Analysis%2520of%2520Binding%2520Site%2520Waters%26jtitle%3DChemMedChem%26date%3D2010%26volume%3D5%26issue%3D4%26spage%3D618%26epage%3D627%26doi%3D10.1002%2Fcmdc.200900501" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Repasky, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greenwood, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tubert-Brohman, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jerome, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Annabhimoju, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boyles, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmitz, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abel, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farid, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friesner, R. A.</span></span> <span> </span><span class="NLM_article-title">WScore: A Flexible and Accurate Treatment of Explicit Water Molecules in Ligand–Receptor Docking</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">4364</span>– <span class="NLM_lpage">4384</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00131</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00131" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=1%3ACAS%3A528%3ADC%252BC28Xls1Gqtr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=4364-4384&issue=9&author=R.+B.+Murphyauthor=M.+P.+Repaskyauthor=J.+R.+Greenwoodauthor=I.+Tubert-Brohmanauthor=S.+Jeromeauthor=R.+Annabhimojuauthor=N.+A.+Boylesauthor=C.+D.+Schmitzauthor=R.+Abelauthor=R.+Faridauthor=R.+A.+Friesner&title=WScore%3A+A+Flexible+and+Accurate+Treatment+of+Explicit+Water+Molecules+in+Ligand%E2%80%93Receptor+Docking&doi=10.1021%2Facs.jmedchem.6b00131"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">WScore: A Flexible and Accurate Treatment of Explicit Water Molecules in Ligand-Receptor Docking</span></div><div class="casAuthors">Murphy, Robert B.; Repasky, Matthew P.; Greenwood, Jeremy R.; Tubert-Brohman, Ivan; Jerome, Steven; Annabhimoju, Ramakrishna; Boyles, Nicholas A.; Schmitz, Christopher D.; Abel, Robert; Farid, Ramy; Friesner, Richard A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">4364-4384</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We have developed a new methodol. for protein-ligand docking and scoring, WScore, incorporating a flexible description of explicit water mols.  The locations and thermodn. of the waters are derived from a WaterMap mol. dynamics simulation.  The water structure is employed to provide an at. level description of ligand and protein desolvation.  WScore also contains a detailed model for localized ligand and protein strain energy and integrates an MM-GBSA scoring component with these terms to assess delocalized strain of the complex.  Ensemble docking is used to take into account induced fit effects on the receptor conformation, and protein reorganization free energies are assigned via fitting to exptl. data.  The performance of the method is evaluated for pose prediction, rank ordering of self-docked complexes, and enrichment in virtual screening, using a large data set of PDB complexes and compared with the Glide SP and Glide XP models; significant improvements are obtained.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonCVRxlzARBbVg90H21EOLACvtfcHk0li055OOXgEcRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xls1Gqtr4%253D&md5=dcb2bc320a1bffe608531c4aa01666bb</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00131&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00131%26sid%3Dliteratum%253Aachs%26aulast%3DMurphy%26aufirst%3DR.%2BB.%26aulast%3DRepasky%26aufirst%3DM.%2BP.%26aulast%3DGreenwood%26aufirst%3DJ.%2BR.%26aulast%3DTubert-Brohman%26aufirst%3DI.%26aulast%3DJerome%26aufirst%3DS.%26aulast%3DAnnabhimoju%26aufirst%3DR.%26aulast%3DBoyles%26aufirst%3DN.%2BA.%26aulast%3DSchmitz%26aufirst%3DC.%2BD.%26aulast%3DAbel%26aufirst%3DR.%26aulast%3DFarid%26aufirst%3DR.%26aulast%3DFriesner%26aufirst%3DR.%2BA.%26atitle%3DWScore%253A%2520A%2520Flexible%2520and%2520Accurate%2520Treatment%2520of%2520Explicit%2520Water%2520Molecules%2520in%2520Ligand%25E2%2580%2593Receptor%2520Docking%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26issue%3D9%26spage%3D4364%26epage%3D4384%26doi%3D10.1021%2Facs.jmedchem.6b00131" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clausen, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nielsen, T. E.</span></span> <span> </span><span class="NLM_article-title">Allosteric Small-Molecule Kinase Inhibitors</span>. <i>Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>156</i></span>,  <span class="NLM_fpage">59</span>– <span class="NLM_lpage">68</span>, <span class="refDoi"> DOI: 10.1016/j.pharmthera.2015.10.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=10.1016%2Fj.pharmthera.2015.10.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=26478442" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhs12qsb3N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=156&publication_year=2015&pages=59-68&author=P.+Wuauthor=M.+H.+Clausenauthor=T.+E.+Nielsen&title=Allosteric+Small-Molecule+Kinase+Inhibitors&doi=10.1016%2Fj.pharmthera.2015.10.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Allosteric small-molecule kinase inhibitors</span></div><div class="casAuthors">Wu, Peng; Clausen, Mads H.; Nielsen, Thomas E.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">156</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">59-68</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Small-mol. kinase inhibitors are invaluable targeted therapeutics for the treatment of various human diseases, esp. cancers.  While the majority of approved and developed preclin. small-mol. inhibitors are characterized as type I or type II inhibitors that target the ATP-binding pocket of kinases, the remarkable sequential and structural similarity among ATP pockets renders the selective inhibition of kinases a daunting challenge.  Therefore, targeting allosteric pockets of kinases outside the highly conversed ATP pocket has been proposed as a promising alternative to overcome current barriers of kinase inhibitors, including poor selectivity and emergence of drug resistance.  In spite of the small no. of identified allosteric inhibitors in comparison with that of inhibitors targeting the ATP pocket, encouraging results, such as the FDA-approval of the first small-mol. allosteric inhibitor trametinib in 2013, the progress of more than 10 other allosteric inhibitors in clin. trials, and the emergence of a pipeline of highly selective and potent preclin. mols., have been reported in the past decade.  In this article, we present the current knowledge on allosteric inhibition in terms of conception, classification, potential advantages, and summarized debatable topics in the field.  Recent progress and allosteric inhibitors that were identified in the past three years are highlighted in this paper.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrK12iPyaK2ObVg90H21EOLACvtfcHk0ljDGa19dx3gUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhs12qsb3N&md5=26e4658d325b8f016be29df27bf69ec2</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2015.10.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2015.10.002%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DP.%26aulast%3DClausen%26aufirst%3DM.%2BH.%26aulast%3DNielsen%26aufirst%3DT.%2BE.%26atitle%3DAllosteric%2520Small-Molecule%2520Kinase%2520Inhibitors%26jtitle%3DPharmacol.%2520Ther.%26date%3D2015%26volume%3D156%26spage%3D59%26epage%3D68%26doi%3D10.1016%2Fj.pharmthera.2015.10.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Efthimiou, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stephanou, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demopoulos, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nikolaropoulos, S. S.</span></span> <span> </span><span class="NLM_article-title">Aneugenic Potential of the Anticancer Drugs Melphalan and Chlorambucil. The Involvement of Apoptosis and Chromosome Segregation Regulating Proteins</span>. <i>J. Appl. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>33</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">537</span>– <span class="NLM_lpage">545</span>, <span class="refDoi"> DOI: 10.1002/jat.1743</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=10.1002%2Fjat.1743" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=22025197" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlKhtrnF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2013&pages=537-545&issue=7&author=M.+Efthimiouauthor=G.+Stephanouauthor=N.+A.+Demopoulosauthor=S.+S.+Nikolaropoulos&title=Aneugenic+Potential+of+the+Anticancer+Drugs+Melphalan+and+Chlorambucil.+The+Involvement+of+Apoptosis+and+Chromosome+Segregation+Regulating+Proteins&doi=10.1002%2Fjat.1743"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Aneugenic potential of the anticancer drugs melphalan and chlorambucil. The involvement of apoptosis and chromosome segregation regulating proteins. Mechanism of aneugenicity of melphalan and chlorambucil</span></div><div class="casAuthors">Efthimiou, Maria; Stephanou, Georgia; Demopoulos, Nikos A.; Nikolaropoulos, Sotiris S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Applied Toxicology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">537-545</span>CODEN:
                <span class="NLM_cas:coden">JJATDK</span>;
        ISSN:<span class="NLM_cas:issn">0260-437X</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">Previous findings showed that the anticancer drugs p-N,N-bis(2-chloroethyl) amino-L-phenylalanine (melphalan, MEL) and p-N,N-bis(2-chloroethyl)aminophenylbutyric acid (chlorambucil, CAB) belonging to the nitrogen mustard group, in addn. to their clastogenic activity, also exert aneugenic potential, nondisjunction and chromosome delay.  Their aneugenic potential is mainly mediated through centrosome defects.  To further investigate their aneugenicity we (a) studied whether apoptosis is a mechanism responsible for the elimination of damaged cells generated by MEL and CAB and (b) investigated if proteins that regulate chromosome segregation are involved in the modulation of their aneugenic potential.  Apoptosis was studied by Annexin-V/Propidium Iodide staining and fluorescence microscopy.  The involvement of apoptosis on the exclusion of cells with genetic damage and centrosome disturbances was analyzed by DAPI staining and immunofluorescence of β- and γ-tubulin in the presence of pan-caspase inhibitor.  The expressions of Aurora-A, Aurora-B, survivin and γ-tubulin were studied by Western blot.  We found that (a) apoptosis is not the mechanism of choice for selectively eliminating cells with supernumerary centrosomes, and (b) the proteins Aurora-A, Aurora-B and survivin are involved in the modulation of MEL and CAB aneugenicity.  These findings are important for the understanding of the mechanism responsible for the aneugenic activity of the anticancer drugs melphalan and chlorambucil.  Copyright © 2011 John Wiley & Sons, Ltd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqtTJOVzIj-2rVg90H21EOLACvtfcHk0ljDGa19dx3gUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlKhtrnF&md5=3a5cb806329d8f5a441f7f91b17de554</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1002%2Fjat.1743&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjat.1743%26sid%3Dliteratum%253Aachs%26aulast%3DEfthimiou%26aufirst%3DM.%26aulast%3DStephanou%26aufirst%3DG.%26aulast%3DDemopoulos%26aufirst%3DN.%2BA.%26aulast%3DNikolaropoulos%26aufirst%3DS.%2BS.%26atitle%3DAneugenic%2520Potential%2520of%2520the%2520Anticancer%2520Drugs%2520Melphalan%2520and%2520Chlorambucil.%2520The%2520Involvement%2520of%2520Apoptosis%2520and%2520Chromosome%2520Segregation%2520Regulating%2520Proteins%26jtitle%3DJ.%2520Appl.%2520Toxicol.%26date%3D2013%26volume%3D33%26issue%3D7%26spage%3D537%26epage%3D545%26doi%3D10.1002%2Fjat.1743" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gollapudi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hasegawa, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eastmond, D. A.</span></span> <span> </span><span class="NLM_article-title">A Comparative Study of the Aneugenic and Polyploidy-Inducing Effects of Fisetin and Two Model Aurora Kinase Inhibitors</span>. <i>Mutat. Res., Genet. Toxicol. Environ. Mutagen.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>767</i></span>,  <span class="NLM_fpage">37</span>– <span class="NLM_lpage">43</span>, <span class="refDoi"> DOI: 10.1016/j.mrgentox.2014.03.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=10.1016%2Fj.mrgentox.2014.03.004" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=767&publication_year=2014&pages=37-43&author=P.+Gollapudiauthor=L.+S.+Hasegawaauthor=D.+A.+Eastmond&title=A+Comparative+Study+of+the+Aneugenic+and+Polyploidy-Inducing+Effects+of+Fisetin+and+Two+Model+Aurora+Kinase+Inhibitors&doi=10.1016%2Fj.mrgentox.2014.03.004"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1016%2Fj.mrgentox.2014.03.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.mrgentox.2014.03.004%26sid%3Dliteratum%253Aachs%26aulast%3DGollapudi%26aufirst%3DP.%26aulast%3DHasegawa%26aufirst%3DL.%2BS.%26aulast%3DEastmond%26aufirst%3DD.%2BA.%26atitle%3DA%2520Comparative%2520Study%2520of%2520the%2520Aneugenic%2520and%2520Polyploidy-Inducing%2520Effects%2520of%2520Fisetin%2520and%2520Two%2520Model%2520Aurora%2520Kinase%2520Inhibitors%26jtitle%3DMutat.%2520Res.%252C%2520Genet.%2520Toxicol.%2520Environ.%2520Mutagen.%26date%3D2014%26volume%3D767%26spage%3D37%26epage%3D43%26doi%3D10.1016%2Fj.mrgentox.2014.03.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Varma, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gardner, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steyn, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nkansah, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rotter, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitney-Pickett, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cram, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fenner, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El-Kattan, A. F.</span></span> <span> </span><span class="NLM_article-title">pH-Dependent Solubility and Permeability Criteria for Provisional Biopharmaceutics Classification (BCS and BDDCS) in Early Drug Discovery</span>. <i>Mol. Pharmaceutics</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">1199</span>– <span class="NLM_lpage">1212</span>, <span class="refDoi"> DOI: 10.1021/mp2004912</span> </span><div class="citationLinks">[<a href="/doi/10.1021/mp2004912" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=1%3ACAS%3A528%3ADC%252BC38Xlt1Ont74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2012&pages=1199-1212&issue=5&author=M.+V.+Varmaauthor=I.+Gardnerauthor=S.+J.+Steynauthor=P.+Nkansahauthor=C.+J.+Rotterauthor=C.+Whitney-Pickettauthor=H.+Zhangauthor=L.+Diauthor=M.+Cramauthor=K.+S.+Fennerauthor=A.+F.+El-Kattan&title=pH-Dependent+Solubility+and+Permeability+Criteria+for+Provisional+Biopharmaceutics+Classification+%28BCS+and+BDDCS%29+in+Early+Drug+Discovery&doi=10.1021%2Fmp2004912"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">pH-Dependent solubility and permeability criteria for provisional biopharmaceutics classification (BCS and BDDCS) in early drug discovery</span></div><div class="casAuthors">Varma, Manthena V.; Gardner, Iain; Steyn, Stefanus J.; Nkansah, Paul; Rotter, Charles J.; Whitney-Pickett, Carrie; Zhang, Hui; Di, Li; Cram, Michael; Fenner, Katherine S.; El-Kattan, Ayman F.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1199-1212</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The Biopharmaceutics Classification System (BCS) is a scientific framework that provides a basis for predicting the oral absorption of drugs.  These concepts have been extended in the Biopharmaceutics Drug Disposition Classification System (BDDCS) to explain the potential mechanism of drug clearance and understand the effects of uptake and efflux transporters on absorption, distribution, metab., and elimination.  The objective of present work is to establish criteria for provisional biopharmaceutics classification using pH-dependent passive permeability and aq. soly. data generated from high throughput screening methodologies in drug discovery settings.  The apparent permeability across monolayers of clonal cell line of Madin-Darby canine kidney cells, selected for low endogenous efflux transporter expression, was measured for a set of 105 drugs, with known BCS and BDDCS class.  The permeability at apical pH 6.5 for acidic drugs and at pH 7.4 for nonacidic drugs showed a good correlation with the fraction absorbed in human (Fa).  Receiver operating characteristic (ROC) curve anal. was utilized to define the permeability class boundary.  At permeability ≥5 × 10-6 cm/s, the accuracy of predicting Fa of ≥0.90 was 87%.  Also, this cutoff showed more than 80% sensitivity and specificity in predicting the literature permeability classes (BCS), and the metab. classes (BDDCS).  The equil. soly. of a subset of 49 drugs was measured in pH 1.2 medium, pH 6.5 phosphate buffer, and in FaSSIF medium (pH 6.5).  Although dose was not considered, good concordance of the measured soly. with BCS and BDDCS soly. class was achieved, when soly. at pH 1.2 was used for acidic compds. and FaSSIF soly. was used for basic, neutral, and zwitterionic compds.  Using a cutoff of 200 μg/mL, the data set suggested a 93% sensitivity and 86% specificity in predicting both the BCS and BDDCS soly. classes.  In conclusion, this study identified pH-dependent permeability and soly. criteria that can be used to assign provisional biopharmaceutics class at early stage of the drug discovery process.  Addnl., such a classification system will enable discovery scientists to assess the potential limiting factors to oral absorption, as well as help predict the drug disposition mechanisms and potential drug-drug interactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr84irw4TD15rVg90H21EOLACvtfcHk0ljDGa19dx3gUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xlt1Ont74%253D&md5=2bcb29ea512d2e0665973292e4a4a0a3</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1021%2Fmp2004912&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fmp2004912%26sid%3Dliteratum%253Aachs%26aulast%3DVarma%26aufirst%3DM.%2BV.%26aulast%3DGardner%26aufirst%3DI.%26aulast%3DSteyn%26aufirst%3DS.%2BJ.%26aulast%3DNkansah%26aufirst%3DP.%26aulast%3DRotter%26aufirst%3DC.%2BJ.%26aulast%3DWhitney-Pickett%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DDi%26aufirst%3DL.%26aulast%3DCram%26aufirst%3DM.%26aulast%3DFenner%26aufirst%3DK.%2BS.%26aulast%3DEl-Kattan%26aufirst%3DA.%2BF.%26atitle%3DpH-Dependent%2520Solubility%2520and%2520Permeability%2520Criteria%2520for%2520Provisional%2520Biopharmaceutics%2520Classification%2520%2528BCS%2520and%2520BDDCS%2529%2520in%2520Early%2520Drug%2520Discovery%26jtitle%3DMol.%2520Pharmaceutics%26date%3D2012%26volume%3D9%26issue%3D5%26spage%3D1199%26epage%3D1212%26doi%3D10.1021%2Fmp2004912" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Di, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitney-Pickett, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Umland, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gebhard, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Federico, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davidson, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reyner, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rotter, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varma, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kempshall, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fenner, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El-kattan, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liston, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Troutman, M. D.</span></span> <span> </span><span class="NLM_article-title">Development of a New Permeability Assay Using Low-Efflux MDCKII Cells</span>. <i>J. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>100</i></span>,  <span class="NLM_fpage">4974</span>– <span class="NLM_lpage">4985</span>, <span class="refDoi"> DOI: 10.1002/jps.22674</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=10.1002%2Fjps.22674" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=21766308" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=1%3ACAS%3A528%3ADC%252BC3MXovFGltb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2011&pages=4974-4985&author=L.+Diauthor=C.+Whitney-Pickettauthor=J.+P.+Umlandauthor=H.+Zhangauthor=X.+Zhangauthor=D.+F.+Gebhardauthor=Y.+Laiauthor=J.+J.+Federicoauthor=R.+E.+Davidsonauthor=R.+Smithauthor=E.+L.+Reynerauthor=C.+Leeauthor=B.+Fengauthor=C.+Rotterauthor=M.+V.+Varmaauthor=S.+Kempshallauthor=K.+Fennerauthor=A.+F.+El-kattanauthor=T.+E.+Listonauthor=M.+D.+Troutman&title=Development+of+a+New+Permeability+Assay+Using+Low-Efflux+MDCKII+Cells&doi=10.1002%2Fjps.22674"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Development of a new permeability assay using low-efflux MDCKII cells</span></div><div class="casAuthors">Di, Li; Whitney-Pickett, Carrie; Umland, John P.; Zhang, Hui; Zhang, Xun; Gebhard, David F.; Lai, Yurong; Federico, James J.; Davidson, Ralph E.; Smith, Russ; Reyner, Eric L.; Lee, Caroline; Feng, Bo; Rotter, Charles; Varma, Manthena V.; Kempshall, Sarah; Fenner, Katherine; El-kattan, Ayman F.; Liston, Theodore E.; Troutman, Matthew D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmaceutical Sciences</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">100</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4974-4985</span>CODEN:
                <span class="NLM_cas:coden">JPMSAE</span>;
        ISSN:<span class="NLM_cas:issn">0022-3549</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Permeability is an important property of drug candidates.  The Madin-Darby canine kidney cell line (MDCK) permeability assay is widely used and the primary concern of using MDCK cells is the presence of endogenous transporters of nonhuman origin.  The canine P-glycoprotein (Pgp) can interfere with permeability and transporter studies, leading to less reliable data.  A new cell line, MDCKII-LE (low efflux), has been developed by selecting a subpopulation of low-efflux cells from MDCKII-WT using an iterative fluorescence-activated cell sorting technique with calcein-AM as a Pgp and efflux substrate.  MDCKII-LE cells are a subpopulation of MDCKII cells with over 200-fold lower canine Pgp mRNA level and fivefold lower protein level than MDCKII-WT.  MDCKII-LE cells showed less functional efflux activity than MDCKII-WT based on efflux ratios.  Notably, MDCKII-MDR1 showed about 1.5-fold decreased expression of endogenous canine Pgp, suggesting that using the net flux ratio might not completely cancel out the background endogenous transporter activities.  MDCKII-LE cells offer clear advantages over the MDCKII-WT by providing less efflux transporter background signals and minimizing interference from canine Pgp.  The MDCKII-LE apparent permeability values well differentiates compds. from high to medium/low human intestinal absorption and can be used for Biopharmaceutical Classification System.  The MDCKII-LE permeability assay (4-in-1 cassette dosing) is high throughput with good precision, reproducibility, robustness, and cost-effective. © 2011 Wiley-Liss, Inc. and the American Pharmacists Assocn. J Pharm Sci.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTVtRmYnbF17Vg90H21EOLACvtfcHk0lhmgnKw4pIqJQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXovFGltb8%253D&md5=97f647fc215ea6d04882351ffc912a1e</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1002%2Fjps.22674&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjps.22674%26sid%3Dliteratum%253Aachs%26aulast%3DDi%26aufirst%3DL.%26aulast%3DWhitney-Pickett%26aufirst%3DC.%26aulast%3DUmland%26aufirst%3DJ.%2BP.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DGebhard%26aufirst%3DD.%2BF.%26aulast%3DLai%26aufirst%3DY.%26aulast%3DFederico%26aufirst%3DJ.%2BJ.%26aulast%3DDavidson%26aufirst%3DR.%2BE.%26aulast%3DSmith%26aufirst%3DR.%26aulast%3DReyner%26aufirst%3DE.%2BL.%26aulast%3DLee%26aufirst%3DC.%26aulast%3DFeng%26aufirst%3DB.%26aulast%3DRotter%26aufirst%3DC.%26aulast%3DVarma%26aufirst%3DM.%2BV.%26aulast%3DKempshall%26aufirst%3DS.%26aulast%3DFenner%26aufirst%3DK.%26aulast%3DEl-kattan%26aufirst%3DA.%2BF.%26aulast%3DListon%26aufirst%3DT.%2BE.%26aulast%3DTroutman%26aufirst%3DM.%2BD.%26atitle%3DDevelopment%2520of%2520a%2520New%2520Permeability%2520Assay%2520Using%2520Low-Efflux%2520MDCKII%2520Cells%26jtitle%3DJ.%2520Pharm.%2520Sci.%26date%3D2011%26volume%3D100%26spage%3D4974%26epage%3D4985%26doi%3D10.1002%2Fjps.22674" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bagal, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bungay, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denton, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibson, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glossop, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hay, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kemp, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lane, C. A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maw, G. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Million, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Payne, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poinsard, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rawson, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stammen, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, L. R.</span></span> <span> </span><span class="NLM_article-title">Discovery and Optimization of Selective Nav1.8 Modulator Series That Demonstrate Efficacy in Preclinical Models of Pain</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">650</span>– <span class="NLM_lpage">654</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.5b00059</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.5b00059" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=1%3ACAS%3A528%3ADC%252BC2MXnsVSqtb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=650-654&issue=6&author=S.+K.+Bagalauthor=P.+J.+Bungayauthor=S.+M.+Dentonauthor=K.+R.+Gibsonauthor=M.+S.+Glossopauthor=T.+L.+Hayauthor=M.+I.+Kempauthor=C.+A.+L.+Laneauthor=M.+L.+Lewisauthor=G.+N.+Mawauthor=W.+A.+Millionauthor=C.+E.+Payneauthor=C.+Poinsardauthor=D.+J.+Rawsonauthor=B.+L.+Stammenauthor=E.+B.+Stevensauthor=L.+R.+Thompson&title=Discovery+and+Optimization+of+Selective+Nav1.8+Modulator+Series+That+Demonstrate+Efficacy+in+Preclinical+Models+of+Pain&doi=10.1021%2Facsmedchemlett.5b00059"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Optimization of Selective Nav1.8 Modulator Series That Demonstrate Efficacy in Preclinical Models of Pain</span></div><div class="casAuthors">Bagal, Sharan K.; Bungay, Peter J.; Denton, Stephen M.; Gibson, Karl R.; Glossop, Melanie S.; Hay, Tanya L.; Kemp, Mark I.; Lane, Charlotte A. L.; Lewis, Mark L.; Maw, Graham N.; Million, William A.; Payne, C. Elizabeth; Poinsard, Cedric; Rawson, David J.; Stammen, Blanda L.; Stevens, Edward B.; Thompson, Lisa R.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">650-654</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Voltage-gated sodium channels, in particular Nav1.8, can be targeted for the treatment of neuropathic and inflammatory pain.  Herein, we described the optimization of Nav1.8 modulator series to deliver subtype selective, state, and use-dependent chem. matter that is efficacious in preclin. models of neuropathic and inflammatory pain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqx8aTxMbmYKrVg90H21EOLACvtfcHk0lhmgnKw4pIqJQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXnsVSqtb4%253D&md5=0871fe7430909b09c710abd3aa8e8f94</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.5b00059&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.5b00059%26sid%3Dliteratum%253Aachs%26aulast%3DBagal%26aufirst%3DS.%2BK.%26aulast%3DBungay%26aufirst%3DP.%2BJ.%26aulast%3DDenton%26aufirst%3DS.%2BM.%26aulast%3DGibson%26aufirst%3DK.%2BR.%26aulast%3DGlossop%26aufirst%3DM.%2BS.%26aulast%3DHay%26aufirst%3DT.%2BL.%26aulast%3DKemp%26aufirst%3DM.%2BI.%26aulast%3DLane%26aufirst%3DC.%2BA.%2BL.%26aulast%3DLewis%26aufirst%3DM.%2BL.%26aulast%3DMaw%26aufirst%3DG.%2BN.%26aulast%3DMillion%26aufirst%3DW.%2BA.%26aulast%3DPayne%26aufirst%3DC.%2BE.%26aulast%3DPoinsard%26aufirst%3DC.%26aulast%3DRawson%26aufirst%3DD.%2BJ.%26aulast%3DStammen%26aufirst%3DB.%2BL.%26aulast%3DStevens%26aufirst%3DE.%2BB.%26aulast%3DThompson%26aufirst%3DL.%2BR.%26atitle%3DDiscovery%2520and%2520Optimization%2520of%2520Selective%2520Nav1.8%2520Modulator%2520Series%2520That%2520Demonstrate%2520Efficacy%2520in%2520Preclinical%2520Models%2520of%2520Pain%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D6%26issue%3D6%26spage%3D650%26epage%3D654%26doi%3D10.1021%2Facsmedchemlett.5b00059" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bagal, S. K.</span>; <span class="NLM_string-name">Cui, J. J.</span>; <span class="NLM_string-name">Greasley, S. E.</span>; <span class="NLM_string-name">Lunney, E. A.</span>; <span class="NLM_string-name">McAlpine, I. J.</span>; <span class="NLM_string-name">Nagata, A.</span>; <span class="NLM_string-name">Ninkovic, S.</span>; <span class="NLM_string-name">Omoto, K.</span>; <span class="NLM_string-name">Skerratt, S. E.</span>; <span class="NLM_string-name">Warmus, J. S.</span></span> <span> </span><span class="NLM_article-title">N-Pyrazolyl Pyridinylbenzamides as Tropomyosin-Related Kinase Inhibitors and Their Preparation</span>. <span class="NLM_patent">WO2015170218A1</span>, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=S.+K.+Bagal&author=J.+J.+Cui&author=S.+E.+Greasley&author=E.+A.+Lunney&author=I.+J.+McAlpine&author=A.+Nagata&author=S.+Ninkovic&author=K.+Omoto&author=S.+E.+Skerratt&author=J.+S.+Warmus&title=N-Pyrazolyl+Pyridinylbenzamides+as+Tropomyosin-Related+Kinase+Inhibitors+and+Their+Preparation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBagal%26aufirst%3DS.%2BK.%26atitle%3DN-Pyrazolyl%2520Pyridinylbenzamides%2520as%2520Tropomyosin-Related%2520Kinase%2520Inhibitors%2520and%2520Their%2520Preparation%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sinha, V. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snoeys, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osselaer, N. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peer, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mackie, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heald, D.</span></span> <span> </span><span class="NLM_article-title">From Preclinical to Human – Prediction of Oral Absorption and Drug–Drug Interaction Potential Using Physiologically Based Pharmacokinetic (PBPK) Modeling Approach in an Industrial Setting: A Workflow by Using Case Example</span>. <i>Biopharm. Drug Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>33</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">111</span>– <span class="NLM_lpage">121</span>, <span class="refDoi"> DOI: 10.1002/bdd.1782</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=10.1002%2Fbdd.1782" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=22383166" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=1%3ACAS%3A528%3ADC%252BC38XktFShuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2012&pages=111-121&issue=2&author=V.+K.+Sinhaauthor=J.+Snoeysauthor=N.+V.+Osselaerauthor=A.+V.+Peerauthor=C.+Mackieauthor=D.+Heald&title=From+Preclinical+to+Human+%E2%80%93+Prediction+of+Oral+Absorption+and+Drug%E2%80%93Drug+Interaction+Potential+Using+Physiologically+Based+Pharmacokinetic+%28PBPK%29+Modeling+Approach+in+an+Industrial+Setting%3A+A+Workflow+by+Using+Case+Example&doi=10.1002%2Fbdd.1782"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">From preclinical to human - prediction of oral absorption and drug-drug interaction potential using physiologically based pharmacokinetic (PBPK) modeling approach in an industrial setting: a workflow by using case examplePREDICTION OF ORAL ABSORPTION AND DDI USING PBPKV. K. SINHA ET AL.</span></div><div class="casAuthors">Sinha, Vikash Kumar; Snoeys, Jan; Osselaer, Nancy Van; Peer, Achiel Van; Mackie, Claire; Heald, Donald</div><div class="citationInfo"><span class="NLM_cas:title">Biopharmaceutics & Drug Disposition</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">111-121</span>CODEN:
                <span class="NLM_cas:coden">BDDID8</span>;
        ISSN:<span class="NLM_cas:issn">0142-2782</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">PurposeA case example is presented in which the physiol. based modeling approach has been used to model the absorption of a lipophilic BCS Class II compd. predominantly metabolized by CYP3A4, and to assess the interplay of absorption related parameters with the drug-drug interaction (DDI) potential.  MethodsThe PBPK model was built in the rat using Gastroplus to study the absorption characteristics of the compd.  Subsequently relevant model parameters were used to predict the non-linear human PK obsd. during first-in-human study after optimizing the absorption model for colonic absorption, bile micelle solubilization and unbound fraction in gut enterocytes (fugut) using SIMCYP simulator.  The model fitted absorption parameters were then used to assess the drug-drug interaction (DDI) potential of the test compd. when administered along with multiple doses of a potent CYP 3A4 inhibitor, ketoconazole.  The impact of fugut in the extent of DDI was assessed using parameter sensitivity anal.  Results and ConclusionsAfter optimizing the preclin. model and taking into consideration bile micelle solubilization and colonic absorption, the non-linear pharmacokinetics of the test compd. was satisfactorily predicted in man.  Sensitivity anal. performed with the absorption parameter fugut indicated that it could be an important parameter in predicting oral absorption.  In addn., DDI simulations using SIMCYP suggest that Cmax and AUC ratios may also be sensitive to the fugut input in the model.  Since fugut cannot be measured exptl., sensitivity anal. may help in assessing the importance of fugut in human PK and DDI prediction using SIMCYP.  Copyright © 2012 John Wiley & Sons, Ltd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpsL3mji8aaJLVg90H21EOLACvtfcHk0lhsoyZvdCjgyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XktFShuro%253D&md5=07ddb89156a07ec83cbd90c709e7a62a</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1002%2Fbdd.1782&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fbdd.1782%26sid%3Dliteratum%253Aachs%26aulast%3DSinha%26aufirst%3DV.%2BK.%26aulast%3DSnoeys%26aufirst%3DJ.%26aulast%3DOsselaer%26aufirst%3DN.%2BV.%26aulast%3DPeer%26aufirst%3DA.%2BV.%26aulast%3DMackie%26aufirst%3DC.%26aulast%3DHeald%26aufirst%3DD.%26atitle%3DFrom%2520Preclinical%2520to%2520Human%2520%25E2%2580%2593%2520Prediction%2520of%2520Oral%2520Absorption%2520and%2520Drug%25E2%2580%2593Drug%2520Interaction%2520Potential%2520Using%2520Physiologically%2520Based%2520Pharmacokinetic%2520%2528PBPK%2529%2520Modeling%2520Approach%2520in%2520an%2520Industrial%2520Setting%253A%2520A%2520Workflow%2520by%2520Using%2520Case%2520Example%26jtitle%3DBiopharm.%2520Drug%2520Dispos.%26date%3D2012%26volume%3D33%26issue%3D2%26spage%3D111%26epage%3D121%26doi%3D10.1002%2Fbdd.1782" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stepan, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kauffman, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keefer, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verhoest, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, M.</span></span> <span> </span><span class="NLM_article-title">Evaluating the Differences in Cycloalkyl Ether Metabolism Using the Design Parameter “Lipophilic Metabolism Efficiency” (LipMetE) and a Matched Molecular Pairs Analysis</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span> (<span class="NLM_issue">17</span>),  <span class="NLM_fpage">6985</span>– <span class="NLM_lpage">6990</span>, <span class="refDoi"> DOI: 10.1021/jm4008642</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm4008642" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFKgurvJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=6985-6990&issue=17&author=A.+F.+Stepanauthor=G.+W.+Kauffmanauthor=C.+E.+Keeferauthor=P.+R.+Verhoestauthor=M.+Edwards&title=Evaluating+the+Differences+in+Cycloalkyl+Ether+Metabolism+Using+the+Design+Parameter+%E2%80%9CLipophilic+Metabolism+Efficiency%E2%80%9D+%28LipMetE%29+and+a+Matched+Molecular+Pairs+Analysis&doi=10.1021%2Fjm4008642"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluating the Differences in Cycloalkyl Ether Metabolism Using the Design Parameter "Lipophilic Metabolism Efficiency" (LipMetE) and a Matched Molecular Pairs Analysis</span></div><div class="casAuthors">Stepan, Antonia F.; Kauffman, Gregory W.; Keefer, Christopher E.; Verhoest, Patrick R.; Edwards, Martin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">6985-6990</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We have obsd. previously that modification of ring size and substitution pattern may be used as a strategy to mitigate the metabolic instability of cycloalkyl ethers.  In this article, we introduce a medicinal chem. design parameter named "lipophilic metab. efficiency" (LipMetE) that indicates that these changes in metabolic stability can be largely ascribed to changes in lipophilicity.  Our matched mol. pair anal. also indicates that this finding is a general phenomenon, widely obsd. across different chemotypes.  It is our hope that both the LipMetE design parameter and the results from our pairwise anal. will be useful tools for medicinal chemists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpiFJ_fPxurbVg90H21EOLACvtfcHk0lhsoyZvdCjgyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFKgurvJ&md5=596673d35831b979b8daf5a4ccb8a218</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1021%2Fjm4008642&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm4008642%26sid%3Dliteratum%253Aachs%26aulast%3DStepan%26aufirst%3DA.%2BF.%26aulast%3DKauffman%26aufirst%3DG.%2BW.%26aulast%3DKeefer%26aufirst%3DC.%2BE.%26aulast%3DVerhoest%26aufirst%3DP.%2BR.%26aulast%3DEdwards%26aufirst%3DM.%26atitle%3DEvaluating%2520the%2520Differences%2520in%2520Cycloalkyl%2520Ether%2520Metabolism%2520Using%2520the%2520Design%2520Parameter%2520%25E2%2580%259CLipophilic%2520Metabolism%2520Efficiency%25E2%2580%259D%2520%2528LipMetE%2529%2520and%2520a%2520Matched%2520Molecular%2520Pairs%2520Analysis%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26issue%3D17%26spage%3D6985%26epage%3D6990%26doi%3D10.1021%2Fjm4008642" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fahmi, O. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boldt, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kish, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obach, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tremaine, L. M.</span></span> <span> </span><span class="NLM_article-title">Prediction of Drug-Drug Interactions from in Vitro Induction Data</span>. <i>Application of the Relative Induction Score Approach Using Cryopreserved Human Hepatocytes</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>36</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">1971</span>– <span class="NLM_lpage">1974</span>, <span class="refDoi"> DOI: 10.1124/dmd.108.021907</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=10.1124%2Fdmd.108.021907" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2008&pages=1971-1974&issue=9&author=O.+A.+Fahmiauthor=S.+Boldtauthor=M.+Kishauthor=R.+S.+Obachauthor=L.+M.+Tremaine&title=Prediction+of+Drug-Drug+Interactions+from+in+Vitro+Induction+Data&doi=10.1124%2Fdmd.108.021907"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1124%2Fdmd.108.021907&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.108.021907%26sid%3Dliteratum%253Aachs%26aulast%3DFahmi%26aufirst%3DO.%2BA.%26aulast%3DBoldt%26aufirst%3DS.%26aulast%3DKish%26aufirst%3DM.%26aulast%3DObach%26aufirst%3DR.%2BS.%26aulast%3DTremaine%26aufirst%3DL.%2BM.%26atitle%3DPrediction%2520of%2520Drug-Drug%2520Interactions%2520from%2520in%2520Vitro%2520Induction%2520Data%26jtitle%3DApplication%2520of%2520the%2520Relative%2520Induction%2520Score%2520Approach%2520Using%2520Cryopreserved%2520Human%2520Hepatocytes%26date%3D2008%26volume%3D36%26issue%3D9%26spage%3D1971%26epage%3D1974%26doi%3D10.1124%2Fdmd.108.021907" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Manning, G.</span></span> <a href="http://kinase.com/web/current/human/" class="extLink">http://kinase.com/web/current/human/</a> (accessed April <span class="NLM_year">2018</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Manning%2C+G.+http%3A%2F%2Fkinase.com%2Fweb%2Fcurrent%2Fhuman%2F+%28accessed+April+2018%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26aulast%3DManning%26aufirst%3DG.%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, F. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zelesky, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Troutman, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, B.</span></span> <span> </span><span class="NLM_article-title">The Effect of Breast Cancer Resistance Protein and P-Glycoprotein on the Brain Penetration of Flavopiridol, Imatinib Mesylate (Gleevec), Prazosin, and 2-Methoxy-3-(4-(2-(5-Methyl-2-Phenyloxazol-4-Yl)Ethoxy)Phenyl)Propanoic Acid (PF-407288) in Mice</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">946</span>– <span class="NLM_lpage">955</span>, <span class="refDoi"> DOI: 10.1124/dmd.108.024489</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=10.1124%2Fdmd.108.024489" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=19225039" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=1%3ACAS%3A528%3ADC%252BD1MXlsVWitLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2009&pages=946-955&author=L.+Zhouauthor=K.+Schmidtauthor=F.+R.+Nelsonauthor=V.+Zeleskyauthor=M.+D.+Troutmanauthor=B.+Feng&title=The+Effect+of+Breast+Cancer+Resistance+Protein+and+P-Glycoprotein+on+the+Brain+Penetration+of+Flavopiridol%2C+Imatinib+Mesylate+%28Gleevec%29%2C+Prazosin%2C+and+2-Methoxy-3-%284-%282-%285-Methyl-2-Phenyloxazol-4-Yl%29Ethoxy%29Phenyl%29Propanoic+Acid+%28PF-407288%29+in+Mice&doi=10.1124%2Fdmd.108.024489"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">The effect of breast cancer resistance protein and P-glycoprotein on the brain penetration of flavopiridol, imatinib mesylate (Gleevec), prazosin, and 2-methoxy-3-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenyl)propanoic acid (PF-407288) in mice</span></div><div class="casAuthors">Zhou, Lin; Schmidt, Kari; Nelson, Frederick R.; Zelesky, Veronica; Troutman, Matthew D.; Feng, Bo</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">946-955</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The role of breast cancer resistance protein (Bcrp) and the combined activities of Bcrp and P-glycoprotein (P-gp, Mdr1a/1b) in limiting the brain penetration of drugs at the blood-brain barrier (BBB) were investigated using wild-type FVB, Mdr1a/1b(-/-), (-/-), Bcrp(-/-), and Mdr1a/1b(-/-), (-/-)Bcrp(-/-) mice.  Four drugs, flavopiridol, imatinib mesylate (Gleevec), PF-407288, and prazosin, with different transport specificity for BCRP/Bcrp and MDR1/Mdr1a were selected, and the drug levels in plasma, cerebrospinal fluid, and brain of mice were detd.  Flavopiridol and prazosin were identified as substrates for both mouse Bcrp and Mdr1a with greater transport assocd. with Bcrp.  The brain/plasma (B/P) ratios at 0.5 and 2 h in Mdr1a/1b(-/-), (-/-) and Bcrp(-/-) mice were 1- to 2-fold for both compds., whereas the ratios in Mdr1a/1b(-/-), (-/-)Bcrp(-/-) mice were more than 5-fold of those obsd. in FVB mice.  For imatinib, a better substrate of P-gp than Bcrp, the B/P ratios in Bcrp(-/-) were comparable to those in FVB mice, whereas the B/P ratios in Mdr1a/1b(-/-), (-/-) and Mdr1a/1b(-/-), (-/-)Bcrp(-/-) mice were more than 4- and 28-fold of those in FVB mice at both time points, resp.  Finally, the Bcrp-specific substrate PF-407288 exhibited comparable B/P ratios in Mdr1a/1b(-/-), (-/-) and Bcrp(-/-) mice and slightly but significantly increased B/P ratios in Mdr1a/1b(-/-), (-/-)Bcrp(-/-) mice compared with those in FVB mice.  The B/P ratios of compds. in Mdr1a/1b(-/-), (-/-)Bcrp(-/-) mice compared with those in Mdr1a/1b(-/-), (-/-) mice clearly demonstrate that Bcrp impairs the brain penetration of its substrates.  Moreover, P-gp and Bcrp at BBB function synergistically to limit the brain penetration of shared substrates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKvZVpc58zzbVg90H21EOLACvtfcHk0lhsoyZvdCjgyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXlsVWitLo%253D&md5=422881b70fa04474e0242a9c3a095093</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1124%2Fdmd.108.024489&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.108.024489%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DL.%26aulast%3DSchmidt%26aufirst%3DK.%26aulast%3DNelson%26aufirst%3DF.%2BR.%26aulast%3DZelesky%26aufirst%3DV.%26aulast%3DTroutman%26aufirst%3DM.%2BD.%26aulast%3DFeng%26aufirst%3DB.%26atitle%3DThe%2520Effect%2520of%2520Breast%2520Cancer%2520Resistance%2520Protein%2520and%2520P-Glycoprotein%2520on%2520the%2520Brain%2520Penetration%2520of%2520Flavopiridol%252C%2520Imatinib%2520Mesylate%2520%2528Gleevec%2529%252C%2520Prazosin%252C%2520and%25202-Methoxy-3-%25284-%25282-%25285-Methyl-2-Phenyloxazol-4-Yl%2529Ethoxy%2529Phenyl%2529Propanoic%2520Acid%2520%2528PF-407288%2529%2520in%2520Mice%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2009%26volume%3D37%26spage%3D946%26epage%3D955%26doi%3D10.1124%2Fdmd.108.024489" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 14 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Zhouling Xie, Xiaoxiao Yang, Yajun Duan, Jihong Han, <span class="NLM_string-name hlFld-ContribAuthor">Chenzhong Liao</span>. </span><span class="cited-content_cbyCitation_article-title">Small-Molecule Kinase Inhibitors for the Treatment of Nononcologic Diseases. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (3)
                                     , 1283-1345. <a href="https://doi.org/10.1021/acs.jmedchem.0c01511" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01511</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01511&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01511%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSmall-Molecule%252BKinase%252BInhibitors%252Bfor%252Bthe%252BTreatment%252Bof%252BNononcologic%252BDiseases%26aulast%3DXie%26aufirst%3DZhouling%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D29082020%26date%3D22012021%26volume%3D64%26issue%3D3%26spage%3D1283%26epage%3D1345" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Govindan Subramanian, Paul D. Johnson, Theresa Zachary, Nicole Roush, Yaqi Zhu, Scott J. Bowen, Ann Janssen, Brian A. Duclos, Tracey Williams, Christopher Javens, Nancy Dekki Shalaly, Daniel Martinez Molina, Arthur J. Wittwer, <span class="NLM_string-name hlFld-ContribAuthor">Jeffrey L. Hirsch</span>. </span><span class="cited-content_cbyCitation_article-title">Deciphering the Allosteric Binding Mechanism of the Human Tropomyosin Receptor Kinase A (hTrkA) Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">ACS Chemical Biology</span><span> <strong>2019,</strong> <em>14 </em>
                                    (6)
                                     , 1205-1216. <a href="https://doi.org/10.1021/acschembio.9b00126" title="DOI URL">https://doi.org/10.1021/acschembio.9b00126</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acschembio.9b00126&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facschembio.9b00126%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Chemical%2520Biology%26atitle%3DDeciphering%252Bthe%252BAllosteric%252BBinding%252BMechanism%252Bof%252Bthe%252BHuman%252BTropomyosin%252BReceptor%252BKinase%252BA%252B%252528hTrkA%252529%252BInhibitors%26aulast%3DSubramanian%26aufirst%3DGovindan%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D15022019%26date%3D06052019%26date%3D14052019%26date%3D06052019%26volume%3D14%26issue%3D6%26spage%3D1205%26epage%3D1216" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Wei Yan, Naga Rajiv Lakkaniga, Francesca Carlomagno, Massimo Santoro, Neil Q. McDonald, Fengping Lv, Naresh Gunaganti, Brendan Frett, <span class="NLM_string-name hlFld-ContribAuthor">Hong-yu Li</span>. </span><span class="cited-content_cbyCitation_article-title">Insights into Current Tropomyosin Receptor Kinase (TRK) Inhibitors: Development and Clinical Application. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (4)
                                     , 1731-1760. <a href="https://doi.org/10.1021/acs.jmedchem.8b01092" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b01092</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b01092&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b01092%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DInsights%252Binto%252BCurrent%252BTropomyosin%252BReceptor%252BKinase%252B%252528TRK%252529%252BInhibitors%25253A%252BDevelopment%252Band%252BClinical%252BApplication%26aulast%3DYan%26aufirst%3DWei%26date%3D2019%26date%3D2018%26date%3D2018%26date%3D11072018%26date%3D19092018%26date%3D06092018%26volume%3D62%26issue%3D4%26spage%3D1731%26epage%3D1760" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Alexios  Chatzigoulas</span>, <span class="hlFld-ContribAuthor ">Zoe  Cournia</span>. </span><span class="cited-content_cbyCitation_article-title">Rational design of allosteric modulators: Challenges and successes. </span><span class="cited-content_cbyCitation_journal-name">WIREs Computational Molecular Science</span><span> <strong>2021,</strong> <em>17 </em><a href="https://doi.org/10.1002/wcms.1529" title="DOI URL">https://doi.org/10.1002/wcms.1529</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/wcms.1529&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fwcms.1529%26sid%3Dliteratum%253Aachs%26jtitle%3DWIREs%2520Computational%2520Molecular%2520Science%26atitle%3DRational%252Bdesign%252Bof%252Ballosteric%252Bmodulators%25253A%252BChallenges%252Band%252Bsuccesses%26aulast%3DChatzigoulas%26aufirst%3DAlexios%26date%3D2021%26date%3D2021%26volume%3D17" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Francis  Giraud</span>, <span class="hlFld-ContribAuthor ">Elisabeth  Pereira</span>, <span class="hlFld-ContribAuthor ">Fabrice  Anizon</span>, <span class="hlFld-ContribAuthor ">Pascale  Moreau</span>. </span><span class="cited-content_cbyCitation_article-title">Recent Advances in Pain Management: Relevant Protein Kinases and Their Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2021,</strong> <em>26 </em>
                                    (9)
                                     , 2696. <a href="https://doi.org/10.3390/molecules26092696" title="DOI URL">https://doi.org/10.3390/molecules26092696</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules26092696&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules26092696%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DRecent%252BAdvances%252Bin%252BPain%252BManagement%25253A%252BRelevant%252BProtein%252BKinases%252Band%252BTheir%252BInhibitors%26aulast%3DGiraud%26aufirst%3DFrancis%26date%3D2021%26date%3D2021%26volume%3D26%26issue%3D9%26spage%3D2696" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiaoyun  Wu</span>, <span class="hlFld-ContribAuthor ">Qinlan  Li</span>, <span class="hlFld-ContribAuthor ">Shanhe  Wan</span>, <span class="hlFld-ContribAuthor ">Jiajie  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Molecular dynamics simulation and free energy calculation studies of the binding mechanism of allosteric inhibitors with TrkA kinase. </span><span class="cited-content_cbyCitation_journal-name">Journal of Biomolecular Structure and Dynamics</span><span> <strong>2021,</strong> <em>39 </em>
                                    (1)
                                     , 202-208. <a href="https://doi.org/10.1080/07391102.2019.1708798" title="DOI URL">https://doi.org/10.1080/07391102.2019.1708798</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/07391102.2019.1708798&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F07391102.2019.1708798%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Biomolecular%2520Structure%2520and%2520Dynamics%26atitle%3DMolecular%252Bdynamics%252Bsimulation%252Band%252Bfree%252Benergy%252Bcalculation%252Bstudies%252Bof%252Bthe%252Bbinding%252Bmechanism%252Bof%252Ballosteric%252Binhibitors%252Bwith%252BTrkA%252Bkinase%26aulast%3DWu%26aufirst%3DXiaoyun%26date%3D2021%26date%3D2019%26volume%3D39%26issue%3D1%26spage%3D202%26epage%3D208" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">A.  Giuliani</span>, <span class="hlFld-ContribAuthor ">L.  Lorenzini</span>, <span class="hlFld-ContribAuthor ">V.A.  Baldassarro</span>, <span class="hlFld-ContribAuthor ">M.  Pannella</span>, <span class="hlFld-ContribAuthor ">M.  Cescatti</span>, <span class="hlFld-ContribAuthor ">M.  Fernandez</span>, <span class="hlFld-ContribAuthor ">G.  Alastra</span>, <span class="hlFld-ContribAuthor ">A.  Flagelli</span>, <span class="hlFld-ContribAuthor ">G.  Villetti</span>, <span class="hlFld-ContribAuthor ">B.P.  Imbimbo</span>, <span class="hlFld-ContribAuthor ">L.  Giardino</span>, <span class="hlFld-ContribAuthor ">L.  Calzà</span>. </span><span class="cited-content_cbyCitation_article-title">Effects of Topical Application of CHF6467, a Mutated Form of Human Nerve Growth Factor, on Skin Wound Healing in Diabetic Mice. </span><span class="cited-content_cbyCitation_journal-name">Journal of Pharmacology and Experimental Therapeutics</span><span> <strong>2020,</strong> <em>375 </em>
                                    (2)
                                     , 317-331. <a href="https://doi.org/10.1124/jpet.120.000110" title="DOI URL">https://doi.org/10.1124/jpet.120.000110</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1124/jpet.120.000110&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1124%2Fjpet.120.000110%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Pharmacology%2520and%2520Experimental%2520Therapeutics%26atitle%3DEffects%252Bof%252BTopical%252BApplication%252Bof%252BCHF6467%25252C%252Ba%252BMutated%252BForm%252Bof%252BHuman%252BNerve%252BGrowth%252BFactor%25252C%252Bon%252BSkin%252BWound%252BHealing%252Bin%252BDiabetic%252BMice%26aulast%3DGiuliani%26aufirst%3DA.%26date%3D2020%26date%3D2020%26volume%3D375%26issue%3D2%26spage%3D317%26epage%3D331" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiaoyun  Lu</span>, <span class="hlFld-ContribAuthor ">Jeff B.  Smaill</span>, <span class="hlFld-ContribAuthor ">Ke  Ding</span>. </span><span class="cited-content_cbyCitation_article-title">Allosterische Kinaseinhibitoren – Erwartungen und Chancen. </span><span class="cited-content_cbyCitation_journal-name">Angewandte Chemie</span><span> <strong>2020,</strong> <em>132 </em>
                                    (33)
                                     , 13868-13881. <a href="https://doi.org/10.1002/ange.201914525" title="DOI URL">https://doi.org/10.1002/ange.201914525</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ange.201914525&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fange.201914525%26sid%3Dliteratum%253Aachs%26jtitle%3DAngewandte%2520Chemie%26atitle%3DAllosterische%252BKinaseinhibitoren%252B%2525E2%252580%252593%252BErwartungen%252Bund%252BChancen%26aulast%3DLu%26aufirst%3DXiaoyun%26date%3D2020%26date%3D2020%26volume%3D132%26issue%3D33%26spage%3D13868%26epage%3D13881" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiaoyun  Lu</span>, <span class="hlFld-ContribAuthor ">Jeff B.  Smaill</span>, <span class="hlFld-ContribAuthor ">Ke  Ding</span>. </span><span class="cited-content_cbyCitation_article-title">New Promise and Opportunities for Allosteric Kinase Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Angewandte Chemie International Edition</span><span> <strong>2020,</strong> <em>59 </em>
                                    (33)
                                     , 13764-13776. <a href="https://doi.org/10.1002/anie.201914525" title="DOI URL">https://doi.org/10.1002/anie.201914525</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/anie.201914525&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fanie.201914525%26sid%3Dliteratum%253Aachs%26jtitle%3DAngewandte%2520Chemie%2520International%2520Edition%26atitle%3DNew%252BPromise%252Band%252BOpportunities%252Bfor%252BAllosteric%252BKinase%252BInhibitors%26aulast%3DLu%26aufirst%3DXiaoyun%26date%3D2020%26date%3D2020%26volume%3D59%26issue%3D33%26spage%3D13764%26epage%3D13776" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Justin J.  Bailey</span>, <span class="hlFld-ContribAuthor ">Carolin  Jaworski</span>, <span class="hlFld-ContribAuthor ">Donovan  Tung</span>, <span class="hlFld-ContribAuthor ">Carmen  Wängler</span>, <span class="hlFld-ContribAuthor ">Björn  Wängler</span>, <span class="hlFld-ContribAuthor ">Ralf  Schirrmacher</span>. </span><span class="cited-content_cbyCitation_article-title">Tropomyosin receptor kinase inhibitors: an updated patent review for 2016–2019. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Therapeutic Patents</span><span> <strong>2020,</strong> <em>30 </em>
                                    (5)
                                     , 325-339. <a href="https://doi.org/10.1080/13543776.2020.1737011" title="DOI URL">https://doi.org/10.1080/13543776.2020.1737011</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/13543776.2020.1737011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F13543776.2020.1737011%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Therapeutic%2520Patents%26atitle%3DTropomyosin%252Breceptor%252Bkinase%252Binhibitors%25253A%252Ban%252Bupdated%252Bpatent%252Breview%252Bfor%252B2016%2525E2%252580%2525932019%26aulast%3DBailey%26aufirst%3DJustin%2BJ.%26date%3D2020%26date%3D2020%26volume%3D30%26issue%3D5%26spage%3D325%26epage%3D339" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Govindan  Subramanian</span>, <span class="hlFld-ContribAuthor ">Rajendran  Vairagoundar</span>, <span class="hlFld-ContribAuthor ">Scott J.  Bowen</span>, <span class="hlFld-ContribAuthor ">Nicole  Roush</span>, <span class="hlFld-ContribAuthor ">Theresa  Zachary</span>, <span class="hlFld-ContribAuthor ">Christopher  Javens</span>, <span class="hlFld-ContribAuthor ">Tracey  Williams</span>, <span class="hlFld-ContribAuthor ">Ann  Janssen</span>, <span class="hlFld-ContribAuthor ">Andrea  Gonzales</span>. </span><span class="cited-content_cbyCitation_article-title">Synthetic inhibitor leads of human tropomyosin receptor kinase A (
              h
              TrkA). </span><span class="cited-content_cbyCitation_journal-name">RSC Medicinal Chemistry</span><span> <strong>2020,</strong> <em>11 </em>
                                    (3)
                                     , 370-377. <a href="https://doi.org/10.1039/C9MD00554D" title="DOI URL">https://doi.org/10.1039/C9MD00554D</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C9MD00554D&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC9MD00554D%26sid%3Dliteratum%253Aachs%26jtitle%3DRSC%2520Medicinal%2520Chemistry%26atitle%3DSynthetic%252Binhibitor%252Bleads%252Bof%252Bhuman%252Btropomyosin%252Breceptor%252Bkinase%252BA%252B%252528%252Bh%252BTrkA%252529%26aulast%3DSubramanian%26aufirst%3DGovindan%26date%3D2020%26date%3D2020%26volume%3D11%26issue%3D3%26spage%3D370%26epage%3D377" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jingqiu  Wang</span>, <span class="hlFld-ContribAuthor ">Jing-Quan  Wang</span>, <span class="hlFld-ContribAuthor ">Chao-Yun  Cai</span>, <span class="hlFld-ContribAuthor ">Qingbin  Cui</span>, <span class="hlFld-ContribAuthor ">Yuqi  Yang</span>, <span class="hlFld-ContribAuthor ">Zhuo-Xun  Wu</span>, <span class="hlFld-ContribAuthor ">Xingduo  Dong</span>, <span class="hlFld-ContribAuthor ">Leli  Zeng</span>, <span class="hlFld-ContribAuthor ">Linguo  Zhao</span>, <span class="hlFld-ContribAuthor ">Dong-Hua  Yang</span>, <span class="hlFld-ContribAuthor ">Zhe-Sheng  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Reversal Effect of ALK Inhibitor NVP-TAE684 on ABCG2-Overexpressing Cancer Cells. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Oncology</span><span> <strong>2020,</strong> <em>10 </em><a href="https://doi.org/10.3389/fonc.2020.00228" title="DOI URL">https://doi.org/10.3389/fonc.2020.00228</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fonc.2020.00228&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffonc.2020.00228%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Oncology%26atitle%3DReversal%252BEffect%252Bof%252BALK%252BInhibitor%252BNVP-TAE684%252Bon%252BABCG2-Overexpressing%252BCancer%252BCells%26aulast%3DWang%26aufirst%3DJingqiu%26date%3D2020%26date%3D2020%26volume%3D10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sandra  Röhm</span>, <span class="hlFld-ContribAuthor ">Andreas  Krämer</span>, <span class="hlFld-ContribAuthor ">Stefan  Knapp</span>. </span><span class="cited-content_cbyCitation_article-title">Function, Structure and Topology of Protein Kinases. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2020,</strong>,, 1-24. <a href="https://doi.org/10.1007/7355_2020_97" title="DOI URL">https://doi.org/10.1007/7355_2020_97</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/7355_2020_97&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F7355_2020_97%26sid%3Dliteratum%253Aachs%26atitle%3DFunction%25252C%252BStructure%252Band%252BTopology%252Bof%252BProtein%252BKinases%26aulast%3DR%25C3%25B6hm%26aufirst%3DSandra%26date%3D2020%26date%3D2020%26spage%3D1%26epage%3D24%26pub%3DSpringer%2520International%2520Publishing%26atitle%3DProteinkinase%252BInhibitors%26aulast%3DLaufer%26aufirst%3DStefan%26date%3D2021%26volume%3D36" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ramon  Martinez</span>, <span class="hlFld-ContribAuthor ">Amy  Defnet</span>, <span class="hlFld-ContribAuthor ">Paul  Shapiro</span>. </span><span class="cited-content_cbyCitation_article-title">Avoiding or Co-Opting ATP Inhibition: Overview of Type III, IV, V, and VI Kinase Inhibitors. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2020,</strong>,, 29-59. <a href="https://doi.org/10.1007/978-3-030-48283-1_3" title="DOI URL">https://doi.org/10.1007/978-3-030-48283-1_3</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/978-3-030-48283-1_3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F978-3-030-48283-1_3%26sid%3Dliteratum%253Aachs%26atitle%3DAvoiding%252Bor%252BCo-Opting%252BATP%252BInhibition%25253A%252BOverview%252Bof%252BType%252BIII%25252C%252BIV%25252C%252BV%25252C%252Band%252BVI%252BKinase%252BInhibitors%26aulast%3DMartinez%26aufirst%3DRamon%26date%3D2020%26date%3D2020%26spage%3D29%26epage%3D59%26pub%3DSpringer%2520International%2520Publishing%26atitle%3DNext%252BGeneration%252BKinase%252BInhibitors%26aulast%3DShapiro%26aufirst%3DPaul%26date%3D2020%26volume%3D50" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-1/acs.jmedchem.8b00280/20190107/images/medium/jm-2018-00280z_0019.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-1/acs.jmedchem.8b00280/20190107/images/large/jm-2018-00280z_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00280&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-1/acs.jmedchem.8b00280/20190107/images/medium/jm-2018-00280z_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-1/acs.jmedchem.8b00280/20190107/images/large/jm-2018-00280z_0001.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Neurotrophins and their receptors. The neurotrophins exhibit specific interactions with the three Trk receptors: NGF binds TrkA, BDNF and NT-4 binds TrkB, and NT-3 binds TrkC.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-1/acs.jmedchem.8b00280/20190107/images/large/jm-2018-00280z_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00280&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-1/acs.jmedchem.8b00280/20190107/images/medium/jm-2018-00280z_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-1/acs.jmedchem.8b00280/20190107/images/large/jm-2018-00280z_0002.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Allosteric inhibitors Trametinib, MK-2206, and GNF-2.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-1/acs.jmedchem.8b00280/20190107/images/large/jm-2018-00280z_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00280&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-1/acs.jmedchem.8b00280/20190107/images/medium/jm-2018-00280z_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-1/acs.jmedchem.8b00280/20190107/images/large/jm-2018-00280z_0003.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Apo crystal structure of TrkA protein highlighting a hydrophobic pocket potentially suitable for an allosteric Type III binder.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-1/acs.jmedchem.8b00280/20190107/images/large/jm-2018-00280z_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00280&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-1/acs.jmedchem.8b00280/20190107/images/medium/jm-2018-00280z_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-1/acs.jmedchem.8b00280/20190107/images/large/jm-2018-00280z_0004.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Schematic illustration of absorption of an orally administered drug across the intestinal epithelium and its distribution across the brain vascular endothelium that forms the BBB. The presence of tight junctions between cells in both structures limits the paracellular movement of drug molecules. <i>C</i><sub>p</sub> = total plasma concentration, <i>C</i><sub>p,u</sub> = unbound plasma concentration, <i>C</i><sub>b,u</sub> = unbound brain concentration, and <i>C</i><sub>i,u</sub> = unbound intracellular concentration. According to the free drug hypothesis, unbound concentrations determine the drug pharmacological effect, and at the BBB, <i>C</i><sub>b,u</sub> may be less than <i>C</i><sub>p,u</sub> if the drug is a substrate for efflux transporters.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-1/acs.jmedchem.8b00280/20190107/images/large/jm-2018-00280z_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00280&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-1/acs.jmedchem.8b00280/20190107/images/medium/jm-2018-00280z_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-1/acs.jmedchem.8b00280/20190107/images/large/jm-2018-00280z_0005.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. (A) Cocrystal structure of pan-Trk inhibitor <b>1</b> bound to TrkA protein in a DFG-out conformation; ligand <b>1</b> shown in CPK space filling model; some parts of the G-loop, activation loop, and JM domain are not solved. (B) Overlay of the bound conformation in TrkA protein of DFG-out binder <b>1</b> (gray) and allosteric ligand <b>2</b> (magenta) indicating a region of common TrkA binding site occupancy. (C) Cocrystal structure of <b>2</b> bound to TrkA protein in a DFG-out conformation that is similar to the apo DFG-out conformation. Ligand <b>2</b> binds in an allosteric pocket created by the activation loop and JM domain; ligand <b>2</b> shown in CPK space filling model.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-1/acs.jmedchem.8b00280/20190107/images/large/jm-2018-00280z_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00280&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-1/acs.jmedchem.8b00280/20190107/images/medium/jm-2018-00280z_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-1/acs.jmedchem.8b00280/20190107/images/large/jm-2018-00280z_0006.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. (A) Cocrystal structure of TrkA selective ligand <b>2</b> bound to TrkA protein highlighting key protein–ligand interactions with white dashed lines with distances given in Å. (B) Cocrystal structure of TrkA selective ligand <b>2</b> bound to TrkA protein highlighting locations and thermodynamic properties of selected water molecules estimated by WaterMap. Oxygen atoms of selected waters are highlighted as CPK spheres with thermodynamic profiles. Water coloring scheme represents the stability of the water: unstable waters (high δG) are colored red and stable waters (low δG) are colored blue.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-1/acs.jmedchem.8b00280/20190107/images/large/jm-2018-00280z_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00280&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-1/acs.jmedchem.8b00280/20190107/images/medium/jm-2018-00280z_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-1/acs.jmedchem.8b00280/20190107/images/large/jm-2018-00280z_0007.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Sequence alignment of the TrkA, TrkB, and TrkC JM domains. The motif interacting with TrkA selective allosteric ligand <b>2</b> is highlighted in red and indicates the putative origin of TrkA selectivity over TrkB/C.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-1/acs.jmedchem.8b00280/20190107/images/large/jm-2018-00280z_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00280&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-1/acs.jmedchem.8b00280/20190107/images/medium/jm-2018-00280z_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-1/acs.jmedchem.8b00280/20190107/images/large/jm-2018-00280z_0012.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Optimization of Allosteric Hit <b>2</b> to Lead Molecule <b>3</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-1/acs.jmedchem.8b00280/20190107/images/large/jm-2018-00280z_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00280&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-1/acs.jmedchem.8b00280/20190107/images/medium/jm-2018-00280z_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-1/acs.jmedchem.8b00280/20190107/images/large/jm-2018-00280z_0008.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. (A) Cocrystal structure of lead molecule <b>3</b> bound to TrkA protein highlighting key protein–ligand interactions with white dashed lines with distances given in Å. (B) Cocrystal structure of lead molecule <b>3</b> bound to TrkA protein highlighting interactions with Arg673 and Asp668 with white dashed lines. Parts of TrkA protein omitted for clarity. (C) Cocrystal structure of lead molecule <b>3</b> bound to TrkA protein highlighting allosteric binding site surface with brown representing hydrophobic regions, green representing neutral polarity regions, and blue representing polar regions.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-1/acs.jmedchem.8b00280/20190107/images/large/jm-2018-00280z_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00280&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch2" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-1/acs.jmedchem.8b00280/20190107/images/medium/jm-2018-00280z_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-1/acs.jmedchem.8b00280/20190107/images/large/jm-2018-00280z_0013.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Lead Molecule <b>3</b> via Introduction of an Aminopyridine Moiety Using a Two-step–One-pot Borylation–Suzuki Coupling Methodology<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-1/acs.jmedchem.8b00280/20190107/images/large/jm-2018-00280z_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00280&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) NaNO<sub>2</sub>, BF<sub>3</sub>·OEt<sub>2</sub>, DCM, −15 °C, 97%; (ii) pyridine, MeOH; (iii) K<sub>2</sub>CO<sub>3</sub>, DCM, rt, 30% over three steps; (iv) T<sub>3</sub>P, pyridine, Me-THF, 85 °C, 73%; (v) bis(pinacolato)diboron, KOAc, Pd(dppf)Cl<sub>2,</sub> dioxane, 100 °C, 3 h; (vi) Na<sub>2</sub>CO<sub>3</sub>, Pd(dppf)Cl, dioxane, H<sub>2</sub>O, 110 °C, 16 h, 60% over two steps; (vii) H<sub>2</sub>O<sub>2</sub>, K<sub>2</sub>CO<sub>3,</sub> DMSO, rt, 3 h, 58%.</p></p></figure><figure data-id="fig9" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-1/acs.jmedchem.8b00280/20190107/images/medium/jm-2018-00280z_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-1/acs.jmedchem.8b00280/20190107/images/large/jm-2018-00280z_0009.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. (A) Cocrystal structure of candidate molecule <b>23</b> bound to TrkA protein highlighting key protein–ligand interactions with white dashed lines with distances given in Å. (B) Cocrystal structure of candidate molecule <b>23</b> bound to TrkA protein highlighting interactions with Arg673 and waters with white dashed lines. Parts of TrkA protein omitted for clarity.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-1/acs.jmedchem.8b00280/20190107/images/large/jm-2018-00280z_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00280&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig11" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-1/acs.jmedchem.8b00280/20190107/images/medium/jm-2018-00280z_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-1/acs.jmedchem.8b00280/20190107/images/large/jm-2018-00280z_0011.jpeg" id="rightTab-gr15" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Effect of <b>23</b> compared with vehicle and ibuprofen on UV induced hyperalgesia in rat, with ipsilateral paw data shown, <i>n</i> = 8 rats per dose group. ***<i>p</i> < 0.001, **<i>p</i> < 0.01, two-way ANOVA vs vehicle.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-1/acs.jmedchem.8b00280/20190107/images/large/jm-2018-00280z_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00280&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch3" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-1/acs.jmedchem.8b00280/20190107/images/medium/jm-2018-00280z_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-1/acs.jmedchem.8b00280/20190107/images/large/jm-2018-00280z_0014.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Scalable Synthesis Route Used To Prepare Candidate Molecule <b>23</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-1/acs.jmedchem.8b00280/20190107/images/large/jm-2018-00280z_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00280&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) MeOH, H<sub>2</sub>SO<sub>4,</sub> reflux, 98%; (ii) (Bpin)<sub>2,</sub> [Ir(cod)OMe]<sub>2,</sub>THF, reflux, 1–7 h; (iii) Pd(PPh<sub>3</sub>)<sub>4</sub>, K<sub>2</sub>CO<sub>3,</sub> H<sub>2</sub>O, THF, reflux, 2 h; (iv) NaOH, IMS or THF, 25 °C, 1 h (84% over three steps); (v) T<sub>3</sub>P, DIPEA, 2-Me-THF, 77%; (vi) NaOH, IMS, 25 °C, 1 h, 70%; (vii) DIPEA, DMF, rt, 2 h, 75%.</p></p></figure><figure data-id="sch4" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-1/acs.jmedchem.8b00280/20190107/images/medium/jm-2018-00280z_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-1/acs.jmedchem.8b00280/20190107/images/large/jm-2018-00280z_0015.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of Key Pyrazole Intermediate <b>34</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-1/acs.jmedchem.8b00280/20190107/images/large/jm-2018-00280z_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00280&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) EtOK, Et<sub>2</sub>O, EtOH, CH<sub>3</sub>CN, 0 °C to rt, 84%; (ii) PhNHNH<sub>2</sub>, EtOH, reflux, 34%.</p></p></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i53">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_32423" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_32423" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 62 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Skaper, S. D.</span></span> <span> </span><span class="NLM_article-title">The Neurotrophin Family of Neurotrophic Factors: An Overview</span>. <i>Methods Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>846</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">12</span>, <span class="refDoi"> DOI: 10.1007/978-1-61779-536-7_1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=10.1007%2F978-1-61779-536-7_1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=22367796" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1ensrvJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=846&publication_year=2012&pages=1-12&author=S.+D.+Skaper&title=The+Neurotrophin+Family+of+Neurotrophic+Factors%3A+An+Overview&doi=10.1007%2F978-1-61779-536-7_1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">The neurotrophin family of neurotrophic factors: an overview</span></div><div class="casAuthors">Skaper, Stephen D.</div><div class="citationInfo"><span class="NLM_cas:title">Methods in Molecular Biology (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">846</span>
        (<span class="NLM_cas:issue">Neurotrophic Factors</span>),
    <span class="NLM_cas:pages">1-12</span>CODEN:
                <span class="NLM_cas:coden">MMBIED</span>;
        ISSN:<span class="NLM_cas:issn">1064-3745</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  The neurotrophins are a family of closely related proteins that were first identified as survival factors for sympathetic and sensory neurons and have since been shown to control a no. of aspects of survival, development, and function of neurons in both the central and peripheral nervous systems.  Limiting quantities of neurotrophins during development control the nos. of surviving neurons to ensure a match between neurons and the requirement for a suitable d. of target innervation.  Biol. effects of each of the four mammalian neurotrophins are mediated through activation of one or more of the three members of the tropomyosin-related kinase (Trk) family of receptor tyrosine kinases (TrkA, TrkB, and TrkC).  In addn., all neurotrophins activate the p75 neurotrophin receptor, a member of the tumor necrosis factor receptor superfamily.  Neurotrophin engagement of Trk receptors leads to activation of Ras, phosphatidylinositol 3-kinase, phospholipase C-γl, and signaling pathways controlled through these proteins, including the mitogen-activated protein kinases.  Neurotrophin availability is required into adulthood, where they control synaptic function and plasticity and sustain neuronal cell survival, morphol., and differentiation.  This chapter will provide an overview of neurotrophin biol., their receptors, and signaling pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrx93j5UxkhubVg90H21EOLACvtfcHk0lh-gJCPn_FA1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1ensrvJ&md5=5f575aa213b4e790fc7d1d3b44ead678</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1007%2F978-1-61779-536-7_1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F978-1-61779-536-7_1%26sid%3Dliteratum%253Aachs%26aulast%3DSkaper%26aufirst%3DS.%2BD.%26atitle%3DThe%2520Neurotrophin%2520Family%2520of%2520Neurotrophic%2520Factors%253A%2520An%2520Overview%26jtitle%3DMethods%2520Mol.%2520Biol.%26date%3D2012%26volume%3D846%26spage%3D1%26epage%3D12%26doi%3D10.1007%2F978-1-61779-536-7_1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hefti, F. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenthal, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walicke, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wyatt, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vergara, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shelton, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, A. M.</span></span> <span> </span><span class="NLM_article-title">Novel Class of Pain Drugs Based on Antagonism of NGF</span>. <i>Trends Pharmacol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>27</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">85</span>– <span class="NLM_lpage">91</span>, <span class="refDoi"> DOI: 10.1016/j.tips.2005.12.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=10.1016%2Fj.tips.2005.12.001" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2006&pages=85-91&issue=2&author=F.+F.+Heftiauthor=A.+Rosenthalauthor=P.+A.+Walickeauthor=S.+Wyattauthor=G.+Vergaraauthor=D.+L.+Sheltonauthor=A.+M.+Davies&title=Novel+Class+of+Pain+Drugs+Based+on+Antagonism+of+NGF&doi=10.1016%2Fj.tips.2005.12.001"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2005.12.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2005.12.001%26sid%3Dliteratum%253Aachs%26aulast%3DHefti%26aufirst%3DF.%2BF.%26aulast%3DRosenthal%26aufirst%3DA.%26aulast%3DWalicke%26aufirst%3DP.%2BA.%26aulast%3DWyatt%26aufirst%3DS.%26aulast%3DVergara%26aufirst%3DG.%26aulast%3DShelton%26aufirst%3DD.%2BL.%26aulast%3DDavies%26aufirst%3DA.%2BM.%26atitle%3DNovel%2520Class%2520of%2520Pain%2520Drugs%2520Based%2520on%2520Antagonism%2520of%2520NGF%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2006%26volume%3D27%26issue%3D2%26spage%3D85%26epage%3D91%26doi%3D10.1016%2Fj.tips.2005.12.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lane, N. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schnitzer, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Birbara, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mokhtarani, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shelton, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, M. T.</span></span> <span> </span><span class="NLM_article-title">Tanezumab for the Treatment of Pain from Osteoarthritis of the Knee</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>363</i></span> (<span class="NLM_issue">16</span>),  <span class="NLM_fpage">1521</span>– <span class="NLM_lpage">1531</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa0901510</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=10.1056%2FNEJMoa0901510" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=20942668" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht12ltrbI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=363&publication_year=2010&pages=1521-1531&issue=16&author=N.+E.+Laneauthor=T.+J.+Schnitzerauthor=C.+A.+Birbaraauthor=M.+Mokhtaraniauthor=D.+L.+Sheltonauthor=M.+D.+Smithauthor=M.+T.+Brown&title=Tanezumab+for+the+Treatment+of+Pain+from+Osteoarthritis+of+the+Knee&doi=10.1056%2FNEJMoa0901510"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Tanezumab for the treatment of pain from osteoarthritis of the knee</span></div><div class="casAuthors">Lane, Nancy E.; Schnitzer, Thomas J.; Birbara, Charles A.; Mokhtarani, Masoud; Shelton, David L.; Smith, Mike D.; Brown, Mark T.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">363</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">1521</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: Increased expression of nerve growth factor in injured or inflamed tissue is assocd. with increased pain.  This proof-of-concept study was designed to investigate the safety and analgesic efficacy of tanezumab, a humanized monoclonal antibody that binds and inhibits nerve growth factor.  Methods: We randomly assigned 450 patients with osteoarthritis of the knee to receive tanezumab (administered at a dose of 10, 25, 50, 100, or 200 Ag per kg of body wt.) or placebo on days 1 and 56.  The primary efficacy measures were knee pain while walking and the patient's global assessment of response to therapy.  We also assessed pain, stiffness, and phys. function using the Western Ontario and Mc-Master Universities Osteoarthritis Index (WOMAC); the rate of response using the criteria of the Outcome Measures for Rheumatol.  Committee and Osteoarthritis Research Society International Standing Committee for Clin. Trials Response Criteria Initiative (OMERACT-OARSI); and safety.  Results: When averaged over weeks 1 through 16, the mean redns. from baseline in knee pain while walking ranged from 45 to 62% with various doses of tanezumab, as compared with 22% with placebo (P < 0.001).  Tanezumab, as compared with placebo, was also assocd. with significantly greater improvements in the response to therapy as assessed with the use of the patients' global assessment measure (mean increases in score of 29 to 47% with various doses of tanezumab, as compared with 19% with placebo; P ≤ 0.001).  The rate of response according to the OMERACT-OARSI criteria ranged from 74 to 93% with tanezumab treatment, as compared with 44% with placebo (P < 0.001).  The rates of adverse events were 68% and 55% in the tanezumab and placebo groups, resp.  The most common adverse events among tanezumab-treated patients were headache (9% of the patients), upper respiratory tract infection (7%), and paresthesia (7%).  Conclusions: In this proof-of-concept study, treatment with tanezumab was assocd. with a redn. in joint pain and improvement in function, with mild and moderate adverse events, among patients with moderate-to-severe osteoarthritis of the knee.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCmt4PNNZ44LVg90H21EOLACvtfcHk0lh-gJCPn_FA1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht12ltrbI&md5=fe69490dfa3d47fe8a0c286d6b020d57</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa0901510&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa0901510%26sid%3Dliteratum%253Aachs%26aulast%3DLane%26aufirst%3DN.%2BE.%26aulast%3DSchnitzer%26aufirst%3DT.%2BJ.%26aulast%3DBirbara%26aufirst%3DC.%2BA.%26aulast%3DMokhtarani%26aufirst%3DM.%26aulast%3DShelton%26aufirst%3DD.%2BL.%26aulast%3DSmith%26aufirst%3DM.%2BD.%26aulast%3DBrown%26aufirst%3DM.%2BT.%26atitle%3DTanezumab%2520for%2520the%2520Treatment%2520of%2520Pain%2520from%2520Osteoarthritis%2520of%2520the%2520Knee%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2010%26volume%3D363%26issue%3D16%26spage%3D1521%26epage%3D1531%26doi%3D10.1056%2FNEJMoa0901510" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schnitzer, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lane, N. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Birbara, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simpson, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, M. T.</span></span> <span> </span><span class="NLM_article-title">Long-Term Open-Label Study of Tanezumab for Moderate to Severe Osteoarthritic Knee Pain</span>. <i>Osteoarthritis Cartilage</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>19</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">639</span>– <span class="NLM_lpage">646</span>, <span class="refDoi"> DOI: 10.1016/j.joca.2011.01.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=10.1016%2Fj.joca.2011.01.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=21251985" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=1%3ACAS%3A280%3ADC%252BC3MrisVektg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2011&pages=639-646&issue=6&author=T.+J.+Schnitzerauthor=N.+E.+Laneauthor=C.+Birbaraauthor=M.+D.+Smithauthor=S.+L.+Simpsonauthor=M.+T.+Brown&title=Long-Term+Open-Label+Study+of+Tanezumab+for+Moderate+to+Severe+Osteoarthritic+Knee+Pain&doi=10.1016%2Fj.joca.2011.01.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Long-term open-label study of tanezumab for moderate to severe osteoarthritic knee pain</span></div><div class="casAuthors">Schnitzer T J; Lane N E; Birbara C; Smith M D; Simpson S L; Brown M T</div><div class="citationInfo"><span class="NLM_cas:title">Osteoarthritis and cartilage</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">639-46</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">OBJECTIVE:  This study was designed to evaluate the long-term safety and effectiveness of repeated doses of the humanized anti-nerve growth factor antibody, tanezumab, during open-label treatment of patients with OA knee pain.  DESIGN:  The current study (clinicaltrials.gov identifier: NCT00399490) was a multicenter, phase II, open-label, multiple-dose extension of an earlier randomized clinical trial.  All patients (N=281) received infusions of tanezumab 50μg/kg on Days 1 and 56 with subsequent doses administered at 8-week intervals (up to a total of eight infusions).  The primary endpoint of this study was safety.  Effectiveness evaluations included overall knee pain, Western Ontario and McMaster Universities Osteoarthritis (WOMAC) index subscales, and subject global assessment (SGA) of response to therapy on 0-100 point visual analog scales.  RESULTS:  Repeated administration of tanezumab resulted in a low incidence of treatment-related adverse events (AEs; 7.5%).  The rate of serious AEs was also low (2.8%) with none considered treatment-related.  Few AEs of abnormal peripheral sensation were reported; hypoesthesia was reported by nine patients (3.2%), paresthesia by seven patients (2.5%), and hyperesthesia, peripheral neuropathy, and sensory disturbance were each reported by one patient (0.4% for each).  Most AEs of abnormal peripheral sensation were rated as mild (95%) and the majority (65%) resolved before study completion.  At Week 8, overall knee pain and SGA improved from baseline by a mean (± standard error) of -12.8 (±1.78) and 8.0 (±1.66), respectively.  Similar improvements occurred for WOMAC subscales.  CONCLUSIONS:  Repeated injections of tanezumab in patients with moderate to severe knee OA provide continued pain relief and improved function with a low incidence of side effects.  Additional studies to define the efficacy and duration of pain reduction and to provide a more complete assessment of long-term safety are warranted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSP3rNjPk9h4A20zIbnCCI3fW6udTcc2eaxMG_DPuEPSrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3MrisVektg%253D%253D&md5=e489a54f543455004fe879ce02744c64</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2Fj.joca.2011.01.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.joca.2011.01.009%26sid%3Dliteratum%253Aachs%26aulast%3DSchnitzer%26aufirst%3DT.%2BJ.%26aulast%3DLane%26aufirst%3DN.%2BE.%26aulast%3DBirbara%26aufirst%3DC.%26aulast%3DSmith%26aufirst%3DM.%2BD.%26aulast%3DSimpson%26aufirst%3DS.%2BL.%26aulast%3DBrown%26aufirst%3DM.%2BT.%26atitle%3DLong-Term%2520Open-Label%2520Study%2520of%2520Tanezumab%2520for%2520Moderate%2520to%2520Severe%2520Osteoarthritic%2520Knee%2520Pain%26jtitle%3DOsteoarthritis%2520Cartilage%26date%3D2011%26volume%3D19%26issue%3D6%26spage%3D639%26epage%3D646%26doi%3D10.1016%2Fj.joca.2011.01.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Evans, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moldwin, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cossons, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darekar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mills, I. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scholfield, D.</span></span> <span> </span><span class="NLM_article-title">Proof of Concept Trial of Tanezumab for the Treatment of Symptoms Associated with Interstitial Cystitis</span>. <i>J. Urol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>185</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">1716</span>– <span class="NLM_lpage">1721</span>, <span class="refDoi"> DOI: 10.1016/j.juro.2010.12.088</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=10.1016%2Fj.juro.2010.12.088" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=21420111" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=1%3ACAS%3A528%3ADC%252BC3MXksFSqsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=185&publication_year=2011&pages=1716-1721&issue=5&author=R.+J.+Evansauthor=R.+M.+Moldwinauthor=N.+Cossonsauthor=A.+Darekarauthor=I.+W.+Millsauthor=D.+Scholfield&title=Proof+of+Concept+Trial+of+Tanezumab+for+the+Treatment+of+Symptoms+Associated+with+Interstitial+Cystitis&doi=10.1016%2Fj.juro.2010.12.088"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Proof of Concept Trial of Tanezumab for the Treatment of Symptoms Associated With Interstitial Cystitis</span></div><div class="casAuthors">Evans, R. J.; Moldwin, R. M.; Cossons, N.; Darekar, A.; Mills, I. W.; Scholfield, D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Urology (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">185</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1716-1721</span>CODEN:
                <span class="NLM_cas:coden">JOURAA</span>;
        ISSN:<span class="NLM_cas:issn">0022-5347</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Purpose: In this randomized, double-blind, placebo controlled phase 2 study we investigated tanezumab, a humanized monoclonal antibody that specifically inhibits nerve growth factor as a treatment for interstitial cystitis pain.  Materials and Methods: Patients with interstitial cystitis received a single i.v. dose of 200 μg/kg tanezumab or placebo.  Patients recorded daily pain scores (on an 11-point numerical rating scale) 7 days before attending study visits and completed a urinary symptom diary for 3 of those days.  Patients also completed the Interstitial Cystitis Symptom Index questionnaire and a global response assessment.  The primary end point was change in av. daily numerical rating scale pain score from baseline to week 6.  Secondary end points included global response assessment, Interstitial Cystitis Symptom Index score, micturition and urgency episode frequency per 24 h, and mean voided vol. per micturition.  The incidence of adverse events was also assessed.  Results: A total of 34 patients received tanezumab and 30 received placebo.  At week 6 tanezumab produced a significant redn. from baseline in av. daily pain score vs placebo (treatment difference [LS mean, 90% CI] was -1.4 [-2.2, -0.5]).  A significantly higher proportion of patients on tanezumab responded as improved in the global response assessment and tanezumab also significantly reduced urgency episode frequency vs placebo.  Tanezumab had no significant effect on Interstitial Cystitis Symptom Index score, micturition frequency or mean voided vol. per micturition.  The most common adverse events were headache (tanezumab 20.6%, placebo 16.7%) and paresthesia (tanezumab 17.6%, placebo 3.3%).  Conclusions: Tanezumab has shown preliminary efficacy in the treatment of pain assocd. with interstitial cystitis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrs8VBnrLDcAbVg90H21EOLACvtfcHk0lhoqYapDA5-Hg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXksFSqsL8%253D&md5=5ac5f081d2cc6eb9b8190148923bcd4f</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2Fj.juro.2010.12.088&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.juro.2010.12.088%26sid%3Dliteratum%253Aachs%26aulast%3DEvans%26aufirst%3DR.%2BJ.%26aulast%3DMoldwin%26aufirst%3DR.%2BM.%26aulast%3DCossons%26aufirst%3DN.%26aulast%3DDarekar%26aufirst%3DA.%26aulast%3DMills%26aufirst%3DI.%2BW.%26aulast%3DScholfield%26aufirst%3DD.%26atitle%3DProof%2520of%2520Concept%2520Trial%2520of%2520Tanezumab%2520for%2520the%2520Treatment%2520of%2520Symptoms%2520Associated%2520with%2520Interstitial%2520Cystitis%26jtitle%3DJ.%2520Urol.%26date%3D2011%26volume%3D185%26issue%3D5%26spage%3D1716%26epage%3D1721%26doi%3D10.1016%2Fj.juro.2010.12.088" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Katz, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borenstein, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Birbara, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bramson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nemeth, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, M. T.</span></span> <span> </span><span class="NLM_article-title">Efficacy and Safety of Tanezumab in the Treatment of Chronic Low Back Pain</span>. <i>Pain</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>152</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">2248</span>– <span class="NLM_lpage">2258</span>, <span class="refDoi"> DOI: 10.1016/j.pain.2011.05.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=10.1016%2Fj.pain.2011.05.003" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=152&publication_year=2011&pages=2248-2258&issue=10&author=N.+Katzauthor=D.+G.+Borensteinauthor=C.+Birbaraauthor=C.+Bramsonauthor=M.+A.+Nemethauthor=M.+D.+Smithauthor=M.+T.+Brown&title=Efficacy+and+Safety+of+Tanezumab+in+the+Treatment+of+Chronic+Low+Back+Pain&doi=10.1016%2Fj.pain.2011.05.003"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2Fj.pain.2011.05.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pain.2011.05.003%26sid%3Dliteratum%253Aachs%26aulast%3DKatz%26aufirst%3DN.%26aulast%3DBorenstein%26aufirst%3DD.%2BG.%26aulast%3DBirbara%26aufirst%3DC.%26aulast%3DBramson%26aufirst%3DC.%26aulast%3DNemeth%26aufirst%3DM.%2BA.%26aulast%3DSmith%26aufirst%3DM.%2BD.%26aulast%3DBrown%26aufirst%3DM.%2BT.%26atitle%3DEfficacy%2520and%2520Safety%2520of%2520Tanezumab%2520in%2520the%2520Treatment%2520of%2520Chronic%2520Low%2520Back%2520Pain%26jtitle%3DPain%26date%3D2011%26volume%3D152%26issue%3D10%26spage%3D2248%26epage%3D2258%26doi%3D10.1016%2Fj.pain.2011.05.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mattson, M. P.</span></span> <span> </span><span class="NLM_article-title">Glutamate and Neurotrophic Factors in Neuronal Plasticity and Disease</span>. <i>Ann. N. Y. Acad. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>1144</i></span>,  <span class="NLM_fpage">97</span>– <span class="NLM_lpage">112</span>, <span class="refDoi"> DOI: 10.1196/annals.1418.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=10.1196%2Fannals.1418.005" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1144&publication_year=2008&pages=97-112&author=M.+P.+Mattson&title=Glutamate+and+Neurotrophic+Factors+in+Neuronal+Plasticity+and+Disease&doi=10.1196%2Fannals.1418.005"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1196%2Fannals.1418.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1196%252Fannals.1418.005%26sid%3Dliteratum%253Aachs%26aulast%3DMattson%26aufirst%3DM.%2BP.%26atitle%3DGlutamate%2520and%2520Neurotrophic%2520Factors%2520in%2520Neuronal%2520Plasticity%2520and%2520Disease%26jtitle%3DAnn.%2520N.%2520Y.%2520Acad.%2520Sci.%26date%3D2008%26volume%3D1144%26spage%3D97%26epage%3D112%26doi%3D10.1196%2Fannals.1418.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Minichiello, L.</span></span> <span> </span><span class="NLM_article-title">TrkB Signalling Pathways in LTP and Learning</span>. <i>Nat. Rev. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">850</span>– <span class="NLM_lpage">860</span>, <span class="refDoi"> DOI: 10.1038/nrn2738</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=10.1038%2Fnrn2738" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=19927149" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsVeqsbvF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2009&pages=850-860&issue=12&author=L.+Minichiello&title=TrkB+Signalling+Pathways+in+LTP+and+Learning&doi=10.1038%2Fnrn2738"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">TrkB signaling pathways in LTP and learning</span></div><div class="casAuthors">Minichiello, Liliana</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Neuroscience</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">850-860</span>CODEN:
                <span class="NLM_cas:coden">NRNAAN</span>;
        ISSN:<span class="NLM_cas:issn">1471-003X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Understanding the mechanisms that underlie learning is one of the most fascinating and central aims of neurobiol. research.  Hippocampal long-term potentiation (LTP) is widely regarded as a prime candidate for the cellular mechanism of learning.  Receptor tyrosine kinase TrkB (also known as NTRK2), known primarily for its function during PNS and CNS development, has emerged in recent years as a potent regulator of hippocampal LTP.  Here, the author describes efforts to understand the signaling pathways and mol. mechanisms that underlie the involvement of TrkB in LTP and learning.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQ0ZpLjq1-0LVg90H21EOLACvtfcHk0lhoqYapDA5-Hg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsVeqsbvF&md5=61bde8b20f142253bcf101c3d418edba</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1038%2Fnrn2738&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrn2738%26sid%3Dliteratum%253Aachs%26aulast%3DMinichiello%26aufirst%3DL.%26atitle%3DTrkB%2520Signalling%2520Pathways%2520in%2520LTP%2520and%2520Learning%26jtitle%3DNat.%2520Rev.%2520Neurosci.%26date%3D2009%26volume%3D10%26issue%3D12%26spage%3D850%26epage%3D860%26doi%3D10.1038%2Fnrn2738" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mason, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lobo, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parada, L. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lutter, M.</span></span> <span> </span><span class="NLM_article-title">Trk B Signaling in Dopamine 1 Receptor Neurons Regulates Food Intake and Body Weight</span>. <i>Obesity</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>21</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">2372</span>– <span class="NLM_lpage">2376</span>, <span class="refDoi"> DOI: 10.1002/oby.20382</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=10.1002%2Foby.20382" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=23512795" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhslarsbrM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2013&pages=2372-2376&issue=11&author=B.+L.+Masonauthor=M.+K.+Loboauthor=L.+F.+Paradaauthor=M.+Lutter&title=Trk+B+Signaling+in+Dopamine+1+Receptor+Neurons+Regulates+Food+Intake+and+Body+Weight&doi=10.1002%2Foby.20382"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Trk B signaling in dopamine 1 receptor neurons regulates food intake and body weight</span></div><div class="casAuthors">Mason, Brittany L.; Lobo, Mary Kay; Parada, Luis F.; Lutter, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Obesity</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2372-2376</span>CODEN:
                <span class="NLM_cas:coden">OBESAX</span>;
        ISSN:<span class="NLM_cas:issn">1930-7381</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Objective : Loss of BDNF-TrkB signaling results in obesity in both humans and mice; however, the neural circuit that mediates this effect is unknown.  The role of TrkB signaling in dopamine-1 receptor expressing neurons in body wt. regulation was tested.  Methods : Mice with a floxed allele of the TrkB gene were paired with mice expressing Cre-recombinase under control of the D1 promoter to conditionally knock out expression of TrkB receptors from D1-neurons.  Results : Deletion of TrkB receptors from D1 neurons results in obesity in chow fed mice due to increased feed efficiency.  In contrast, loss of Trk B signaling in D1 neurons induced hyperphagia and hyperglycemia in mice maintained on high fat diet.  Conclusions : These findings indicate TrkB signaling in D1 neurons regulates body wt. by distinct mechanisms for chow and high fat diet and may be important for defending the body against the development of obesity and obesity-related disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpV2qD8g4-gkLVg90H21EOLACvtfcHk0lgSNbdrCAIWEQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhslarsbrM&md5=6876ea2b71a0f18c54c3d66638306471</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1002%2Foby.20382&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Foby.20382%26sid%3Dliteratum%253Aachs%26aulast%3DMason%26aufirst%3DB.%2BL.%26aulast%3DLobo%26aufirst%3DM.%2BK.%26aulast%3DParada%26aufirst%3DL.%2BF.%26aulast%3DLutter%26aufirst%3DM.%26atitle%3DTrk%2520B%2520Signaling%2520in%2520Dopamine%25201%2520Receptor%2520Neurons%2520Regulates%2520Food%2520Intake%2520and%2520Body%2520Weight%26jtitle%3DObesity%26date%3D2013%26volume%3D21%26issue%3D11%26spage%3D2372%26epage%3D2376%26doi%3D10.1002%2Foby.20382" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Noble, E. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Billington, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kotz, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span> <span> </span><span class="NLM_article-title">The Lighter Side of BDNF</span>. <i>Am. J. Physiol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>300</i></span>,  <span class="NLM_fpage">R1053</span>– <span class="NLM_lpage">R1069</span>, <span class="refDoi"> DOI: 10.1152/ajpregu.00776.2010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=10.1152%2Fajpregu.00776.2010" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=300&publication_year=2011&pages=R1053-R1069&author=E.+E.+Nobleauthor=C.+J.+Billingtonauthor=C.+M.+Kotzauthor=C.+Wang&title=The+Lighter+Side+of+BDNF&doi=10.1152%2Fajpregu.00776.2010"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1152%2Fajpregu.00776.2010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1152%252Fajpregu.00776.2010%26sid%3Dliteratum%253Aachs%26aulast%3DNoble%26aufirst%3DE.%2BE.%26aulast%3DBillington%26aufirst%3DC.%2BJ.%26aulast%3DKotz%26aufirst%3DC.%2BM.%26aulast%3DWang%26aufirst%3DC.%26atitle%3DThe%2520Lighter%2520Side%2520of%2520BDNF%26jtitle%3DAm.%2520J.%2520Physiol.%26date%3D2011%26volume%3D300%26spage%3DR1053%26epage%3DR1069%26doi%3D10.1152%2Fajpregu.00776.2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yeo, G. S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Connie Hung, C.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rochford, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keogh, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sivaramakrishnan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Rahilly, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farooqi, I. S.</span></span> <span> </span><span class="NLM_article-title">A De Novo Mutation Affecting Human TrkB Associated with Severe Obesity and Developmental Delay</span>. <i>Nat. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1187</span>– <span class="NLM_lpage">1189</span>, <span class="refDoi"> DOI: 10.1038/nn1336</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=10.1038%2Fnn1336" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=15494731" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=1%3ACAS%3A528%3ADC%252BD2cXovFamu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2004&pages=1187-1189&issue=11&author=G.+S.+H.+Yeoauthor=C.-C.+Connie+Hungauthor=J.+Rochfordauthor=J.+Keoghauthor=J.+Grayauthor=S.+Sivaramakrishnanauthor=S.+O%E2%80%99Rahillyauthor=I.+S.+Farooqi&title=A+De+Novo+Mutation+Affecting+Human+TrkB+Associated+with+Severe+Obesity+and+Developmental+Delay&doi=10.1038%2Fnn1336"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">A de novo mutation affecting human TrkB associated with severe obesity and developmental delay</span></div><div class="casAuthors">Yeo, Giles S. H.; Connie Hung, Chiao-Chien; Rochford, Justin; Keogh, Julia; Gray, Juliette; Sivaramakrishnan, Shoba; O'Rahilly, Stephen; Farooqi, I. Sadaf</div><div class="citationInfo"><span class="NLM_cas:title">Nature Neuroscience</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1187-1189</span>CODEN:
                <span class="NLM_cas:coden">NANEFN</span>;
        ISSN:<span class="NLM_cas:issn">1097-6256</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">An 8-yr-old male with a complex developmental syndrome and severe obesity was heterozygous for a de novo missense mutation resulting in a Y722C substitution in the neurotrophin receptor TrkB.  This mutation markedly impaired receptor autophosphorylation and signaling to MAP kinase.  Mutation of NTRK2, which encodes TrkB, seems to result in a unique human syndrome of hyperphagic obesity.  The assocd. impairment in memory, learning and nociception seen in the proband reflects the crucial role of TrkB in the human nervous system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoOFn7CEYjaXLVg90H21EOLACvtfcHk0lgSNbdrCAIWEQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXovFamu7s%253D&md5=1df8713e7b0f3b437cb552a81c2ca628</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1038%2Fnn1336&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnn1336%26sid%3Dliteratum%253Aachs%26aulast%3DYeo%26aufirst%3DG.%2BS.%2BH.%26aulast%3DConnie%2BHung%26aufirst%3DC.-C.%26aulast%3DRochford%26aufirst%3DJ.%26aulast%3DKeogh%26aufirst%3DJ.%26aulast%3DGray%26aufirst%3DJ.%26aulast%3DSivaramakrishnan%26aufirst%3DS.%26aulast%3DO%25E2%2580%2599Rahilly%26aufirst%3DS.%26aulast%3DFarooqi%26aufirst%3DI.%2BS.%26atitle%3DA%2520De%2520Novo%2520Mutation%2520Affecting%2520Human%2520TrkB%2520Associated%2520with%2520Severe%2520Obesity%2520and%2520Developmental%2520Delay%26jtitle%3DNat.%2520Neurosci.%26date%3D2004%26volume%3D7%26issue%3D11%26spage%3D1187%26epage%3D1189%26doi%3D10.1038%2Fnn1336" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Caporali, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emanueli, C.</span></span> <span> </span><span class="NLM_article-title">Cardiovascular Actions of Neurotrophins</span>. <i>Physiol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>89</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">279</span>– <span class="NLM_lpage">308</span>, <span class="refDoi"> DOI: 10.1152/physrev.00007.2008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=10.1152%2Fphysrev.00007.2008" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=89&publication_year=2009&pages=279-308&issue=1&author=A.+Caporaliauthor=C.+Emanueli&title=Cardiovascular+Actions+of+Neurotrophins&doi=10.1152%2Fphysrev.00007.2008"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1152%2Fphysrev.00007.2008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1152%252Fphysrev.00007.2008%26sid%3Dliteratum%253Aachs%26aulast%3DCaporali%26aufirst%3DA.%26aulast%3DEmanueli%26aufirst%3DC.%26atitle%3DCardiovascular%2520Actions%2520of%2520Neurotrophins%26jtitle%3DPhysiol.%2520Rev.%26date%3D2009%26volume%3D89%26issue%3D1%26spage%3D279%26epage%3D308%26doi%3D10.1152%2Fphysrev.00007.2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Martin, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jenkins, V. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsieh, H.-y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balkowiec, A.</span></span> <span> </span><span class="NLM_article-title">Brain-Derived Neurotrophic Factor in Arterial Baroreceptor Pathways: Implications for Activity-Dependent Plasticity at Baroafferent Synapses</span>. <i>J. Neurochem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>108</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">450</span>– <span class="NLM_lpage">464</span>, <span class="refDoi"> DOI: 10.1111/j.1471-4159.2008.05781.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=10.1111%2Fj.1471-4159.2008.05781.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=19054281" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=1%3ACAS%3A528%3ADC%252BD1MXptFCqsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2009&pages=450-464&issue=2&author=J.+L.+Martinauthor=V.+K.+Jenkinsauthor=H.-y.+Hsiehauthor=A.+Balkowiec&title=Brain-Derived+Neurotrophic+Factor+in+Arterial+Baroreceptor+Pathways%3A+Implications+for+Activity-Dependent+Plasticity+at+Baroafferent+Synapses&doi=10.1111%2Fj.1471-4159.2008.05781.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Brain-derived neurotrophic factor in arterial baroreceptor pathways: implications for activity-dependent plasticity at baroafferent synapses</span></div><div class="casAuthors">Martin, Jessica L.; Jenkins, Victoria K.; Hsieh, Hui-ya; Balkowiec, Agnieszka</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neurochemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">108</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">450-464</span>CODEN:
                <span class="NLM_cas:coden">JONRA9</span>;
        ISSN:<span class="NLM_cas:issn">0022-3042</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Functional characteristics of the arterial baroreceptor reflex change throughout ontogenesis, including perinatal adjustments of the reflex gain and adult resetting during hypertension.  However, the cellular mechanisms that underlie these functional changes are not completely understood.  Here, we provide evidence that brain-derived neurotrophic factor (BDNF), a neurotrophin with a well-established role in activity-dependent neuronal plasticity, is abundantly expressed in vivo by a large subset of developing and adult rat baroreceptor afferents.  Immunoreactivity to BDNF is present in the cell bodies of baroafferent neurons in the nodose ganglion, their central projections in the solitary tract, and terminal-like structures in the lower brainstem nucleus tractus solitarius.  Using ELISA in situ combined with elec. field stimulation, we show that native BDNF is released from cultured newborn nodose ganglion neurons in response to patterns that mimic the in vivo activity of baroreceptor afferents.  In particular, high-frequency bursting patterns of baroreceptor firing, which are known to evoke plastic changes at baroreceptor synapses, are significantly more effective at releasing BDNF than tonic patterns of the same av. frequency.  Together, our study indicates that BDNF expressed by first-order baroreceptor neurons is a likely mediator of both developmental and post-developmental modifications at first-order synapses in arterial baroreceptor pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrsiGm9hRdDRbVg90H21EOLACvtfcHk0li5VbRWp7ujpw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXptFCqsg%253D%253D&md5=06d33880034c6d000dd689a27f0d58a5</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1111%2Fj.1471-4159.2008.05781.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1471-4159.2008.05781.x%26sid%3Dliteratum%253Aachs%26aulast%3DMartin%26aufirst%3DJ.%2BL.%26aulast%3DJenkins%26aufirst%3DV.%2BK.%26aulast%3DHsieh%26aufirst%3DH.-y.%26aulast%3DBalkowiec%26aufirst%3DA.%26atitle%3DBrain-Derived%2520Neurotrophic%2520Factor%2520in%2520Arterial%2520Baroreceptor%2520Pathways%253A%2520Implications%2520for%2520Activity-Dependent%2520Plasticity%2520at%2520Baroafferent%2520Synapses%26jtitle%3DJ.%2520Neurochem.%26date%3D2009%26volume%3D108%26issue%3D2%26spage%3D450%26epage%3D464%26doi%3D10.1111%2Fj.1471-4159.2008.05781.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fulgenzi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomassoni-Ardori, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Babini, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Becker, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrick, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puverel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tessarollo, L.</span></span> <span> </span><span class="NLM_article-title">BDNF Modulates Heart Contraction Force and Long-Term Homeostasis through Truncated TrkB.T1 Receptor Activation</span>. <i>J. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>210</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1003</span>– <span class="NLM_lpage">1012</span>, <span class="refDoi"> DOI: 10.1083/jcb.201502100</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=10.1083%2Fjcb.201502100" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=210&publication_year=2015&pages=1003-1012&issue=6&author=G.+Fulgenziauthor=F.+Tomassoni-Ardoriauthor=L.+Babiniauthor=J.+Beckerauthor=C.+Barrickauthor=S.+Puverelauthor=L.+Tessarollo&title=BDNF+Modulates+Heart+Contraction+Force+and+Long-Term+Homeostasis+through+Truncated+TrkB.T1+Receptor+Activation&doi=10.1083%2Fjcb.201502100"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1083%2Fjcb.201502100&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1083%252Fjcb.201502100%26sid%3Dliteratum%253Aachs%26aulast%3DFulgenzi%26aufirst%3DG.%26aulast%3DTomassoni-Ardori%26aufirst%3DF.%26aulast%3DBabini%26aufirst%3DL.%26aulast%3DBecker%26aufirst%3DJ.%26aulast%3DBarrick%26aufirst%3DC.%26aulast%3DPuverel%26aufirst%3DS.%26aulast%3DTessarollo%26aufirst%3DL.%26atitle%3DBDNF%2520Modulates%2520Heart%2520Contraction%2520Force%2520and%2520Long-Term%2520Homeostasis%2520through%2520Truncated%2520TrkB.T1%2520Receptor%2520Activation%26jtitle%3DJ.%2520Cell%2520Biol.%26date%3D2015%26volume%3D210%26issue%3D6%26spage%3D1003%26epage%3D1012%26doi%3D10.1083%2Fjcb.201502100" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lindholm, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castrén, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsoulfas, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolbeck, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berzaghi, M. d. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leingärtner, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heisenberg, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tessarollo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parada, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thoenen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tesarollo, L.</span></span> <span> </span><span class="NLM_article-title">Neurotrophin-3 Induced by Tri-Iodothyronine in Cerebellar Granule Cells Promotes Purkinje Cell Differentiation</span>. <i>J. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>122</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">443</span>– <span class="NLM_lpage">450</span>, <span class="refDoi"> DOI: 10.1083/jcb.122.2.443</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=10.1083%2Fjcb.122.2.443" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=122&publication_year=1993&pages=443-450&issue=2&author=D.+Lindholmauthor=E.+Castr%C3%A9nauthor=P.+Tsoulfasauthor=R.+Kolbeckauthor=M.+d.+P.+Berzaghiauthor=A.+Leing%C3%A4rtnerauthor=C.+Heisenbergauthor=L.+Tessarolloauthor=L.+Paradaauthor=H.+Thoenenauthor=L.+Tesarollo&title=Neurotrophin-3+Induced+by+Tri-Iodothyronine+in+Cerebellar+Granule+Cells+Promotes+Purkinje+Cell+Differentiation&doi=10.1083%2Fjcb.122.2.443"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1083%2Fjcb.122.2.443&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1083%252Fjcb.122.2.443%26sid%3Dliteratum%253Aachs%26aulast%3DLindholm%26aufirst%3DD.%26aulast%3DCastr%25C3%25A9n%26aufirst%3DE.%26aulast%3DTsoulfas%26aufirst%3DP.%26aulast%3DKolbeck%26aufirst%3DR.%26aulast%3DBerzaghi%26aufirst%3DM.%2Bd.%2BP.%26aulast%3DLeing%25C3%25A4rtner%26aufirst%3DA.%26aulast%3DHeisenberg%26aufirst%3DC.%26aulast%3DTessarollo%26aufirst%3DL.%26aulast%3DParada%26aufirst%3DL.%26aulast%3DThoenen%26aufirst%3DH.%26aulast%3DTesarollo%26aufirst%3DL.%26atitle%3DNeurotrophin-3%2520Induced%2520by%2520Tri-Iodothyronine%2520in%2520Cerebellar%2520Granule%2520Cells%2520Promotes%2520Purkinje%2520Cell%2520Differentiation%26jtitle%3DJ.%2520Cell%2520Biol.%26date%3D1993%26volume%3D122%26issue%3D2%26spage%3D443%26epage%3D450%26doi%3D10.1083%2Fjcb.122.2.443" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, X.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rush, R. A.</span></span> <span> </span><span class="NLM_article-title">Functional Roles of Neurotrophin 3 in the Developing and Mature Sympathetic Nervous System</span>. <i>Mol. Neurobiol.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">185</span>– <span class="NLM_lpage">197</span>, <span class="refDoi"> DOI: 10.1007/BF02740622</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=10.1007%2FBF02740622" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=8989769" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=1%3ACAS%3A528%3ADyaK2sXms1Chuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=1996&pages=185-197&issue=3&author=X.-F.+Zhouauthor=R.+A.+Rush&title=Functional+Roles+of+Neurotrophin+3+in+the+Developing+and+Mature+Sympathetic+Nervous+System&doi=10.1007%2FBF02740622"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Functional roles of neurotrophin 3 in the developing and mature sympathetic nervous system</span></div><div class="casAuthors">Zhou, Xin-Fu; Rush, Robert A.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Neurobiology</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">185-197</span>CODEN:
                <span class="NLM_cas:coden">MONBEW</span>;
        ISSN:<span class="NLM_cas:issn">0893-7648</span>.
    
            (<span class="NLM_cas:orgname">Humana</span>)
        </div><div class="casAbstract">A review, with ∼75 refs., on the evidence published in recent years indicating that another member of the NGF family, neurotrophin 3 (NT3), plays both a complementary and overlapping role in the development and maturation of sympathetic neurons.  In migratory neural crest cells, expression of the high-affinity receptor, trkC, and promotion of mitosis by NT3 suggest an involvement in gangliogenesis, since sympathetic neuroblasts express both NT3 and trkC and require NT3 for their proliferation, differentiation, and survival, it has been proposed that the factor acts at this developmental stage as an autocrine or paracrine factor.  However, NT3 also acts in parallel with NGF to promote the survival of postmitotic neurons during late development.  Both trkC and trkA are expressed in sympathetic neurons and function as high-affinity receptors for NT3.  NT3 is synthesized in sympathetic effector tissues and the endogenous factor is retrogradely transported to accumulate within the cell soma.  Thus, in addn. to its role in the differentiation of sympathetic neurons, NT3, like NGF, is also an effector tissue-derived neurotrophic factor for these neurons in maturity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr975ZuRFusjrVg90H21EOLACvtfcHk0li5VbRWp7ujpw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXms1Chuw%253D%253D&md5=871d2498b71e56ae44f375bd21a3df2f</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1007%2FBF02740622&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252FBF02740622%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DX.-F.%26aulast%3DRush%26aufirst%3DR.%2BA.%26atitle%3DFunctional%2520Roles%2520of%2520Neurotrophin%25203%2520in%2520the%2520Developing%2520and%2520Mature%2520Sympathetic%2520Nervous%2520System%26jtitle%3DMol.%2520Neurobiol.%26date%3D1996%26volume%3D13%26issue%3D3%26spage%3D185%26epage%3D197%26doi%3D10.1007%2FBF02740622" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Flanagan, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blumenkopf, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brissette, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casavant, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shang-Poa, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doty, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elliott, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hines, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kent, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kudlacz, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lillie, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magnuson, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCurdy, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munchhof, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perry, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sawyer, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strelevitz, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Subramanyam, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whipple, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Changelian, P. S.</span></span> <span> </span><span class="NLM_article-title">Discovery of CP-690,550: A Potent and Selective Janus Kinase (JAK) Inhibitor for the Treatment of Autoimmune Diseases and Organ Transplant Rejection</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span> (<span class="NLM_issue">24</span>),  <span class="NLM_fpage">8468</span>– <span class="NLM_lpage">8484</span>, <span class="refDoi"> DOI: 10.1021/jm1004286</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm1004286" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVOgt7vP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=8468-8484&issue=24&author=M.+E.+Flanaganauthor=T.+A.+Blumenkopfauthor=W.+H.+Brissetteauthor=M.+F.+Brownauthor=J.+M.+Casavantauthor=C.+Shang-Poaauthor=J.+L.+Dotyauthor=E.+A.+Elliottauthor=M.+B.+Fisherauthor=M.+Hinesauthor=C.+Kentauthor=E.+M.+Kudlaczauthor=B.+M.+Lillieauthor=K.+S.+Magnusonauthor=S.+P.+McCurdyauthor=M.+J.+Munchhofauthor=B.+D.+Perryauthor=P.+S.+Sawyerauthor=T.+J.+Strelevitzauthor=C.+Subramanyamauthor=J.+Sunauthor=D.+A.+Whippleauthor=P.+S.+Changelian&title=Discovery+of+CP-690%2C550%3A+A+Potent+and+Selective+Janus+Kinase+%28JAK%29+Inhibitor+for+the+Treatment+of+Autoimmune+Diseases+and+Organ+Transplant+Rejection&doi=10.1021%2Fjm1004286"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of CP-690,550: A Potent and Selective Janus Kinase (JAK) Inhibitor for the Treatment of Autoimmune Diseases and Organ Transplant Rejection</span></div><div class="casAuthors">Flanagan, Mark E.; Blumenkopf, Todd A.; Brissette, William H.; Brown, Matthew F.; Casavant, Jeffrey M.; Chang, Shang-Poa; Doty, Jonathan L.; Elliott, Eileen A.; Fisher, Michael B.; Hines, Michael; Kent, Craig; Kudlacz, Elizabeth M.; Lillie, Brett M.; Magnuson, Kelly S.; McCurdy, Sandra P.; Munchhof, Michael J.; Perry, Bret D.; Sawyer, Perry S.; Strelevitz, Timothy J.; Subramanyam, Chakrapani; Sun, Jianmin; Whipple, David A.; Changelian, Paul S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">8468-8484</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">There is a crit. need for safer and more convenient treatments for organ transplant rejection and autoimmune disorders such as rheumatoid arthritis.  Janus tyrosine kinases (JAK1, JAK3) are expressed in lymphoid cells and are involved in the signaling of multiple cytokines important for various T cell functions.  Blockade of the JAK1/JAK3-STAT pathway with a small mol. was anticipated to provide therapeutic immunosuppression/immunomodulation.  The Pfizer compd. library was screened against the catalytic domain of JAK3 resulting in the identification of a pyrrolopyrimidine-based series of inhibitors represented by the hexahydrocarbazolyl pyrrolopyrimidine CP-352,664.  Synthetic analogs of CP-352,664 were screened against the JAK enzymes and evaluated in an IL-2 induced T cell blast proliferation assay.  Select compds. were evaluated in rodent efficacy models of allograft rejection and destructive inflammatory arthritis.  Optimization within this chem. series led to identification of the cyanoacetylpiperidinylamino pyrrolopyrimidine CP-690,550, a potential first-in-class JAK inhibitor for treatment of autoimmune diseases and organ transplant rejection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbFS_8DSHkDbVg90H21EOLACvtfcHk0li5VbRWp7ujpw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVOgt7vP&md5=c1d31ce42ab3f1c1f3029c6f4f48df1a</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1021%2Fjm1004286&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm1004286%26sid%3Dliteratum%253Aachs%26aulast%3DFlanagan%26aufirst%3DM.%2BE.%26aulast%3DBlumenkopf%26aufirst%3DT.%2BA.%26aulast%3DBrissette%26aufirst%3DW.%2BH.%26aulast%3DBrown%26aufirst%3DM.%2BF.%26aulast%3DCasavant%26aufirst%3DJ.%2BM.%26aulast%3DShang-Poa%26aufirst%3DC.%26aulast%3DDoty%26aufirst%3DJ.%2BL.%26aulast%3DElliott%26aufirst%3DE.%2BA.%26aulast%3DFisher%26aufirst%3DM.%2BB.%26aulast%3DHines%26aufirst%3DM.%26aulast%3DKent%26aufirst%3DC.%26aulast%3DKudlacz%26aufirst%3DE.%2BM.%26aulast%3DLillie%26aufirst%3DB.%2BM.%26aulast%3DMagnuson%26aufirst%3DK.%2BS.%26aulast%3DMcCurdy%26aufirst%3DS.%2BP.%26aulast%3DMunchhof%26aufirst%3DM.%2BJ.%26aulast%3DPerry%26aufirst%3DB.%2BD.%26aulast%3DSawyer%26aufirst%3DP.%2BS.%26aulast%3DStrelevitz%26aufirst%3DT.%2BJ.%26aulast%3DSubramanyam%26aufirst%3DC.%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DWhipple%26aufirst%3DD.%2BA.%26aulast%3DChangelian%26aufirst%3DP.%2BS.%26atitle%3DDiscovery%2520of%2520CP-690%252C550%253A%2520A%2520Potent%2520and%2520Selective%2520Janus%2520Kinase%2520%2528JAK%2529%2520Inhibitor%2520for%2520the%2520Treatment%2520of%2520Autoimmune%2520Diseases%2520and%2520Organ%2520Transplant%2520Rejection%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26issue%3D24%26spage%3D8468%26epage%3D8484%26doi%3D10.1021%2Fjm1004286" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Capdeville, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buchdunger, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmermann, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matter, A.</span></span> <span> </span><span class="NLM_article-title">Glivec (STI571, Imatinib), a Rationally Developed, Targeted Anticancer Drug</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>1</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">493</span>– <span class="NLM_lpage">502</span>, <span class="refDoi"> DOI: 10.1038/nrd839</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=10.1038%2Fnrd839" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=12120256" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=1%3ACAS%3A528%3ADC%252BD38XkvFKlurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2002&pages=493-502&issue=7&author=R.+Capdevilleauthor=E.+Buchdungerauthor=J.+Zimmermannauthor=A.+Matter&title=Glivec+%28STI571%2C+Imatinib%29%2C+a+Rationally+Developed%2C+Targeted+Anticancer+Drug&doi=10.1038%2Fnrd839"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug</span></div><div class="casAuthors">Capdeville, Renaud; Buchdunger, Elisabeth; Zimmermann, Juerg; Matter, Alex</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">493-502</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  In the early 1980s, it became apparent that the work of pioneers such as Robert Weinberg, Mariano Barbacid and many others in identifying cancer-causing genes in humans was opening the door to a new era in anticancer research.  Motivated by this, and by dissatisfaction with the limited efficacy and tolerability of available anticancer modalities, a drug discovery program was initiated with the aim of rationally developing targeted anticancer therapies.  Here, we describe how this program led to the discovery and continuing development of Glivec (Gleevec in the United States), the first selective tyrosine-kinase inhibitor to be approved for the treatment of a cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoeI0HV4de6ObVg90H21EOLACvtfcHk0lhIoltro3HkWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XkvFKlurY%253D&md5=c8f6b7a66f74b64f0dedb5e641097acc</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1038%2Fnrd839&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd839%26sid%3Dliteratum%253Aachs%26aulast%3DCapdeville%26aufirst%3DR.%26aulast%3DBuchdunger%26aufirst%3DE.%26aulast%3DZimmermann%26aufirst%3DJ.%26aulast%3DMatter%26aufirst%3DA.%26atitle%3DGlivec%2520%2528STI571%252C%2520Imatinib%2529%252C%2520a%2520Rationally%2520Developed%252C%2520Targeted%2520Anticancer%2520Drug%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2002%26volume%3D1%26issue%3D7%26spage%3D493%26epage%3D502%26doi%3D10.1038%2Fnrd839" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Skerratt, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bagal, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bilsland, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bungay, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cole, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibson, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morao, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nedderman, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Omoto, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryckmans, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skinner, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stupple, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waldron, G.</span></span> <span> </span><span class="NLM_article-title">The Discovery of a Potent, Selective, and Peripherally Restricted Pan-Trk Inhibitor (PF-06273340) for the Treatment of Pain</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span> (<span class="NLM_issue">22</span>),  <span class="NLM_fpage">10084</span>– <span class="NLM_lpage">10099</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00850</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00850" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslWjsbfL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=10084-10099&issue=22&author=S.+E.+Skerrattauthor=M.+Andrewsauthor=S.+K.+Bagalauthor=J.+Bilslandauthor=D.+Brownauthor=P.+J.+Bungayauthor=S.+Coleauthor=K.+R.+Gibsonauthor=R.+Jonesauthor=I.+Moraoauthor=A.+Neddermanauthor=K.+Omotoauthor=C.+Robinsonauthor=T.+Ryckmansauthor=K.+Skinnerauthor=P.+Stuppleauthor=G.+Waldron&title=The+Discovery+of+a+Potent%2C+Selective%2C+and+Peripherally+Restricted+Pan-Trk+Inhibitor+%28PF-06273340%29+for+the+Treatment+of+Pain&doi=10.1021%2Facs.jmedchem.6b00850"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">The Discovery of a Potent, Selective, and Peripherally Restricted Pan-Trk Inhibitor (PF-06273340) for the Treatment of Pain</span></div><div class="casAuthors">Skerratt, Sarah E.; Andrews, Mark; Bagal, Sharan K.; Bilsland, James; Brown, David; Bungay, Peter J.; Cole, Susan; Gibson, Karl R.; Jones, Russell; Morao, Inaki; Nedderman, Angus; Omoto, Kiyoyuki; Robinson, Colin; Ryckmans, Thomas; Skinner, Kimberly; Stupple, Paul; Waldron, Gareth</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">10084-10099</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The neurotrophin family of growth factors, comprised of nerve growth factor (NGF), brain derived neurotrophic factor (BDNF), neurotrophin 3 (NT3) and neurotrophin 4 (NT4), is implicated in the physiol. of chronic pain.  Given the clin. efficacy of anti-NGF monoclonal antibody (mAb) therapies, there is significant interest in the development of small mol. modulators of neurotrophin activity.  Neurotrophins signal through the tropomyosin related kinase (Trk) family of tyrosine kinase receptors, hence Trk kinase inhibition represents a potentially "druggable" point of intervention.  To deliver the safety profile required for chronic, non-life threatening pain indications, highly kinase-selective Trk inhibitors with minimal brain availability are sought.  Herein the authors describe how the use of SBDD, 2D QSAR models and Matched Mol. Pair data in compd. design enabled the delivery of the highly potent, kinase-selective and peripherally restricted clin. candidate PF-06273340.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo67CFmGAkmRrVg90H21EOLACvtfcHk0lhIoltro3HkWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslWjsbfL&md5=f8c904a92c1716062c217fefe2374ce6</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00850&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00850%26sid%3Dliteratum%253Aachs%26aulast%3DSkerratt%26aufirst%3DS.%2BE.%26aulast%3DAndrews%26aufirst%3DM.%26aulast%3DBagal%26aufirst%3DS.%2BK.%26aulast%3DBilsland%26aufirst%3DJ.%26aulast%3DBrown%26aufirst%3DD.%26aulast%3DBungay%26aufirst%3DP.%2BJ.%26aulast%3DCole%26aufirst%3DS.%26aulast%3DGibson%26aufirst%3DK.%2BR.%26aulast%3DJones%26aufirst%3DR.%26aulast%3DMorao%26aufirst%3DI.%26aulast%3DNedderman%26aufirst%3DA.%26aulast%3DOmoto%26aufirst%3DK.%26aulast%3DRobinson%26aufirst%3DC.%26aulast%3DRyckmans%26aufirst%3DT.%26aulast%3DSkinner%26aufirst%3DK.%26aulast%3DStupple%26aufirst%3DP.%26aulast%3DWaldron%26aufirst%3DG.%26atitle%3DThe%2520Discovery%2520of%2520a%2520Potent%252C%2520Selective%252C%2520and%2520Peripherally%2520Restricted%2520Pan-Trk%2520Inhibitor%2520%2528PF-06273340%2529%2520for%2520the%2520Treatment%2520of%2520Pain%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26issue%3D22%26spage%3D10084%26epage%3D10099%26doi%3D10.1021%2Facs.jmedchem.6b00850" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gavrin, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saiah, E.</span></span> <span> </span><span class="NLM_article-title">Approaches to Discover Non-ATP Site Kinase Inhibitors</span>. <i>MedChemComm</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>4</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">41</span>– <span class="NLM_lpage">51</span>, <span class="refDoi"> DOI: 10.1039/C2MD20180A</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=10.1039%2FC2MD20180A" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvVymsr7N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=41-51&issue=1&author=L.+K.+Gavrinauthor=E.+Saiah&title=Approaches+to+Discover+Non-ATP+Site+Kinase+Inhibitors&doi=10.1039%2FC2MD20180A"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Approaches to discover non-ATP site kinase inhibitors</span></div><div class="casAuthors">Gavrin, Lori Krim; Saiah, Eddine</div><div class="citationInfo"><span class="NLM_cas:title">MedChemComm</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">41-51</span>CODEN:
                <span class="NLM_cas:coden">MCCEAY</span>;
        ISSN:<span class="NLM_cas:issn">2040-2503</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A review.  The catalytic domain of kinases shows a high degree of sequence homol., esp. for kinases that belong to the same family.  They share a common ATP binding site with a conserved activation loop and similar three-dimensional structure.  Consequently, a major challenge in kinase research exists in achieving selectivity among the >500 family members, since they all process the same substrate.  In addn. to requiring selectivity against other kinases, ATP site inhibitors must also bind tightly to overcome the high physiol. concn. of ATP in the cell.  Furthermore, the development of novel ATP site inhibitors is becoming increasingly challenging, as many ATP competitive scaffolds have previously been disclosed.  In order to develop compds. with better selectivity among kinases, inhibitors that bind outside the ATP site show great promise and are currently being explored by many groups.  This review will highlight the most commonly used methods to discover small mol. Type III and IV kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo7xJcf4-RJ9rVg90H21EOLACvtfcHk0lhIoltro3HkWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvVymsr7N&md5=97acf2247e5516c1649c1d964c867656</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1039%2FC2MD20180A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC2MD20180A%26sid%3Dliteratum%253Aachs%26aulast%3DGavrin%26aufirst%3DL.%2BK.%26aulast%3DSaiah%26aufirst%3DE.%26atitle%3DApproaches%2520to%2520Discover%2520Non-ATP%2520Site%2520Kinase%2520Inhibitors%26jtitle%3DMedChemComm%26date%3D2013%26volume%3D4%26issue%3D1%26spage%3D41%26epage%3D51%26doi%3D10.1039%2FC2MD20180A" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Abe, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kikuchi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayakawa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iida, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagahashi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maeda, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakamoto, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsumoto, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miura, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsumura, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seki, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inaba, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawasaki, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamaguchi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kakefuda, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nanayama, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurachi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hori, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshida, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kakegawa, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilmartin, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richter, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moss, K. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laquerre, S. G.</span></span> <span> </span><span class="NLM_article-title">Discovery of a Highly Potent and Selective MEK Inhibitor: GSK1120212 (JTP-74057 DMSO Solvate)</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>2</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">320</span>– <span class="NLM_lpage">324</span>, <span class="refDoi"> DOI: 10.1021/ml200004g</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml200004g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2011&pages=320-324&issue=4&author=H.+Abeauthor=S.+Kikuchiauthor=K.+Hayakawaauthor=T.+Iidaauthor=N.+Nagahashiauthor=K.+Maedaauthor=J.+Sakamotoauthor=N.+Matsumotoauthor=T.+Miuraauthor=K.+Matsumuraauthor=N.+Sekiauthor=T.+Inabaauthor=H.+Kawasakiauthor=T.+Yamaguchiauthor=R.+Kakefudaauthor=T.+Nanayamaauthor=H.+Kurachiauthor=Y.+Horiauthor=T.+Yoshidaauthor=J.+Kakegawaauthor=Y.+Watanabeauthor=A.+G.+Gilmartinauthor=M.+C.+Richterauthor=K.+G.+Mossauthor=S.+G.+Laquerre&title=Discovery+of+a+Highly+Potent+and+Selective+MEK+Inhibitor%3A+GSK1120212+%28JTP-74057+DMSO+Solvate%29&doi=10.1021%2Fml200004g"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Fml200004g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml200004g%26sid%3Dliteratum%253Aachs%26aulast%3DAbe%26aufirst%3DH.%26aulast%3DKikuchi%26aufirst%3DS.%26aulast%3DHayakawa%26aufirst%3DK.%26aulast%3DIida%26aufirst%3DT.%26aulast%3DNagahashi%26aufirst%3DN.%26aulast%3DMaeda%26aufirst%3DK.%26aulast%3DSakamoto%26aufirst%3DJ.%26aulast%3DMatsumoto%26aufirst%3DN.%26aulast%3DMiura%26aufirst%3DT.%26aulast%3DMatsumura%26aufirst%3DK.%26aulast%3DSeki%26aufirst%3DN.%26aulast%3DInaba%26aufirst%3DT.%26aulast%3DKawasaki%26aufirst%3DH.%26aulast%3DYamaguchi%26aufirst%3DT.%26aulast%3DKakefuda%26aufirst%3DR.%26aulast%3DNanayama%26aufirst%3DT.%26aulast%3DKurachi%26aufirst%3DH.%26aulast%3DHori%26aufirst%3DY.%26aulast%3DYoshida%26aufirst%3DT.%26aulast%3DKakegawa%26aufirst%3DJ.%26aulast%3DWatanabe%26aufirst%3DY.%26aulast%3DGilmartin%26aufirst%3DA.%2BG.%26aulast%3DRichter%26aufirst%3DM.%2BC.%26aulast%3DMoss%26aufirst%3DK.%2BG.%26aulast%3DLaquerre%26aufirst%3DS.%2BG.%26atitle%3DDiscovery%2520of%2520a%2520Highly%2520Potent%2520and%2520Selective%2520MEK%2520Inhibitor%253A%2520GSK1120212%2520%2528JTP-74057%2520DMSO%2520Solvate%2529%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D2%26issue%3D4%26spage%3D320%26epage%3D324%26doi%3D10.1021%2Fml200004g" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yap, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patnaik, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fearen, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olmos, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papadopoulos, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baird, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delgado, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lupinacci, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riisnaes, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pope, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heaton, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garrett, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sullivan, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Bono, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tolcher, A. W.</span></span> <span> </span><span class="NLM_article-title">First-in-Man Clinical Trial of the Oral Pan-AKT Inhibitor MK-2206 in Patients with Advanced Solid Tumors</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>29</i></span> (<span class="NLM_issue">35</span>),  <span class="NLM_fpage">4688</span>– <span class="NLM_lpage">4695</span>, <span class="refDoi"> DOI: 10.1200/JCO.2011.35.5263</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=10.1200%2FJCO.2011.35.5263" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=22025163" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtlOnsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2011&pages=4688-4695&issue=35&author=T.+A.+Yapauthor=L.+Yanauthor=A.+Patnaikauthor=I.+Fearenauthor=D.+Olmosauthor=K.+Papadopoulosauthor=R.+D.+Bairdauthor=L.+Delgadoauthor=A.+Taylorauthor=L.+Lupinacciauthor=R.+Riisnaesauthor=L.+L.+Popeauthor=S.+P.+Heatonauthor=G.+Thomasauthor=M.+D.+Garrettauthor=D.+M.+Sullivanauthor=J.+S.+de+Bonoauthor=A.+W.+Tolcher&title=First-in-Man+Clinical+Trial+of+the+Oral+Pan-AKT+Inhibitor+MK-2206+in+Patients+with+Advanced+Solid+Tumors&doi=10.1200%2FJCO.2011.35.5263"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors</span></div><div class="casAuthors">Yap, Timothy A.; Yan, Li; Patnaik, Amita; Fearen, Ivy; Olmos, David; Papadopoulos, Kyriakos; Baird, Richard D.; Delgado, Liliana; Taylor, Adekemi; Lupinacci, Lisa; Riisnaes, Ruth; Pope, Lorna L.; Heaton, Simon P.; Thomas, George; Garrett, Michelle D.; Sullivan, Daniel M.; de Bono, Johann S.; Tolcher, Anthony W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">35</span>),
    <span class="NLM_cas:pages">4688-4695</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose AKT signaling is frequently deregulated in human cancers.  MK-2206 is a potent, oral allosteric inhibitor of all AKT isoforms with antitumor activity in preclin. models.  A phase I study of MK-2206 was conducted to investigate its safety, max.-tolerated dose (MTD), pharmacokinetics (PKs), pharmacodynamics (PDs), and preliminary antitumor efficacy.  Patients and Methods Patients with advanced solid tumors received MK-2206 on alternate days.  Paired tumor biopsies were mandated at the MTD for biomarker studies.  PD studies incorporated tumor and hair follicle analyses, and putative predictive biomarker studies included tumor somatic mutation analyses and immunohistochem. for phosphatase and tensin homolog (PTEN) loss.  Results Thirty-three patients received MK-2206 at 30, 60, 75, or 90 mg on alternate days.  Dose-limiting toxicities included skin rash and stomatitis, establishing the MTD at 60 mg.  Drug-related toxicities included skin rash (51.5%), nausea (36.4%), pruritus (24.2%), hyperglycemia (21.2%), and diarrhea (21.2%).  PKs (area under the concn.-time curve from 0 to 48 h and max. measured plasma concn.) were dose proportional.  Phosphorylated serine 473 AKT declined in all tumor biopsies assessed (P = .015), and phosphorylated threonine 246 proline-rich AKT substrate 40 was suppressed in hair follicles at 6 h (P = .008), on days 7 (P = .028) and 15 (P = .025) with MK-2206; reversible hyperglycemia and increases in insulin c-peptide were also obsd., confirming target modulation.  A patient with pancreatic adenocarcinoma (PTEN loss; KRAS G12D mutation) treated at 60 mg on alternate days experienced a decrease of approx. 60% in cancer antigen 19-9 levels and 23% shrinkage in tumor measurements.  Two patients with pancreatic neuroendocrine tumors had minor tumor responses.  Conclusion MK-2206 was well tolerated, with evidence of AKT signaling blockade.  Rational combination trials are ongoing to maximize clin. benefit with this therapeutic strategy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdHD9mhSwVT7Vg90H21EOLACvtfcHk0lgqDwZldVft8w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtlOnsLw%253D&md5=2ee8b8985e337a161807b9c862b573d2</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1200%2FJCO.2011.35.5263&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2011.35.5263%26sid%3Dliteratum%253Aachs%26aulast%3DYap%26aufirst%3DT.%2BA.%26aulast%3DYan%26aufirst%3DL.%26aulast%3DPatnaik%26aufirst%3DA.%26aulast%3DFearen%26aufirst%3DI.%26aulast%3DOlmos%26aufirst%3DD.%26aulast%3DPapadopoulos%26aufirst%3DK.%26aulast%3DBaird%26aufirst%3DR.%2BD.%26aulast%3DDelgado%26aufirst%3DL.%26aulast%3DTaylor%26aufirst%3DA.%26aulast%3DLupinacci%26aufirst%3DL.%26aulast%3DRiisnaes%26aufirst%3DR.%26aulast%3DPope%26aufirst%3DL.%2BL.%26aulast%3DHeaton%26aufirst%3DS.%2BP.%26aulast%3DThomas%26aufirst%3DG.%26aulast%3DGarrett%26aufirst%3DM.%2BD.%26aulast%3DSullivan%26aufirst%3DD.%2BM.%26aulast%3Dde%2BBono%26aufirst%3DJ.%2BS.%26aulast%3DTolcher%26aufirst%3DA.%2BW.%26atitle%3DFirst-in-Man%2520Clinical%2520Trial%2520of%2520the%2520Oral%2520Pan-AKT%2520Inhibitor%2520MK-2206%2520in%2520Patients%2520with%2520Advanced%2520Solid%2520Tumors%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2011%26volume%3D29%26issue%3D35%26spage%3D4688%26epage%3D4695%26doi%3D10.1200%2FJCO.2011.35.5263" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adrian, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jahnke, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowan-Jacob, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iacob, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sim, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powers, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dierks, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, G.-R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okram, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wojciechowski, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fendrich, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strauss, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vajpai, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grzesiek, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuntland, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bursulaya, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Azam, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manley, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engen, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daley, G. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warmuth, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span> <span> </span><span class="NLM_article-title">Targeting Bcr-Abl by Combining Allosteric with ATP-Binding-Site Inhibitors</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>463</i></span> (<span class="NLM_issue">7280</span>),  <span class="NLM_fpage">501</span>– <span class="NLM_lpage">506</span>, <span class="refDoi"> DOI: 10.1038/nature08675</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=10.1038%2Fnature08675" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=463&publication_year=2010&pages=501-506&issue=7280&author=J.+Zhangauthor=F.+J.+Adrianauthor=W.+Jahnkeauthor=S.+W.+Cowan-Jacobauthor=A.+G.+Liauthor=R.+E.+Iacobauthor=T.+Simauthor=J.+Powersauthor=C.+Dierksauthor=F.+Sunauthor=G.-R.+Guoauthor=Q.+Dingauthor=B.+Okramauthor=Y.+Choiauthor=A.+Wojciechowskiauthor=X.+Dengauthor=G.+Liuauthor=G.+Fendrichauthor=A.+Straussauthor=N.+Vajpaiauthor=S.+Grzesiekauthor=T.+Tuntlandauthor=Y.+Liuauthor=B.+Bursulayaauthor=M.+Azamauthor=P.+W.+Manleyauthor=J.+R.+Engenauthor=G.+Q.+Daleyauthor=M.+Warmuthauthor=N.+S.+Gray&title=Targeting+Bcr-Abl+by+Combining+Allosteric+with+ATP-Binding-Site+Inhibitors&doi=10.1038%2Fnature08675"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1038%2Fnature08675&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature08675%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DAdrian%26aufirst%3DF.%2BJ.%26aulast%3DJahnke%26aufirst%3DW.%26aulast%3DCowan-Jacob%26aufirst%3DS.%2BW.%26aulast%3DLi%26aufirst%3DA.%2BG.%26aulast%3DIacob%26aufirst%3DR.%2BE.%26aulast%3DSim%26aufirst%3DT.%26aulast%3DPowers%26aufirst%3DJ.%26aulast%3DDierks%26aufirst%3DC.%26aulast%3DSun%26aufirst%3DF.%26aulast%3DGuo%26aufirst%3DG.-R.%26aulast%3DDing%26aufirst%3DQ.%26aulast%3DOkram%26aufirst%3DB.%26aulast%3DChoi%26aufirst%3DY.%26aulast%3DWojciechowski%26aufirst%3DA.%26aulast%3DDeng%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DG.%26aulast%3DFendrich%26aufirst%3DG.%26aulast%3DStrauss%26aufirst%3DA.%26aulast%3DVajpai%26aufirst%3DN.%26aulast%3DGrzesiek%26aufirst%3DS.%26aulast%3DTuntland%26aufirst%3DT.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DBursulaya%26aufirst%3DB.%26aulast%3DAzam%26aufirst%3DM.%26aulast%3DManley%26aufirst%3DP.%2BW.%26aulast%3DEngen%26aufirst%3DJ.%2BR.%26aulast%3DDaley%26aufirst%3DG.%2BQ.%26aulast%3DWarmuth%26aufirst%3DM.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DTargeting%2520Bcr-Abl%2520by%2520Combining%2520Allosteric%2520with%2520ATP-Binding-Site%2520Inhibitors%26jtitle%3DNature%26date%3D2010%26volume%3D463%26issue%3D7280%26spage%3D501%26epage%3D506%26doi%3D10.1038%2Fnature08675" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, E. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aggarwal, A. K.</span></span> <span> </span><span class="NLM_article-title">The Ins and Outs of Bcr-Abl Inhibition</span>. <i>Genes Cancer</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>3</i></span> (<span class="NLM_issue">5–6</span>),  <span class="NLM_fpage">447</span>– <span class="NLM_lpage">454</span>, <span class="refDoi"> DOI: 10.1177/1947601912462126</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=10.1177%2F1947601912462126" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=23226582" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjsVSlur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=447-454&issue=5%E2%80%936&author=E.+P.+Reddyauthor=A.+K.+Aggarwal&title=The+Ins+and+Outs+of+Bcr-Abl+Inhibition&doi=10.1177%2F1947601912462126"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">The ins and outs of Bcr-Abl inhibition</span></div><div class="casAuthors">Reddy, E. Premkumar; Aggarwal, Aneel K.</div><div class="citationInfo"><span class="NLM_cas:title">Genes & Cancer</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">5-6</span>),
    <span class="NLM_cas:pages">447-454, 8</span>CODEN:
                <span class="NLM_cas:coden">GCEAAY</span>;
        ISSN:<span class="NLM_cas:issn">1947-6019</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">The development of inhibitors against Abl has changed the landscape for the treatment of chronic myelogenous leukemia (CML) and cancer in general.  Beginning with the monumental discovery and approval of imatinib for CML, a second generation of inhibitors, nilotinib and dasatinib, has now gained approval for the treatment of CML.  Notably, these second-generation inhibitors are active against many of the mutations in the Abl kinase that confer resistance to imatinib.  However, resistance remains a major problem, and new inhibitors such as ponatinib and GNF2/GNF5 have been developed, with activity towards the common gatekeeper T315I mutation.  We review here the mechanisms of Abl inhibition with an emphasis on structural elements that are important for the selectivity and design of new mols.  In particular, we focus on how changes in the conformation of the P-loop, the activation loop, the DFG motif, and other structural elements of Abl have been instrumental in developing an understanding of inhibitor binding.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkLh2d24eNB7Vg90H21EOLACvtfcHk0lgB02-iGhS67A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjsVSlur4%253D&md5=0e8f9f9577b585c0bc28e06beee83d49</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1177%2F1947601912462126&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1947601912462126%26sid%3Dliteratum%253Aachs%26aulast%3DReddy%26aufirst%3DE.%2BP.%26aulast%3DAggarwal%26aufirst%3DA.%2BK.%26atitle%3DThe%2520Ins%2520and%2520Outs%2520of%2520Bcr-Abl%2520Inhibition%26jtitle%3DGenes%2520Cancer%26date%3D2012%26volume%3D3%26issue%3D5%25E2%2580%25936%26spage%3D447%26epage%3D454%26doi%3D10.1177%2F1947601912462126" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Craig, W. L.</span></span> <span> </span><span class="NLM_article-title">The Akt/PKB Family of Protein Kinases: A Review of Small Molecule Inhibitors and Progress Towards Target Validation: A 2009 Update</span>. <i>Curr. Top. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">458</span>– <span class="NLM_lpage">477</span>, <span class="refDoi"> DOI: 10.2174/156802610790980602</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=10.2174%2F156802610790980602" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=20180757" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2010&pages=458-477&issue=4&author=W.+L.+Craig&title=The+Akt%2FPKB+Family+of+Protein+Kinases%3A+A+Review+of+Small+Molecule+Inhibitors+and+Progress+Towards+Target+Validation%3A+A+2009+Update&doi=10.2174%2F156802610790980602"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.2174%2F156802610790980602&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F156802610790980602%26sid%3Dliteratum%253Aachs%26aulast%3DCraig%26aufirst%3DW.%2BL.%26atitle%3DThe%2520Akt%252FPKB%2520Family%2520of%2520Protein%2520Kinases%253A%2520A%2520Review%2520of%2520Small%2520Molecule%2520Inhibitors%2520and%2520Progress%2520Towards%2520Target%2520Validation%253A%2520A%25202009%2520Update%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2010%26volume%3D10%26issue%3D4%26spage%3D458%26epage%3D477%26doi%3D10.2174%2F156802610790980602" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Simard, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kluter, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grutter, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Getlik, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rabiller, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rode, H. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rauh, D.</span></span> <span> </span><span class="NLM_article-title">A New Screening Assay for Allosteric Inhibitors of cSrc</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>5</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">394</span>– <span class="NLM_lpage">396</span>, <span class="refDoi"> DOI: 10.1038/nchembio.162</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=10.1038%2Fnchembio.162" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=19396179" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=1%3ACAS%3A528%3ADC%252BD1MXltValtLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2009&pages=394-396&issue=6&author=J.+R.+Simardauthor=S.+Kluterauthor=C.+Grutterauthor=M.+Getlikauthor=M.+Rabillerauthor=H.+B.+Rodeauthor=D.+Rauh&title=A+New+Screening+Assay+for+Allosteric+Inhibitors+of+cSrc&doi=10.1038%2Fnchembio.162"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">A new screening assay for allosteric inhibitors of cSrc</span></div><div class="casAuthors">Simard, Jeffrey R.; Klueter, Sabine; Gruetter, Christian; Getlik, Matthaeus; Rabiller, Matthias; Rode, Haridas B.; Rauh, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">394-396</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Targeting kinases outside the highly conserved ATP pocket is thought to be a promising strategy for overcoming bottlenecks in kinase inhibitor research, such as limited selectivity and drug resistance.  Here we report the development and application of a direct binding assay to detect small mols. that stabilize the inactive conformation of the tyrosine kinase cSrc.  Protein X-ray crystallog. validated the assay results and confirmed an exclusively allosteric binding mode.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpMs1P4WsnsYLVg90H21EOLACvtfcHk0lgB02-iGhS67A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXltValtLY%253D&md5=2ae7854a35d3eae39a764f8ef4f9fd47</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.162&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.162%26sid%3Dliteratum%253Aachs%26aulast%3DSimard%26aufirst%3DJ.%2BR.%26aulast%3DKluter%26aufirst%3DS.%26aulast%3DGrutter%26aufirst%3DC.%26aulast%3DGetlik%26aufirst%3DM.%26aulast%3DRabiller%26aufirst%3DM.%26aulast%3DRode%26aufirst%3DH.%2BB.%26aulast%3DRauh%26aufirst%3DD.%26atitle%3DA%2520New%2520Screening%2520Assay%2520for%2520Allosteric%2520Inhibitors%2520of%2520cSrc%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2009%26volume%3D5%26issue%3D6%26spage%3D394%26epage%3D396%26doi%3D10.1038%2Fnchembio.162" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Heinrich, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grädler, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Böttcher, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blaukat, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shutes, A.</span></span> <span> </span><span class="NLM_article-title">Allosteric IGF-1R Inhibitors</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>1</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">199</span>– <span class="NLM_lpage">203</span>, <span class="refDoi"> DOI: 10.1021/ml100044h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml100044h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2010&pages=199-203&issue=5&author=T.+Heinrichauthor=U.+Gr%C3%A4dlerauthor=H.+B%C3%B6ttcherauthor=A.+Blaukatauthor=A.+Shutes&title=Allosteric+IGF-1R+Inhibitors&doi=10.1021%2Fml100044h"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Fml100044h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml100044h%26sid%3Dliteratum%253Aachs%26aulast%3DHeinrich%26aufirst%3DT.%26aulast%3DGr%25C3%25A4dler%26aufirst%3DU.%26aulast%3DB%25C3%25B6ttcher%26aufirst%3DH.%26aulast%3DBlaukat%26aufirst%3DA.%26aulast%3DShutes%26aufirst%3DA.%26atitle%3DAllosteric%2520IGF-1R%2520Inhibitors%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D1%26issue%3D5%26spage%3D199%26epage%3D203%26doi%3D10.1021%2Fml100044h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mueller, M.</span></span> <span> </span><span class="NLM_article-title">In Vivo Function of NGF/TrkA Signaling in the Cholinergic Neurons of the Murine Basal Forebrain</span>. Ph.D Dissertation, Ludwig-Maximilians-University, Munich, <span class="NLM_year">2005</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2005&author=M.+Mueller&title=In+Vivo+Function+of+NGF%2FTrkA+Signaling+in+the+Cholinergic+Neurons+of+the+Murine+Basal+Forebrain"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMueller%26aufirst%3DM.%26atitle%3DIn%2520Vivo%2520Function%2520of%2520NGF%252FTrkA%2520Signaling%2520in%2520the%2520Cholinergic%2520Neurons%2520of%2520the%2520Murine%2520Basal%2520Forebrain%26date%3D2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mufson, E. J.</span>; <span class="NLM_string-name">Kordower, J. H.</span></span> <span> </span><span class="NLM_article-title">Nerve Growth Factor Systems in Alzheimer’s Disease</span>. In  <i>Cerebral Cortex</i>, <span class="NLM_contrib-group"><span class="NLM_string-name">Peters, A.</span>, <span class="NLM_string-name">Morrison, J. H.</span></span>, Eds.; <span class="NLM_publisher-name">Springer</span>: <span class="NLM_publisher-loc">Boston</span>, <span class="NLM_year">1999</span>; Vol.  <span class="NLM_volume">14</span>, pp  <span class="NLM_fpage">681</span>– <span class="NLM_lpage">731</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=10.1007%2F978-1-4615-4885-0_19" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1999&pages=681-731&author=E.+J.+Mufson&author=J.+H.+Kordowerauthor=A.+Peters&author=J.+H.+Morrison&title=Cerebral+Cortex"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1007%2F978-1-4615-4885-0_19&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1007%252F978-1-4615-4885-0_19%26sid%3Dliteratum%253Aachs%26aulast%3DMufson%26aufirst%3DE.%2BJ.%26atitle%3DNerve%2520Growth%2520Factor%2520Systems%2520in%2520Alzheimer%25E2%2580%2599s%2520Disease%26btitle%3DCerebral%2520Cortex%26aulast%3DPeters%26aufirst%3DA.%26pub%3DSpringer%26date%3D1999%26volume%3D14%26spage%3D681%26epage%3D731" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez-Ortiz, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yui, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rubenstein, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reichardt, L. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parada, L. F.</span></span> <span> </span><span class="NLM_article-title">TrkA Gene Ablation in Basal Forebrain Results in Dysfunction of the Cholinergic Circuitry</span>. <i>J. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>32</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">4065</span>– <span class="NLM_lpage">4079</span>, <span class="refDoi"> DOI: 10.1523/JNEUROSCI.6314-11.2012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=10.1523%2FJNEUROSCI.6314-11.2012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=22442072" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=1%3ACAS%3A528%3ADC%252BC38XkslCmt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2012&pages=4065-4079&issue=12&author=E.+Sanchez-Ortizauthor=D.+Yuiauthor=D.+Songauthor=Y.+Liauthor=J.+L.+Rubensteinauthor=L.+F.+Reichardtauthor=L.+F.+Parada&title=TrkA+Gene+Ablation+in+Basal+Forebrain+Results+in+Dysfunction+of+the+Cholinergic+Circuitry&doi=10.1523%2FJNEUROSCI.6314-11.2012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">TrkA gene ablation in basal forebrain results in dysfunction of the cholinergic circuitry</span></div><div class="casAuthors">Sanchez-Ortiz, Efrain; Yui, Daishi; Song, Dongli; Li, Yun; Rubenstein, John L.; Reichardt, Louis F.; Parada, Luis F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">4065-4079</span>CODEN:
                <span class="NLM_cas:coden">JNRSDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-6474</span>.
    
            (<span class="NLM_cas:orgname">Society for Neuroscience</span>)
        </div><div class="casAbstract">Dysfunction of basal forebrain cholinergic neurons (BFCNs) is an early pathol. hallmark of Alzheimer's disease (AD).  Numerous studies have indicated that nerve growth factor (NGF) supports survival and phenotypic differentiation of BFCNs.  Consistent with a potential link to AD pathogenesis, TrkA, a NGF receptor, is expressed in cholinergic forebrain neuronal populations including those in BF and striatum, and is markedly reduced in individuals with mild cognitive impairment (MCI) without dementia and early-stage AD.  To investigate the role of TrkA in the development, connectivity, and function of the BF cholinergic system and its contribution to AD pathol., we have generated a forebrain-specific conditional TrkA knock-out mouse line.  Our findings show a key role for TrkA signaling in establishing the BF cholinergic circuitry through the ERK pathway, and demonstrate that the normal developmental increase of choline acetyltransferase expression becomes critically dependent on TrkA signaling before neuronal connections are established.  Moreover, the anatomical and physiol. deficits caused by lack of TrkA signaling in BFCNs have selective impact on cognitive activity.  These data demonstrate that TrkA loss results in cholinergic BF dysfunction and cognitive decline that is reminiscent of MCI and early AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9qproimMfdrVg90H21EOLACvtfcHk0libbtatEKz9Aw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XkslCmt74%253D&md5=fac45c446552ea69e72cdd15200d54c2</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1523%2FJNEUROSCI.6314-11.2012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1523%252FJNEUROSCI.6314-11.2012%26sid%3Dliteratum%253Aachs%26aulast%3DSanchez-Ortiz%26aufirst%3DE.%26aulast%3DYui%26aufirst%3DD.%26aulast%3DSong%26aufirst%3DD.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DRubenstein%26aufirst%3DJ.%2BL.%26aulast%3DReichardt%26aufirst%3DL.%2BF.%26aulast%3DParada%26aufirst%3DL.%2BF.%26atitle%3DTrkA%2520Gene%2520Ablation%2520in%2520Basal%2520Forebrain%2520Results%2520in%2520Dysfunction%2520of%2520the%2520Cholinergic%2520Circuitry%26jtitle%3DJ.%2520Neurosci.%26date%3D2012%26volume%3D32%26issue%3D12%26spage%3D4065%26epage%3D4079%26doi%3D10.1523%2FJNEUROSCI.6314-11.2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamb, M. L.</span></span> <span> </span><span class="NLM_article-title">Trk Kinase Inhibitors as New Treatments for Cancer and Pain</span>. <i>Expert Opin. Ther. Pat.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>19</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">305</span>– <span class="NLM_lpage">319</span>, <span class="refDoi"> DOI: 10.1517/13543770902721261</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=10.1517%2F13543770902721261" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=19441906" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjslWlu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=305-319&issue=3&author=T.+Wangauthor=D.+Yuauthor=M.+L.+Lamb&title=Trk+Kinase+Inhibitors+as+New+Treatments+for+Cancer+and+Pain&doi=10.1517%2F13543770902721261"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Trk kinase inhibitors as new treatments for cancer and pain</span></div><div class="casAuthors">Wang, Tao; Yu, Dingwei; Lamb, Michelle L.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">305-319</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Background: Tropomyosin-related kinases (Trks) are a family of receptor tyrosine kinases activated by neurotrophins.  Trks play important roles in pain sensation as well as tumor cell growth and survival signaling.  Thus, inhibitors of Trk receptor kinases might provide targeted treatments for pain and cancer.  Objective: This paper reviews those patent applications since 2002 claiming small-mol. inhibitors of Trk receptor kinases.  Methods: Primary literature and patents were searched with SciFinder and Google Scholar.  Patents were selected based on their relevance to Trks and were evaluated and representative compds. were listed as examples.  Results/conclusion: Several series of Trk inhibitors with excellent in vitro potencies have been reported and a no. of compds. have gone into the clinic.  It should be noted that few of these inhibitors are Trk selective, demonstrating that targeting Trk kinases for treatment of pain and/or cancer offers a promising but also challenging approach.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvknvXUUz2DbVg90H21EOLACvtfcHk0libbtatEKz9Aw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjslWlu7o%253D&md5=ffc2d3e33102631cac7b89dce7f96a5a</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1517%2F13543770902721261&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543770902721261%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DT.%26aulast%3DYu%26aufirst%3DD.%26aulast%3DLamb%26aufirst%3DM.%2BL.%26atitle%3DTrk%2520Kinase%2520Inhibitors%2520as%2520New%2520Treatments%2520for%2520Cancer%2520and%2520Pain%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2009%26volume%3D19%26issue%3D3%26spage%3D305%26epage%3D319%26doi%3D10.1517%2F13543770902721261" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bagal, S. K.</span></span> The Discovery and Optimization of a Series of Potent, Selective and CNS Restricted Pan-Trk Ligands. In  <i>Kinase 2014: Past, Present and Beyond, 6th RSC/SCI Symposium on Kinase Inhibitor Design</i>, The Barry Cross Conference Centre, Cambridge, 19–20 May 2014.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Bagal%2C+S.+K.+The+Discovery+and+Optimization+of+a+Series+of+Potent%2C+Selective+and+CNS+Restricted+Pan-Trk+Ligands.+In+Kinase+2014%3A+Past%2C+Present+and+Beyond%2C+6th+RSC%2FSCI+Symposium+on+Kinase+Inhibitor+Design%2C+The+Barry+Cross+Conference+Centre%2C+Cambridge%2C+19%E2%80%9320+May+2014."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dconf-proc%26sid%3Dliteratum%253Aachs%26aulast%3DBagal%26aufirst%3DS.%2BK.%26jtitle%3DKinase%25202014%253A%2520Past%252C%2520Present%2520and%2520Beyond%252C%25206th%2520RSC%252FSCI%2520Symposium%2520on%2520Kinase%2520Inhibitor%2520Design" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bagal, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bungay, P.</span></span> <span> </span><span class="NLM_article-title">Restricting CNS Penetration of Drugs to Minimise Adverse Events: Role of Drug Transporters</span>. <i>Drug Discovery Today: Technol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">79</span>– <span class="NLM_lpage">85</span>, <span class="refDoi"> DOI: 10.1016/j.ddtec.2014.03.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=10.1016%2Fj.ddtec.2014.03.008" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2014&pages=79-85&author=S.+Bagalauthor=P.+Bungay&title=Restricting+CNS+Penetration+of+Drugs+to+Minimise+Adverse+Events%3A+Role+of+Drug+Transporters&doi=10.1016%2Fj.ddtec.2014.03.008"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1016%2Fj.ddtec.2014.03.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ddtec.2014.03.008%26sid%3Dliteratum%253Aachs%26aulast%3DBagal%26aufirst%3DS.%26aulast%3DBungay%26aufirst%3DP.%26atitle%3DRestricting%2520CNS%2520Penetration%2520of%2520Drugs%2520to%2520Minimise%2520Adverse%2520Events%253A%2520Role%2520of%2520Drug%2520Transporters%26jtitle%3DDrug%2520Discovery%2520Today%253A%2520Technol.%26date%3D2014%26volume%3D12%26spage%3D79%26epage%3D85%26doi%3D10.1016%2Fj.ddtec.2014.03.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cole, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bagal, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El-Kattan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fenner, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hay, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kempshall, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lunn, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varma, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stupple, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Speed, W.</span></span> <span> </span><span class="NLM_article-title">Full Efficacy with No CNS Side-Effects: Unachievable Panacea or Reality?? DMPK Considerations in Design of Drugs with Limited Brain Penetration</span>. <i>Xenobiotica</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>42</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">11</span>– <span class="NLM_lpage">27</span>, <span class="refDoi"> DOI: 10.3109/00498254.2011.617847</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=10.3109%2F00498254.2011.617847" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2012&pages=11-27&issue=1&author=S.+Coleauthor=S.+Bagalauthor=A.+El-Kattanauthor=K.+Fennerauthor=T.+Hayauthor=S.+Kempshallauthor=G.+Lunnauthor=M.+Varmaauthor=P.+Stuppleauthor=W.+Speed&title=Full+Efficacy+with+No+CNS+Side-Effects%3A+Unachievable+Panacea+or+Reality%3F%3F+DMPK+Considerations+in+Design+of+Drugs+with+Limited+Brain+Penetration&doi=10.3109%2F00498254.2011.617847"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.3109%2F00498254.2011.617847&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F00498254.2011.617847%26sid%3Dliteratum%253Aachs%26aulast%3DCole%26aufirst%3DS.%26aulast%3DBagal%26aufirst%3DS.%26aulast%3DEl-Kattan%26aufirst%3DA.%26aulast%3DFenner%26aufirst%3DK.%26aulast%3DHay%26aufirst%3DT.%26aulast%3DKempshall%26aufirst%3DS.%26aulast%3DLunn%26aufirst%3DG.%26aulast%3DVarma%26aufirst%3DM.%26aulast%3DStupple%26aufirst%3DP.%26aulast%3DSpeed%26aufirst%3DW.%26atitle%3DFull%2520Efficacy%2520with%2520No%2520CNS%2520Side-Effects%253A%2520Unachievable%2520Panacea%2520or%2520Reality%253F%253F%2520DMPK%2520Considerations%2520in%2520Design%2520of%2520Drugs%2520with%2520Limited%2520Brain%2520Penetration%26jtitle%3DXenobiotica%26date%3D2012%26volume%3D42%26issue%3D1%26spage%3D11%26epage%3D27%26doi%3D10.3109%2F00498254.2011.617847" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wager, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liras, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mente, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trapa, P.</span></span> <span> </span><span class="NLM_article-title">Strategies to Minimize CNS Toxicity: In Vitro High-Throughput Assays and Computational Modeling</span>. <i>Expert Opin. Drug Metab. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">531</span>– <span class="NLM_lpage">542</span>, <span class="refDoi"> DOI: 10.1517/17425255.2012.677028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=10.1517%2F17425255.2012.677028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=22458547" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=1%3ACAS%3A528%3ADC%252BC38XlvV2qs7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2012&pages=531-542&issue=5&author=T.+T.+Wagerauthor=J.+L.+Lirasauthor=S.+Menteauthor=P.+Trapa&title=Strategies+to+Minimize+CNS+Toxicity%3A+In+Vitro+High-Throughput+Assays+and+Computational+Modeling&doi=10.1517%2F17425255.2012.677028"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Strategies to minimize CNS toxicity: in vitro high-throughput assays and computational modeling</span></div><div class="casAuthors">Wager, Travis T.; Liras, Jennifer L.; Mente, Scot; Trapa, Patrick</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Metabolism & Toxicology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">531-542</span>CODEN:
                <span class="NLM_cas:coden">EODMAP</span>;
        ISSN:<span class="NLM_cas:issn">1742-5255</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: Healthy functioning of the brain is dependent on the ability of the blood-brain barrier (BBB) and other central nervous system (CNS) barriers to protect the neurocompartments from potential disruptive and damaging xenobiotic agents.  In vitro high-throughput (HT) screens and computational models that assess a compd.'s ability to pass through or disrupt the BBB have become important tools in the identification of new well-tolerated peripheral drugs and safer chem. products such as pesticides.  Leveraging these HT in vitro assays and computational BBB tools together with the current understanding of brain penetration may enable the drug discovery community to minimize access of drug candidates into the CNS compartment.  Areas covered: This article reviews aspects of the most recent in vitro and computational approaches designed to provide an early assessment of a compd.'s ability to access the neurocompartment.  This article also provides insight into using these tools to identify compds. that have restricted access to the neurocompartment.  Expert opinion: The development of safer peripheral-acting medicines and chem. products can be achieved through prospective design and early assessment with HT assays of the BBB in conjunction with computational models.  Exclusion or significantly reduced access of a compd. to the neurocompartment will increase the odds of identifying a compd. with reduced CNS-related adverse drug reactions.  A holistic approach to compd. design and evaluation that incorporates prospective design principles (e.g., optimization of physicochem. properties), leverages HT in vitro assays and integrates the use of BBB computational models may yield the best-in-class' peripherally acting product.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOhde-T8d1UrVg90H21EOLACvtfcHk0libbtatEKz9Aw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XlvV2qs7s%253D&md5=d4bb73a8839594465407435be2019601</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1517%2F17425255.2012.677028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17425255.2012.677028%26sid%3Dliteratum%253Aachs%26aulast%3DWager%26aufirst%3DT.%2BT.%26aulast%3DLiras%26aufirst%3DJ.%2BL.%26aulast%3DMente%26aufirst%3DS.%26aulast%3DTrapa%26aufirst%3DP.%26atitle%3DStrategies%2520to%2520Minimize%2520CNS%2520Toxicity%253A%2520In%2520Vitro%2520High-Throughput%2520Assays%2520and%2520Computational%2520Modeling%26jtitle%3DExpert%2520Opin.%2520Drug%2520Metab.%2520Toxicol.%26date%3D2012%26volume%3D8%26issue%3D5%26spage%3D531%26epage%3D542%26doi%3D10.1517%2F17425255.2012.677028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kalvass, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polli, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bourdet, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, Q. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zamek-Gliszczynski, M.
J.</span></span> <span> </span><span class="NLM_article-title">Why Clinical Modulation of Efflux Transport at the Human Blood-Brain Barrier Is Unlikely: The ITC Evidence-Based Position</span>. <i>Clin. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>94</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">80</span>– <span class="NLM_lpage">94</span>, <span class="refDoi"> DOI: 10.1038/clpt.2013.34</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=10.1038%2Fclpt.2013.34" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=23588303" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=1%3ACAS%3A528%3ADC%252BC3sXpvVOrtbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=94&publication_year=2013&pages=80-94&issue=1&author=J.+C.+Kalvassauthor=J.+W.+Polliauthor=D.+L.+Bourdetauthor=B.+Fengauthor=S.+M.+Huangauthor=X.+Liuauthor=Q.+R.+Smithauthor=L.+K.+Zhangauthor=M.%0AJ.+Zamek-Gliszczynski&title=Why+Clinical+Modulation+of+Efflux+Transport+at+the+Human+Blood-Brain+Barrier+Is+Unlikely%3A+The+ITC+Evidence-Based+Position&doi=10.1038%2Fclpt.2013.34"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Why Clinical Modulation of Efflux Transport at the Human Blood-Brain Barrier Is Unlikely: The ITC Evidence-Based Position</span></div><div class="casAuthors">Kalvass, J. C.; Polli, J. W.; Bourdet, D. L.; Feng, B.; Huang, S.-M.; Liu, X.; Smith, Q. R.; Zhang, L. K.; Zamek-Gliszczynski, M. J.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacology & Therapeutics (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">94</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">80-94</span>CODEN:
                <span class="NLM_cas:coden">CLPTAT</span>;
        ISSN:<span class="NLM_cas:issn">0009-9236</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Drug interactions due to efflux transport inhibition at the blood-brain barrier (BBB) have been receiving increasing scrutiny because of the theor. possibility of adverse central nervous system (CNS) effects identified in preclin. studies.  In this review, evidence from pharmacokinetic, pharmacodynamic, imaging, pharmacogenetic, and pharmacovigilance studies, along with drug safety reports, is presented supporting a low probability of modulating transporters at the human BBB by currently marketed drugs.  Clin. Pharmacol. & Therapeutics (2013); 94 1, 80-94. doi:10.1038/clpt.2013.34.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfxdzZMTG6_7Vg90H21EOLACvtfcHk0lgX1rZplyBJTw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXpvVOrtbY%253D&md5=c106f689e1c83f58eb6d0dbc527cf0fa</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1038%2Fclpt.2013.34&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fclpt.2013.34%26sid%3Dliteratum%253Aachs%26aulast%3DKalvass%26aufirst%3DJ.%2BC.%26aulast%3DPolli%26aufirst%3DJ.%2BW.%26aulast%3DBourdet%26aufirst%3DD.%2BL.%26aulast%3DFeng%26aufirst%3DB.%26aulast%3DHuang%26aufirst%3DS.%2BM.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DSmith%26aufirst%3DQ.%2BR.%26aulast%3DZhang%26aufirst%3DL.%2BK.%26aulast%3DZamek-Gliszczynski%26aufirst%3DM.%2BJ.%26atitle%3DWhy%2520Clinical%2520Modulation%2520of%2520Efflux%2520Transport%2520at%2520the%2520Human%2520Blood-Brain%2520Barrier%2520Is%2520Unlikely%253A%2520The%2520ITC%2520Evidence-Based%2520Position%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%26date%3D2013%26volume%3D94%26issue%3D1%26spage%3D80%26epage%3D94%26doi%3D10.1038%2Fclpt.2013.34" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Giacomini, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, S.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tweedie, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benet, L. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brouwer, K. L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dahlin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evers, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hillgren, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffmaster, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishikawa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keppler, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niemi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polli, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugiyama, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swaan, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ware, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wah Yee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zamek-Gliszczynski, M.
J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span> <span> </span><span class="NLM_article-title">Membrane Transporters in Drug Development</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">215</span>– <span class="NLM_lpage">236</span>, <span class="refDoi"> DOI: 10.1038/nrd3028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=10.1038%2Fnrd3028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=20190787" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=1%3ACAS%3A528%3ADC%252BC3cXisFelu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2010&pages=215-236&issue=3&author=K.+M.+Giacominiauthor=S.-M.+Huangauthor=D.+J.+Tweedieauthor=L.+Z.+Benetauthor=K.+L.+R.+Brouwerauthor=X.+Chuauthor=A.+Dahlinauthor=R.+Eversauthor=V.+Fischerauthor=K.+M.+Hillgrenauthor=K.+A.+Hoffmasterauthor=T.+Ishikawaauthor=D.+Kepplerauthor=R.+B.+Kimauthor=C.+A.+Leeauthor=M.+Niemiauthor=J.+W.+Polliauthor=Y.+Sugiyamaauthor=P.+W.+Swaanauthor=J.+A.+Wareauthor=S.+H.+Wrightauthor=S.+Wah+Yeeauthor=M.%0AJ.+Zamek-Gliszczynskiauthor=L.+Zhang&title=Membrane+Transporters+in+Drug+Development&doi=10.1038%2Fnrd3028"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Membrane transporters in drug development</span></div><div class="casAuthors">Giacomini, Kathleen M.; Huang, Shiew-Mei; Tweedie, Donald J.; Benet, Leslie Z.; Brouwer, Kim L. R.; Chu, Xiaoyan; Dahlin, Amber; Evers, Raymond; Fischer, Volker; Hillgren, Kathleen M.; Hoffmaster, Keith A.; Ishikawa, Toshihisa; Keppler, Dietrich; Kim, Richard B.; Lee, Caroline A.; Niemi, Mikko; Polli, Joseph W.; Sugiyama, Yuicchi; Swaan, Peter W.; Ware, Joseph A.; Wright, Stephen H.; Wah Yee, Sook; Zamek-Gliszczynski, Maciej J.; Zhang, Lei</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">215-236</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Membrane transporters can be major determinants of the pharmacokinetic, safety and efficacy profiles of drugs.  This presents several key questions for drug development, including which transporters are clin. important in drug absorption and disposition, and which in vitro methods are suitable for studying drug interactions with these transporters.  In addn., what criteria should trigger follow-up clin. studies, and which clin. studies should be conducted if needed.  In this article, we provide the recommendations of the International Transporter Consortium on these issues, and present decision trees that are intended to help guide clin. studies on the currently recognized most important drug transporter interactions.  The recommendations are generally intended to support clin. development and filing of a new drug application.  Overall, it is advised that the timing of transporter investigations should be driven by efficacy, safety and clin. trial enrollment questions (for example, exclusion and inclusion criteria), as well as a need for further understanding of the absorption, distribution, metab. and excretion properties of the drug mol., and information required for drug labeling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoiBIf0gk93W7Vg90H21EOLACvtfcHk0lgX1rZplyBJTw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXisFelu74%253D&md5=89d9ce746284c1814fb01cd9b9a72027</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1038%2Fnrd3028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3028%26sid%3Dliteratum%253Aachs%26aulast%3DGiacomini%26aufirst%3DK.%2BM.%26aulast%3DHuang%26aufirst%3DS.-M.%26aulast%3DTweedie%26aufirst%3DD.%2BJ.%26aulast%3DBenet%26aufirst%3DL.%2BZ.%26aulast%3DBrouwer%26aufirst%3DK.%2BL.%2BR.%26aulast%3DChu%26aufirst%3DX.%26aulast%3DDahlin%26aufirst%3DA.%26aulast%3DEvers%26aufirst%3DR.%26aulast%3DFischer%26aufirst%3DV.%26aulast%3DHillgren%26aufirst%3DK.%2BM.%26aulast%3DHoffmaster%26aufirst%3DK.%2BA.%26aulast%3DIshikawa%26aufirst%3DT.%26aulast%3DKeppler%26aufirst%3DD.%26aulast%3DKim%26aufirst%3DR.%2BB.%26aulast%3DLee%26aufirst%3DC.%2BA.%26aulast%3DNiemi%26aufirst%3DM.%26aulast%3DPolli%26aufirst%3DJ.%2BW.%26aulast%3DSugiyama%26aufirst%3DY.%26aulast%3DSwaan%26aufirst%3DP.%2BW.%26aulast%3DWare%26aufirst%3DJ.%2BA.%26aulast%3DWright%26aufirst%3DS.%2BH.%26aulast%3DWah%2BYee%26aufirst%3DS.%26aulast%3DZamek-Gliszczynski%26aufirst%3DM.%2BJ.%26aulast%3DZhang%26aufirst%3DL.%26atitle%3DMembrane%2520Transporters%2520in%2520Drug%2520Development%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2010%26volume%3D9%26issue%3D3%26spage%3D215%26epage%3D236%26doi%3D10.1038%2Fnrd3028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leeson, P.
D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Springthorpe, B.</span></span> <span> </span><span class="NLM_article-title">The Influence of Drug-Like Concepts on Decision-Making in Medicinal Chemistry</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">881</span>– <span class="NLM_lpage">890</span>, <span class="refDoi"> DOI: 10.1038/nrd2445</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=10.1038%2Fnrd2445" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=17971784" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=1%3ACAS%3A528%3ADC%252BD2sXht1els7rL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=881-890&issue=11&author=P.%0AD.+Leesonauthor=B.+Springthorpe&title=The+Influence+of+Drug-Like+Concepts+on+Decision-Making+in+Medicinal+Chemistry&doi=10.1038%2Fnrd2445"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">The influence of drug-like concepts on decision-making in medicinal chemistry</span></div><div class="casAuthors">Leeson, Paul D.; Springthorpe, Brian</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">881-890</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Despite the wide acceptance of drug-like principles such as the 'rule of five', this anal. of mols. currently being synthesized in leading pharmaceutical companies reveals that their phys. properties differ significantly from those of recently discovered oral drugs.  The marked increase in lipophilicity in particular could increase the likelihood of attrition in drug development.  The application of guidelines linked to the concept of drug-likeness, such as the 'rule of five', has gained wide acceptance as an approach to reduce attrition in drug discovery and development.  However, despite this acceptance, anal. of recent trends reveals that the phys. properties of mols. that are currently being synthesized in leading drug discovery companies differ significantly from those of recently discovered oral drugs and compds. in clin. development.  The consequences of the marked increase in lipophilicity - the most important drug-like phys. property - include a greater likelihood of lack of selectivity and attrition in drug development.  Tackling the threat of compd.-related toxicol. attrition needs to move to the mainstream of medicinal chem. decision-making.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTUeonLD6iebVg90H21EOLACvtfcHk0lgX1rZplyBJTw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXht1els7rL&md5=5665a9e2dc266a1ee096e20625757ef7</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1038%2Fnrd2445&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2445%26sid%3Dliteratum%253Aachs%26aulast%3DLeeson%26aufirst%3DP.%2BD.%26aulast%3DSpringthorpe%26aufirst%3DB.%26atitle%3DThe%2520Influence%2520of%2520Drug-Like%2520Concepts%2520on%2520Decision-Making%2520in%2520Medicinal%2520Chemistry%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2007%26volume%3D6%26issue%3D11%26spage%3D881%26epage%3D890%26doi%3D10.1038%2Fnrd2445" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bagal, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bungay, P. J.</span></span> <span> </span><span class="NLM_article-title">Minimizing Drug Exposure in the CNS While Maintaining Good Oral Absorption</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>3</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">948</span>– <span class="NLM_lpage">950</span>, <span class="refDoi"> DOI: 10.1021/ml300378n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml300378n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=948-950&issue=12&author=S.+K.+Bagalauthor=P.+J.+Bungay&title=Minimizing+Drug+Exposure+in+the+CNS+While+Maintaining+Good+Oral+Absorption&doi=10.1021%2Fml300378n"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1021%2Fml300378n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml300378n%26sid%3Dliteratum%253Aachs%26aulast%3DBagal%26aufirst%3DS.%2BK.%26aulast%3DBungay%26aufirst%3DP.%2BJ.%26atitle%3DMinimizing%2520Drug%2520Exposure%2520in%2520the%2520CNS%2520While%2520Maintaining%2520Good%2520Oral%2520Absorption%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D3%26issue%3D12%26spage%3D948%26epage%3D950%26doi%3D10.1021%2Fml300378n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tachibana, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kato, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugiyama, Y.</span></span> <span> </span><span class="NLM_article-title">Prediction of Nonlinear Intestinal Absorption of CYP3A4 and P-Glycoprotein Substrates from Their in Vitro Km Values</span>. <i>Pharm. Res.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>29</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">651</span>– <span class="NLM_lpage">668</span>, <span class="refDoi"> DOI: 10.1007/s11095-011-0579-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=10.1007%2Fs11095-011-0579-2" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2012&pages=651-668&issue=3&author=T.+Tachibanaauthor=M.+Katoauthor=Y.+Sugiyama&title=Prediction+of+Nonlinear+Intestinal+Absorption+of+CYP3A4+and+P-Glycoprotein+Substrates+from+Their+in+Vitro+Km+Values&doi=10.1007%2Fs11095-011-0579-2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1007%2Fs11095-011-0579-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11095-011-0579-2%26sid%3Dliteratum%253Aachs%26aulast%3DTachibana%26aufirst%3DT.%26aulast%3DKato%26aufirst%3DM.%26aulast%3DSugiyama%26aufirst%3DY.%26atitle%3DPrediction%2520of%2520Nonlinear%2520Intestinal%2520Absorption%2520of%2520CYP3A4%2520and%2520P-Glycoprotein%2520Substrates%2520from%2520Their%2520in%2520Vitro%2520Km%2520Values%26jtitle%3DPharm.%2520Res.%26date%3D2012%26volume%3D29%26issue%3D3%26spage%3D651%26epage%3D668%26doi%3D10.1007%2Fs11095-011-0579-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, M. D.</span>; <span class="NLM_string-name">Bagal, S. K.</span>; <span class="NLM_string-name">Gibson, K. R.</span>; <span class="NLM_string-name">Omoto, K.</span>; <span class="NLM_string-name">Ryckmans, T.</span>; <span class="NLM_string-name">Skerratt, S. E.</span>; <span class="NLM_string-name">Stupple, P. A.</span></span> <span> </span><span class="NLM_article-title">Pyrrolo[2,3-<span class="smallcaps smallerCapital">d</span>]Pyrimidine Derivatives as Inhibitors of Tropomyosin-Related Kinases and Their Preparation and Use in the Treatment of Pain</span>. <span class="NLM_patent">WO2012137089A1</span>, <span class="NLM_year">2012</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=M.+D.+Andrews&author=S.+K.+Bagal&author=K.+R.+Gibson&author=K.+Omoto&author=T.+Ryckmans&author=S.+E.+Skerratt&author=P.+A.+Stupple&title=Pyrrolo%5B2%2C3-d%5DPyrimidine+Derivatives+as+Inhibitors+of+Tropomyosin-Related+Kinases+and+Their+Preparation+and+Use+in+the+Treatment+of+Pain"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DAndrews%26aufirst%3DM.%2BD.%26atitle%3DPyrrolo%255B2%252C3-d%255DPyrimidine%2520Derivatives%2520as%2520Inhibitors%2520of%2520Tropomyosin-Related%2520Kinases%2520and%2520Their%2520Preparation%2520and%2520Use%2520in%2520the%2520Treatment%2520of%2520Pain%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xing, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rai, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lunney, E. A.</span></span> <span> </span><span class="NLM_article-title">Scaffold Mining of Kinase Hinge Binders in Crystal Structure Database</span>. <i>J. Comput.-Aided Mol. Des.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>28</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">13</span>– <span class="NLM_lpage">23</span>, <span class="refDoi"> DOI: 10.1007/s10822-013-9700-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=10.1007%2Fs10822-013-9700-4" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2014&pages=13-23&issue=1&author=L.+Xingauthor=B.+Raiauthor=E.+A.+Lunney&title=Scaffold+Mining+of+Kinase+Hinge+Binders+in+Crystal+Structure+Database&doi=10.1007%2Fs10822-013-9700-4"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1007%2Fs10822-013-9700-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10822-013-9700-4%26sid%3Dliteratum%253Aachs%26aulast%3DXing%26aufirst%3DL.%26aulast%3DRai%26aufirst%3DB.%26aulast%3DLunney%26aufirst%3DE.%2BA.%26atitle%3DScaffold%2520Mining%2520of%2520Kinase%2520Hinge%2520Binders%2520in%2520Crystal%2520Structure%2520Database%26jtitle%3DJ.%2520Comput.-Aided%2520Mol.%2520Des.%26date%3D2014%26volume%3D28%26issue%3D1%26spage%3D13%26epage%3D23%26doi%3D10.1007%2Fs10822-013-9700-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bagal, S. K.</span>; <span class="NLM_string-name">Cui, J. J.</span>; <span class="NLM_string-name">Greasley, S. E.</span>; <span class="NLM_string-name">Lunney, E. A.</span>; <span class="NLM_string-name">McAlpine, I. J.</span>; <span class="NLM_string-name">Nagata, A.</span>; <span class="NLM_string-name">Ninkovic, S.</span>; <span class="NLM_string-name">Omoto, K.</span>; <span class="NLM_string-name">Skerratt, S. E.</span>; <span class="NLM_string-name">Warmus, J. S.</span></span> <span> </span><span class="NLM_article-title">Pyrazole Derivatives as Tropomyosin-Related Kinase Antagonists and Their Preparation and Use for the Treatment of TrkA-Related Diseases</span>. <span class="NLM_patent">WO2015159175A1</span>, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=S.+K.+Bagal&author=J.+J.+Cui&author=S.+E.+Greasley&author=E.+A.+Lunney&author=I.+J.+McAlpine&author=A.+Nagata&author=S.+Ninkovic&author=K.+Omoto&author=S.+E.+Skerratt&author=J.+S.+Warmus&title=Pyrazole+Derivatives+as+Tropomyosin-Related+Kinase+Antagonists+and+Their+Preparation+and+Use+for+the+Treatment+of+TrkA-Related+Diseases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBagal%26aufirst%3DS.%2BK.%26atitle%3DPyrazole%2520Derivatives%2520as%2520Tropomyosin-Related%2520Kinase%2520Antagonists%2520and%2520Their%2520Preparation%2520and%2520Use%2520for%2520the%2520Treatment%2520of%2520TrkA-Related%2520Diseases%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Su, H.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rickert, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burlein, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narayan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bukhtiyarova, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurzy, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stump, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reid, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krasowska-Zoladek, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tummala, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shipman, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kornienko, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lemaire, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krosky, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heller, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Achab, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chamberlin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saradjian, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sauvagnat, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ziebell, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nickbarg, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanders, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bilodeau, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carroll, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lumb, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soisson, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henze, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooke, A. J.</span></span> <span> </span><span class="NLM_article-title">Structural Characterization of Nonactive Site, TrkA-Selective Kinase Inhibitors</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>114</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">E297</span>– <span class="NLM_lpage">E306</span>, <span class="refDoi"> DOI: 10.1073/pnas.1611577114</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=10.1073%2Fpnas.1611577114" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2017&pages=E297-E306&issue=3&author=H.-P.+Suauthor=K.+Rickertauthor=C.+Burleinauthor=K.+Narayanauthor=M.+Bukhtiyarovaauthor=D.+M.+Hurzyauthor=C.+A.+Stumpauthor=X.+Zhangauthor=J.+Reidauthor=A.+Krasowska-Zoladekauthor=S.+Tummalaauthor=J.+M.+Shipmanauthor=M.+Kornienkoauthor=P.+A.+Lemaireauthor=D.+Kroskyauthor=A.+Hellerauthor=A.+Achabauthor=C.+Chamberlinauthor=P.+Saradjianauthor=B.+Sauvagnatauthor=X.+Yangauthor=M.+R.+Ziebellauthor=E.+Nickbargauthor=J.+M.+Sandersauthor=M.+T.+Bilodeauauthor=S.+S.+Carrollauthor=K.+J.+Lumbauthor=S.+M.+Soissonauthor=D.+A.+Henzeauthor=A.+J.+Cooke&title=Structural+Characterization+of+Nonactive+Site%2C+TrkA-Selective+Kinase+Inhibitors&doi=10.1073%2Fpnas.1611577114"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1611577114&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1611577114%26sid%3Dliteratum%253Aachs%26aulast%3DSu%26aufirst%3DH.-P.%26aulast%3DRickert%26aufirst%3DK.%26aulast%3DBurlein%26aufirst%3DC.%26aulast%3DNarayan%26aufirst%3DK.%26aulast%3DBukhtiyarova%26aufirst%3DM.%26aulast%3DHurzy%26aufirst%3DD.%2BM.%26aulast%3DStump%26aufirst%3DC.%2BA.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DReid%26aufirst%3DJ.%26aulast%3DKrasowska-Zoladek%26aufirst%3DA.%26aulast%3DTummala%26aufirst%3DS.%26aulast%3DShipman%26aufirst%3DJ.%2BM.%26aulast%3DKornienko%26aufirst%3DM.%26aulast%3DLemaire%26aufirst%3DP.%2BA.%26aulast%3DKrosky%26aufirst%3DD.%26aulast%3DHeller%26aufirst%3DA.%26aulast%3DAchab%26aufirst%3DA.%26aulast%3DChamberlin%26aufirst%3DC.%26aulast%3DSaradjian%26aufirst%3DP.%26aulast%3DSauvagnat%26aufirst%3DB.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DZiebell%26aufirst%3DM.%2BR.%26aulast%3DNickbarg%26aufirst%3DE.%26aulast%3DSanders%26aufirst%3DJ.%2BM.%26aulast%3DBilodeau%26aufirst%3DM.%2BT.%26aulast%3DCarroll%26aufirst%3DS.%2BS.%26aulast%3DLumb%26aufirst%3DK.%2BJ.%26aulast%3DSoisson%26aufirst%3DS.%2BM.%26aulast%3DHenze%26aufirst%3DD.%2BA.%26aulast%3DCooke%26aufirst%3DA.%2BJ.%26atitle%3DStructural%2520Characterization%2520of%2520Nonactive%2520Site%252C%2520TrkA-Selective%2520Kinase%2520Inhibitors%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2017%26volume%3D114%26issue%3D3%26spage%3DE297%26epage%3DE306%26doi%3D10.1073%2Fpnas.1611577114" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Furuya, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Momose, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katsuno, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fushimi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muranaka, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Handa, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ozawa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinoshita, T.</span></span> <span> </span><span class="NLM_article-title">The Juxtamembrane Region of TrkA Kinase Is Critical for Inhibitor Selectivity</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>27</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">1233</span>– <span class="NLM_lpage">1236</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2017.01.056</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=10.1016%2Fj.bmcl.2017.01.056" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2017&pages=1233-1236&issue=5&author=N.+Furuyaauthor=T.+Momoseauthor=K.+Katsunoauthor=N.+Fushimiauthor=H.+Muranakaauthor=C.+Handaauthor=T.+Ozawaauthor=T.+Kinoshita&title=The+Juxtamembrane+Region+of+TrkA+Kinase+Is+Critical+for+Inhibitor+Selectivity&doi=10.1016%2Fj.bmcl.2017.01.056"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2017.01.056&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2017.01.056%26sid%3Dliteratum%253Aachs%26aulast%3DFuruya%26aufirst%3DN.%26aulast%3DMomose%26aufirst%3DT.%26aulast%3DKatsuno%26aufirst%3DK.%26aulast%3DFushimi%26aufirst%3DN.%26aulast%3DMuranaka%26aufirst%3DH.%26aulast%3DHanda%26aufirst%3DC.%26aulast%3DOzawa%26aufirst%3DT.%26aulast%3DKinoshita%26aufirst%3DT.%26atitle%3DThe%2520Juxtamembrane%2520Region%2520of%2520TrkA%2520Kinase%2520Is%2520Critical%2520for%2520Inhibitor%2520Selectivity%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D27%26issue%3D5%26spage%3D1233%26epage%3D1236%26doi%3D10.1016%2Fj.bmcl.2017.01.056" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McTigue, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, Y.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solowiej, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kania, R. S.</span></span> <span> </span><span class="NLM_article-title">Molecular Conformations, Interactions, and Properties Associated with Drug Efficiency and Clinical Performance among VEGFR TK Inhibitors</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>109</i></span> (<span class="NLM_issue">45</span>),  <span class="NLM_fpage">18281</span>– <span class="NLM_lpage">18289</span>, <span class="refDoi"> DOI: 10.1073/pnas.1207759109</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=10.1073%2Fpnas.1207759109" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=22988103" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhslymtb3I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2012&pages=18281-18289&issue=45&author=M.+McTigueauthor=B.+W.+Murrayauthor=J.+H.+Chenauthor=Y.-L.+Dengauthor=J.+Solowiejauthor=R.+S.+Kania&title=Molecular+Conformations%2C+Interactions%2C+and+Properties+Associated+with+Drug+Efficiency+and+Clinical+Performance+among+VEGFR+TK+Inhibitors&doi=10.1073%2Fpnas.1207759109"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular conformations, interactions, and properties associated with drug efficiency and clinical performance among VEGFR TK inhibitors</span></div><div class="casAuthors">McTigue, Michele; Murray, Brion William; Chen, Jeffrey H.; Deng, Ya-Li; Solowiej, James; Kania, Robert S.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue">45</span>),
    <span class="NLM_cas:pages">18281-18289, S18281/1-S18281/7</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Analyses of compds. in clin. development have shown that ligand efficient-mols. with privileged phys. properties and low dose are less likely to fail in the various stages of clin. testing, have fewer postapproval withdrawals, and are less likely to receive black box safety warnings.  However, detailed side-by-side examn. of mol. interactions and properties within single drug classes are lacking.  As a class, VEGF receptor tyrosine kinase inhibitors (VEGFR TKIs) have changed the landscape of how cancer is treated, particularly in clear cell renal cell carcinoma, which is molecularly linked to the VEGF signaling axis.  Despite the clear role of the mol. target, member mols. of this validated drug class exhibit distinct clin. efficacy and safety profiles in comparable renal cell carcinoma clin. studies.  The first head-to-head randomized phase III comparative study between active VEGFR TKIs has confirmed significant differences in clin. performance.  To elucidate how fundamental drug potency-efficiency is achieved and impacts differentiation within the VEGFR TKI class, we detd. potencies, time dependence, selectivities, and X-ray structures of the drug-kinase complexes using a VEGFR2 TK construct inclusive of the important juxtamembrane domain.  Collectively, the studies elucidate unique drug-kinase interactions that are dependent on distinct juxtamembrane domain conformations, resulting in significant potency and ligand efficiency differences.  The identified structural trends are consistent with in vitro measurements, which translate well to clin. performance, underscoring a principle that may be broadly applicable to prospective drug design for optimal in vivo performance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpsIUWiD4sXtbVg90H21EOLACvtfcHk0lgt0nyIzb6-7w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhslymtb3I&md5=4a5ec677298a8c924c0f9557ca688a79</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1207759109&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1207759109%26sid%3Dliteratum%253Aachs%26aulast%3DMcTigue%26aufirst%3DM.%26aulast%3DMurray%26aufirst%3DB.%2BW.%26aulast%3DChen%26aufirst%3DJ.%2BH.%26aulast%3DDeng%26aufirst%3DY.-L.%26aulast%3DSolowiej%26aufirst%3DJ.%26aulast%3DKania%26aufirst%3DR.%2BS.%26atitle%3DMolecular%2520Conformations%252C%2520Interactions%252C%2520and%2520Properties%2520Associated%2520with%2520Drug%2520Efficiency%2520and%2520Clinical%2520Performance%2520among%2520VEGFR%2520TK%2520Inhibitors%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2012%26volume%3D109%26issue%3D45%26spage%3D18281%26epage%3D18289%26doi%3D10.1073%2Fpnas.1207759109" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schindler, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bornmann, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pellicena, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, W. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clarkson, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuriyan, J.</span></span> <span> </span><span class="NLM_article-title">Structural Mechanism for STI-571 Inhibition of Abelson Tyrosine Kinase</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>289</i></span> (<span class="NLM_issue">5486</span>),  <span class="NLM_fpage">1938</span>– <span class="NLM_lpage">1942</span>, <span class="refDoi"> DOI: 10.1126/science.289.5486.1938</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=10.1126%2Fscience.289.5486.1938" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=10988075" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=1%3ACAS%3A528%3ADC%252BD3cXms1altLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=289&publication_year=2000&pages=1938-1942&issue=5486&author=T.+Schindlerauthor=W.+Bornmannauthor=P.+Pellicenaauthor=W.+T.+Millerauthor=B.+Clarksonauthor=J.+Kuriyan&title=Structural+Mechanism+for+STI-571+Inhibition+of+Abelson+Tyrosine+Kinase&doi=10.1126%2Fscience.289.5486.1938"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Structural mechanism for STI-571 inhibition of Abelson tyrosine kinase</span></div><div class="casAuthors">Schindler, Thomas; Bornmann, William; Pellicena, Patricia; Miller, W. Todd; Clarkson, Bayard; Kuriyan, John</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, D. C.)</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">289</span>
        (<span class="NLM_cas:issue">5486</span>),
    <span class="NLM_cas:pages">1938-1942</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">The inadvertent activation of the Abelson tyrosine kinase (Abl) causes chronic myelogenous leukemia (CML).  A small-mol. inhibitor of Abl (STI-571) is effective in the treatment of CML.  We report the crystal structure of the catalytic domain of Abl, complexed to a variant of STI-571.  Crit. to the binding of STI-571 is the adoption by the kinase of an inactive conformation, in which a centrally located "activation loop" is not phosphorylated.  The conformation of this loop is distinct from that in active protein kinases, as well as in the inactive form of the closely related Src kinases.  These results suggest that compds. that exploit the distinctive inactivation mechanisms of individual protein kinases can achieve both high affinity and high specificity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9eAZqIQ1aebVg90H21EOLACvtfcHk0lgVgyqqwIlneg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXms1altLc%253D&md5=56bb233f010f099d0073020ac6b9db59</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1126%2Fscience.289.5486.1938&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.289.5486.1938%26sid%3Dliteratum%253Aachs%26aulast%3DSchindler%26aufirst%3DT.%26aulast%3DBornmann%26aufirst%3DW.%26aulast%3DPellicena%26aufirst%3DP.%26aulast%3DMiller%26aufirst%3DW.%2BT.%26aulast%3DClarkson%26aufirst%3DB.%26aulast%3DKuriyan%26aufirst%3DJ.%26atitle%3DStructural%2520Mechanism%2520for%2520STI-571%2520Inhibition%2520of%2520Abelson%2520Tyrosine%2520Kinase%26jtitle%3DScience%26date%3D2000%26volume%3D289%26issue%3D5486%26spage%3D1938%26epage%3D1942%26doi%3D10.1126%2Fscience.289.5486.1938" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pargellis, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Churchill, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cirillo, P. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilmore, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graham, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grob, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hickey, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moss, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pav, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Regan, J.</span></span> <span> </span><span class="NLM_article-title">Inhibition of P38 MAP Kinase by Utilizing a Novel Allosteric Binding Site</span>. <i>Nat. Struct. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">268</span>– <span class="NLM_lpage">272</span>, <span class="refDoi"> DOI: 10.1038/nsb770</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=10.1038%2Fnsb770" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2002&pages=268-272&issue=4&author=C.+Pargellisauthor=L.+Tongauthor=L.+Churchillauthor=P.+F.+Cirilloauthor=T.+Gilmoreauthor=A.+G.+Grahamauthor=P.+M.+Grobauthor=E.+R.+Hickeyauthor=N.+Mossauthor=S.+Pavauthor=J.+Regan&title=Inhibition+of+P38+MAP+Kinase+by+Utilizing+a+Novel+Allosteric+Binding+Site&doi=10.1038%2Fnsb770"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1038%2Fnsb770&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnsb770%26sid%3Dliteratum%253Aachs%26aulast%3DPargellis%26aufirst%3DC.%26aulast%3DTong%26aufirst%3DL.%26aulast%3DChurchill%26aufirst%3DL.%26aulast%3DCirillo%26aufirst%3DP.%2BF.%26aulast%3DGilmore%26aufirst%3DT.%26aulast%3DGraham%26aufirst%3DA.%2BG.%26aulast%3DGrob%26aufirst%3DP.%2BM.%26aulast%3DHickey%26aufirst%3DE.%2BR.%26aulast%3DMoss%26aufirst%3DN.%26aulast%3DPav%26aufirst%3DS.%26aulast%3DRegan%26aufirst%3DJ.%26atitle%3DInhibition%2520of%2520P38%2520MAP%2520Kinase%2520by%2520Utilizing%2520a%2520Novel%2520Allosteric%2520Binding%2520Site%26jtitle%3DNat.%2520Struct.%2520Biol.%26date%3D2002%26volume%3D9%26issue%3D4%26spage%3D268%26epage%3D272%26doi%3D10.1038%2Fnsb770" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sherman, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farid, R.</span></span> <span> </span><span class="NLM_article-title">Understanding Kinase Selectivity through Energetic Analysis of Binding Site Waters</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>5</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">618</span>– <span class="NLM_lpage">627</span>, <span class="refDoi"> DOI: 10.1002/cmdc.200900501</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=10.1002%2Fcmdc.200900501" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=20183853" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=1%3ACAS%3A528%3ADC%252BC3cXktFyqtLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2010&pages=618-627&issue=4&author=D.+D.+Robinsonauthor=W.+Shermanauthor=R.+Farid&title=Understanding+Kinase+Selectivity+through+Energetic+Analysis+of+Binding+Site+Waters&doi=10.1002%2Fcmdc.200900501"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Understanding Kinase Selectivity Through Energetic Analysis of Binding Site Waters</span></div><div class="casAuthors">Robinson, Daniel D.; Sherman, Woody; Farid, Ramy</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">618-627</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Kinases remain an important drug target class within the pharmaceutical industry; however, the rational design of kinase inhibitors is plagued by the complexity of gaining selectivity for a small no. of proteins within a family of more than 500 related enzymes.  Herein we show how a computational method for identifying the location and thermodn. properties of water mols. within a protein binding site can yield insight into previously inexplicable selectivity and structure-activity relationships.  Four kinase systems (Src family, Abl/c-Kit, Syk/ZAP-70, and CDK2/4) were investigated, and differences in predicted water mol. locations and energetics were able to explain the exptl. obsd. binding selectivity profiles.  The successful predictions across the range of kinases studied here suggest that this methodol. could be generally applicable for predicting selectivity profiles in related targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqlI79hNfoE67Vg90H21EOLACvtfcHk0lgVgyqqwIlneg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXktFyqtLk%253D&md5=5b68c7a5768c46eb50bb27cb34df2c09</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.200900501&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.200900501%26sid%3Dliteratum%253Aachs%26aulast%3DRobinson%26aufirst%3DD.%2BD.%26aulast%3DSherman%26aufirst%3DW.%26aulast%3DFarid%26aufirst%3DR.%26atitle%3DUnderstanding%2520Kinase%2520Selectivity%2520through%2520Energetic%2520Analysis%2520of%2520Binding%2520Site%2520Waters%26jtitle%3DChemMedChem%26date%3D2010%26volume%3D5%26issue%3D4%26spage%3D618%26epage%3D627%26doi%3D10.1002%2Fcmdc.200900501" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Repasky, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greenwood, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tubert-Brohman, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jerome, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Annabhimoju, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boyles, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmitz, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abel, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farid, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friesner, R. A.</span></span> <span> </span><span class="NLM_article-title">WScore: A Flexible and Accurate Treatment of Explicit Water Molecules in Ligand–Receptor Docking</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">4364</span>– <span class="NLM_lpage">4384</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00131</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00131" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=1%3ACAS%3A528%3ADC%252BC28Xls1Gqtr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=4364-4384&issue=9&author=R.+B.+Murphyauthor=M.+P.+Repaskyauthor=J.+R.+Greenwoodauthor=I.+Tubert-Brohmanauthor=S.+Jeromeauthor=R.+Annabhimojuauthor=N.+A.+Boylesauthor=C.+D.+Schmitzauthor=R.+Abelauthor=R.+Faridauthor=R.+A.+Friesner&title=WScore%3A+A+Flexible+and+Accurate+Treatment+of+Explicit+Water+Molecules+in+Ligand%E2%80%93Receptor+Docking&doi=10.1021%2Facs.jmedchem.6b00131"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">WScore: A Flexible and Accurate Treatment of Explicit Water Molecules in Ligand-Receptor Docking</span></div><div class="casAuthors">Murphy, Robert B.; Repasky, Matthew P.; Greenwood, Jeremy R.; Tubert-Brohman, Ivan; Jerome, Steven; Annabhimoju, Ramakrishna; Boyles, Nicholas A.; Schmitz, Christopher D.; Abel, Robert; Farid, Ramy; Friesner, Richard A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">4364-4384</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We have developed a new methodol. for protein-ligand docking and scoring, WScore, incorporating a flexible description of explicit water mols.  The locations and thermodn. of the waters are derived from a WaterMap mol. dynamics simulation.  The water structure is employed to provide an at. level description of ligand and protein desolvation.  WScore also contains a detailed model for localized ligand and protein strain energy and integrates an MM-GBSA scoring component with these terms to assess delocalized strain of the complex.  Ensemble docking is used to take into account induced fit effects on the receptor conformation, and protein reorganization free energies are assigned via fitting to exptl. data.  The performance of the method is evaluated for pose prediction, rank ordering of self-docked complexes, and enrichment in virtual screening, using a large data set of PDB complexes and compared with the Glide SP and Glide XP models; significant improvements are obtained.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonCVRxlzARBbVg90H21EOLACvtfcHk0likN2VHdYaSxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xls1Gqtr4%253D&md5=dcb2bc320a1bffe608531c4aa01666bb</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00131&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00131%26sid%3Dliteratum%253Aachs%26aulast%3DMurphy%26aufirst%3DR.%2BB.%26aulast%3DRepasky%26aufirst%3DM.%2BP.%26aulast%3DGreenwood%26aufirst%3DJ.%2BR.%26aulast%3DTubert-Brohman%26aufirst%3DI.%26aulast%3DJerome%26aufirst%3DS.%26aulast%3DAnnabhimoju%26aufirst%3DR.%26aulast%3DBoyles%26aufirst%3DN.%2BA.%26aulast%3DSchmitz%26aufirst%3DC.%2BD.%26aulast%3DAbel%26aufirst%3DR.%26aulast%3DFarid%26aufirst%3DR.%26aulast%3DFriesner%26aufirst%3DR.%2BA.%26atitle%3DWScore%253A%2520A%2520Flexible%2520and%2520Accurate%2520Treatment%2520of%2520Explicit%2520Water%2520Molecules%2520in%2520Ligand%25E2%2580%2593Receptor%2520Docking%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26issue%3D9%26spage%3D4364%26epage%3D4384%26doi%3D10.1021%2Facs.jmedchem.6b00131" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clausen, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nielsen, T. E.</span></span> <span> </span><span class="NLM_article-title">Allosteric Small-Molecule Kinase Inhibitors</span>. <i>Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>156</i></span>,  <span class="NLM_fpage">59</span>– <span class="NLM_lpage">68</span>, <span class="refDoi"> DOI: 10.1016/j.pharmthera.2015.10.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=10.1016%2Fj.pharmthera.2015.10.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=26478442" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhs12qsb3N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=156&publication_year=2015&pages=59-68&author=P.+Wuauthor=M.+H.+Clausenauthor=T.+E.+Nielsen&title=Allosteric+Small-Molecule+Kinase+Inhibitors&doi=10.1016%2Fj.pharmthera.2015.10.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Allosteric small-molecule kinase inhibitors</span></div><div class="casAuthors">Wu, Peng; Clausen, Mads H.; Nielsen, Thomas E.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">156</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">59-68</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Small-mol. kinase inhibitors are invaluable targeted therapeutics for the treatment of various human diseases, esp. cancers.  While the majority of approved and developed preclin. small-mol. inhibitors are characterized as type I or type II inhibitors that target the ATP-binding pocket of kinases, the remarkable sequential and structural similarity among ATP pockets renders the selective inhibition of kinases a daunting challenge.  Therefore, targeting allosteric pockets of kinases outside the highly conversed ATP pocket has been proposed as a promising alternative to overcome current barriers of kinase inhibitors, including poor selectivity and emergence of drug resistance.  In spite of the small no. of identified allosteric inhibitors in comparison with that of inhibitors targeting the ATP pocket, encouraging results, such as the FDA-approval of the first small-mol. allosteric inhibitor trametinib in 2013, the progress of more than 10 other allosteric inhibitors in clin. trials, and the emergence of a pipeline of highly selective and potent preclin. mols., have been reported in the past decade.  In this article, we present the current knowledge on allosteric inhibition in terms of conception, classification, potential advantages, and summarized debatable topics in the field.  Recent progress and allosteric inhibitors that were identified in the past three years are highlighted in this paper.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrK12iPyaK2ObVg90H21EOLACvtfcHk0likN2VHdYaSxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhs12qsb3N&md5=26e4658d325b8f016be29df27bf69ec2</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2015.10.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2015.10.002%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DP.%26aulast%3DClausen%26aufirst%3DM.%2BH.%26aulast%3DNielsen%26aufirst%3DT.%2BE.%26atitle%3DAllosteric%2520Small-Molecule%2520Kinase%2520Inhibitors%26jtitle%3DPharmacol.%2520Ther.%26date%3D2015%26volume%3D156%26spage%3D59%26epage%3D68%26doi%3D10.1016%2Fj.pharmthera.2015.10.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Efthimiou, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stephanou, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demopoulos, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nikolaropoulos, S. S.</span></span> <span> </span><span class="NLM_article-title">Aneugenic Potential of the Anticancer Drugs Melphalan and Chlorambucil. The Involvement of Apoptosis and Chromosome Segregation Regulating Proteins</span>. <i>J. Appl. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>33</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">537</span>– <span class="NLM_lpage">545</span>, <span class="refDoi"> DOI: 10.1002/jat.1743</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=10.1002%2Fjat.1743" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=22025197" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlKhtrnF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2013&pages=537-545&issue=7&author=M.+Efthimiouauthor=G.+Stephanouauthor=N.+A.+Demopoulosauthor=S.+S.+Nikolaropoulos&title=Aneugenic+Potential+of+the+Anticancer+Drugs+Melphalan+and+Chlorambucil.+The+Involvement+of+Apoptosis+and+Chromosome+Segregation+Regulating+Proteins&doi=10.1002%2Fjat.1743"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Aneugenic potential of the anticancer drugs melphalan and chlorambucil. The involvement of apoptosis and chromosome segregation regulating proteins. Mechanism of aneugenicity of melphalan and chlorambucil</span></div><div class="casAuthors">Efthimiou, Maria; Stephanou, Georgia; Demopoulos, Nikos A.; Nikolaropoulos, Sotiris S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Applied Toxicology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">537-545</span>CODEN:
                <span class="NLM_cas:coden">JJATDK</span>;
        ISSN:<span class="NLM_cas:issn">0260-437X</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">Previous findings showed that the anticancer drugs p-N,N-bis(2-chloroethyl) amino-L-phenylalanine (melphalan, MEL) and p-N,N-bis(2-chloroethyl)aminophenylbutyric acid (chlorambucil, CAB) belonging to the nitrogen mustard group, in addn. to their clastogenic activity, also exert aneugenic potential, nondisjunction and chromosome delay.  Their aneugenic potential is mainly mediated through centrosome defects.  To further investigate their aneugenicity we (a) studied whether apoptosis is a mechanism responsible for the elimination of damaged cells generated by MEL and CAB and (b) investigated if proteins that regulate chromosome segregation are involved in the modulation of their aneugenic potential.  Apoptosis was studied by Annexin-V/Propidium Iodide staining and fluorescence microscopy.  The involvement of apoptosis on the exclusion of cells with genetic damage and centrosome disturbances was analyzed by DAPI staining and immunofluorescence of β- and γ-tubulin in the presence of pan-caspase inhibitor.  The expressions of Aurora-A, Aurora-B, survivin and γ-tubulin were studied by Western blot.  We found that (a) apoptosis is not the mechanism of choice for selectively eliminating cells with supernumerary centrosomes, and (b) the proteins Aurora-A, Aurora-B and survivin are involved in the modulation of MEL and CAB aneugenicity.  These findings are important for the understanding of the mechanism responsible for the aneugenic activity of the anticancer drugs melphalan and chlorambucil.  Copyright © 2011 John Wiley & Sons, Ltd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqtTJOVzIj-2rVg90H21EOLACvtfcHk0likN2VHdYaSxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlKhtrnF&md5=3a5cb806329d8f5a441f7f91b17de554</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1002%2Fjat.1743&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjat.1743%26sid%3Dliteratum%253Aachs%26aulast%3DEfthimiou%26aufirst%3DM.%26aulast%3DStephanou%26aufirst%3DG.%26aulast%3DDemopoulos%26aufirst%3DN.%2BA.%26aulast%3DNikolaropoulos%26aufirst%3DS.%2BS.%26atitle%3DAneugenic%2520Potential%2520of%2520the%2520Anticancer%2520Drugs%2520Melphalan%2520and%2520Chlorambucil.%2520The%2520Involvement%2520of%2520Apoptosis%2520and%2520Chromosome%2520Segregation%2520Regulating%2520Proteins%26jtitle%3DJ.%2520Appl.%2520Toxicol.%26date%3D2013%26volume%3D33%26issue%3D7%26spage%3D537%26epage%3D545%26doi%3D10.1002%2Fjat.1743" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gollapudi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hasegawa, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eastmond, D. A.</span></span> <span> </span><span class="NLM_article-title">A Comparative Study of the Aneugenic and Polyploidy-Inducing Effects of Fisetin and Two Model Aurora Kinase Inhibitors</span>. <i>Mutat. Res., Genet. Toxicol. Environ. Mutagen.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>767</i></span>,  <span class="NLM_fpage">37</span>– <span class="NLM_lpage">43</span>, <span class="refDoi"> DOI: 10.1016/j.mrgentox.2014.03.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=10.1016%2Fj.mrgentox.2014.03.004" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=767&publication_year=2014&pages=37-43&author=P.+Gollapudiauthor=L.+S.+Hasegawaauthor=D.+A.+Eastmond&title=A+Comparative+Study+of+the+Aneugenic+and+Polyploidy-Inducing+Effects+of+Fisetin+and+Two+Model+Aurora+Kinase+Inhibitors&doi=10.1016%2Fj.mrgentox.2014.03.004"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1016%2Fj.mrgentox.2014.03.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.mrgentox.2014.03.004%26sid%3Dliteratum%253Aachs%26aulast%3DGollapudi%26aufirst%3DP.%26aulast%3DHasegawa%26aufirst%3DL.%2BS.%26aulast%3DEastmond%26aufirst%3DD.%2BA.%26atitle%3DA%2520Comparative%2520Study%2520of%2520the%2520Aneugenic%2520and%2520Polyploidy-Inducing%2520Effects%2520of%2520Fisetin%2520and%2520Two%2520Model%2520Aurora%2520Kinase%2520Inhibitors%26jtitle%3DMutat.%2520Res.%252C%2520Genet.%2520Toxicol.%2520Environ.%2520Mutagen.%26date%3D2014%26volume%3D767%26spage%3D37%26epage%3D43%26doi%3D10.1016%2Fj.mrgentox.2014.03.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Varma, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gardner, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steyn, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nkansah, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rotter, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitney-Pickett, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cram, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fenner, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El-Kattan, A. F.</span></span> <span> </span><span class="NLM_article-title">pH-Dependent Solubility and Permeability Criteria for Provisional Biopharmaceutics Classification (BCS and BDDCS) in Early Drug Discovery</span>. <i>Mol. Pharmaceutics</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">1199</span>– <span class="NLM_lpage">1212</span>, <span class="refDoi"> DOI: 10.1021/mp2004912</span> </span><div class="citationLinks">[<a href="/doi/10.1021/mp2004912" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=1%3ACAS%3A528%3ADC%252BC38Xlt1Ont74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2012&pages=1199-1212&issue=5&author=M.+V.+Varmaauthor=I.+Gardnerauthor=S.+J.+Steynauthor=P.+Nkansahauthor=C.+J.+Rotterauthor=C.+Whitney-Pickettauthor=H.+Zhangauthor=L.+Diauthor=M.+Cramauthor=K.+S.+Fennerauthor=A.+F.+El-Kattan&title=pH-Dependent+Solubility+and+Permeability+Criteria+for+Provisional+Biopharmaceutics+Classification+%28BCS+and+BDDCS%29+in+Early+Drug+Discovery&doi=10.1021%2Fmp2004912"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">pH-Dependent solubility and permeability criteria for provisional biopharmaceutics classification (BCS and BDDCS) in early drug discovery</span></div><div class="casAuthors">Varma, Manthena V.; Gardner, Iain; Steyn, Stefanus J.; Nkansah, Paul; Rotter, Charles J.; Whitney-Pickett, Carrie; Zhang, Hui; Di, Li; Cram, Michael; Fenner, Katherine S.; El-Kattan, Ayman F.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1199-1212</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The Biopharmaceutics Classification System (BCS) is a scientific framework that provides a basis for predicting the oral absorption of drugs.  These concepts have been extended in the Biopharmaceutics Drug Disposition Classification System (BDDCS) to explain the potential mechanism of drug clearance and understand the effects of uptake and efflux transporters on absorption, distribution, metab., and elimination.  The objective of present work is to establish criteria for provisional biopharmaceutics classification using pH-dependent passive permeability and aq. soly. data generated from high throughput screening methodologies in drug discovery settings.  The apparent permeability across monolayers of clonal cell line of Madin-Darby canine kidney cells, selected for low endogenous efflux transporter expression, was measured for a set of 105 drugs, with known BCS and BDDCS class.  The permeability at apical pH 6.5 for acidic drugs and at pH 7.4 for nonacidic drugs showed a good correlation with the fraction absorbed in human (Fa).  Receiver operating characteristic (ROC) curve anal. was utilized to define the permeability class boundary.  At permeability ≥5 × 10-6 cm/s, the accuracy of predicting Fa of ≥0.90 was 87%.  Also, this cutoff showed more than 80% sensitivity and specificity in predicting the literature permeability classes (BCS), and the metab. classes (BDDCS).  The equil. soly. of a subset of 49 drugs was measured in pH 1.2 medium, pH 6.5 phosphate buffer, and in FaSSIF medium (pH 6.5).  Although dose was not considered, good concordance of the measured soly. with BCS and BDDCS soly. class was achieved, when soly. at pH 1.2 was used for acidic compds. and FaSSIF soly. was used for basic, neutral, and zwitterionic compds.  Using a cutoff of 200 μg/mL, the data set suggested a 93% sensitivity and 86% specificity in predicting both the BCS and BDDCS soly. classes.  In conclusion, this study identified pH-dependent permeability and soly. criteria that can be used to assign provisional biopharmaceutics class at early stage of the drug discovery process.  Addnl., such a classification system will enable discovery scientists to assess the potential limiting factors to oral absorption, as well as help predict the drug disposition mechanisms and potential drug-drug interactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr84irw4TD15rVg90H21EOLACvtfcHk0ljXpOpcBFK9Ig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xlt1Ont74%253D&md5=2bcb29ea512d2e0665973292e4a4a0a3</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1021%2Fmp2004912&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fmp2004912%26sid%3Dliteratum%253Aachs%26aulast%3DVarma%26aufirst%3DM.%2BV.%26aulast%3DGardner%26aufirst%3DI.%26aulast%3DSteyn%26aufirst%3DS.%2BJ.%26aulast%3DNkansah%26aufirst%3DP.%26aulast%3DRotter%26aufirst%3DC.%2BJ.%26aulast%3DWhitney-Pickett%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DDi%26aufirst%3DL.%26aulast%3DCram%26aufirst%3DM.%26aulast%3DFenner%26aufirst%3DK.%2BS.%26aulast%3DEl-Kattan%26aufirst%3DA.%2BF.%26atitle%3DpH-Dependent%2520Solubility%2520and%2520Permeability%2520Criteria%2520for%2520Provisional%2520Biopharmaceutics%2520Classification%2520%2528BCS%2520and%2520BDDCS%2529%2520in%2520Early%2520Drug%2520Discovery%26jtitle%3DMol.%2520Pharmaceutics%26date%3D2012%26volume%3D9%26issue%3D5%26spage%3D1199%26epage%3D1212%26doi%3D10.1021%2Fmp2004912" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Di, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitney-Pickett, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Umland, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gebhard, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Federico, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davidson, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reyner, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rotter, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varma, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kempshall, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fenner, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El-kattan, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liston, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Troutman, M. D.</span></span> <span> </span><span class="NLM_article-title">Development of a New Permeability Assay Using Low-Efflux MDCKII Cells</span>. <i>J. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>100</i></span>,  <span class="NLM_fpage">4974</span>– <span class="NLM_lpage">4985</span>, <span class="refDoi"> DOI: 10.1002/jps.22674</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=10.1002%2Fjps.22674" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=21766308" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=1%3ACAS%3A528%3ADC%252BC3MXovFGltb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2011&pages=4974-4985&author=L.+Diauthor=C.+Whitney-Pickettauthor=J.+P.+Umlandauthor=H.+Zhangauthor=X.+Zhangauthor=D.+F.+Gebhardauthor=Y.+Laiauthor=J.+J.+Federicoauthor=R.+E.+Davidsonauthor=R.+Smithauthor=E.+L.+Reynerauthor=C.+Leeauthor=B.+Fengauthor=C.+Rotterauthor=M.+V.+Varmaauthor=S.+Kempshallauthor=K.+Fennerauthor=A.+F.+El-kattanauthor=T.+E.+Listonauthor=M.+D.+Troutman&title=Development+of+a+New+Permeability+Assay+Using+Low-Efflux+MDCKII+Cells&doi=10.1002%2Fjps.22674"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Development of a new permeability assay using low-efflux MDCKII cells</span></div><div class="casAuthors">Di, Li; Whitney-Pickett, Carrie; Umland, John P.; Zhang, Hui; Zhang, Xun; Gebhard, David F.; Lai, Yurong; Federico, James J.; Davidson, Ralph E.; Smith, Russ; Reyner, Eric L.; Lee, Caroline; Feng, Bo; Rotter, Charles; Varma, Manthena V.; Kempshall, Sarah; Fenner, Katherine; El-kattan, Ayman F.; Liston, Theodore E.; Troutman, Matthew D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmaceutical Sciences</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">100</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4974-4985</span>CODEN:
                <span class="NLM_cas:coden">JPMSAE</span>;
        ISSN:<span class="NLM_cas:issn">0022-3549</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Permeability is an important property of drug candidates.  The Madin-Darby canine kidney cell line (MDCK) permeability assay is widely used and the primary concern of using MDCK cells is the presence of endogenous transporters of nonhuman origin.  The canine P-glycoprotein (Pgp) can interfere with permeability and transporter studies, leading to less reliable data.  A new cell line, MDCKII-LE (low efflux), has been developed by selecting a subpopulation of low-efflux cells from MDCKII-WT using an iterative fluorescence-activated cell sorting technique with calcein-AM as a Pgp and efflux substrate.  MDCKII-LE cells are a subpopulation of MDCKII cells with over 200-fold lower canine Pgp mRNA level and fivefold lower protein level than MDCKII-WT.  MDCKII-LE cells showed less functional efflux activity than MDCKII-WT based on efflux ratios.  Notably, MDCKII-MDR1 showed about 1.5-fold decreased expression of endogenous canine Pgp, suggesting that using the net flux ratio might not completely cancel out the background endogenous transporter activities.  MDCKII-LE cells offer clear advantages over the MDCKII-WT by providing less efflux transporter background signals and minimizing interference from canine Pgp.  The MDCKII-LE apparent permeability values well differentiates compds. from high to medium/low human intestinal absorption and can be used for Biopharmaceutical Classification System.  The MDCKII-LE permeability assay (4-in-1 cassette dosing) is high throughput with good precision, reproducibility, robustness, and cost-effective. © 2011 Wiley-Liss, Inc. and the American Pharmacists Assocn. J Pharm Sci.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTVtRmYnbF17Vg90H21EOLACvtfcHk0ljXpOpcBFK9Ig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXovFGltb8%253D&md5=97f647fc215ea6d04882351ffc912a1e</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1002%2Fjps.22674&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjps.22674%26sid%3Dliteratum%253Aachs%26aulast%3DDi%26aufirst%3DL.%26aulast%3DWhitney-Pickett%26aufirst%3DC.%26aulast%3DUmland%26aufirst%3DJ.%2BP.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DGebhard%26aufirst%3DD.%2BF.%26aulast%3DLai%26aufirst%3DY.%26aulast%3DFederico%26aufirst%3DJ.%2BJ.%26aulast%3DDavidson%26aufirst%3DR.%2BE.%26aulast%3DSmith%26aufirst%3DR.%26aulast%3DReyner%26aufirst%3DE.%2BL.%26aulast%3DLee%26aufirst%3DC.%26aulast%3DFeng%26aufirst%3DB.%26aulast%3DRotter%26aufirst%3DC.%26aulast%3DVarma%26aufirst%3DM.%2BV.%26aulast%3DKempshall%26aufirst%3DS.%26aulast%3DFenner%26aufirst%3DK.%26aulast%3DEl-kattan%26aufirst%3DA.%2BF.%26aulast%3DListon%26aufirst%3DT.%2BE.%26aulast%3DTroutman%26aufirst%3DM.%2BD.%26atitle%3DDevelopment%2520of%2520a%2520New%2520Permeability%2520Assay%2520Using%2520Low-Efflux%2520MDCKII%2520Cells%26jtitle%3DJ.%2520Pharm.%2520Sci.%26date%3D2011%26volume%3D100%26spage%3D4974%26epage%3D4985%26doi%3D10.1002%2Fjps.22674" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bagal, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bungay, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denton, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibson, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glossop, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hay, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kemp, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lane, C. A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maw, G. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Million, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Payne, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poinsard, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rawson, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stammen, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, L. R.</span></span> <span> </span><span class="NLM_article-title">Discovery and Optimization of Selective Nav1.8 Modulator Series That Demonstrate Efficacy in Preclinical Models of Pain</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">650</span>– <span class="NLM_lpage">654</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.5b00059</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.5b00059" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=1%3ACAS%3A528%3ADC%252BC2MXnsVSqtb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=650-654&issue=6&author=S.+K.+Bagalauthor=P.+J.+Bungayauthor=S.+M.+Dentonauthor=K.+R.+Gibsonauthor=M.+S.+Glossopauthor=T.+L.+Hayauthor=M.+I.+Kempauthor=C.+A.+L.+Laneauthor=M.+L.+Lewisauthor=G.+N.+Mawauthor=W.+A.+Millionauthor=C.+E.+Payneauthor=C.+Poinsardauthor=D.+J.+Rawsonauthor=B.+L.+Stammenauthor=E.+B.+Stevensauthor=L.+R.+Thompson&title=Discovery+and+Optimization+of+Selective+Nav1.8+Modulator+Series+That+Demonstrate+Efficacy+in+Preclinical+Models+of+Pain&doi=10.1021%2Facsmedchemlett.5b00059"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Optimization of Selective Nav1.8 Modulator Series That Demonstrate Efficacy in Preclinical Models of Pain</span></div><div class="casAuthors">Bagal, Sharan K.; Bungay, Peter J.; Denton, Stephen M.; Gibson, Karl R.; Glossop, Melanie S.; Hay, Tanya L.; Kemp, Mark I.; Lane, Charlotte A. L.; Lewis, Mark L.; Maw, Graham N.; Million, William A.; Payne, C. Elizabeth; Poinsard, Cedric; Rawson, David J.; Stammen, Blanda L.; Stevens, Edward B.; Thompson, Lisa R.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">650-654</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Voltage-gated sodium channels, in particular Nav1.8, can be targeted for the treatment of neuropathic and inflammatory pain.  Herein, we described the optimization of Nav1.8 modulator series to deliver subtype selective, state, and use-dependent chem. matter that is efficacious in preclin. models of neuropathic and inflammatory pain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqx8aTxMbmYKrVg90H21EOLACvtfcHk0ljXpOpcBFK9Ig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXnsVSqtb4%253D&md5=0871fe7430909b09c710abd3aa8e8f94</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.5b00059&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.5b00059%26sid%3Dliteratum%253Aachs%26aulast%3DBagal%26aufirst%3DS.%2BK.%26aulast%3DBungay%26aufirst%3DP.%2BJ.%26aulast%3DDenton%26aufirst%3DS.%2BM.%26aulast%3DGibson%26aufirst%3DK.%2BR.%26aulast%3DGlossop%26aufirst%3DM.%2BS.%26aulast%3DHay%26aufirst%3DT.%2BL.%26aulast%3DKemp%26aufirst%3DM.%2BI.%26aulast%3DLane%26aufirst%3DC.%2BA.%2BL.%26aulast%3DLewis%26aufirst%3DM.%2BL.%26aulast%3DMaw%26aufirst%3DG.%2BN.%26aulast%3DMillion%26aufirst%3DW.%2BA.%26aulast%3DPayne%26aufirst%3DC.%2BE.%26aulast%3DPoinsard%26aufirst%3DC.%26aulast%3DRawson%26aufirst%3DD.%2BJ.%26aulast%3DStammen%26aufirst%3DB.%2BL.%26aulast%3DStevens%26aufirst%3DE.%2BB.%26aulast%3DThompson%26aufirst%3DL.%2BR.%26atitle%3DDiscovery%2520and%2520Optimization%2520of%2520Selective%2520Nav1.8%2520Modulator%2520Series%2520That%2520Demonstrate%2520Efficacy%2520in%2520Preclinical%2520Models%2520of%2520Pain%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D6%26issue%3D6%26spage%3D650%26epage%3D654%26doi%3D10.1021%2Facsmedchemlett.5b00059" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bagal, S. K.</span>; <span class="NLM_string-name">Cui, J. J.</span>; <span class="NLM_string-name">Greasley, S. E.</span>; <span class="NLM_string-name">Lunney, E. A.</span>; <span class="NLM_string-name">McAlpine, I. J.</span>; <span class="NLM_string-name">Nagata, A.</span>; <span class="NLM_string-name">Ninkovic, S.</span>; <span class="NLM_string-name">Omoto, K.</span>; <span class="NLM_string-name">Skerratt, S. E.</span>; <span class="NLM_string-name">Warmus, J. S.</span></span> <span> </span><span class="NLM_article-title">N-Pyrazolyl Pyridinylbenzamides as Tropomyosin-Related Kinase Inhibitors and Their Preparation</span>. <span class="NLM_patent">WO2015170218A1</span>, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=S.+K.+Bagal&author=J.+J.+Cui&author=S.+E.+Greasley&author=E.+A.+Lunney&author=I.+J.+McAlpine&author=A.+Nagata&author=S.+Ninkovic&author=K.+Omoto&author=S.+E.+Skerratt&author=J.+S.+Warmus&title=N-Pyrazolyl+Pyridinylbenzamides+as+Tropomyosin-Related+Kinase+Inhibitors+and+Their+Preparation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBagal%26aufirst%3DS.%2BK.%26atitle%3DN-Pyrazolyl%2520Pyridinylbenzamides%2520as%2520Tropomyosin-Related%2520Kinase%2520Inhibitors%2520and%2520Their%2520Preparation%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sinha, V. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snoeys, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osselaer, N. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peer, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mackie, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heald, D.</span></span> <span> </span><span class="NLM_article-title">From Preclinical to Human – Prediction of Oral Absorption and Drug–Drug Interaction Potential Using Physiologically Based Pharmacokinetic (PBPK) Modeling Approach in an Industrial Setting: A Workflow by Using Case Example</span>. <i>Biopharm. Drug Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>33</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">111</span>– <span class="NLM_lpage">121</span>, <span class="refDoi"> DOI: 10.1002/bdd.1782</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=10.1002%2Fbdd.1782" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=22383166" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=1%3ACAS%3A528%3ADC%252BC38XktFShuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2012&pages=111-121&issue=2&author=V.+K.+Sinhaauthor=J.+Snoeysauthor=N.+V.+Osselaerauthor=A.+V.+Peerauthor=C.+Mackieauthor=D.+Heald&title=From+Preclinical+to+Human+%E2%80%93+Prediction+of+Oral+Absorption+and+Drug%E2%80%93Drug+Interaction+Potential+Using+Physiologically+Based+Pharmacokinetic+%28PBPK%29+Modeling+Approach+in+an+Industrial+Setting%3A+A+Workflow+by+Using+Case+Example&doi=10.1002%2Fbdd.1782"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">From preclinical to human - prediction of oral absorption and drug-drug interaction potential using physiologically based pharmacokinetic (PBPK) modeling approach in an industrial setting: a workflow by using case examplePREDICTION OF ORAL ABSORPTION AND DDI USING PBPKV. K. SINHA ET AL.</span></div><div class="casAuthors">Sinha, Vikash Kumar; Snoeys, Jan; Osselaer, Nancy Van; Peer, Achiel Van; Mackie, Claire; Heald, Donald</div><div class="citationInfo"><span class="NLM_cas:title">Biopharmaceutics & Drug Disposition</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">111-121</span>CODEN:
                <span class="NLM_cas:coden">BDDID8</span>;
        ISSN:<span class="NLM_cas:issn">0142-2782</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">PurposeA case example is presented in which the physiol. based modeling approach has been used to model the absorption of a lipophilic BCS Class II compd. predominantly metabolized by CYP3A4, and to assess the interplay of absorption related parameters with the drug-drug interaction (DDI) potential.  MethodsThe PBPK model was built in the rat using Gastroplus to study the absorption characteristics of the compd.  Subsequently relevant model parameters were used to predict the non-linear human PK obsd. during first-in-human study after optimizing the absorption model for colonic absorption, bile micelle solubilization and unbound fraction in gut enterocytes (fugut) using SIMCYP simulator.  The model fitted absorption parameters were then used to assess the drug-drug interaction (DDI) potential of the test compd. when administered along with multiple doses of a potent CYP 3A4 inhibitor, ketoconazole.  The impact of fugut in the extent of DDI was assessed using parameter sensitivity anal.  Results and ConclusionsAfter optimizing the preclin. model and taking into consideration bile micelle solubilization and colonic absorption, the non-linear pharmacokinetics of the test compd. was satisfactorily predicted in man.  Sensitivity anal. performed with the absorption parameter fugut indicated that it could be an important parameter in predicting oral absorption.  In addn., DDI simulations using SIMCYP suggest that Cmax and AUC ratios may also be sensitive to the fugut input in the model.  Since fugut cannot be measured exptl., sensitivity anal. may help in assessing the importance of fugut in human PK and DDI prediction using SIMCYP.  Copyright © 2012 John Wiley & Sons, Ltd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpsL3mji8aaJLVg90H21EOLACvtfcHk0lgVSb9TTR-CMA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XktFShuro%253D&md5=07ddb89156a07ec83cbd90c709e7a62a</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1002%2Fbdd.1782&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fbdd.1782%26sid%3Dliteratum%253Aachs%26aulast%3DSinha%26aufirst%3DV.%2BK.%26aulast%3DSnoeys%26aufirst%3DJ.%26aulast%3DOsselaer%26aufirst%3DN.%2BV.%26aulast%3DPeer%26aufirst%3DA.%2BV.%26aulast%3DMackie%26aufirst%3DC.%26aulast%3DHeald%26aufirst%3DD.%26atitle%3DFrom%2520Preclinical%2520to%2520Human%2520%25E2%2580%2593%2520Prediction%2520of%2520Oral%2520Absorption%2520and%2520Drug%25E2%2580%2593Drug%2520Interaction%2520Potential%2520Using%2520Physiologically%2520Based%2520Pharmacokinetic%2520%2528PBPK%2529%2520Modeling%2520Approach%2520in%2520an%2520Industrial%2520Setting%253A%2520A%2520Workflow%2520by%2520Using%2520Case%2520Example%26jtitle%3DBiopharm.%2520Drug%2520Dispos.%26date%3D2012%26volume%3D33%26issue%3D2%26spage%3D111%26epage%3D121%26doi%3D10.1002%2Fbdd.1782" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stepan, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kauffman, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keefer, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verhoest, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, M.</span></span> <span> </span><span class="NLM_article-title">Evaluating the Differences in Cycloalkyl Ether Metabolism Using the Design Parameter “Lipophilic Metabolism Efficiency” (LipMetE) and a Matched Molecular Pairs Analysis</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span> (<span class="NLM_issue">17</span>),  <span class="NLM_fpage">6985</span>– <span class="NLM_lpage">6990</span>, <span class="refDoi"> DOI: 10.1021/jm4008642</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm4008642" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFKgurvJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=6985-6990&issue=17&author=A.+F.+Stepanauthor=G.+W.+Kauffmanauthor=C.+E.+Keeferauthor=P.+R.+Verhoestauthor=M.+Edwards&title=Evaluating+the+Differences+in+Cycloalkyl+Ether+Metabolism+Using+the+Design+Parameter+%E2%80%9CLipophilic+Metabolism+Efficiency%E2%80%9D+%28LipMetE%29+and+a+Matched+Molecular+Pairs+Analysis&doi=10.1021%2Fjm4008642"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluating the Differences in Cycloalkyl Ether Metabolism Using the Design Parameter "Lipophilic Metabolism Efficiency" (LipMetE) and a Matched Molecular Pairs Analysis</span></div><div class="casAuthors">Stepan, Antonia F.; Kauffman, Gregory W.; Keefer, Christopher E.; Verhoest, Patrick R.; Edwards, Martin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">6985-6990</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We have obsd. previously that modification of ring size and substitution pattern may be used as a strategy to mitigate the metabolic instability of cycloalkyl ethers.  In this article, we introduce a medicinal chem. design parameter named "lipophilic metab. efficiency" (LipMetE) that indicates that these changes in metabolic stability can be largely ascribed to changes in lipophilicity.  Our matched mol. pair anal. also indicates that this finding is a general phenomenon, widely obsd. across different chemotypes.  It is our hope that both the LipMetE design parameter and the results from our pairwise anal. will be useful tools for medicinal chemists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpiFJ_fPxurbVg90H21EOLACvtfcHk0lgVSb9TTR-CMA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFKgurvJ&md5=596673d35831b979b8daf5a4ccb8a218</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1021%2Fjm4008642&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm4008642%26sid%3Dliteratum%253Aachs%26aulast%3DStepan%26aufirst%3DA.%2BF.%26aulast%3DKauffman%26aufirst%3DG.%2BW.%26aulast%3DKeefer%26aufirst%3DC.%2BE.%26aulast%3DVerhoest%26aufirst%3DP.%2BR.%26aulast%3DEdwards%26aufirst%3DM.%26atitle%3DEvaluating%2520the%2520Differences%2520in%2520Cycloalkyl%2520Ether%2520Metabolism%2520Using%2520the%2520Design%2520Parameter%2520%25E2%2580%259CLipophilic%2520Metabolism%2520Efficiency%25E2%2580%259D%2520%2528LipMetE%2529%2520and%2520a%2520Matched%2520Molecular%2520Pairs%2520Analysis%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26issue%3D17%26spage%3D6985%26epage%3D6990%26doi%3D10.1021%2Fjm4008642" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fahmi, O. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boldt, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kish, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obach, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tremaine, L. M.</span></span> <span> </span><span class="NLM_article-title">Prediction of Drug-Drug Interactions from in Vitro Induction Data</span>. <i>Application of the Relative Induction Score Approach Using Cryopreserved Human Hepatocytes</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>36</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">1971</span>– <span class="NLM_lpage">1974</span>, <span class="refDoi"> DOI: 10.1124/dmd.108.021907</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=10.1124%2Fdmd.108.021907" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2008&pages=1971-1974&issue=9&author=O.+A.+Fahmiauthor=S.+Boldtauthor=M.+Kishauthor=R.+S.+Obachauthor=L.+M.+Tremaine&title=Prediction+of+Drug-Drug+Interactions+from+in+Vitro+Induction+Data&doi=10.1124%2Fdmd.108.021907"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1124%2Fdmd.108.021907&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.108.021907%26sid%3Dliteratum%253Aachs%26aulast%3DFahmi%26aufirst%3DO.%2BA.%26aulast%3DBoldt%26aufirst%3DS.%26aulast%3DKish%26aufirst%3DM.%26aulast%3DObach%26aufirst%3DR.%2BS.%26aulast%3DTremaine%26aufirst%3DL.%2BM.%26atitle%3DPrediction%2520of%2520Drug-Drug%2520Interactions%2520from%2520in%2520Vitro%2520Induction%2520Data%26jtitle%3DApplication%2520of%2520the%2520Relative%2520Induction%2520Score%2520Approach%2520Using%2520Cryopreserved%2520Human%2520Hepatocytes%26date%3D2008%26volume%3D36%26issue%3D9%26spage%3D1971%26epage%3D1974%26doi%3D10.1124%2Fdmd.108.021907" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Manning, G.</span></span> <a href="http://kinase.com/web/current/human/" class="extLink">http://kinase.com/web/current/human/</a> (accessed April <span class="NLM_year">2018</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Manning%2C+G.+http%3A%2F%2Fkinase.com%2Fweb%2Fcurrent%2Fhuman%2F+%28accessed+April+2018%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26aulast%3DManning%26aufirst%3DG.%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, F. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zelesky, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Troutman, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, B.</span></span> <span> </span><span class="NLM_article-title">The Effect of Breast Cancer Resistance Protein and P-Glycoprotein on the Brain Penetration of Flavopiridol, Imatinib Mesylate (Gleevec), Prazosin, and 2-Methoxy-3-(4-(2-(5-Methyl-2-Phenyloxazol-4-Yl)Ethoxy)Phenyl)Propanoic Acid (PF-407288) in Mice</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">946</span>– <span class="NLM_lpage">955</span>, <span class="refDoi"> DOI: 10.1124/dmd.108.024489</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=10.1124%2Fdmd.108.024489" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=19225039" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;key=1%3ACAS%3A528%3ADC%252BD1MXlsVWitLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2009&pages=946-955&author=L.+Zhouauthor=K.+Schmidtauthor=F.+R.+Nelsonauthor=V.+Zeleskyauthor=M.+D.+Troutmanauthor=B.+Feng&title=The+Effect+of+Breast+Cancer+Resistance+Protein+and+P-Glycoprotein+on+the+Brain+Penetration+of+Flavopiridol%2C+Imatinib+Mesylate+%28Gleevec%29%2C+Prazosin%2C+and+2-Methoxy-3-%284-%282-%285-Methyl-2-Phenyloxazol-4-Yl%29Ethoxy%29Phenyl%29Propanoic+Acid+%28PF-407288%29+in+Mice&doi=10.1124%2Fdmd.108.024489"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">The effect of breast cancer resistance protein and P-glycoprotein on the brain penetration of flavopiridol, imatinib mesylate (Gleevec), prazosin, and 2-methoxy-3-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenyl)propanoic acid (PF-407288) in mice</span></div><div class="casAuthors">Zhou, Lin; Schmidt, Kari; Nelson, Frederick R.; Zelesky, Veronica; Troutman, Matthew D.; Feng, Bo</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">946-955</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The role of breast cancer resistance protein (Bcrp) and the combined activities of Bcrp and P-glycoprotein (P-gp, Mdr1a/1b) in limiting the brain penetration of drugs at the blood-brain barrier (BBB) were investigated using wild-type FVB, Mdr1a/1b(-/-), (-/-), Bcrp(-/-), and Mdr1a/1b(-/-), (-/-)Bcrp(-/-) mice.  Four drugs, flavopiridol, imatinib mesylate (Gleevec), PF-407288, and prazosin, with different transport specificity for BCRP/Bcrp and MDR1/Mdr1a were selected, and the drug levels in plasma, cerebrospinal fluid, and brain of mice were detd.  Flavopiridol and prazosin were identified as substrates for both mouse Bcrp and Mdr1a with greater transport assocd. with Bcrp.  The brain/plasma (B/P) ratios at 0.5 and 2 h in Mdr1a/1b(-/-), (-/-) and Bcrp(-/-) mice were 1- to 2-fold for both compds., whereas the ratios in Mdr1a/1b(-/-), (-/-)Bcrp(-/-) mice were more than 5-fold of those obsd. in FVB mice.  For imatinib, a better substrate of P-gp than Bcrp, the B/P ratios in Bcrp(-/-) were comparable to those in FVB mice, whereas the B/P ratios in Mdr1a/1b(-/-), (-/-) and Mdr1a/1b(-/-), (-/-)Bcrp(-/-) mice were more than 4- and 28-fold of those in FVB mice at both time points, resp.  Finally, the Bcrp-specific substrate PF-407288 exhibited comparable B/P ratios in Mdr1a/1b(-/-), (-/-) and Bcrp(-/-) mice and slightly but significantly increased B/P ratios in Mdr1a/1b(-/-), (-/-)Bcrp(-/-) mice compared with those in FVB mice.  The B/P ratios of compds. in Mdr1a/1b(-/-), (-/-)Bcrp(-/-) mice compared with those in Mdr1a/1b(-/-), (-/-) mice clearly demonstrate that Bcrp impairs the brain penetration of its substrates.  Moreover, P-gp and Bcrp at BBB function synergistically to limit the brain penetration of shared substrates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKvZVpc58zzbVg90H21EOLACvtfcHk0lgRvKK8BA_MJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXlsVWitLo%253D&md5=422881b70fa04474e0242a9c3a095093</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1124%2Fdmd.108.024489&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.108.024489%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DL.%26aulast%3DSchmidt%26aufirst%3DK.%26aulast%3DNelson%26aufirst%3DF.%2BR.%26aulast%3DZelesky%26aufirst%3DV.%26aulast%3DTroutman%26aufirst%3DM.%2BD.%26aulast%3DFeng%26aufirst%3DB.%26atitle%3DThe%2520Effect%2520of%2520Breast%2520Cancer%2520Resistance%2520Protein%2520and%2520P-Glycoprotein%2520on%2520the%2520Brain%2520Penetration%2520of%2520Flavopiridol%252C%2520Imatinib%2520Mesylate%2520%2528Gleevec%2529%252C%2520Prazosin%252C%2520and%25202-Methoxy-3-%25284-%25282-%25285-Methyl-2-Phenyloxazol-4-Yl%2529Ethoxy%2529Phenyl%2529Propanoic%2520Acid%2520%2528PF-407288%2529%2520in%2520Mice%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2009%26volume%3D37%26spage%3D946%26epage%3D955%26doi%3D10.1124%2Fdmd.108.024489" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6D22" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6D22','PDB','6D22'); return false;">PDB: 6D22</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6D1Y" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6D1Y','PDB','6D1Y'); return false;">PDB: 6D1Y</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6D1Z" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6D1Z','PDB','6D1Z'); return false;">PDB: 6D1Z</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6D20" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6D20','PDB','6D20'); return false;">PDB: 6D20</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-2"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i49"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.8b00280">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_78431"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the ACS publications Web site. . The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.8b00280">10.1021/acs.jmedchem.8b00280</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Surface plasmon resonance data for ligands <b>3</b> and <b>23</b>, comparison of TrkA cell IC<sub>50</sub> data with nonactivated TrkA enzyme activity and activated phosphorylated TrkA enzyme activity, TrkA enzyme and cell assay protocols, inhibition of NGF induced phosphorylated ERK formation in native adult rat DRGs by ligand <b>23</b> data, protocol for ultraviolet irradiation-induced thermal hyperalgesia in rats, measurement of CNS penetration in rats, Kinase selectivity profile of lead molecule <b>3</b> and candidate molecule <b>23</b>, experimental procedures and spectral data for compounds, <sup>1</sup>H NMR spectra for compounds <b>3</b> and <b>23</b>; remaining chemistry details (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.8b00280/suppl_file/jm8b00280_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.8b00280/suppl_file/jm8b00280_si_002.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b00280/suppl_file/jm8b00280_si_001.pdf">jm8b00280_si_001.pdf (1.55 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b00280/suppl_file/jm8b00280_si_002.csv">jm8b00280_si_002.csv (1.85 kb)</a></li></ul></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">PDB codes are <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6D22">6D22</a> for Apo TrkA, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6D1Y">6D1Y</a> for compound <b>2</b>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6D1Z">6D1Z</a> for compound <b>3</b>, and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6D20">6D20</a> for compound <b>23</b>.</p><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.8b00280&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2019.62.issue-1%3Bwgroup%3Astring%3AACHS+website+Group%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.8b00280%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.8b00280" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                8MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-b425991822a79ada59b3.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-fb88834b824b41b135ad.js"></script>

<script type="text/javascript" src="/wro/ke1q~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"667988de5ef1124c","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.6.0","si":10}'></script>
</body>
</html>
